-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QUsIoTqd+1TibYYE65pHz0KfopK7N+KjKr/Uu3XnOiqcltiuIYwH7qOjKfhqEa2c
 QxGPacuUhRK1EGaZvt68sQ==

<SEC-DOCUMENT>0001213809-07-000008.txt : 20070122
<SEC-HEADER>0001213809-07-000008.hdr.sgml : 20070122
<ACCEPTANCE-DATETIME>20070122160506
ACCESSION NUMBER:		0001213809-07-000008
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20070122
DATE AS OF CHANGE:		20070122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-139542
		FILM NUMBER:		07543474

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424bs011807.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. FORM S-3 424(B)(3) PROSPECTUS 01.18.2007
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Form S-3 424(b)(3) Prospectus 01.18.2007
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 288pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>Filed
      Pursuant to
      Rule&#160;424(b)(3)</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 288pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Registration
      No.
      333-139542</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>PROSPECTUS</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<
/font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      International, Inc.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="dyadiclogo1.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5,581,484
      Shares of</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Common
      Stock</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      5,581,484 shares of our common stock offered by this prospectus include (i)
      2,136,752 shares of common stock issued to a selling stockholder identified
      in
      this prospectus in a private placement completed on November 8, 2006; (ii)
      2,787,000 shares of common stock issued to selling stockholders identified
      in
      this prospectus in a private placement completed on December 1, 2006; and (iii)
      657,732 shares of common stock issuable upon the exercise of warrants issued
      to
      the selling stockholders in the private placement completed on December 1,
      2006.
      For further information regarding these private placements, please see &#8220;Summary
      Description of our Business&#8212;Recent Developments&#8221; on page 4 of this
      prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      not selling any shares of our common stock under this prospectus and will not
      receive any of the proceeds from the resale of the shares by the selling
      stockholders. However, we will receive the exercise price of the warrants when
      and if they are exercised to the extent so exercised for cash. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      common stock trades on the American Stock Exchange under the symbol "DIL."
      On
      January 17, 2007, the last reported sale price of our common stock as reported
      on the American Stock Exchange was $5.15 per share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders, or their pledgees, donees, transferees or other
      successors-in-interest, may offer the shares from time to time through public
      or
      private transactions, on or off the American Stock Exchange, at prevailing
      market prices or at privately negotiated prices. They may make sales directly
      to
      purchasers or to or through agents, broker-dealers or underwriters.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>_______________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investing
      in our common stock involves a high degree of risk. You should consider
      carefully the risk factors beginning on page </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      this prospectus for a discussion of these risks.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>_______________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Neither
      the Securities and Exchange Commission nor any state securities commission
      has
      approved or disapproved of these securities or passed upon the accuracy or
      adequacy of this prospectus. Any representation to the contrary is a criminal
      offense.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      date of this prospectus is January 18, 2007.</strong></font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>TABLE
      OF CONTENTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong><u><font size="2">Page</font></u></strong></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Summary
                  Description of Our Business</u></font></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Risk
                  Factors</u></font></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Disclosure
                Regarding Forward-Looking Statements</u></font></td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Use
                  of Proceeds</u></font>&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Selling
                  Stockholders</u></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">21</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">&#160;</td>
              <td colspan="2" valign="bottom" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Plan
                  of Distribution</u></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">25</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">&#160;</td>
              <td colspan="2" valign="bottom" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Legal
                  Matters</u></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">26</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">&#160;</td>
              <td colspan="2" valign="bottom" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Experts</u></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">26</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Where
                    You Can Find More Information</u></font></div>
                </div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">&#160;</td>
              <td colspan="2" valign="bottom" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" valign="bottom" width="63%">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Incorporation
                  of Certain Documents by Reference</u></font></div>
              </td>
              <td colspan="2" valign="bottom" width="9%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SUMMARY
      DESCRIPTION OF OUR BUSINESS </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      summary highlights selected information and does not contain all the information
      that is important to you. You should carefully read this prospectus and the
      documents we have referred you to in &#8220;Incorporation of Certain Documents by
      Reference&#8221; on page&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      information about us and our financial statements. As used herein, and except
      as
      the context may otherwise require, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or
&#8220;Dyadic&#8221; mean, collectively, Dyadic International, Inc. and all of its
      consolidated subsidiaries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Our
      Business</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are a
      global biotechnology company based in Jupiter, Florida, with operations in
      the
      United States of America, Hong Kong and mainland China, Poland and The
      Netherlands. We are engaged in research and development, the collaborative
      licensing of our patented and other proprietary technologies to develop and
      manufacture biological products and the manufacture and sale of industrial
      enzymes and other proteins for the industrial, biorefinery and pharmaceutical
      industries, including:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                textile, pulp &amp; paper, animal feed, alcohol, starch, and food and
                beverage industries, where we currently sell more than 45 liquid
                and dry
                enzyme products to more than 200 industrial customers in approximately
                50
                countries, which we refer to as our Enzyme Business;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">enzymes
                and related biotechnological processes for&#160;use in converting various
                agricultural products (e.g. corn), agricultural residue products
                (e.g.
                dried distillers grains (DDG&#8217;s), wheat straw, and sugar cane
                bagasse)&#160;and forestry industry residues (e.g. wood pulp and chips)
                into fermentable sugars, which can then be used in the production
                of
                traditional and cellulosic ethanol, as well as other products currently
                derived from petroleum, such as plastics and polymers, which we
                collectively refer to as &#8220;Biorefinery Products&#8221;;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">human
                therapeutic protein candidates, with focus on antibodies, for use
                by
                pharmaceutical and biotechnology companies in pre-clinical and clinical
                drug development applications and commercialization following drug
                approval, which we refer to as our BioSciences Business.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      developed and use a number of proprietary fungal strains to produce enzymes
      and
      other biomaterials, but the one on which we have principally focused is a
      patented system for protein production, or protein expression, which we call
      the
      C1 Expression System. This System is based on our patented </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chrysosporium
      lucknowense</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      fungus,
      known as C1, as its host production organism. A host production organism is
      an
      organism which has been genetically altered to express genes to produce targeted
      protein products. We discovered the C1 microorganism in the mid-1990's and
      initially developed it, without the application of molecular biology, to produce
      neutral cellulases for our textile manufacturing customers. By 1998, we began
      to
      apply molecular genetics and other proprietary biotechnology tools to C1 to
      create a technology, which we refer to as the C1 Host Technology. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      were
      organized under the name CCP Worldwide, Inc., as a Delaware corporation on
      September 23, 2002. On October 29, 2004, we completed the merger of our newly
      created and wholly owned subsidiary, CCP Acquisition Corp., a Florida
      corporation, with and into a Florida corporation formerly known as Dyadic
      International, Inc., which was the surviving corporation of the merger and
      became our wholly owned subsidiary. Following the merger, our new subsidiary
      changed its name to Dyadic International (USA), Inc. (&#8220;Dyadic-Florida&#8221;) from
      Dyadic International, Inc., and our name was changed to Dyadic International,
      Inc. from CCP Worldwide, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      connection with the merger, we disposed of our then sole operating subsidiary,
      Custom Craft Packaging, Inc., which was engaged in the packaging business,
      in a
      sale of all of the shares of that subsidiary to its founder; all of the then
      officers and directors of the Company resigned from their positions and were
      replaced with Dyadic-Florida's officers and directors; and Dyadic-Florida became
      our sole operating subsidiary. For accounting purposes, the merger was accounted
      for in a manner identical to a reverse acquisition of the Company by
      Dyadic-Florida, except that no goodwill or other intangible assets have been
      recorded. Accordingly, Dyadic-Florida was deemed to be the accounting acquirer
      of the Company because the former stockholders of Dyadic-Florida became the
      owners of a majority of the Company&#8217;s issued and outstanding shares of common
      stock after the merger, inclusive of shares of common stock issued in the
      initial closing of the private placement of the Company&#8217;s securities on the same
      date as the merger. For reporting purposes, the transaction is equivalent to
      the
      issuance of stock by Dyadic-Florida for the net monetary assets of the Company,
      which after the transactions effected on October 29, 2004 were nil, accompanied
      by a recapitalization. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        executive offices are located at 140 Intracoastal Pointe Drive, Suite 404,
        Jupiter, Florida 33477, and our telephone number is (561) 743-8333. The address
        of our website is www.Dyadic-Group.com. The contents of our website are not
        part
        of this prospectus, and our Internet address is included in this prospectus
        as
        an inactive textual reference only.</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3</strong></font></div>
        <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Recent
      Developments</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      October 26, 2006, we entered into a securities purchase agreement (the &#8220;ABRD
      Securities Purchase Agreement&#8221;) with Abengoa Bioenergy R&amp;D, Inc. (&#8220; ABRD&#8221;),
      a subsidiary of Abengoa Bioenergy Corporation. Also on October 26, 2006,
      Dyadic-Florida entered into a non-exclusive research and development agreement
      with ABRD pertaining to the conduct of a research and development (&#8220;R&amp;D&#8221;)
      program to be completed over a period of approximately three years, under which
      Dyadic-Florida will seek to apply its proprietary technologies to the
      development of cost-effective enzyme mixtures and related processing and
      manufacturing technologies for commercial application in ABRD&#8217;s bioethanol
      (cellulosic ethanol) production process (the &#8220;R&amp;D Agreement&#8221;). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the ABRD Securities Purchase Agreement, ABRD invested $10 million
      in
      us, for which it was issued 2,136,752 shares of our common stock at $4.68 per
      share (the closing share price on October 25, 2006, as reported on the American
      Stock Exchange (&#8220;AMEX&#8221;)). We completed this private sale on November 8, 2006.
      Under certain circumstances, as described below, we may have to issue additional
      securities of the Company to ABRD.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      use the proceeds from this private sale to fund the performance of our R&amp;D
      obligations under the R&amp;D Agreement over a period of approximately three
      years, as described below, under which we will seek to apply our proprietary
      technologies to the development of one or more enzyme mixtures and related
      processing and manufacturing technologies customized to ABRD&#8217;s proprietary
      biomass substrates. The R&amp;D Agreement contemplates that we will perform both
      (i) research of general application to the cellulosic ethanol field furthering
      our extensive research and development and large-scale manufacturing
      technologies for producing large volumes of low cost cellulases, xylanases
      and
      other hemicellulases and (ii) research of specific applications for the
      achievement of the goals of the ABRD R&amp;D Program to develop an economically
      viable commercial process for the production of large volumes of effective,
      low
      cost enzyme mixtures for the proprietary biomass substrates of specific interest
      to ABRD. In general, we are granted exclusive ownership of all intellectual
      property we develop in connection with our performance obligation under the
      R&amp;D Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the R&amp;D Agreement, if we successfully develop one or more enzyme
      mixtures and related processing and manufacturing&#160;technologies for ABRD and
      ABRD&#160;exercises an option to&#160;license on a non-exclusive basis such
      technologies, we will be entitled to receive license fees, technology transfer
      fees and royalties on ethanol production by ABRD affiliates, which will be
      recognized as earned. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      under the ABRD Securities Purchase Agreement, we have agreed to use the $10
      million to fund our performance of certain foundational and applications
      research in the cellulosic ethanol field and to spend not less than $10.0
      million (the &#8220;R&amp;D Spending Obligation&#8221;) over the course of the &#8220;R&amp;D
      Spend Measurement Period&#8221; (the period commencing on October 26, 2006 and ending
      three years following Steering Committee approval of the initial Statement
      of
      Work for calendar year 2007), during which we are to perform research (the
      amount so expended by Dyadic being referred to as the &#8220;Applicable R&amp;D
      Spend&#8221;). If we breach our R&amp;D Spending Obligation, in addition to certain
      royalty-free, non-exclusive licensing rights which would be granted to ABRD,
      we
      are obligated, at ABRD&#8217;s election, to either (x) issue additional shares of our
      common stock or (y) remit to ABRD a cash sum, in either instance having a dollar
      value equal to the amount by which $10.0 million exceeds the dollar value of
      the
      Applicable R&amp;D Spend, and if shares are used, they are valued at the greater
      of (x) $4.68 per share or (y) the closing selling price of the shares on the
      AMEX on the last trading day in the R&amp;D Spend Measurement Period.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      within
      180 days following November 8, 2006 (the closing date of the transactions
      contemplated by the ABRD Securities Purchase Agreement and the R&amp;D
      Agreement), we have completed a specified type of transaction involving the
      sale
      of our common stock (or convertible securities other than warrants or options)
      at a price lower than $4.68 per share, ABRD is entitled to have additional
      shares issued to them so that its investment is at the same price. If within
      180
      days following November 8, 2006 we have not completed a specified type of
      transaction involving the sale of our common stock totaling at least $20 million
      in gross proceeds, then ABRD is entitled to receive three-year warrants to
      purchase up to 427,351 shares of our common stock at an exercise price of $5.85
      per share. If within 180 days following November 8, 2006 we have completed
      a
      specified type of transaction involving the sale of our common stock or
      convertible securities (other than warrants) totaling at least $20 million
      in
      gross proceeds in which, in addition to our issuance of common stock, we issue
      warrants, then ABRD is entitled to receive, in lieu of the three-year warrants,
      warrants having terms and conditions identical to the terms and conditions
      of
      the warrants issued in such specified transaction and for which ABRD would
      receive pro rata warrant coverage.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2">The
      shares issued to ABRD on November 8, 2006 were not
      registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)
      or any state securities laws. Pursuant to the ABRD Securities Purchase
      Agreement, we agreed to file a registration statement with the Securities and
      Exchange Commission (&#8220;SEC&#8221;) covering the resale of the shares issued on November
      8, 2006, as well as additional shares, if any, issuable after November 8, 2006.
      We agreed to file the registration statement of which this prospectus is a
      part
      with the SEC by December 23, 2006 and cause it to become effective with the
      SEC
      within 210 days following November 8, 2006. We are required to keep the
      registration statement of which this prospectus is a part effective until the
      earlier of the date on which the shares have been sold or can be sold
</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">publicly
      under Rule 144(k) of the Securities Act. We may suspend the use of the
      registration statement of which this prospectus is a part for a 20-day trading
      period for as many as two times in any 12-month period. In certain events,
      including in the event the registration statement of which this prospectus
      is a
      part does not become effective timely or ceases to be effective during the
      registration period due to certain events, we have agreed to pay to ABRD cash,
      as liquidated damages, on such event and on each monthly anniversary of such
      event, an amount equal to 1% of (x) the number of shares held by ABRD at time
      of
      such event multiplied by (y) the purchase price paid by ABRD for such shares
      then held, provided that the total amount of all of these payments is not
      permitted to exceed 10% of the aggregate purchase price paid by ABRD.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      ABRD Securities Purchase Agreement, ABRD has agreed for a period of one year
      following November 8, 2006 to maintain exclusive beneficial ownership of, as
      well as an exclusive pecuniary interest in, all of the shares and other
      securities, if any, issuable to it pursuant to the ABRD Securities Purchase
      Agreement. Furthermore, ABRD has agreed for a period of two years following
      November 8, 2006 to refrain from directly or indirectly increasing its
      beneficial ownership, or pecuniary interest, to more than 15% of our
      shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      foregoing description of the ABRD Securities Purchase Agreement and the R&amp;D
      Agreement is qualified in its entirety by reference to our Current Report on
      Form 8-K dated October 26, 2006, as filed with the SEC on November 1,
      2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      November 17, 2006, we entered into a securities purchase agreement (the
&#8220;Securities Purchase Agreement&#8221;) with certain investors to purchase in a private
      placement 2,787,000 shares of our common stock at a price of $4.68 per share
      and
      warrants to purchase up to 557,400 shares of our common stock at an exercise
      price of $6.33 per share for gross proceeds of $13,043,160. We completed this
      private placement on December 1, 2006. Cowen and Company, LLC acted as the
      exclusive placement agent for the private placement for which we issued to
      it
      warrants to purchase up to 83,610 shares of our common stock at $5.24 per share
      and warrants to purchase up to 16,722 shares of our common stock at $6.33 per
      share. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      warrants issued to the investors become exercisable on May 31, 2007, expire
      three years thereafter, contain price adjustment and economic anti-dilution
      features, as well as anti-dilution protection from stock splits and similar
      events, contain limited cashless exercise procedures and are callable by us
      under certain circumstances. The warrants issued to the placement agent are
      substantially identical to the warrants issued to the investors, except that
      (i)
      the warrant for 83,610 shares has an exercise price of $5.24 per share rather
      than $6.33 per share and (ii) they have a five-year term rather than a
      three-year term and (iii) they provide for unqualified cashless exercise
      procedures rather than limited cashless exercise procedures. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      use the resulting net proceeds of approximately $12,300,000 to continue
      development of our C1 Host Technology for applications in the markets targeted
      by our businesses, with the goal of strengthening our product pipeline and
      accelerating the commercial launch of new products in pulp and paper, animal
      feed and other areas, and expanding R&amp;D infrastructure as well as sales and
      marketing efforts. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        securities issuable to the investors at the closing of the private placement
        were not be registered under the Securities Act or any state securities laws.
        Pursuant to the Securities Purchase Agreement, we have agreed to file a
        registration statement with the SEC covering the resale of the shares issued
        to
        the investors at closing and the shares of common stock underlying the warrants
        issued to the investors at closing. We agreed to file the registration statement
        of which this prospectus is a part with the SEC within 45 days following
        December 1, 2006 and cause it to become effective with the SEC within 135
        days
        following December 1, 2006. We are required to keep the registration statement
        of which this prospectus is a part effective until the earlier of the date
        on
        which the shares have been sold or can be sold publicly under Rule 144(k)
        of the
        Securities Act. We may suspend the use of the registration statement for
        a
        20-day trading period for as many as two times in any 12-month period. In
        certain events, including in the event the registration statement of which
        this
        prospectus is a part does not become effective timely or ceases to be effective
        during the registration period due to certain events, we have agreed to pay
        each
        investor cash, as liquidated damages, on such event and on each monthly
        anniversary of such event, an amount equal to 1% of (x) the number of shares
        held by such investor at time of such event multiplied by (y) the purchase
        price
        paid by such investor for such shares then held, provided that the total
        amount
        of all of these payments is not permitted to exceed 10% of the aggregate
        purchase price paid by all investors. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        foregoing description of the Securities Purchase Agreement and the private
        placement and the other transactions contemplated thereby is qualified in
        its
        entirety by reference to our Current Report on Form 8-K dated November 17,
        2006,
        as filed with the SEC on November 21, 2006.</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RISK
      FACTORS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>In
      addition to the other information contained and incorporated by reference in
      this prospectus, you should carefully consider the following factors before
      purchasing any of the common stock offered under this
      prospectus.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Ge</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>neral
      to Our Businesses</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      should be viewed as an early-stage company.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      combination of our Enzyme Business&#8217;s reliance upon the expansion of the
      capabilities of our C1 Expression System and the early-stage, developmental
      nature of our BioSciences Business and our Biorefineries Products require that
      we be characterized as an early-stage company. Our conduct of the BioSciences
      Business and our commercialization of Biorefinery Products are subject to the
      risks customarily attending the operations of any early-stage company, including
      the development of new technologies and products, the assembly and development
      of production and R&amp;D capabilities, the construction of channels of
      distribution and the management of growth, as discussed in the following risk
      factors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have a history of net losses, and may not achieve or maintain
      profitability.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      an accumulated deficit of approximately $41.7 million at September 30, 2006.
      Because we accelerated our R&amp;D activities and expanded both our sales and
      marketing and technical support staffs, we have experienced increased levels
      of
      net losses and negative cash flow. Whether we achieve profitability, and the
      size of our net losses prior to that time, will depend, in large part, on the
      rate of growth, if any, of our Enzyme Business, whether our BioSciences Business
      is able to generate contract sales or other sales, whether we can commercialize
      Biorefinery Products and on the level of our expenses. To date, we have derived
      almost 100% of our sales from the operations of our Enzyme Business. We do
      not
      anticipate material sales from the operation of the BioSciences Business sooner
      than 2007 or later. Our Enzyme Business may not be able to penetrate new markets
      or enjoy the improved profit margins we anticipate, which could materially
      adversely impact that business&#8217;s growth potential and profitability. Sales from
      our BioSciences Business are uncertain because our ability to secure future
      collaboration agreements will depend upon the ability of the BioSciences
      Business to perfect our C1 Host Technology to address the needs of the
      pharmaceutical and biotech industries. Similarly, our ability to commercialize
      Biorefinery Products is uncertain. We expect to spend significant amounts to
      fund R&amp;D and enhance our core technologies. As a result, we expect that our
      operating expenses will increase significantly in the near term and,
      consequently, that we will need to generate significant additional sales to
      achieve profitability. Even if we do achieve profitability, we may not be able
      to sustain or increase profitability on a quarterly or annual
      basis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      could fail to manage our growth, which would impair our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      business plan contemplates that we will grow at a rapid rate, both in terms
      of
      sales and personnel. It is difficult to manage growth, and our future success
      depends on our ability to efficiently and effectively implement:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">research
                and product development programs which overcome scientific challenges
                and
                develop new products and processes;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales,
                marketing, technical service and customer support
                programs;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">operational
                and financial control systems; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recruiting
                and training programs.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      ability to offer products and services successfully and to implement our
      business plan in a rapidly evolving global market requires effective planning,
      reporting and management processes. We expect that we will need to continue
      to
      improve our financial and managerial controls, reporting systems and procedures
      and to expand and train our workforce worldwide. We also need to continue to
      manufacture our products efficiently and to control or </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">adjust
      the expenses related to R&amp;D, marketing, sales and general and administrative
      activities in response to changes in sales. If we are not successful in
      efficiently manufacturing our products or managing such expenses, there could
      be
      an adverse impact on our results of operations, our financial condition and
      the
      continued viability of our business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to Our Enzyme Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      market share growth depends on costly new product introductions and market
      acceptance.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      future success of our Enzyme Business will depend greatly on our ability to
      continuously and timely develop and introduce new products that address evolving
      market requirements and are attractive to customers. We are relying on our
      C1
      Expression System and our other proprietary technologies to expand our Enzyme
      Business product line and improve our gross margins on those products. If we
      fail to introduce new and innovative products, we could fail to obtain an
      adequate return on our R&amp;D investments and could lose market share to our
      competitors, which might be difficult or impossible to regain. Any inability,
      for technological or other reasons, to develop successfully and introduce new
      products could reduce our growth rate or otherwise damage our
      business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      in the past we have experienced, and we are likely in the future to experience,
      delays in the development and introduction of products. For example, our efforts
      to complete the development of a high throughput system using our C1 organism
      have taken considerably longer, cost more and have proven to be much more
      difficult than we had anticipated, forcing us to sharply scale back our
      continued development efforts and seek a new collaborative partner. We may
      not
      be able to keep pace with the rapid rate of change in our markets or to develop
      new products or processes that will meet the requirements of the marketplace
      or
      achieve market acceptance. Some of the factors affecting market acceptance
      of
      our products include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">availability,
                quality, performance and price as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                functionality of new and existing
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing of introduction of our products as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">scientists&#8217;
                and customers&#8217; opinions of our products&#8217; utility and our ability to
                incorporate their feedback into our future products;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">citation
                of the products in published
                research.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      expenses or losses associated with unsuccessful product development activities
      or lack of market acceptance of our new products could seriously harm our
      business, financial condition and results of operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      dependence on contract manufacturers could harm our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      Enzyme Business currently relies on contract manufacturers for all of its
      manufacturing. If we require additional manufacturing capacity and are unable
      to
      obtain it in sufficient quantity, we may not be able to increase our sales,
      or
      may be required to make very substantial capital investments to build that
      capacity.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      manufacturing capabilities, and any current or future arrangements with third
      parties for these activities, may not be adequate for the successful
      commercialization of our industrial enzyme products. In the operation of the
      Enzyme Business, all of our industrial enzymes have over the past decade, and
      are expected over the foreseeable future to be, produced at the manufacturing
      facilities of contract manufacturers. As a result, we are dependent upon the
      performance and plant capacity of third-party manufacturers. Though we formerly
      used two contract manufacturers, we let our agreement with one of those contract
      manufacturers expire and now only use it on a highly limited basis. Our Enzyme
      Business, therefore, faces risks of difficulties with, and interruptions in,
      performance by these third parties of their manufacturing responsibilities,
      the
      occurrence of which could adversely impact the availability, launch and/or
      sales
      of our products in the future. For example, our principal contract manufacturer,
      Polfa Tarchomin, S.A., which has been producing a number of our products since
      2001 without interruption has concluded an agreement with us to provide an
      additional 50 cubic meters of fermentation capacity and associated recovery
      capacity with the majority of the capital necessary for this expansion to be
      provided by them. This expansion has been substantially completed. Dyadic has
      committed to direct payment for certain removable equipment for this expansion
      of approximately $1.0 million.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">However,
      with the expiration of our contract manufacturing agreement with our second,
      and
      only other, contract manufacturer, we are currently utilizing their services
      on
      an as needed basis. The majority of our production requirements will be
      satisfied by the single manufacturing facility operated by our Polish contract
      manufacturer, leaving us vulnerable to a failure of performance by it.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Regulations
      may limit or impair our ability to sell genetically engineered products in
      the
      future.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      develop enzyme products using both non-genetically engineered
      microorganisms,&#160;as well as those that have undergone some degree
      of&#160;genetic modification.&#160;&#160;Products derived from genetically
      modified organisms, or GMOs, are subject to regulation by&#160;federal, state,
      local and foreign government agencies.&#160;These agencies administering
      existing or future applicable regulation or legislation may not allow&#160;us to
      produce and market&#160;our products derived from GMOs in a timely manner or
      under technically or commercially feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, regulatory action or private litigation could result in expenses,
      delays or other impediments to&#160;our product development programs or the
      commercialization of resulting products.&#160; The U.S. Food and Drug
      Administration, or FDA, currently applies the same regulatory standards to
      products made through genetic engineering as those applied to products developed
      through traditional methodologies.&#160;Depending on&#160;a product's
      application and regardless of its GMO status, it may be subject to lengthy
      FDA
      reviews and unfavorable FDA determinations if there are safety concerns or
      if
      the FDA changes its current regulatory&#160;policy.&#160; The European Union, or
      the EU, has regulations regarding the development, production and marketing
      of
      products from GMOs&#160;which are generally&#160;more restrictive than present
      U.S. regulations.&#160; For example, among other requirements, EU animal feed
      registration requires in-vivo&#160;efficacy testing, as well as toxicological
      testing of all enzyme products, including products from non-GMO
      microorganisms.&#160; The regulatory agencies administering these and future
      regulations may hinder our ability to produce and bring to&#160;market some of
      our enzyme products in a timely manner or under technically or commercially
      feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to Our BioSciences Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may fail to commercialize our C1 Expression System for the expression of
      therapeutic proteins. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      our Enzyme Business has developed and sold industrial enzyme products and has
      used our C1 Expression System to develop such products, our BioSciences Business
      has not yet completed commercialization of our C1 Expression System for the
      expression of therapeutic proteins. If our BioSciences Business fails to do
      this, we may be forced to terminate the BioSciences Business&#8217;s operations and
      liquidate it.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      BioSciences Business must be evaluated as having the same risks as those
      inherent in early-stage biotechnology companies because the application of
      our
      C1 Expression System to the expression of pre-clinical and clinical quantities
      of therapeutic proteins is still in development. We may not be able to
      successfully harness the C1 Expression System to achieve those objectives.
      Further, we may not be able to expand the capabilities of the C1 Expression
      System to produce commercial volumes of therapeutic proteins at reasonable
      costs. Also, we may not ever be able to successfully complete development of
      our
      fungal high throughput system. And, even if the BioSciences Business is able
      to
      achieve any of those accomplishments, we may not be able to successfully develop
      the C1 Screening System to serve the functions of gene discovery or the
      development of new and/or improved protein drugs. Successful development of
      the
      C1 Host Technology for these purposes will require significant development
      and
      investment, including testing, to prove its efficacy and cost-effectiveness.
      To
      date, drug companies have developed and commercialized only a small number
      of
      gene-based products in comparison to the total number of drug molecules
      available in the marketplace. In this regard, we are heavily dependent upon
      our
      use of third-party research organizations to assist us in the development of
      the
      C1 Host Technology. In general, our experience has been that each step in the
      process has taken longer and cost more to accomplish then we had originally
      projected, and we anticipate that this is likely to remain the case with respect
      to our BioSciences Business&#8217; continuing development efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
        of our C1 Expression System for therapeutic proteins depends on
        collaborations.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercialization
        of our C1 Expression System by our BioSciences Business depends on
        collaborations with other parties. If we are not able to find collaborators
        in
        the future, the BioSciences Business may not be able to develop the C1
        Expression System or therapeutic protein products. Further, our business
        model
        relies on a revenue stream derived from collaboration projects to be conducted
        with our customers to express laboratory-testing quantities of therapeutic
        proteins. A large portion of the anticipated financial reward depends on
        those
        therapeutic proteins progressing through drug development and into commercially
        successful drugs. Apart from risks relating to whether our BioSciences Business
        can capture such customers, or capture them on satisfactory terms, we will
        have
        no control over post-collaboration project drug development and
        commercialization. Further, conflicts could arise between us and our customers
        or among them and third parties that could discourage or impede the activities
        of our BioSciences Business.</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      we
      do not currently possess the financial resources necessary to develop and
      commercialize potential drug products that may result from our C1 Expression
      System, or the resources to complete any approval processes which may be
      required for these products, we must enter into collaborative arrangements
      to
      develop and commercialize drug products. It is expected that these arrangements
      will be for fixed terms and will expire after a fixed period of time. If they
      are not renewed or if we do not enter into new collaborative agreements, our
      sales will be reduced and our products may not be commercialized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have limited or no control over the resources that any collaborator may devote
      to our programs.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      limited or no control over the resources that any collaborator may devote to
      our
      products. Any of our future collaborators may not perform their obligations
      as
      expected. These collaborators may breach or terminate their agreement with
      us or
      otherwise fail to conduct their collaborative activities successfully and in
      a
      timely manner. Further, our collaborators may elect not to develop products
      arising out of our collaborative arrangements or devote sufficient resources
      to
      the development, manufacture, market or sale of these products. If any of these
      events occur, we may not be able to develop our technologies or commercialize
      our products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Potential
      therapeutic products developed by us or with our customers or collaborators
      are
      subject to a lengthy and uncertain regulatory process. If these therapeutic
      protein products are not approved, we or our customers or collaborators will
      not
      be able to commercialize them, and we may not receive the milestone and royalty
      payments which are based upon the successful advancement of these products
      through the drug development and approval process.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      FDA
      must approve any therapeutic product before it can be marketed in the United
      States. Before our collaborators can file a new drug application or biologic
      license application with the FDA, the product candidate must undergo extensive
      testing, including animal and human clinical trials, which can take many years
      and require substantial expenditures. Data obtained from such testing are
      susceptible to varying interpretations which could delay, limit or prevent
      regulatory approval. In addition, changes in regulatory policy for product
      approval during the period of product development and regulatory agency review
      of each submitted new application or product license application may cause
      delays or rejections.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      these products involve the application of new technologies and may be based
      upon
      new therapeutic approaches, they may be subject to substantial review by
      government regulatory authorities and, government regulatory authorities may
      grant regulatory approvals more slowly for these products than for products
      using more conventional technologies. While we anticipate that most of our
      collaborators will have experience submitting an application to the FDA or
      any
      other regulatory authority, we have no such experience, and neither we nor
      any
      collaborator has yet submitted an application with the FDA or any other
      regulatory authority for any product candidate generated through the use of
      our
      C1 Expression System, nor has the FDA nor any other regulatory authority
      approved any therapeutic product candidate developed using our C1 Expression
      System for commercialization in the United States or elsewhere. Our
      collaborators may not be able to conduct clinical testing or obtain the
      necessary approvals from the FDA or other regulatory authorities for our
      products. The regulatory agencies of foreign governments must also approve
      our
      therapeutic products before the products can be sold in those other
      countries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2">Even
      after investing significant time and expenditures,
      our collaborators may not obtain regulatory approval for their products. Even
      if
      they receive regulatory approval, this approval may entail limitations on the
      indicated uses for which we can market a product. Further, once regulatory
      approval is obtained, a marketed product and its manufacturer are subject to
      continual review, and discovery of previously unknown problems with a product
      or
      manufacturer may result in restrictions on the product, manufacturer and
      manufacturing facility, including withdrawal of the product from the market.
      In
      certain countries, regulatory agencies also set or approve prices. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Health
        care reform may limit our profitability or that of our
        customers.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        C1
        Host Technology is being developed to assist our customers or collaborators
        in
        the development of future therapeutic products, including pharmaceutical
        products. The ability of our collaborators to commercialize pharmaceutical
        products developed with our C1 Host Technology may depend in part on the
        extent
        to which reimbursement for the cost of those products will be available from
        government health administration authorities, private health insurers and
        other
        organizations. Third-party payers are increasingly challenging prices of
        medical
        products and services. Significant uncertainty exists as to the reimbursement
        status of newly approved health care products, and there can be no assurance
        that adequate third party coverage will be available for any product to enable
        us to maintain price levels sufficient to realize an appropriate return on
        our
        investment in research and product development. </font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Adverse
      events in the field of therapeutic products may adversely affect us or our
      collaborators.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
      we are not engaged in developing therapeutic products for our own account,
      but
      instead intend to collaborate with drug companies to express therapeutic
      products requested by them for the ultimate purpose of their development,
      testing and introduction as new drugs. We may, however, engage in these
      activities in the future for our own account. If we or our collaborators develop
      therapeutic products, these products may encounter substantial delays in
      development and approval due to the government regulation and approval process.
      Adverse events reported in gene therapy clinical trials may lead to more
      government scrutiny of proposed clinical trials of therapeutic products,
      stricter labeling requirements for these products and delays in the approval
      of
      other types of products for commercial sale.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      Expression System has been tested for use in pulp and paper production, which
      requires FDA approval as generally regarded as safe, or GRAS, and has generated
      promising safety and toxicity data for one enzyme. A risk nonetheless exists
      that the C1 Expression System will produce therapeutic products and enzymes
      that
      have safety and toxicity issues associated with them.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe our determination of the genome sequence of our C1 host organism could
      help to mitigate our risk that there are unexpected safety and toxicity issues
      associated with our C1 Expression System and facilitate our ability to find
      and
      express new genes of bio-therapeutic and other commercial value. However, there
      can be no assurance that annotation of the C1 will be fully or adequately
      completed, and until it is successfully completed, we are at a distinct
      competitive disadvantage to some of our competitors, whose host organisms have
      been more thoroughly researched and whose genomes have been fully annotated.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Applicable to the Commercialization of Biorefinery Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commerc</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ialization
      of Biorefinery Products depends on collaborative
      partnerships.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      we do not have the manufacturing infrastructure and financial resources to
      develop large scale-enzyme production and manufacturing processes for the
      commercialization of our Biorefinery Products, our ability to commercialize
      our
      Biorefinery Products will depend on our entering into collaborative partnerships
      like our recent one with Abengoa Bioenergy R&amp;D, Inc. We are considering
      additional collaborative partnerships, though there is no assurance that we
      will
      able to complete any additional ones on terms acceptable to us or at all.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      of Cellulosic Ethanol may not be feasible. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      cellulosic ethanol should reduce the United States' dependence on imported
      oil,
      increase its energy security and reduce its trade deficit, commercialization
      of
      cellulosic ethanol in the United States or elsewhere may not be feasible for
      a
      variety of reasons.&#160; Among others, there has been to date a lack of
      significant private and government funding for research and development in
      conversion and processing technologies, as well as for the <font size="2">development of biorefineries. Furthermore, there has been to
      date very
      little, if any, well directed public policies emphasizing investment and
      providing incentives for the commercialization and transition to cellulosic
      ethanol. The current United States Presidential administration has recently
      been
      publicizing the benefits of cellulosic ethanol, though it remains to be seen
      whether or not such publicity will engender significant government funding
      and
      economic incentives to mitigate some of the foregoing barriers to
      commercialization of cellulosic ethanol.&#160; Our recent collaborative
      partnership with Abengoa Bioenergy R&amp;D, Inc. may suggest that these barriers
      are surmountable, although there are no assurances in this regard.
</font></font>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br></font>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
          United States Ethanol Industry is highly dependent upon a myriad of federal
          and
          state legislation and regulations and any changes in such legislation or
          regulation could materially and adversely affect the demand for our Biorefinery
          Products. </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          United States Ethanol Industry is highly dependent upon a myriad of federal
          and
          state legislation and regulations. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
          changes in such legislation or regulation could materially and adversely
          affect
          the demand for our Biorefinery Products. For example, under the Energy
          Policy
          Act of 2005, the U.S. Department of Energy, in consultation with the U.S.
          Secretary of Agriculture and the U.S. Secretary of Energy, may waive the
          Renewable Fuels Standard, or RFS, mandate with respect to one or more states
          if
          the Administrator determines that implementing the requirements would severely
          harm the economy or the environment of a state, a region or the United
          States,
          or that <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">there
          is
          inadequate supply to meet the requirement. In addition, the Department
          of Energy
          was directed under the Energy Policy Act of 2005 to conduct a study by
          January
          2006 to determine if the RFS will have a severe adverse impact on consumers
          in
          2006 on a national, regional or state basis. Based on the results of the
          study,
          the Secretary of Energy must make a recommendation to the EPA as to whether
          the
          RFS should be waived for 2006. Any waiver of the RFS with respect to one
          or more
          states or with respect to 2006 would adversely offset demand for ethanol
          and,
          thus, diminish demand for Biorefinery Products.</font></font></div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Applic</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>able
      to Our Enzyme Business, BioSciences Business and Biorefinery
      Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alternative
      technologies may diminish the need for producing some enzymes the way we
      do.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many
      of
      our enzyme products are produced in fermenters. Some of the product segments
      we
      hope to serve may not find it efficient to use the fermenter processes we
      employ. For example, bio-ethanol and other bio-fuels production represents
      a
      considerable market opportunity for enzymes comprising Biorefinery Products.
      However, research being conducted within the auspices of major seed producers,
      U.S. federal government and corn growers association may supplant the need
      for
      enzymes produced in fermenters, which is the enzyme production process we
      currently use.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Reductions
      in R&amp;D budgets may affect the sales of our Businesses.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      customers include researchers at customers of our Enzyme Business, potential
      drug company customers of our BioSciences Business and potential energy
      companies for our Biorefinery Products. Fluctuations in the R&amp;D budgets of
      these researchers and their organizations could have a significant effect on
      the
      demand for our products. Research and development budgets fluctuate due to
      changes in available resources, consolidation in the pharmaceutical and energy
      industries, spending priorities and institutional budgetary policies. Our
      Businesses could be seriously damaged by any significant decrease in life
      sciences and/or renewable fuels R&amp;D expenditures by these existing and
      potential customers, academic institutions, government laboratories or private
      foundations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Conflicts
      with our collaborators could harm our business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      important part of our strategy involves conducting proprietary research
      programs. We may pursue opportunities in fields that could conflict with those
      of our collaborators. Moreover, disagreements with our collaborators could
      develop over rights to our intellectual property. Any conflict with our
      collaborators could reduce our ability to obtain future collaboration agreements
      and negatively impact our relationship with existing collaborators, which could
      reduce our sales.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      of our collaborators could also become competitors in the future. Our
      collaborators could develop competing products, preclude us from entering into
      collaborations with their competitors, fail to obtain timely regulatory
      approvals, terminate their agreements with us prematurely or fail to devote
      sufficient resources to the development and commercialization of products.
      Any
      of these developments could harm our product development efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        will
        either commercialize products resulting from our proprietary programs directly
        or through licensing to other companies. We have limited experience in
        manufacturing and marketing products for the pharmaceutical, biotechnology
        and
        energy industries. In order for us to commercialize these products directly,
        we
        would need to develop, or obtain through outsourcing arrangements, the
        capability to market and sell these products. We do not have these capabilities,
        and we may not be able to develop or otherwise obtain the requisite marketing
        and sales capabilities. If we are unable to successfully commercialize products
        resulting from our proprietary research efforts, we will continue to incur
        losses. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Public
          views on ethical and social issues may limit use of our technologies and
          reduce
          our sales.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          success will depend in part upon our ability to develop products discovered
          through our C1 Host Technology. Governmental authorities could, for social
          or
          other purposes, limit the use of genetic processes or prohibit the practice
          of
          our C1 Host Technology. Ethical and other concerns about our C1 Host Technology,
          particularly the use of genes from nature for commercial purposes, and
          products
          resulting there from, could adversely affect their market acceptance.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>If
            the public does not accept genetically engineered products, our product
            demand
            could decline.</strong></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            commercial success of our potential products will depend in part on public
            acceptance of the use of genetically engineered products including drugs,
            plants
            and plant products. Claims that genetically engineered products are unsafe
            for
            consumption or pose a danger to the environment may influence public
            attitudes.
            Our genetically engineered products may not gain public acceptance in
            the
            various industrial, pharmaceutical, biotechnology or energy industries.
            Negative
            public reaction to genetically modified organisms and products could
            result in
            greater government regulation of genetic research and resultant products,
            including stricter labeling laws or regulations, and could cause a decrease
            in
            the demand for our products.</font></div>
        </div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      subject of genetically modified organisms has received negative publicity in
      Europe and other countries, which has aroused public debate. The adverse
      publicity in Europe could lead to greater regulation and trade restrictions
      on
      imports of genetically altered products. If similar adverse public reaction
      occurs in the United States, genetic research and resultant products could
      be
      subject to greater domestic regulation and a decrease in the demand for our
      products could result.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
      Business Risks That We Face</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      must continually offer new products and technologies.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      industrial enzymes and biotechnology industries are characterized by rapid
      technological change, and the area of gene research is a rapidly evolving field.
      Our future success will depend on our ability to maintain a competitive position
      with respect to technological advances. Rapid technological development by
      others may result in our products and technologies becoming
      obsolete.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      products that we develop through our C1 Host Technology will compete in highly
      competitive markets. Many of the organizations competing with us in the markets
      for such products have greater capital resources, R&amp;D and marketing staffs
      and facilities and capabilities, and greater experience in obtaining regulatory
      approvals, manufacturing products and marketing. Accordingly, our competitors
      may be able to develop technologies and products more easily which would render
      our technologies and products and those of our collaborators obsolete and
      noncompetitive. If a competitor develops superior technology or cost-effective
      alternatives to our products or processes, our business, operating results
      and
      financial condition could be seriously harmed. In addition, demand for our
      products may weaken due to reduction in R&amp;D budgets or loss of distributors,
      any of which might have an adverse effect on our financial
      condition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      markets for our Enzyme Business&#8217;s products are, in many cases, very competitive
      and price sensitive. Our Enzyme Business currently competes with five much
      larger competitors, each with dominant market positions in segments in which
      we
      compete and who, as a group, hold approximately 70% market share in the present
      industrial enzymes marketplace. Each of these competitors has substantially
      greater financial, operational, sales and marketing <font size="2">resources than
      we do and very significant experience in R&amp;D. Further, these competitors may
      possess other complementary technologies, such as proprietary directed molecular
      evolution technology, which may be more effective at implementing their
      technologies to develop commercial products than our complementary technologies
      implement our C1 Host Technology. Also, some of these competitors have entered
      into collaborations with leading companies within our Enzyme Business&#8217;s target
      markets to produce enzymes for commercial purposes.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Well-known,
        and better financed, biotechnology companies offer competing technologies
        for
        the same products and services as our BioSciences Business plans to offer
        using
        our C1 Host Technology. Customers may prefer existing competing technologies
        over our C1 Host Technology. Our BioSciences Business also faces, and will
        continue to face, intense competition from organizations such as large
        biotechnology companies, as well as academic and research institutions and
        government agencies that are pursuing competing technologies to enable
        production of therapeutic and other proteins and bio-molecules of commercial
        interest at economically viable costs. These organizations may develop
        technologies that are superior alternatives to our C1 Host Technology. We
        anticipate that our BioSciences Business will face increased competition
        as new
        companies enter our markets and as development of biological products
        evolves.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
          may need additional capital in the future. </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          future capital requirements may be substantial, particularly as we continue
          to
          develop the C1 Host Technology to commercialize Biorefinery Products and
          if
          completion of the development of our C1 Expression System for our BioSciences
          Business takes longer or requires greater resources than we had expected,
          if we
          continue to develop the C1 Expression System to expand its production
          capabilities to manufacture commercial volumes of therapeutic proteins,
          if we
          continue to develop a C1 Screening System, or if our BioSciences Business
          develops a number of therapeutic products. Although we believe that we
          have
          sufficient cash on hand to fund our operations and meet our obligations
          through
          December 31, 2008, our need for additional capital will depend on many
          factors,
          including the financial success of our Enzyme Business, whether we are
          successful in obtaining payments from BioSciences Business customers under
          collaborative agreements, whether we are successful in our R&amp;D efforts with
          Abengoa Bioenergy R&amp;D, Inc., whether we can enter into additional
          collaborative partnerships for commercialization of our Biorefinery Products,
          the progress and scope of our collaborative and independent R&amp;D projects
          performed by our customers and collaboration partners, the effect of any
          acquisitions of other businesses that we may make in the future, and the
          filing,
          prosecution and enforcement of patent claims.</font></div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      our
      capital resources are insufficient to meet our capital requirements through
      December 31, 2008, we will have to raise additional funds to continue the
      development of our technologies and complete the commercialization of products,
      if any, resulting from our technologies. If future raises of funds do occur,
      they may cause dilution to our existing stockholders. We may not be able to
      raise additional funds on terms that are acceptable to us or on any terms
      whatsoever, or we may be unable to raise sufficient additional capital. If
      we
      fail to raise sufficient funds, and our Enzyme Business is unable to generate
      sufficient levels of profitability, we may have to curtail or cease, or dispose
      of, one or more of our operations. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      will need to expand our existing</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      marketing and sales resources.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
      we
      have recently expanded our marketing and sales functions, our Enzyme Business
      will need to continue to expand them to achieve our contemplated annual rates
      of
      growth and for our BioSciences Business to successfully market the C1 Expression
      System and our contemplated C1 Screening System. Currently, we rely primarily
      on
      our direct sales force for the United States market and contract with
      professional sales agents and distributors for the international market,
      including two controlled foreign subsidiaries. Direct salespeople are our
      employees and are paid a salary plus commissions on sales they make within
      their
      assigned territories. Contracted sales agents are paid a base rate of
      compensation plus commissions on sales they make within their assigned
      territories. Distributors purchase products from us and then resell our products
      and services to third parties. Our officers and employees develop and implement
      our marketing strategy, although we do periodically engage non-employee
      consultants, acting as independent contractors, to assist us in these
      efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Market
      forces, such as increasing competition, increasing cost pressures on our
      customers and general economic conditions, may require us to devote more
      resources to our sales and marketing efforts than we currently contemplate,
      such
      as changing the composition of our sales and marketing staff and changing our
      marketing methods. These changes may result in additional expenses. In addition,
      we will incur additional salary expenses because we intend to increase our
      direct sales force. We also may hire direct sales representatives to replace
      independent sales representatives or distributors that we use. Similarly, if
      we
      increase our reliance on marketing consultants to assist us, we will incur
      greater costs. If we decide to increase our advertising, we will also incur
      higher sales and marketing costs. Our incurrence of increased costs will make
      it
      more difficult for us to operate profitably, and we may not have sufficient
      funds to support all of these costs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      we
      expand our sales force and increase our marketing activities, we can offer
      no
      assurances that those efforts will result in more sales or higher revenue.
      Also,
      the increased costs we incur by expanding our sales and marketing resources
      may
      not result in greater sales or in higher revenue. Further, even if we increase
      our spending on sales and marketing, we may not be able to maintain our current
      level of sales and revenue. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Loss
      of key personnel could hurt our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      highly dependent on the principal members of our management and scientific
      staff, the loss of whose services might adversely impact the achievement of
      our
      objectives. In addition, recruiting and retaining qualified scientific personnel
      to perform future R&amp;D work will be critical to our success. We currently do
      not have sufficient executive management personnel to fully execute our business
      plan. Although we believe we will be successful in attracting and retaining
      qualified management and scientific personnel, such as the addition of our
      Chief
      Scientific Officer, Glenn Nedwin in March 2006, competition for experienced
      scientists from numerous companies and academic and other research institutions
      may limit our ability to do so on acceptable terms. Failure to attract and
      retain scientific personnel would prevent us from pursuing collaborations or
      developing our products or core technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      planned activities will require additional expertise in specific industries
      and
      areas applicable to the products developed through our technologies. These
      activities will require the addition of new personnel, including management,
      and
      the development of additional expertise by existing management personnel. The
      inability to acquire these services or to develop this expertise could impair
      the growth, if any, of our business. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      directors and senior officers require that we maintain directors and officers
      insurance at levels comparable to those of similar sized public companies.
      We
      have purchased such directors&#8217; and officers&#8217; liability insurance. Our efforts to
      recruit additional directors could be impeded if the amount of insurance
      coverage is viewed to be insufficient. Further, if we are unable to provide
      adequate compensation or are unable to maintain sufficient directors&#8217; and
      officers&#8217; insurance coverage, we may not be able to attract or retain key
      personnel.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personnel
      changes may disrupt our operations. Hiring and training new personnel will
      entail costs and may divert our resources and attention from revenue-generating
      efforts. From time to time, we also engage consultants to assist us in our
      business and operations. These consultants serve as independent contractors,
      and
      we, therefore, do not have as much control over their activities as we do over
      the activities of our employees. Our consultants may be affiliated with or
      employed by other parties, and some may have consulting or other advisory
      arrangements with other entities that may conflict or compete with their
      obligations to us. Inventions or processes discovered by these persons will
      not
      necessarily become our property. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inability
      to protect our technologies could harm our ability to compete.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      success will depend in part on our ability to obtain patents and maintain
      adequate protection of our other intellectual property for our technologies
      and
      products in the United States and other countries. If we do not adequately
      protect our intellectual property, competitors may be able to practice our
      technologies and erode our competitive advantage. The laws of some foreign
      countries do not protect proprietary rights to the same extent as the laws
      of
      the United States, and many companies have encountered significant problems
      in
      protecting their proprietary rights in these foreign countries. These problems
      can be caused by, for example, a lack of rules and methods for defending
      intellectual property rights.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      hold
      four issued U.S. patents and 27 issued and 2 allowed international patents,
      including claims that cover the C1 Expression System and various other aspects
      of the C1 Host Technology, and 50 U.S. and international filed and pending
      patent applications which we believe provide broad protection for our C1
      Expression System, our underlying C1 Host Technology and C1 Screening System
      and
      their products and commercial applications. However, the patent positions of
      biotechnology companies, including our patent position, are generally uncertain
      and involve complex legal and factual questions. We will be able to protect
      our
      proprietary rights from unauthorized use by third parties only to the extent
      that our proprietary technologies are covered by valid and enforceable patents
      or are effectively maintained as trade secrets. We intend to apply for patents
      covering both our technologies and products as we deem appropriate. However,
      existing and future patent applications may be challenged and may not result
      in
      issued patents. Our existing patents and any future patents we obtain may not
      be
      sufficiently broad to prevent others from practicing our technologies or from
      developing competing products. Furthermore, others may independently develop
      similar or alternative technologies or design around our patented technologies.
      In addition, others may challenge or invalidate our patents, or our patents
      may
      fail to provide us with any competitive advantages.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
      all
      of our proprietary technology is eligible for patent protection. Accordingly,
      as
      to significant portions of our various proprietary technologies, we rely upon
      trade secret protection for our confidential and proprietary information. We
      have taken security measures to protect our proprietary information. These
      measures may not provide adequate protection for our trade secrets or other
      proprietary information. We seek to protect our proprietary information by
      entering into confidentiality agreements with employees, collaborators and
      consultants. Nevertheless, employees, collaborators or consultants may still
      disclose our proprietary information, and we may not be able to meaningfully
      protect our trade secrets. In addition, others may independently develop
      substantially equivalent proprietary information or techniques or otherwise
      gain
      access to our trade secrets. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Intellectual
      property litigation could harm our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      commercial success depends in part on neither infringing patents and proprietary
      rights of third parties, nor breaching any licenses that we have entered into
      with regard to our technologies and products. Others have filed, and in the
      future are likely to file, patent applications covering genes or gene fragments
      that we may wish to utilize with our C1 Host Technology, our C1 Expression
      System, our C1 Screening System or products or systems that are similar to
      products developed with the use of our C1 Host Technology. If these patent
      applications result in issued patents and we wish to use the claimed technology,
      we would need to obtain a license from the third party. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
      parties may assert that we are employing their proprietary technology without
      authorization. In addition, third parties may obtain patents in the future
      and
      claim that use of our technologies infringes these patents. We could incur
      substantial costs and diversion of management and technical personnel in
      defending ourselves against any of these claims or enforcing our patents or
      other intellectual property rights against others. Furthermore, parties making
      claims against us may be able to obtain injunctive or other equitable relief
      which could effectively block our ability to further develop, commercialize
      and
      sell products, and could result in the award of substantial damages against
      us.
      If a claim of infringement against us is successful, we may be required to
      pay
      damages and obtain one or more licenses from third parties. We may not be able
      to obtain these licenses at a reasonable cost, if at all. In that event, we
      could encounter delays in product commercialization while we attempt to develop
      alternative methods or products. Defense of any lawsuit or failure to obtain
      any
      of these licenses could prevent us from commercializing available
      products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      the taxonomic classification of our C1 host organism was determined using
      classical morphological methods. More modern taxonomic classification methods
      indicate that our C1 host organism will be reclassified as a different genus
      and
      species. We anticipate that with the genomic sequence and after the expected
      completion of the annotation of the C1 genome, we will be better positioned
      to
      determine the genus and species of the C1 Host organism. Some of the possible
      species that the C1 host could be reclassified as could be the subject of patent
      rights owned by others. We believe, based on our evaluation of the relevant
      field of science and our discussions with our consulting professionals, that
      any
      such patent rights would be invalid, and were litigation over the issue to
      ensue, we believe we should prevail. If we did not prevail, to settle any such
      litigation or pre-litigation claims, we could be required to enter into a
      cross-licensing arrangement, pay royalties or be forced to stop
      commercialization of some of our activities. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      do not
      fully monitor the public disclosures of other companies operating in our
      industry regarding their technological development efforts. If we did evaluate
      the public disclosures of these companies in connection with their technological
      development efforts and determined that they violated our intellectual property
      or other rights, we would anticipate taking appropriate action, which could
      include litigation. However, any action we take could result in substantial
      costs and diversion of management and technical personnel. Furthermore, the
      outcome of any action we take to protect our rights may not be resolved in
      our
      favor or may not be resolved for a lengthy period of time. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may be sued for product liability. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      may be
      held liable if any product we develop, or any product which is made with the
      use
      or incorporation of, any of our technologies, causes injury or is found
      otherwise unsuitable during product testing, manufacturing, marketing or sale.
      These risks are inherent in the development of chemical, agricultural and
      pharmaceutical products. While we maintain product liability insurance, it
      may
      not fully cover our potential liabilities. Inability to obtain sufficient
      insurance coverage at an acceptable cost or otherwise to protect against
      potential product liability claims could prevent or inhibit the
      commercialization of products developed by us or our collaborators. If we are
      sued for any injury caused by our products, our liability could exceed our
      total
      assets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>International
      unrest or foreign currency fluctuations could adversely affect our
      results.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">International
      sales accounted for approximately 86% and 91% of our net sales in 2004 and
      2005,
      respectively, and accounted for a vast portion of our net sales for the
      nine-months ended September 30, 2006. Our key international markets are the
      European Union, Hong Kong, the Peoples Republic of China and India. Our
      international sales are made through international distributors and their wholly
      owned subsidiaries, including our Asian subsidiary, and direct to end-user
      plants with payments to us, in many cases, denominated in currencies other
      than
      U.S. dollars. In the conduct of our business, in a number of instances, we
      are
      required to pay our obligations in currencies other than U.S. dollars.
      Accordingly, we are exposed to changes in currency exchange rates with respect
      to our international sales and payment obligations. We incurred currency losses
      in 2004 of $213,471 and currency gains in 2005 of $16,785. For the nine-months
      ended September 30, 2006, we incurred currency losses of approximately $111,000
      as compared to currency gains of approximately $27,000 for the nine-months
      ended
      September 30, 2005. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fluctuations
      in currency exchange rates have in the past and may in the future negatively
      affect our ability to price competitively against products denominated in local
      currencies. Also, changes in foreign currency exchange rates may have an adverse
      effect on our financial position and results of operations as expressed in
      U.S.
      dollars. Our management monitors foreign currency exposures and may, in the
      ordinary course of business, enter into foreign currency forward contracts
      or
      options contracts related to specific foreign currency transactions or
      anticipated cash flows. We do not hedge, and have no current plans to hedge
      in
      the future, the translation of financial statements of consolidated subsidiaries
      whose local books and records are maintained in foreign currency. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      imposition of duties or other trade barriers, trade embargoes, acts of
      terrorism, wars and other events outside our control may adversely affect
      international commerce and impinge on our ability to manufacture, transport
      or
      sell our products in international markets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Business
      interruptions could keep us from developing our products and increasing our
      sales. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Natural
      or man-made disasters, such as fires, earthquakes, hurricanes, power losses,
      telecommunications failures, terrorist attacks, military operations and other
      events beyond our control may interrupt our operations. We do not have a
      detailed disaster recovery plan. In addition, we may not carry sufficient
      business interruption insurance to compensate us for losses that may occur
      and
      any losses or damages we incur could have a material adverse effect on our
      cash
      flows and success as an overall business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are dependent on several key customers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2005,
      there were two customers that accounted for approximately 10% each of net sales.
      In 2004, there were no customers that accounted for greater than 10% of net
      sales. There were three customers in 2005 whose trade receivable balances
      equaled or exceeded 5% of total receivables, representing approximately 16%,
      7%,
      and 6%, respectively, of total accounts receivable. During the nine-months
      ended
      September 30, 2006 there was one customer that accounted for approximately
      9.4%
      of net sales. During the nine-months ended September 30, 2005, there were two
      customers that accounted for approximately 10.3% and 9.4%, respectively, of
      net
      sales. There were two customers as of September 30, 2006, whose trade receivable
      balances equaled or exceeded 5% of total receivables, representing approximately
      15.3% and 6.8%, respectively, of total accounts receivable. The loss of business
      from one or a combination of our significant customers and/or the failure to
      collect the accounts receivable attributable to one or more of our significant
      customers could adversely affect our business, results of operations and
      financial condition. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Related to Our Common Stock</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
      of Biotechnology companies are often volatile. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      trading prices of biotechnology company stocks in general tend to experience
      extreme price fluctuations. The valuations of many biotechnology companies
      without consistent product sales and earnings are extraordinarily high based
      on
      conventional valuation standards such as price to earnings and price to sales
      ratios. These trading prices and valuations may not be sustained. Any negative
      change in the public&#8217;s perception of the prospects of biotechnology companies
      could depress our stock price regardless of our results of operations. Other
      broad market and industry factors may decrease the trading price of our common
      stock, regardless of our performance. Market fluctuations, as well as general
      political and economic conditions such as war, recession or interest rate or
      currency rate fluctuations, also may decrease the trading price of our common
      stock. In addition, our stock price could be subject to wide fluctuations in
      response to factors including, but not limited to, the following: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                of new technological innovations or new products by us or our competitors;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in financial estimates by securities analysts;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">conditions
                or trends in the biotechnology industry;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in the market valuations of other biotechnology companies;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in domestic and international governmental policy or regulations;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                by us or our competitors of significant acquisitions, strategic
                partnerships, joint ventures or capital commitments;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in patent or other proprietary rights held by us or by others;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">loss
                or expiration of our intellectual property rights;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">lawsuits
                initiated by or against us;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">period-to-period
                fluctuations in our operating results;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">future
                royalties from product sales, if any, by our strategic partners;
                and
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales
                of our common stock or other securities in the open market.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      past, stockholders have often instituted securities class action litigation
      after periods of volatility in the market price of a company&#8217;s securities. If a
      stockholder files a securities class action suit against us, we would incur
      substantial legal fees and our management&#8217;s attention and resources would be
      diverted from operating our business to respond to the litigation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      operating results and the market price of stock could be volatile.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      quarterly operating results have fluctuated in the past and are likely to do
      so
      in the future. These fluctuations could cause our stock price to fluctuate
      significantly or decline. Some of the factors which could cause our operating
      results to fluctuate include: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expiration
                of research contracts with collaborators, which may not be renewed
                or
                replaced; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                success rate of our discovery efforts leading to milestones and royalties;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing and willingness of collaborators to commercialize our products
                which would result in royalties; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">general
                and industry specific economic conditions, which may affect our
                collaborators&#8217; R&amp;D
                expenditures;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of our industrial enzymes and other products
                by
                customers of our Enzyme Business;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of our C1 Host Technology, C1 Expression
                System
                and C1 Screening System by biotechnology and pharmaceutical companies
                being marketed by our BioSciences
                Business;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                introduction by our competitors of new industrial enzyme products
                or lower
                prices of existing products to our Enzyme Business&#8217;s
                customers;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                addition or loss of one or more collaborative partners to commercialize
                our Biorefinery Products; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                introduction by our competitors of new expression technologies competitive
                with our C1 Expression System; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">disruption
                in our manufacturing capacity or our failure to bring on additional
                manufacturing capacity required to meet our projected
                growth.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      large
      portion of our expenses are relatively fixed, including expenses for facilities,
      equipment and personnel. Accordingly, if sales decline or do not grow as
      anticipated due to expiration of research contracts or government research
      grants, if any, failure to obtain new contracts or other factors, we may not
      be
      able to correspondingly reduce our operating expenses. Failure to achieve
      anticipated levels of sales could, therefore, significantly harm our operating
      results for a particular fiscal period. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
      to
      the possibility of fluctuations in our revenues and expenses, we believe that
      quarter-to-quarter comparisons of our operating results are not a good
      indication of our future performance. Our operating results in some quarters
      may
      not meet the expectations of stock market analysts and investors. In that case,
      our stock price would probably decline. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may not be able to maintain our American Stock Exchange listing
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      common stock has been listed on the American Stock Exchange since May 27,
      2005.&#160; There is no assurance that we will be able to satisfy the American
      Stock Exchange&#8217;s continued listing standards, which include, among others,
      minimum stockholders&#8217; equity, market capitalization, pre-tax income and per
      share sales price.&#160; If our common stock is de-listed from the American
      Stock Exchange, we would be forced to list our common stock on the OTC Bulletin
      Board or some other quotation medium, depending on our ability to meet the
      specific requirements of those quotation systems.&#160; Selling our common stock
      would be more difficult because smaller quantities of shares would likely be
      bought and sold and transactions could be delayed. These factors could result
      in
      lower prices and larger spreads in the bid and ask prices for shares of our
      common stock. If this happens, we will have greater difficulty accessing the
      capital markets to raise any additional necessary capital.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      do not expect to pay dividends in the future. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      never paid cash dividends on our stock and do not anticipate paying cash
      dividends on our stock in the foreseeable future. The payment of dividends
      on
      our shares, if ever, will depend on our earnings, financial condition and other
      business and economic factors affecting us at such time as the board of
      directors may consider relevant. If we do not pay dividends, our stock may
      be
      less valuable because a return on investment will only occur if and to the
      extent that our stock price appreciates, and if the price of our stock does
      not
      appreciate, then there will be no return on investment. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>17</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      anti-takeover defense provisions may deter potential acquirers and depress
      our
      stock price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      provisions of our certificate of incorporation, bylaws and Delaware law, as
      well
      as certain agreements we have with our executives, could be used by our
      incumbent management to make it substantially more difficult for a third party
      to acquire control of us. These provisions include the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                may issue preferred stock with rights senior to those of our common
                stock;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                have a classified Board of
                Directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">action
                by written consent by stockholders is not
                permitted;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
                Board of Directors has the exclusive right to fill vacancies and
                set the
                number of directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cumulative
                voting by our stockholders is not allowed;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                require advance notice for nomination of directors by our stockholders
                and
                for stockholder proposals.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
      provisions may discourage certain types of transactions involving an actual
      or
      potential change in control. These provisions may also limit our stockholders&#8217;
ability to approve transactions that they may deem to be in their best interests
      and discourage transactions in which our stockholders might otherwise receive
      a
      premium for their shares over the then current market price.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have controlling stockholders. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      officers, directors and principal stockholders together control approximately
      36.5% of our outstanding common stock as of December 12, 2006. Our founder
      and
      chief executive officer, Mark Emalfarb, through a trust of which he is the
      trustee and beneficiary, the Mark&#160;A. Emalfarb Trust, owns approximately 20%
      of our outstanding common stock as of December 12, 2006. Further, the Francisco
      Trust, whose beneficiaries are the spouse and descendants of Mark Emalfarb,
      owns
      approximately 16% of our outstanding common stock as of December 12, 2006,
      while
      friends and relatives of Mr. Emalfarb, who are not officers, directors, or
      principal stockholders, own approximately an additional 5% of our outstanding
      common stock as of December 12, 2006. As a result, these stockholders, if they
      act together, will be able to exert a significant degree of influence over
      our
      management and affairs and over matters requiring stockholder approval,
      including the election of directors and approval of significant corporate
      transactions. In addition, this concentration of ownership may delay or prevent
      a change in control of us and might affect the market price of our shares,
      even
      when a change may be in the best interests of all stockholders. Moreover, the
      interests of this concentration of ownership may not always coincide with our
      interests or the interests of other stockholders, and, accordingly, they could
      cause us to enter into transactions or agreements which we would not otherwise
      consider.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are indebted to our largest stockholders.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      September 30, 2006, we owed the Mark&#160;A. Emalfarb Trust indebtedness of
      approximately $2.4 million under a bridge loan. All of our assets are mortgaged
      or pledged to secure the bridge loan owed to the Mark&#160;A. Emalfarb Trust. If
      we were unable to generate sufficient cash flow or otherwise obtain funds
      necessary to pay this indebtedness when due, we would be in default, and this
      debt holder would have the right to foreclose on its liens and security
      interests that secure the defaulted debt. Further, not only is this indebtedness
      evidenced by a promissory note that is transferable by its holder, but we could
      decide to refinance this indebtedness through similar secured borrowings from
      banks or other commercial lenders. Any transferee or new lender, no longer
      constrained by the stockholder interests of the Mark&#160;A. Emalfarb Trust, may
      not have the same attitude about any failure on our part to meet our binding
      repayment obligations as the Mark&#160;A. Emalfarb Trust might.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are exposed to potential risks resulting from new requirements that we evaluate
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>financial
      reporting controls under Section 404 of the Sarbanes-Oxley Act of 2002.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      evaluating our internal controls in order to allow management to report on,
      and
      our independent registered public accounting firm to attest to, our internal
      controls over financial reporting, as required by Section 404 of the
      Sarbanes-Oxley Act of 2002. We may encounter unexpected delays in implementing
      the requirements relating to internal controls over financial reporting,
      therefore, we cannot be certain about the timing of completion of our
      evaluation, testing and remediation actions or the impact that these activities
      will have on our operations since there is no precedent available by which
      to
      measure the adequacy of our compliance. We also expect to incur additional
      </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>18</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expenses
      and diversion of management&#8217;s time as a result of performing the system and
      process evaluation, testing and remediation required in order to comply with
      the
      management certification and independent registered public accounting firm
      attestation requirements. If we are not able to timely comply with the
      requirements set forth in Section 404, we might be subject to sanctions or
      investigation by regulatory authorities. Any such action could adversely affect
      our business and financial results. The requirement to comply with Section
      404
      of the Sarbanes-Oxley Act of 2002 will become effective no earlier than for
      our
      fiscal year ending December 31, 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, in our system of internal controls we may rely on the internal
      controls of third parties. In our evaluation of our internal controls, we will
      consider the implication of our reliance on the internal controls of third
      parties. Until we have completed our evaluation, we are unable to determine
      the
      extent of our reliance on those controls, the extent and nature of the testing
      of those controls, and remediation actions necessary where that reliance cannot
      be adequately evaluated and tested. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Future
      sales of shares of our common stock may negatively affect our stock
      price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 12, 2006, there were 29,748,856 shares of our common stock outstanding.
      Approximately 36.5% of these shares are beneficially owned by our executive
      officers, directors and principal stockholders. Accordingly, our common stock
      has a relatively small public float. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      previously registered for resale a substantial number of shares of our common
      stock, including shares underlying warrants. Beginning October 29, 2006,
      virtually all the shares of our common stock not previously eligible for resale
      pursuant to Rule 144(k) of the Securities Act became eligible for resale under
      Rule 144(k). In addition, this prospectus covers the resale of 5,581,484 shares
      of our common stock, including shares underlying warrants. The selling
      stockholders named in this prospectus will be permitted, subject to few
      limitations, to freely resell these shares of common stock. As a result of
      our
      relatively small public float, sales of substantial amounts of shares of our
      common stock, or even the potential for such sales, may materially and adversely
      affect prevailing market prices for our common stock. In addition, any adverse
      effect on the market price of our common stock could make it difficult for
      us to
      raise additional capital through sales of equity securities at a time and at
      a
      price that we deem appropriate.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>19</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DISCLOSURE
      REGARDING FORWARD-LOOKING STATEMENTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      statements contained or incorporated by reference in this prospectus that are
      not historical facts are forward-looking. These statements are made pursuant
      to
      the safe harbor provisions of the Private Securities Litigation Reform Act
      of
      1995. Such statements include, without limitation, our expectations regarding
      sales, earnings or other future financial and operating performance and
      liquidity, conduct and completion of clinical trials, product introductions,
      entry into new geographic regions, and general optimism about future operations
      or operating results. Some of these statements can be identified by the use
      of
      forward-looking terminology such as &#8220;prospects,&#8221; &#8220;outlook,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;anticipates,&#8221; &#8220;expects&#8221; or
&#8220;plans,&#8221; or the negative or other variation of these or similar words, or by
      discussion of trends and conditions, strategy or risks and uncertainties.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
      forward-looking expectations are based on current assumptions within the bounds
      of management&#8217;s knowledge of our business and operations and which management
      believes are reasonable. These assumptions are subject to risks and
      uncertainties, and actual results could differ materially from expectations
      because of issues and uncertainties such as those listed under the caption
&#8220;Risk
      Factors&#8221; and elsewhere in this prospectus and in documents incorporated into
      this prospectus which, among others, should be considered in evaluating our
      future financial and operating performance. All subsequent written and oral
      forward-looking statements attributable to us or persons acting on our behalf
      are expressly qualified in their entirety by the cautionary statements in this
      prospectus. Readers are advised to consult any further disclosures we may make
      on related subjects in our subsequent reports filed with the SEC. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
      information on factors that may affect our business and financial and operating
      results can be found in our filings with the SEC. All forward-looking statements
      should be considered in light of these risks and uncertainties. We assume no
      responsibility to update forward-looking statements made in this prospectus.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>20</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>USE
      OF PROCEEDS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares of common stock being offered are solely for the accounts of the selling
      stockholders pursuant to their contractual registration rights. We will not
      receive any proceeds from the resale of the shares of the selling stockholders.
      However, we will receive the exercise price of the warrants when and if they
      are
      exercised to the extent so exercised for cash. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SELLING
      STOCKHOLDERS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares of common stock being offered by the selling stockholders are those
      issued to the selling stockholders in the private placements completed on
      November 8 and December 1, 2006 and those issuable to the selling stockholders
      upon exercise of the warrants issued in connection with the private placement
      completed on December 1, 2006. We are registering the shares of common stock
      in
      order to permit the selling stockholders to offer the shares for resale from
      time to time. Except for the ownership of the shares of common stock and the
      warrants, and except for Abengoa Bioenergy R&amp;D, Inc. with whom we have a
      collaborative partnership as described in this prospectus under &#8220;Summary
      Description of Our Business&#8212;Recent Developments,&#8221; none of the selling
      stockholders have had any position, office or other material relationship with
      us within the past three years. Under the terms of the securities purchase
      agreements we entered into with the selling stockholders in connection with
      the
      private placements, we have agreed to keep the registration statement of which
      this prospectus is a part effective until the earlier of the date on which
      the
      shares have been sold or can be sold publicly under Rule 144(k) of the
      Securities Act. We may suspend the use of the registration statement of which
      this prospectus is a part for a 20-day trading period for as many as two times
      in any 12-month period. If we default in our registration obligations, we have
      agreed to pay the selling stockholders liquidated damages in cash as described
      in this prospectus under &#8220;Summary Description of Our Business&#8212;Recent
      Developments.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      table
      below lists the selling stockholders and other information regarding the
      beneficial ownership of shares of our common stock by each of the selling
      stockholders as of December 12, 2006. Under the terms of the warrants, the
      selling stockholders may not exercise any of the warrants until May 31, 2007.
      Furthermore, under the terms of the warrants, a selling stockholder may not
      exercise any warrant owned by it, to the extent such exercise would cause such
      selling stockholder, together with its affiliates or any other persons whose
      beneficial ownership of our shares of common stock would be aggregated with
      such
      selling stockholder&#8217;s beneficial ownership for purposes of Section 13(d) of the
      Securities Exchange Act of 1934, as amended, to beneficially own a number of
      shares of our common stock which would exceed 9.99% of our then outstanding
      shares of common stock following such exercise (excluding for purposes of such
      determination shares of common stock issuable upon exercise of the warrants
      which have not been exercised). Notwithstanding these limitations on exercise
      of
      the warrants, the shares issuable upon exercise of the warrants are deemed
      beneficially owned by the selling stockholders and reported as such in the
      table. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may sell all, some or none of their shares in this
      offering. See &#8220;Plan of Distribution.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 12, 2006, there were 29,748,856 shares of our common stock outstanding.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ownership
                Prior</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>to
                the Offering</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of Shares Offered</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ownership
                After</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>the
                Offering</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Percentage</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Percentage</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abengoa
                Bioenergy R&amp;D, Inc.(1)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7.2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Emerson
                Partners(2)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">96,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">60,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Emerson
                Family Foundation (3)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">85,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">60,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bear
                Stearns Securities Corporation FBO J. Steven Emerson IRA R/O
                II(4)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">461,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.5</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">161,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bear
                Stearns Securities Corporation FBO J. Steven Emerson Roth IRA
                (5)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">770,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.6</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">660,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">110,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Pinnacle Fund, L.P.(6)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,473,557</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">8.3</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">412,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,061,357</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fort
                Mason Master, LP(7)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">387,097</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.3</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">387,097</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fort
                Mason Partners, LP(8)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,103</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,103</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Associates, Inc.(9)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Health Sciences Fund, Inc. (10)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">330,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">330,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Health Sciences Portfolio, Inc. (11)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TD
                Mutual Funds-TD Health Sciences Fund (12)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Valic
                Company I-Health Sciences Fund (13)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,
                360</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,360</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John
                Hancock Trust- Health Sciences Trust (14)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Raytheon
                Company Combined DB/DC Master Trust- Health Sciences (15)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,840</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,840</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price New Horizons Fund, Inc.(16)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">960,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">960,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">City
                of New York Deferred Compensation Plan-NYC 457/401K Small Cap Account
                (4137)(17)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price New Horizons Trust (18)</font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,800</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,800</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cowen
                and Company, LLC(19)</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100,332</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100,332</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TOTAL</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,581,484</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">&#160;</td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
      ownership of less than 1%.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                2,136,752 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on November 8, 2006, which may not
                be
                disposed of by the selling stockholder in whole or in part until
                November
                8, 2007. Mr. Javier Salgado, President and Chief Executive Officer
                of the
                selling stockholder, has voting and investment power over the shares
                owned
                by the selling stockholder. The address of Abengoa Bioenergy R&amp;D,
                Inc., a Missouri corporation, is 1400 Elbridge Payne, Suite 212,
                Chesterfield, Missouri 63017.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                50,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 10,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Mr. J. Steven Emerson, authorized
                trader of the selling stockholder, has voting and investment power
                over
                the shares owned by the selling stockholder. The address of Emerson
                Partners, a California limited partnership, is 1522 Ensley Avenue,
                Los
                Angeles, California 90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                50,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 10,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Mr. J. Steven Emerson, President
                of
                the selling stockholder, has voting and investment power over the
                shares
                owned by the selling stockholder. The address of Emerson Family
                Foundation, a California family foundation, is 1522 Ensley Avenue,
                Los
                Angeles, California 90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                250,000 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 50,000 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Mr. J. Steven Emerson,
                sole
                beneficiary of the selling stockholder, has voting and investment
                power
                over the shares owned by the selling stockholder. The address of
                Bear
                Stearns Securities Corporation FBO J. Steven Emerson IRA R/O II,
                a self
                directed IRA, is 1522 Ensley Avenue, Los Angeles, California
                90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>22</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                  550,000 shares of our common stock issued to the selling stockholder
                  in
                  the private placement completed on December 1, 2006 and 110,000
                  shares of
                  our common stock issuable upon exercise of the warrants issued
                  to the
                  selling stockholder in such private placement. Mr. J. Steven Emerson,
                  sole
                  beneficiary of the selling stockholder, has voting and investment
                  power
                  over the shares owned by the selling stockholder. The address of
                  Bear
                  Stearns Securities Corporation FBO J. Steven Emerson Roth IRA,
                  a self
                  directed IRA, is 1522 Ensley Avenue, Los Angeles, California
                  90024.</font></div>
              </td>
            </tr>

        </table>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                343,500 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 68,700 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Barry M. Kitt, as
                the sole
                member of the Pinnacle Fund Management, L.L.C., the general partner
                of
                Pinnacle Advisers, L.P., the general partner of the selling stockholder,
                has voting and investment power over the shares owned by the selling
                stockholder. Mr. Kitt disclaims beneficial ownership of such shares,
                except to the extent of his pecuniary interest therein, if any. The
                address of The Pinnacle Fund, L.P., a Texas limited partnership,
                is 4965
                Preston Park Boulevard, Suite 240, Plano Texas 75093.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                322,581 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 64,516 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Fort Mason Capital,
                LLC
                serves as the general partner of the selling stockholder and, in
                such
                capacity, exercises sole voting and investment power over the shares
                owned
                by the selling stockholder. Mr. Daniel German serves as the sole
                managing
                member of Fort Mason Capital, LLC. Fort Mason Capital, LLC and Mr.
                German
                each disclaim beneficial ownership of such shares, except to the
                extent of
                its or his pecuniary interest therein, if any. The address of Fort
                Mason
                Master, LP, a Delaware limited partnership, is 4 Embarcadero Center,
                Suite
                2050, San Francisco, California 94111.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                20,919 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 4,184 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Fort Mason Capital, LLC serves
                as
                the general partner of the selling stockholder and, in such capacity,
                exercises sole voting and investment power over the shares owned
                by the
                selling stockholder. Mr. Daniel German serves as the sole managing
                member
                of Fort Mason Capital, LLC. Fort Mason Capital, LLC and Mr. German
                each
                disclaim beneficial ownership of such shares, except to the extent
                of its
                or his pecuniary interest therein, if any. The address of Fort Mason
                Partners, LP, a Delaware limited partnership, is 4 Embarcadero Center,
                Suite 2050, San Francisco, California 94111.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Associates, Inc. (&#8220;T. Rowe Price Associates&#8221;) serves as
                investment adviser with power to direct investments and/or sole power
                to
                vote the shares owned by the funds and advisory clients listed under
                its
                name in the table above. For purposes of the reporting requirements
                of the
                Securities Exchange Act of 1934, T. Rowe Price Associates may be
                deemed to
                be the beneficial owner of all of the shares listed above; however,
                T.
                Rowe Price Associates expressly disclaims that it is, in fact, the
                beneficial owner of such securities. T. Rowe Price Associates is
                a wholly
                owned subsidiary of T. Rowe Price Group, Inc., which is a publicly
                traded
                financial services holding company.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                275,000 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 55,000 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(11)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                2,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 400 shares of
                our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(12)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                27,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 5,400 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(13)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                22,800 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 4,560 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(14)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                30,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 6,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(15)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                3,200 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 640 shares of
                our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>23</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(16)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                  800,000 shares of our common stock issued to the selling stockholder
                  in
                  the private placement completed on December 1, 2006 and 160,000
                  shares of
                  our common stock issuable upon exercise of the warrants issued
                  to the
                  selling stockholder in such private placement.
</font></div>
              </td>
            </tr>

        </table>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(17)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                23,500 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 4,700 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(18)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                16,500 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 3,300 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(19)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                100,332 shares of our common stock issuable upon the exercise of
                the
                warrants issued to the selling stockholder for serving as sole placement
                agent in the private placement completed on December 1, 2006. Cowen
                and
                Company, LLC is a wholly-owned subsidiary of Cowen Group, Inc., which
                is
                quoted on the NASDAQ under the symbol &#8220;COWN.&#8221; The address of Cowen and
                Company, LLC is 1221 Avenue of the Americas, New York, NY
                10020.</font></div>
            </td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>24</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PLAN
      OF DISTRIBUTION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      registering the shares on behalf of the selling stockholders. As used in this
      prospectus, the term &#8220;selling stockholders&#8221; includes the pledgees, donees,
      transferees or other successors-in-interest selling shares received after the
      date of this prospectus from a named selling stockholder as a gift, pledge,
      partnership distribution or other non-sale related transfer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may, from time to time, sell any or all of their shares
      of
      common stock on any stock exchange, market or trading facility on which the
      shares are traded or in private transactions. These sales may be at fixed or
      negotiated prices. The selling stockholders may use any one or more of the
      following methods when selling shares:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ordinary
                brokerage transactions and transactions in which the broker-dealer
                solicits purchasers;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">block
                trades in which the broker-dealer will attempt to sell the shares
                as agent
                but may position and resell a portion of the block as principal to
                facilitate the transaction;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">purchases
                by a broker-dealer as principal and resale by the broker-dealer for
                its
                account;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
                exchange distribution in accordance with the rules of the applicable
                exchange;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">privately
                negotiated transactions;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">short
                sales;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">broker-dealers
                may agree with the selling stockholders to sell a specified number
                of such
                shares at a stipulated price per
                share;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a
                combination of any such methods of sale;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any
                other method permitted pursuant to applicable
                law.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may also sell shares under Rule 144 under the Securities
      Act, if available, rather than under this prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Broker-dealers
      engaged by the selling stockholders may arrange for other brokers-dealers to
      participate in sales. Broker-dealers may receive commissions or discounts from
      the selling stockholders (or, if any broker-dealer acts as agent for the
      purchaser of shares, from the purchaser) in amounts to be negotiated. The
      selling stockholders do not expect these commissions and discounts to exceed
      what is customary in the types of transactions involved. Any profits on the
      resale of shares of common stock by a broker-dealer acting as principal might
      be
      deemed to be underwriting discounts or commissions under the Securities Act.
      Discounts, concessions, commissions and similar selling expenses, if any,
      attributable to the sale of shares will be borne by a selling stockholder.
      The
      selling stockholders may agree to indemnify any agent, dealer or broker-dealer
      that participates in transactions involving sales of the shares if liabilities
      are imposed on that person under the Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>25</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
        <div style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div><br><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may from time to time pledge or grant a security interest
      in some or all of the shares of common stock owned by them and, if they default
      in the performance of their secured obligations, the pledgees or secured parties
      may offer and sell the shares of common stock from time to time under this
      prospectus after we have filed a supplement to this prospectus under Rule
      424(b)(3) or other applicable provision of the Securities Act of 1933
      supplementing or amending the list of selling stockholders to include the
      pledgee, transferee or other successors in interest as selling stockholders
      under this prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders also may transfer the shares of common stock in other
      circumstances, in which case the transferees, pledgees or other successors
      in
      interest will be the selling beneficial owners for purposes of this prospectus
      and may sell the shares of common stock from time to time under this prospectus
      after we have filed a supplement to this prospectus under Rule 424(b)(3) or
      other applicable provision of the Securities Act of 1933 supplementing or
      amending the list of selling stockholders to include the pledgee, transferee
      or
      other successors in interest as selling stockholders under this
      prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders and any broker-dealers or agents that are involved in
      selling the shares of common stock may be deemed to be &#8220;underwriters&#8221; within the
      meaning of the Securities Act in connection with such sales. In such event,
      any
      commissions received by such broker-dealers or agents and any profit on the
      resale of the shares of common stock purchased by them may be deemed to be
      underwriting commissions or discounts under the Securities Act. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      required to pay all fees and expenses incident to the registration of the shares
      of common stock. We have agreed to indemnify the selling stockholders against
      certain losses, claims, damages and liabilities, including liabilities under
      the
      Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders have advised us that they have not entered into any
      agreements, understandings or arrangements with any underwriters or
      broker-dealers regarding the sale of their shares of common stock, nor is there
      an underwriter or coordinating broker acting in connection with a proposed
      sale
      of shares of common stock by any selling stockholder. If we are notified by
      any
      selling stockholder that any material arrangement has been entered into with
      a
      broker-dealer for the sale of shares of common stock, if required, we will
      file
      a supplement to this prospectus. If the selling stockholders use this prospectus
      for any sale of the shares of common stock, they will be subject to the
      prospectus delivery requirements of the Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      anti-manipulation rules of Regulation M under the Securities Exchange Act of
      1934 may apply to sales of our common stock and activities of the selling
      stockholders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>LEGAL
      MATTERS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      validity of the shares of our common stock offered under this prospectus will
      be
      passed upon for us by Greenberg Traurig, P.A., Miami, Florida, of which an
      attorney currently beneficially owns in the aggregate 102,056 shares of our
      common stock. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXPERTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      consolidated financial statements of Dyadic International, Inc. appearing in
      Dyadic International, Inc.&#8217;s Annual Report (Form 10-KSB) for the year ended
      December 31, 2005 have been audited by Ernst &amp; Young LLP, an independent
      registered public accounting firm, as set forth in their report thereon included
      therein, and incorporated herein by reference. Such consolidated financial
      statements are incorporated herein by reference in reliance upon such report,
      given on the authority of such firm as experts in accounting and
      auditing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>26</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>WHERE
      YOU CAN FIND MORE INFORMATION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      file
      annual, quarterly and current reports, proxy statements and other information
      with the SEC. The reports, proxy statements and other information filed by
      us
      may be inspected without charge at the public reference room of the SEC, which
      is located at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies
      of all or any part of the reports, proxy statements and other information from
      the public reference room, upon the payment of the prescribed fees. You may
      obtain information on the operation of the public reference room by calling
      the
      SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains
      reports, proxy statements and other information regarding registrants like
      us
      that file electronically with the SEC. You can inspect the reports, proxy
      statements and other information on this website. You may also find information
      about us at our website: www.Dyadic-Group.com. The contents of our website
      are
      not part of this prospectus and our Internet address is included in this
      prospectus as an inactive textual reference only. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      filed a registration statement on Form S-3 to register with the SEC the shares
      of our common stock offered by this prospectus. This prospectus is a part of
      that registration statement. As allowed by the rules of the SEC, this prospectus
      does not contain all of the information you can find in our registration
      statement or the exhibits to the registration statement. You can obtain a copy
      of the registration statement from the SEC at the address listed above or from
      the SEC&#8217;s website. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
      should rely only on the information contained in this prospectus or any
      prospectus supplement. We have not authorized anyone else to provide you with
      different information. The delivery of this prospectus does not, under any
      circumstances, mean that there has not been a change in our affairs since the
      date of this prospectus. It also does not mean that the information in this
      prospectus is correct after this date</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INCORPORATION
      OF CERTAIN DOCUMENTS BY REFERENCE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      SEC
      allows us to &#8220;incorporate by reference&#8221; certain of our publicly-filed documents
      in this prospectus, which means that we can disclose important information
      to
      you by referring you to another document filed separately with the SEC. The
      information incorporated by reference is considered part of this prospectus.
      This prospectus incorporates by reference the documents listed below.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Annual Report on Form 10-KSB for the year ended December 31,
                2005;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Quarterly Reports on Form 10-QSB for the quarterly periods ended
                March 31,
                2006, June 30, 2006 and September 30,
                2006;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                definitive Proxy Statement dated April 28, 2006 relating to the 2006
                annual stockholders&#8217; meeting; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Current Reports on Form 8-K dated October 26, 2006 and November 17,
                2006;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                description of our common stock filed as part of our registration
                statement on Form 8-A dated May 24, 2005, including any amendment
                or
                report filed for the purpose of updating such
                description.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      documents filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities
      Exchange Act of 1934, as amended (which we refer to as the &#8220;Exchange Act&#8221;),
      after the date of this prospectus and prior to the termination of this offering
      shall be deemed to be incorporated by reference in this prospectus and to be
      a
      part of this prospectus from the date they are filed. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      statement contained in this prospectus, or in a document incorporated by
      reference in this prospectus, shall be deemed to be modified or superseded
      for
      purposes of this prospectus to the extent that a statement contained in this
      prospectus, any prospectus supplement or in any other subsequently filed
      document which is also incorporated in this prospectus modifies or replaces
      such
      statement. Any statements so modified or superseded shall not be deemed, except
      as so modified or superseded, to constitute a part of this prospectus.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>27</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
      may
      request a copy of these documents, which will be provided to you at no cost,
      by
      writing or telephoning us using the following contact information: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">140
      Intracoastal Pointe Drive</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite
      404</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jupiter,
      Florida 33477</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Investor Relations</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(561)
      743-8333</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>28</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="center" noshade size="2" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">January
      18, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>DYADIC
      INTERNATIONAL, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5,581,484
      Shares of Common Stock</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="25%">&#160;</td>
            <td valign="top" width="29%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>P
                R O S P E C T U S</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="24%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="25%">&#160;</td>
            <td align="left" valign="top" width="29%">&#160;</td>
            <td align="left" valign="top" width="24%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="78%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
                have not authorized any dealer, salesperson or other person to give
                you
                written information other than this prospectus or to make representations
                as to matters not stated in this prospectus. You must not rely on
                unauthorized information. This prospectus is not an offer to sell
                these
                securities or our solicitation of your offer to buy the securities
                in any
                jurisdiction where that would not be permitted or legal. Neither
                the
                delivery of this prospectus nor any of the sales made hereunder after
                the
                date of this prospectus shall create an implication that the information
                contained herein or our affairs have not changed since the date
                hereof.</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>2
<FILENAME>form424bs011807.pdf
<DESCRIPTION>DYADIC INTERNATIONAL, INC. FORM S-3 424(B)(3) PROSPECTUS 01.18.07
<TEXT>
<PDF>
begin 644 form424bs011807.pdf
M)5!$1BTQ+C(-"@T*-C`@,"!O8FH-"CP\#0HO12`R-3DR-@T*+T@@6R`Y-S8@
M,C4U(%T-"B],(#$R,38Y,PT*+TQI;F5A<FEZ960@,0T*+TX@,CD-"B]/(#8S
M#0HO5"`Q,C`T-#(-"CX^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`T*96YD;V)J
M#0H-"GAR968-"C8P(#$Q#0HP,#`P,#`P,#$R(#`P,#`P(&X-"C`P,#`P,#`X
M-#D@,#`P,#`@;@T*,#`P,#`P,#DW-B`P,#`P,"!N#0HP,#`P,#`Q,C,R(#`P
M,#`P(&X-"C`P,#`P,#$U,S,@,#`P,#`@;@T*,#`P,#`P,38T,B`P,#`P,"!N
M#0HP,#`P,#`Q-S4R(#`P,#`P(&X-"C`P,#`P,#$X-C<@,#`P,#`@;@T*,#`P
M,#`P,3DW."`P,#`P,"!N#0HP,#`P,#`R,#@V(#`P,#`P(&X-"C`P,#`P,C,T
M,#(@,#`P,#`@;@T*=')A:6QE<@T*/#P-"B]!0D-P9&8@-3`P.`T*+TE$(%L@
M*&EP=VIM8W1V>G!I:7EI;W0I#0HH=FEE8GAZ=W!W9F9E=&IL92D@70T*+TQE
M;F=T:"`P#0HO4')E=B`Q,C`T,S$-"B]2;V]T(#8Q(#`@4@T*+U-I>F4@-S$-
M"B]4>7!E("]84F5F#0H^/B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`T*<W1A<G1X<F5F#0HP#0HE)45/1@T*-C$@,"!O
M8FH-"CP\#0HO3W!E;D%C=&EO;B!;(#8S(#`@4@T*+T9I="!=#0HO3W5T;&EN
M97,@-3<@,"!2#0HO4&%G94UO9&4@+U5S94YO;F4-"B]086=E<R`U."`P(%(-
M"B]4>7!E("]#871A;&]G#0H^/@T*96YD;V)J#0H-"C8R(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,38Q#0HO4R`U,#`-"CX^
M#0IS=')E86T-"GB<8V!@8&)@8+[(H,#`P%(+(N%``0I3@&PV!KJ#Z)]`IRDS
M,/#),C#P5C(P<'H",0\0GV5@X,X'TM4,#%Q10%H$2)L!Z0]`6@>(/S(P<"P!
MTLQ`K`WT53W0^4#WL\UC8!!7!]*G&1@8'1@8V".![)=`?;D0^Q@/T=^/`^E/
MY@M`@@.*&1ARP'%_$*2``9PF&-A!BB!J@VX`]1>`6```<"#T#0IE;F1S=')E
M86T-"@T*96YD;V)J#0H-"B`V,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#<P
M(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X
M(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2
M#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2
M#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0HO6$]B:F5C="`\/`T*+TEA
M8F,Q,2`V.2`P(%(-"CX^#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-
M"@T*-C0@,"!O8FH-"CP\#0HO0F%S949O;G0@+U1I;65S+4)O;&0-"B]%;F-O
M9&EN9R`O5VEN06YS:45N8V]D:6YG#0HO4W5B='EP92`O5'EP93$-"B]4>7!E
M("]&;VYT#0H^/@T*96YD;V)J#0H-"C8U(#`@;V)J#0H\/`T*+T)A<V5&;VYT
M("]4:6UE<RU2;VUA;@T*+T5N8V]D:6YG("]7:6Y!;G-I16YC;V1I;F<-"B]3
M=6)T>7!E("]4>7!E,0T*+U1Y<&4@+T9O;G0-"CX^#0IE;F1O8FH-"@T*-C8@
M,"!O8FH-"CP\#0HO0F%S949O;G0@+U1I;65S+4)O;&1)=&%L:6,-"B]%;F-O
M9&EN9R`O5VEN06YS:45N8V]D:6YG#0HO4W5B='EP92`O5'EP93$-"B]4>7!E
M("]&;VYT#0H^/@T*96YD;V)J#0H-"C8W(#`@;V)J#0H\/`T*+T)A<V5&;VYT
M("]4:6UE<RU)=&%L:6,-"B]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG#0HO
M4W5B='EP92`O5'EP93$-"B]4>7!E("]&;VYT#0H^/@T*96YD;V)J#0H-"C8X
M(#`@;V)J#0H\/`T*+T)A<V5&;VYT("](96QV971I8V$-"B]%;F-O9&EN9R`O
M5VEN06YS:45N8V]D:6YG#0HO4W5B='EP92`O5'EP93$-"B]4>7!E("]&;VYT
M#0H^/@T*96YD;V)J#0H-"C8Y(#`@;V)J#0H\/`T*+T)I='-097)#;VUP;VYE
M;G0@.`T*+T-O;&]R4W!A8V4@+T1E=FEC95)'0@T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B](96EG:'0@,38S#0HO3&5N9W1H(#(Q,3(U#0HO4W5B='EP92`O
M26UA9V4-"B]4>7!E("]83V)J96-T#0HO5VED=&@@,3DT#0H^/@T*<W1R96%M
M#0IXG.V]!Y0=QWDF6AUOG(0,D!@`@TS2LK3V6N_MT8:G]^RU94NRK$A18B8A
M@B`)B`1!@""(G($98`:#"1A@,,@$DRG+VN,]QY;][+4MB;1(4Q8E2F)`FG1S
MZESO___JOO<.,*`LC[7$>>?6J=/3MV_?ZNJ_OOISU7!>*[525;R@5HI+U;ZF
MBNNU4BO7%.\#@'15K95:N4[QK@>D6JF5?W7Q?L5:*[5R;:FAJ%;^W4L-1;7R
M;RGN./97#4*U\BL40([%N4%'NV:(U<J_J0!R#,-*<%XTK:SK&<52UC1+XCO3
M-`N%G&!6\!4@K5C*U)!6*]<4NV@D/`Y0*0*</&XB8%P[E\O1MRCF3*M0+*5,
M.RWNJ:&H5JXI+H&GE,F.NAY`R+4L2WQ1+!JE4LDPBIXO\HJ)U/L$)/O#[7&M
MW)#%]3S'/_7XR'`:CK95K4[[NE.A-%Q#4:V,6]*I@NL@4G(9SP*6X_C5*&(5
M6,IFLT*#`MVI)M%JY>KB$2@<;A*/,0MXS";]Z&LIS[,INL'CKHLZ=J%8TZYK
MY9KB(81&KJ#(*@&;,;$64GC,)A!(^32Q)I>/CF2N^MT8-](8V6?A"7WA>67!
MZ(J?5=UL!S?;8QH5#@>O^C8#CYZ/9[KN>EC%)]?S&QGK]:KV<56ZYXY-42@7
M=\Q%+[CW.EXRO!R\754[]!OW`QQKMD^<<N-C2J4/8UUTKM!+?8>,?]7R!$W\
M1JP*E:KJ=1Q^XX;:W;%?C=.3JOY497IXKD!1)LG!CI\U^?<B\N\H[#?GS/Q=
M75HZ;=+'AR]SS^;%/-Y8+#FH+]G^B)O<M;&2]"-ZBE<KFI<Y3]E."8'@\$(1
M;\B;!9=;./`N6(`<!"B><[B8M-Q!SG/%?,$'(-Q02G+XN8.<D-H$:Q'TL5PA
M6_%IV5[)]*!#O&3!!0/>(%N$F9#/YP0;=7.9/+3@!8-62.?%N],-^5QAT.-@
M-=BFA1UW;.ZX,`1YJI;?$YI0T(*`BNM8CFV6(93)VS8P<!L?!NVDDCF\:AM(
M$J!+SJG,ES+X\0\@(34T>`%:+J8K<\5V:"IX\-2"AV0Q<7@\I)6#-U@E^_V2
M\S/.!STG$0QXINBD\SDDLH<4A3D_6C1&X*O!2_A6A0*.&C0,+9BN)X;<\6%@
M!ZC#6@2:T/>CH\-HH7/+08,K[_"\A^=(7YO:2><+,'2I[`B\B.=ET0)+7>%`
M.A?!!C2(QW[7R*-$,PI`7-2NC1)O:/B/CL4=(A<T,CR2*,\>D^[R@>1AAP6*
MX%TX3XR,)."'V)2%W?)1"V01E+?QA%[*I0[2SVU^Y3UZ#&+;3B5H-*$!>XCS
MRZXW"A^+60YVY.!E!YY8HD;@F,A[!0\:L1+)RP)"KEGT+&S*`0P7\#'PT;:*
M`DAP&]P,E$EE.=BC0#^+O!?#0Y>X5T#">CZ*8%1AC(CRV'VS9."XT]#`2\$G
M>!<3V['%R#KYK)O+(OPL/@Z*/(&BA`W/@UF2`WN8J`$#Y/H,7W!O>)CI8<M0
M"X`W&`+$/.`DX;HYI!JRG)3#<_##8I$72EG#A7>'FA'*";R422-D&-A5FA#5
M*"J[FHL^BX-I2^3.Y>&9/%?B!<,?KRO#W("AM'DZ2UW"*8R=1%9@6H(M)0:3
M19-/GODQP^2,_9'"OM80NY>Q_RCH`U66;H5^)M.^TCV:202LV:)J^\,>3+>2
M-63::20UX*>(;S0R`C.7%RPD"+"F7($7\G@"_81'0_>R.6Y"GTLXE>%7R5$:
M7"#*T/O`-&#RIG._@*,87^1O.:)/B2<2P"%YR<37!'JF,P4`K25FCY/'82UB
MQ1/X"(\R';@ADRXX9(3"0ZT\3P\#A^)>B1L^ZS-\(+EE<0PCF!>B9.@*\"1$
M7:D$[6`+0$B8]<(,,>'='+RQ,%2H2-(Q@MBVK"0B]CV`'+X%T#F3XZD4$@HJ
M-%LT`!4XCM`8TLKDB1PO>=BM/+$^P?D+YDC13):*.)H$D$PB\U.X!<@"X!^^
MB+A`^I?`,L+Y,@9%7IDW6J-#[P*0<OF41RWGBWQPA&!3X"'E'L:^NF1!.V./
M0XVH3VGRP_'X_;D<L'XD(/!PJT2$(1SHT=^`N9G.<)W=9Z;Q=4+AWTZD\`6;
M&OZ+36,$'4ADDTZ@.3C(YZ!:0D/PIQ*68CJ;22;XC"F?"TEW,/:E^OA=\?JO
M1!J_%&Z\(Q)_.!)](A)9&XD^&8L]'*N[/Q2YD['/SISQI,3N&![$"0ZO`+/O
MPI5A&#Z8`3`S`):%$K"X#-`2R%Y?]W_61;X4UQ]LJELAL7LEMAR>DL\BP*"K
MA3P0K&@827PQ`7W;P8^\"%_9Q%Y`$$CL#U5VC\H>GAQ9VZ`N;PQ]J2GV<<<2
M[#1#H@W`8Q"$X+DY$EL.W""Q_Q35OAP/W]58]U5%^;2N?"&L_3[0<WBXZ`.&
M+)1@F*Y52FR0&RTSEZOL+L8^I:J?J:N_9]JT1^MC#T*-QQX"LD1B*\.Q)\+1
MM>'H&BW\&+Q=X[2[\Q;/FKP$/-!!3B4XI-#-Z'GY@G$%77^@P5[A+3?=J;//
M,_85C=W54'?/S%F?)PC97C6*`H5J:/221TV,))'X,`2,?8&QE9JTNRG>P]@6
MQMH:HB<9VZE)@*@MLO24KB\'/@",;G@$CZ!7P&QB;+'A8@N3HM#GN\/J'\-%
M9&@>U]7?@L$5*`(>9K@^ZR,*&YYP95?IBN+58);%]*_([!&%/1V/;&#L&TQ=
MP=153'J6L=V,M5+=23W<$(WL86SUE*:#A/G[XDWW`>,"0J5R6<<?2J`13,<,
M\!OH!K"RF/:`Q-;4A7<I;`=CSTYMW&_F^:7WD3GB2&*PIIA)#I%:8^,)+\)%
ME%0VW@:">]JD38P]H;.]C=I!F:V)JP^!HH+:`9(S09K8*#'`#*$H;X)0=/G%
M"[PQMDQG:R2V.AY])!8!`#_2,GO+T!"2R'>R.;Y$J^@]516UQ#R/2/>'V;I8
M:'4TO%IBZ^#U)094`N)L)_KL#TBT/][0(VMPY0E97Q6?_#!C_Q<0)5'D>6#"
MAC]O<]DT/;)H6@5D4UD>D^^(LL?KU"TQ=;O"GF+L,RB&D)ANQ7"@4].%&<"3
M61A9%`UU]7>&]!6:LK$AUL?8(1JC?;*Z3PUUA*-]JMK/6'M3PXN,[8W'X:LO
MPI0%-6XD3^"9\KO0*Y`.4?D!X$7I(:ZI'P5QEBL"P)8Z)I)H*`&,R,VC+Z!L
M%%B\C*)`XEJ."3P99$U,OY^Q-5/KCH?D-EW?R]3-3-W.9(!*+V/'J4(_NU7E
M"&,=#;'3C!U0Y0.*LHVQA]3P/8-#*-`OC8PX*-)08EIN$;1HT*5!-$>U^V9-
MZB:"=\1#YQC;)+-OV`5D/T.CF:)12J6%@U0HS$7X"!?A*]3'"EQAT+>GZL-`
MDS8@U,V3#D>5AX'_.PA"-T#1L&!*'FF7R7P>G@M\?EK]#I4=B$I=C#T&2-;8
M7FAJ=`05!IQHCE7,%'SM[BH4"46:X[2-J4_$U+:(ODM1H,*+=,JL`VI`G(&`
M/O!QKZSU-S6]`._8,+F-A1]AX3_)DGH)5D\VFQ=VF>>0'Z:0`Q3!>-6ICS3(
M^^-R=XAUAZ3#BK3"1L3E?7/8\PU,1W`QD%]@Y^1AK/]`41]E[)OU47CTP?HX
M/+03B"RI@&<8EWW83P4N'E:4$W!EQLV[)\]:_M9%GO60'<7BGX172R9Y5+US
MZ'V4IS.F_]^@7\"C8V%2L.F)AF-7;%.A$*-0="N:(?$KN`F$X_1)3RF`6/TL
M]`>KM)?)0'!@B4!_0,X1B?5(K"ND'(6+"NN7&)RTJ6I/O`Y(][3,'@`1/YPB
MO99DD(/V/!`OE7,%UUT648^%I/.*U"^S`Y/C\(Z?`Z+B,)$MY;H9T[X,%4XX
M782OLDBKS\'-"CNH24?":G=4!Q(M`WL06(3CB`'/DV%8H;E#VNE(!GX+\G>;
MRDXW15\)(6VWUNMG9+9OYLQ5%RX#P^+D<W!=VQG7QD9&ZJ#NH3&0X$`*($B;
M)#_/V',P-'!%0LH`MH$4/42K]OJ&L]$(W-`5CWX['`:QLE:)/Z[%OP9B$0R-
M?$[8VF#/I`7W`TL2E*LPLME."7%X5&=G=?59Y#A^YH80)14(P7L!\U>C7VF<
MO%[5MM;5':/IV=U0]W(D!+.[5=>.:CITK#42.:5I@)_.<`RZ]PR(&#7V8+CI
M:S"W+PWR>7-OSV5X?>Q/;IYZ;US_(]`5+9/'H_\AD^)S9G^R0*IBH93'1U>[
M1H3=X579%]PMVJB7@*ZN2M]0<*9W*]))1>UC<BN3=S%YCRQ!W:5@W:FRG3+;
M41<&7.T+R4<4=D3&%^\+:T>B*KS(EX6.A.:\C4,,JGBB]`ZH3F!41J(/$M>%
MWW9J2@?PA+BV&IZ+/`%T@T268#!*-0\?X2(R$W@O;;7&VC3I*$VT38T-VZ&I
M9`H!FDB+`7?+^/&-+Y@7!@(`I$-C^(5Z[2]@E&/AX\0]^C3LP]=!R8<73^2N
MD$SW*H+#5Y!<,FOP'M"<(]HS,O4<Z,/8*\!\8"(HTG:5M2IP`D)$WBZKST`%
MV.AZ3T@%#@#S\7@X!(.XB2F/-L7N&WX?=;Q2";%K%(0?QD2W0(G7*<_H[+B*
M/SDC,?CMT\"@:.);PBYS4+:CV@!:UDB*RZ$[9`VXT`8]!-#=UE!_)AX&G#S5
MV-"JJNMQPL:A)T_*RB88/L:@[E*U`[H.0NV)2-U33/HRS.OA(3YKVMW)86[F
M?0,>9BZ(U[FS/P6\VO$9L^T))Y0H3B#%JJU4="\44;LUN:8M`VHH.+..D(1]
MMJEI%V/+X]'5C-T3#3\$NE\L]"`(%XT]TA3?JK+-8>500QC`WSZMX3MA"4"U
M+A+[8HE,16!NZ-6!M^9ID^=@4A50G5LEXT#L5;5#,G*\=0UU=P/PH!.HR'DY
M$DD9.'&$$\3B<`/<!K_2)1B.-D4!5>0K,!]!:Q4D%2\KC$%XJ5+!1U&)IBTH
M<B'V4@C'_5@L`F,$\[V?%)C58%B1)97SRDY7=PR0//**"%-+D==0S]N9!(SW
M)8"'JJP+:<LCRF,A]3$X"87N"46^I$>^`OALJ`?M<:_$CL755R0VH$H]86VW
MSAZ='/\:VA15WE'3A"[D`1]AM@90)#-X1Z#G64G:YAAE6Q74RY&B.V)0&!ZY
MD/YU27Y2TV!TMD2B`)[-]?4P_1\,1[XVG,2Y`S08SN.)&OZLQ%8H;'=,@7<_
M-B7^'=!#&-L1C6P`65_(H+:@LD].F_S[FGK;I*:/-=1_9$K3)P:%UQ&-#[MH
M9KF(T@:F?H5*OH'FD@I!-I+%-?T^8#C$HF'2[9\^;?\OWD9'(C"ZG##M#=1R
MT1K-\9!TNXRZRJJHW!Z5SP![AU_);%M=W2/)+$IMG,(Y877!6!B74\-`KUDW
M@=[X=!BGSX&8?K0A!N/R``@FT*,*!G3&'AZY`!5.X"/PF4(.8/``W!;33L#H
MAS6@V,,SYBP#_?!B$K@4O8?0&1R<39P<I);I)5)VQN!RY',:2IG3&CNO*:>%
M=`Z'@:?MN&D&<,7;J9]VP<JA+5=FT144H7L-400\37D<82^U,1F(`WK=83`9
MA+%ODGENDA/`0"T0;-*OUX>>;@H#3?;7:Z#9MFOL4)VR76)W"ET.[/U\S@B>
MDH/Y$I96Z^P8*0D@G@8D>1,ZA$BH>7S$XY=!0S=I7ER\S*=/WZ8@>SFH*UVH
M!6F;89H#0Q,65M8&5(*"#),7(0?#)X'BRG;/JH.I='A*[,]55.$V3VEXZ,H%
MGAA&NA4+ONQ(IWDJB3T$24?LV1I)7J@R#RO\IS+ID.3PWCE_NH7N5.2MDG08
MX2K#;+H?X`K@@68S&3S)I?&]BAF4[_".Q1QOC*Z0V1-1=BBJ'%7D_;*^M:$)
MWNBS`)@KJ8Q#+@4@+PETZ]W!7,'DX2BPHYVD^&V)A;KCP&:5%<*E/#*:%CV%
M$YL<L&%Y!=P`MS&T[+I`X(:CCP(EWQDTR>ELE)R"'3!8QQ:.>B`DO!2RJ6C]
M,F!?4?D[Q&!W-4XZP:3]9/G"+-X0"Z_-&_CB#DG_RN2J0I'`)H@335D)C)I)
MN\G<&&#R;C!M8(:Z)E6+?'KDWX.AS&7YX$4^M0Y,N?4:Z[RYX3N@4NI@OJG/
M-$3OASD^FL`GI%,%8J)Y0%&$/:ZS;@E%0">3NB5EO5<D:8KB;-3C%TU0#<AS
M&X\])+.-"L[TKI`&TW"=&GDD:^(8`9<KY$UBK<!@,P``,A]PX!C[[V'Y48UM
MA->?'#D;E0XJ[#Z`M$UJ`[QD<E1$!'#(`%08F46_%LPST#2@V8`95<>8*JHU
M$#Q?A:+-B@1,>[^D;)C:]!A,,>'5(>];P<AGQ'@E1RWA+4^-\OKHPXU10,53
MDKZ5R1M"T3U,>A!T$B2^C1F8!OFBT]F$31PO%/D"W!S1NL*1;K3RT*AY'$?$
M0S\&Z.=8R0T+%^$K!6\X$`WW1%&K?R84^CK.+T!:\1*0IV2E4`\W/-/P`H9K
M)#.7DUF/L8_7UZ]7<6H#$SNBZOOPYW6`GV=FSSX>48^$E:VJ^JE43OB*QI%H
M9"6X`D6Z\BA,?TG:P>1]R"Z4388]CB>'*B(*M)ILBD?D%;,:85;NTI#)[(HH
MNQIBZS%`X/%4/ND+8FX![XA(JT)H]`&O@RG<(:EKT:V*DPF=YQZH,)F+J3PZ
M;#7Y$5"$ZO23.K8)-'\D`\H,`0"5+`KAY0M72#?(678QF;1P?I7XI/H'@./%
MM=:8#'QXRZ0PR(6/XP.\G&6A]QAPF$R[)=,HH5,81RV;'Z)V>$!>7_>DJ1I8
MCN37LG'0A$2[6Y6V*C@=]LLR:&B?@2\</RQ5<CUT`V)\PG-'AW$NY0OD9L]P
M6;X_%%G'Y-52;`?R?/;XY.E?,M`0M+*Y$1BD]!!HD8ZPFE-9/J7A25T&57PO
MV1&=LR8?CT>_#K:8F`@>Q1?@(UR$K^`&'6_;&Y9W3JE?CTYC#-``589'T^^1
MVL(MWP]CDV_!H#@7GSGM,85MB<JG`(2-]<>8M&$X"[!\$*0P8QOKPJ"!/+MH
MWK9T"G7"?+'`QT#"#11L[#-P@+"\4F5[P+)@$J"H%WB%@5$48`\6YGJY?E@-
M6)%A9HI&#MZV8"!38NRN$-LSM?Y<4]V`A!QXDR;=:^`KE)*IO``O3$G@12%V
M4`8;$-J7#\KJXQY,)5#=O()A#GDXRU%B)M$AL[XAU$4*\YY(^-DI,QZ[-`IP
MH<EN"ENN@$',W,52?L0LH=<95*S<*.@_]\OLJ1":F=OK]`Z%/1!6_G/1!NTI
ME<JX:.U6U.G`BD?+-^''3'G@743'M84O7.5\L%'?(>U:OP],,!7YZ@%`45/#
M?6AK4TPME;EH6NC/<:V"ASYTVX'9[_)TB8/Z`>R4A1X,3]X.Y@FPV8;ZGG#D
MOHN7A.F$420SXXD)GB]FD(46.'HU)>!@H&,#K]@;5;]IDF<UES>AP@E\A(OH
M>\$;#M'-]Z,I`5,&O3M@?B8*I2$1YO#\F((%PY<OF$"-]WZ!C@68_O7ZN5E3
M7D$KB7TS87!]TC>4R)I8[`"9#R";OFD&[H)Q(^9"5P)5)RRMTL$08SMD0I$L
MKS.1YCD_";"B)`A-)@^L`T8V7<#(42P$<F0#^0-!G^F*A]?FT(F!%K1+DQ0&
M(,)65Z'H@*RN2HUPBO8*GSQRH1^]R6/A>]`[I!_6L?/0[/V@`(&T,;FO[A;2
M>1.CX!05<DSQ`JBV&:B,U=4]INM/UM?OU+0U,R<]EDN1-'<'192\4`0"ED"X
M%X$?%86/'4/&R=%$&44.,F91[2"OS8^Z(HH,L-%`!]NGHE_HD"QM!(7_\B`7
M@2;?W@3TD08[.`C/!=+:PD7XS@@/3X$Y_D3=].?)$&X/*1L`*M2-E&LF@1I6
MSC*!H#R'@U+B34T/1>)@*.W1M.ZPTMZ@@KKR97(A4D31!@Q\&2["5W`#3KIX
MZ^3&9?!J9)&!/GRY:%U`M=?`:6(43<<N&2:."R!JZ`J?,WWYY/`A\N%TDR$,
MD_<;(%-9Y(^9OHH<SATSXB].1G7];L<2_I#JO!>W['5$KY<_RF#1[U98J\SZ
M%&E]$<<N8WL%VT7='.:[0^-FP(LZHT5^Q4#B\<L)WC@%9,=&/=)1WP!F2#\H
M)S`/K^3>R15=C.\[:+!$V=HJ%'7(VDIRR^<\*U7(IT&31S.\R!NB*^/:=O+_
M;P0S>=;T1X=&";4F2J*RUPM%&YVD4@E@*UG#$`D0:M-O*TV??.LRSUBH2*-W
MVN-#R4$,$\.]N4M>>48@ZTN6K)];SD5>#BQ6H4AX`*K9$3P34*0KRU76JK*C
M$CLL2YM``P'Q"#.NA$(2+"@CGRV4573@15E@W:`BNM@])O]W4(J8?I*QDV!,
MU8<.)8?(P0&SU2-[TA7>CT3!'($A`\$$D@54(TV!.;6U0>V/*<_`XV"2YBA6
M"Q_K-5")M\(-I$&M@I\XF+AB41`'?8RN"_VQG9(8<3>9!"T4&1JPEQ!;`:RF
M*?+GP'-"*IAFZX"#9<C.D?5O1D.@E/9HK%]A!^NU]3;%^@4;\2/FGA\D0A)Y
MQ(O0$@>-=#]YAWHU:9WI\#(Q?<U<.!21J@#NRV"7Y,B^DT-W*/K3D@*B9'=8
M>JDA?N#GF&GB6F01!"A:0RAJ8Q+I1=I*>%G'2AB%44X)&(E1C#Z#Q0K*%8`Y
M).V*A0"<GT27N"5<.*[P>J$GRO7]41QCW9A+D#&'04(.&W;2074Y2ZXA>'I1
MN.UY+I7_A0@^PF^!=]%*(LSPP<P$4&CR[E42[=HX&GQ1`A2IRT#T*VCI'Y:D
M+:'079A*X4M(],WX_%U4ZC99\5Q8E$S92%8JF*M=.CL05AXRD,Y&E4YF49PK
MAYH`J-G:@QI:@KM",CP1H+M/"M^><=$Y`B>D0AP-2T=0-96WA/3[32>@53E.
M0:\AR`6?1M+#-EKY/#/*0^BR.!$*O\Q8:UWD`&BD8`AC8-3FC770SU:`>@@]
M,WL:ZK>!]@$&!JH55M;`K*<<\B;B26C.5UGZ$FN3$4N=FOPX]<>J:-:!(\X3
MO<3)5S))O(%1IJNK)(RU'579"9UM#T<^9?B9-A3$,X5V#2A"AXE`$>A=I9*(
M$[NH.5,B:U3;HJ*9V:HJK;+\1(E2%+A@P67KNZ+=V6.228+8KN?Y21WEF$]@
M<04OXE^R`^=YI1#]@^1`I^(RPDB:AU(FK#Y01A%8^@)%MI\3`&@JC$&1_TQ;
M.'B!>X`09.@WZP-2P+0%(YTT.UO8^X$)DR&$DUL;:"NOC*G[H\HQG9U2E,.A
M^K4_O<RAZO5K-1D:.05?P0UP6ZDDTJ[LRMP/+"F+A/]H.F.C/65=&.*Z](VF
M&.#Y@!P^K2@@U]9$]:_FR3(:26),)*("`^R:TO@2C>RRJ;-6I(NB7<2Y:XTX
M8)H6_*Q`9'P`;&T5Z5$'"$4=NKR*4!3$W(7SW//_$A/#-"B'^#R\:4A]1&;[
M`;HJZT<4A=#)+Q+)$$46H.A1'5'4@Y$XN8/I*S'5!T'J9O,9Y+$V#RF@'F^5
MT-5P4%;:)?E)@*DE4.1:5Z.H(J`-/Q?$<\M0'P.V<>N84M'Y?G44W7,UBJI_
MZ(^E14X5?,=K4/0HH<@='T4N3E1%N9VQI\$JE-`MO%,);6Z<O@NJ'-X,'^$B
M&8Q/PVTEDX^3*1'$N2W,GD174=9R8([/F@(_WU(_Z1RPFGA\?SB\/)/SS01@
M#LD4GS+I6=)UMTZ>?#A>_S1CGP-+&<0U*.=D1*21Q3I@6IK7H*A=9F#==(Z/
M(M_B$BAR*.'+#5#T,$BK#T31RJM0!%:J1Q$^D6D,;3%V>UWDH"0!33IDX%<"
M138]W2N-Q8`;=,DN4^EJGW,U5+RJXP>6?Q\4C?&HV,2PK2H4#00HZK@:1?[]
M(F:*TP):S(/5$%ZOL+UUT6[R0^YB;#-5.-D'%S7X*K(.;C.\L2BJ#!Q>R1N^
M8R=90/N:L>5-L>,8YI``0AM5[2N($-,3F@MT58]\56*;0RH\]&DUM)ZQKPTF
M?-E-/<R@<03<,HL]%R@"HVDLBH1$<ZM09/GLR"Y#&PE@$FU_"8I,@:(.&8G?
MQZ1.,`'262%],#>W9#@C";YT`5CWSY!;^+`L=U:A"!Z=#>*V5;4:5V7\...A
MZ%]=?F44Z?=5H0ATBASG]E@462(Q[`-1Q*M0Y`J[57BK1,Z<IMT%$H>Q]:K<
M'@[UR_)1J'`"'^$B?*5I7S=(BR4(N5597KZL-TQ79%*-9#&K-A+^0D3>(A2,
M^ACHYX]+[+-^Z)]2%PR7J^'?US4P<WKJZT`UVC)]>ONDR8^`^HVI)-ALKIA)
M")H;Y#X%30Y01)'<0S)RR"[M:A39%10YPI<(*E@.HS%DDX:TY542;6=8OQU-
MW#$H6J5CM@E%0*0N0)&)841TJF1R:=3Z$C`[[I51HT/#4Y:[$$44@A3^;3\%
MO=K&K,;/.&X,'ORY]OCK0Q&AW?6JQ)E!R3Q%S(4#%(&-]DM0Q`,+R,]5!FT$
M'C&W&73L=8QMHF0JX`^]=+()+L)7<`,J+7Z">AE%11*.1<&+?$N38XA?E>^+
MJGO15XGQ\5WUD6?-`L;CP%;Q*'0+S.'R*`^'MV($03VGJZ<P8AM:`R.2*?$,
M+19`7H0Q-)XO(`SRKD!1)WF9N@A%JP-MOXRB((O#1Q$*2?*'"!1](T#1P/@H
MP@A(EXR1FN-(!$(12%@PC2T'7=*4FGC_U(93%&OKK:#(]PT.T=&X&D77@F>,
MVE/]A7TMR/Y]4%0:#T45\53\U5'DKZPA<]C-%)%[@+E:7[<M'CE*].EBZ/8\
M"A_A(GR%RT6*`D)&1>"33U7,OGP1C#1^*9G`>'>>3VO:%L;`"FCLYQEKT]D*
ML*-=]/"C.`;AF#,QV*V'UY#<!*2=!2S5U^V[0HZ73,%?_I,>&11#`28YH>AQ
M0M'A#T01K0SR#=A_!8K<<5$T@*J1]GB1<I\HX=/-Y6Q`44-X':F+<$_?6!2!
MY7ME?!1=HS`'633EE5SE>M45MQHZ_U84;0/C^AH4&16+TL][N0I%UVK7019A
M-8I\H>T6+50;DAD>"3U!YM+>:/0L5$JKV`\7X2OT95FV5T91Q3,_2D]'W1YS
M43#;FRORW3)Z=/>'971;Q4.'XJ%[+,.WOH6SHT0_8^P+D?@!$!^J](JN/,?8
M4]'&KX%]A_$.L*\]VRKFR`F"RU\`163I=PF0R]4H\JY!D2NHG;L.BOJOCR)H
M^7@9192YFB*'/&;5`HI4]EA4/7(=%`T%$LT>@Z)*<>GM15XZCEH5\RFCR!K3
MPCBV_[\SBAR,M!9=5&RSH`T`BC1M4S0*PW&@/G(\C"K$/9@8[%C70Q''>*MM
M40`>K`^07_&Z/I$N2"?K,'/#1B,0;@O4US&\2*Q0@_;3!N:!`$EE]F@<$P`.
MJNQ(71B&8SEFJINDG>!6/$6Q"&D4I*3-E=A*]%;I8,JU1F.[M=A=>8=G2SPE
MEL)YMEW"Y2CCHDA15HNU6E4H*I97*6(>&DXNU(LNCSHF*OQ?"VN@G/<IK*\^
M#//E,X62GWQP#8I."A054/)C8,[Q;-<5$NV^:8UG*2GWB(P)*H^10YB373GJ
M.TNK]>H`)*.I09$"1&O68+8E*79CETJE0*XA,`K%]!C-ZM>"HO187B3V1S+$
M.))EM!:TD9!R5)>![>^>7+<F;UYEHU4DFNACL8"K`X%UIS)\TM2-V()\B*$-
MLA8^PL4BN>CAMD"&EM>Q%BE+WRJ[/0&QT(>("O;=#A7Y81=&`]75)<JE-&D%
M@^MB9X:S?+B(+G>EX0&F[A(A&UJ&<'N6\IGAB<G1E/#*.<AEK2)Z'5?+>"=:
MXA^,(@JL8P_SUJBPT7[Q,SYM\GJ,;K!N%<G[^)SF%6#(EZQK)=H87F18!>%+
MR>7-1(HWS]C.V'99ZL/L9>GPE*F[+E[!WA(7HG6.8UR.ON02;+QDI3*ED:*3
MIO@%8,E(IE.BZR;F*[NT2M2FW:Z"M=*_9A3Y`H):<SSTY(/=&D8GS[YHJ!_#
M7M+!D/Q0NG`5BH0%%.2#B=5\#G_G?=0AM.B=C#VKZ4<T_2B>1.^$B^]0BJDI
M5C?Z`0;Q-A8!F%"13J(Q#C"6_D23=DV*/P_\4)%APNZ;?G/'S]ZEU90FY3QG
M,%4;<)4U^4\O<JUQ.04T.YH:SX6C[='&#:'Z.X<2F$Z`<QHC=JYE%ZM0U"M0
MA*J1\OAU>9%+&6AD@Z;S.7219'D\_"1CV^)AT.3W1U10[/\?D>[[`2@J(9W`
M`LVYY"$'&RTD/2RS?9$PW+,['H?;GH!W&<&PCT7!RFK5V"T+V6QA%)-NW&+6
MS*)+S3"&DAF35-,KE]*Y+#XFG<YRSL>*ME^S1$.RF.5F1Q.XK`&D_/3I!TCY
M!+Z]?<Z,TRB/O"K?=05%AD`1KG"B;L`=[UWF6OP+35/;Z><=<`(?X:(M`@JH
M>#E5$KSL1_6M,P,74/.FIE6ZU$H#?5A1>Q3]&&-/3Y[^E*9_B;'?J],_WQ3_
M[,TS[@=1&XX]&6Y:B5DB\@X],D"6%ZZ-BC8^6J#0H2"AD<]1CHD%>I>&&;.]
ME`B**`)E^P-0)*;88.(R-)4KB?C7"DQR8QVSIKY0%P:6\GLHT8"'FU;@=126
M?F"C:=A^.ILRK3S)-?0ZJNR^AE@'>AVE;EK2]4U`D0-2.)U#HW*,$\8-)AHZ
M]!+9I"#<A<L%4ZR0<?FE"QCU<<CU;1I>H5"JHO"O62\B2Q_4/;Q4M'F0#I3"
M;#J8VAVJW$%K6#;>/&-M"GF1X52Z8!/O]=>QBCY8M*`86I<CGU64';28HA].
MX&.)M@BPC#)P!&7R%?U<K'/QT(P1SD9=[HB%3E+:TAXF#Y`:LSD<>C8B/SDE
M^HR.F45/Q)3#M!QIM8*ZT"%9!P%Q(AIZ?O*T$P`PD,(8MTT'VCCRH3**^@(4
M=5X?12AS+UT<Y11D=&CT\RD^:^J>&.888(:GPM;5UW\!&%')OLIWW5'Q%VF/
M&\2S+;N02`]93BE;%$M?5X.9INK=TZ:=U?3U!<J_Y=4>19<'BWT,X<T;3>+:
M+I`7N+I9+$PV,9D9<.<G-!+P:&TI]SSGUXFB0AE%F62I@GD7N?%;;V7C\4]-
MG]X:B1W%=Y3VSIS<>_E]?(UD<>@:%!6K491.9A(9#,LSY;,PXA']!:CHOE80
M1<FTDTIE_-YZ0JU*4;)<.7KN3SG&_J"^;EM(Z13K'6)-)YC2+T4P03H>[0VS
M70WJ_@@[J+.C85QA<5H'R:NT:O$VROPY1K5##F]4(E\T;)\!9A))`H,-PZU)
M:VFU2QE%JXRK;;0*BG"B&5:N9`!A!X?YI/C]N&1/`KUHRYR;7IPQ91\,J$F$
MS13R8^-H1\HH*AH\0XO7A(,6V-KP%7[3S$Y)V1MO.$JR^*&&AB]FR='N,V4?
M$G9@0?M:JTDBH5CB]?6?":F?&[F"*5[)0?S)T"5\C6R:$F[LLN/QUXXB`0#;
MX/FLBYN3.#@=&AO_&'F1W-Y8WQ>/@E1:`S@O8NBJ6(4BBXNT+D*1D32I`YB>
M#<ILTZ05.J9PX/)).(&/(VGA>D$4&<E2@*)1D?E67E=G8S2?U]4MH[6Z,%(=
MDZ>=(E_002;3,CK4D3:J8%\#SV'?8NA'.AF-`);VR+C<9G5#_5E=.Z_ADN3U
M2OAKF"YJ5A2,*A0=^^4H\ORL,%MHSIZPK;XXN6Y'/"(8-8S^PR6#]F?`>Y!E
MC44114!(HHF6<\5$R<J`JE7"[+YODC]VQ_099YN:=D4BGW/(HBJE@I7TOA/&
M"%#DIK)V@;@K]"JJW\'87=,;M]9IRV/*)^#&]*@//TP?\/>\^F`4B<R0*BO)
M%Z`HD@(4[510K^B1V,Z(^@VK(!:?0LV"X5(6)9A_DD=A#52"^6K2OA/U]1VR
M`A3>*K&-,Z;NQ&YC3D6J'":@#O@1$]$!%_=K&$T6$C!,LG8_"9JS5-O@(\B1
M9`$>.HJWD79-JQ<3@A=YE&EL4L9XP<%%`8RMF]1PDH*5S\K172RVC6$J^-Z0
M#LVN#4G/ZFB+=4258R19=FN1'4Q=H<?7T<=N-.&U-CVT"NQ[/]T"K,A\R2->
M$69K591H1\LH,D7^3L4F\AUW)JG%'MFM)F52*>P!!8=^:RP"EN.6NCAJQ06+
M?%-.07C;!(HD5"R[B1>MACZ0S\'"]'Z>M2G#)!Y=4Q??#TWI2H^(4P/Q@1U5
MB3,AR_+!&F'*CS(PUU&3/U\?>BR,"PJVQ>2UD^)_Q%BS1Z9'D!<MV-%X*`J*
M,/$\6O#E1T4]?^X`2P3`A)5EJK19P1?IEUA[H[[&3F%[F*18>)>8`*+(\O.,
MK.'\*"CX!70^?T:2GI91#SFLA]KU*-@C?R`\@04[)12\(!D)%TP8=*27S=D<
M+:R\R]7(`Z3EOD3U$'S,NT);%1$BX/P)AZ?08T8:?I$R/6",@:6I=5^3M(V*
MUD7J_;YH%-37!]3('6KT*VKX'CUT?TB_+Z+=#_,BI#T8"MTS9<H*QKX:B2Z+
M15=&-&!'SS9&S@`\=.TH9AS%EMM(N;0O=CT,F,=!]V:]E-AV#$-IZJ,H*H0N
M/68$T061S%X0$;21%)\\^2%@=W&]1\&LDAVAT!K&/@6PR:!V[6;,I$V\+BRM
M4BE_"=>8@/*LKBO0KB9%,^GAWDM#T/2ER[PA_D!,WQ&6C@">-7S91QG[_3SE
M?Z.FFLL'LBQ3,`=AQ,$B*]`N-,D4KZ\#Q?5Q[`/K"4O;)C5\J:[NM\!HM?W%
M@#Q;<()DR;%^)Z]:*;$IJZKHAZV%<"'<@15LY8$7W:<J3RN8?G\44*2RAZTD
M9BE2QX8=^W*QD!-$`[LB60*YC4N>LLBQ'YO<"*-P)J0_!Q,DVO`(]MS#C0*\
M*M9:MJ<(12)?+EC'!"B*WDN\Z!S5-O@8H$@X]HL4W"QBQH6-;X<;`5E\,(4;
M`>CU*]%+*?<UU$,'GJV//`/\6>SA@T?:%`BKZ5_T=_@Q<$LZ(\-OF7.,(K_M
M,#11&73LAVBE6V;P2LI'D<'KV.,QUJU7H\CE%4O!+FMN=M$8L2D_#7H,[*BN
M[FF55JQ'E,,2>R:LHSC+DX&6S(W:>)>+?A+I<4+1;EQC(G<Q=;U)J?@CR0NT
M\5$J#9:ZRT>&,>L2E,\H.UVOGVEL."#KR](.'Z+$.HY+*M*.A\N(#)[*VSF1
M0)A(<4V_'23IO)M`83B@D?]<D3XE=BO*&[C5S$C2+:N?'X`BAY(_JU04@S*7
MN##W0*+IH:^JZC<E=0?#Q40[ZR++;=I0(ET0NW!@KI1%BT9PX3/F^F(%.:O+
MA\BVZJZ+]44C(/<_#V09]7U:1L732'TAS8PBG4*HT01&(RAZA\RV40`%ZC;X
M6'("5SZ]D!/X,%S;\>PL<2?TE"5QY>.=4Z;@VD^-'5-1NWZ@E*?=FFB!+9Y8
M5"FF:U&B49I67()VETOP$/NZPE;&_>R40V%U/2CVJ4+."U0CUP)>M"K"NC1V
ME'3L+DE;6<)T2/2'BD0]46V:U+B=BX.R'H@CH2P[2'F5NV9/:5?876:1IX17
M"E>>ICU?+P)+OQ77F."J]@Y)69>B_3D=#TQS3(I.%D<R19P(=>$5$65'/;+-
M-ESOAKSTRS"7,2+CAW=Q;IJ8!,T3!9&6+QQ6CT>DCKB&RVHTMC$>^S00`==P
MN3Y-:`LOZY>@2"Q&=JOE.-[FB6Q,D)OA+ROZ8Y*VA5:`[F1LV84+-&=%+I#8
MB,S$+28N7,39-'7&`ZJ^/![;K2)ACTVJA^X]&M*6Y[(H;J#9%-HX!FUP%J24
M!,N7_(@8K5Y!K0Q8>N1V1=JHL`Z5=2BX=@##'WZ';7^K-&"8N$<6X@ZW*4MF
MAD?37`__R4VS#I+JVQ5FQZ/*MH;(?;;I3YGJ[%`A^I/I%$:F."H#>3"WTWSN
MM*]'U0=QM:-V='+3RR"`U,A_@R$8'A7C8N"J0VEE"..PPNO8"[P"]+&2``PF
M)=+:6*KOOD=;6TB?J:]?&=8W:5+[E(8_HY7=&T/L$3N'K^#Z6SC8^0)N9A6L
M)#J@L)VTK+Y3EC?DLGYR8JH`XBP%J,B2%P*N2^SAZ4V(^<GU_>3*V*&''X&'
M%DQ^><1/B"KAX@[4-T837)$>F];8%<&M3O;&,9M]#RBN`,B26.,#6D&6YK+M
M9_M^`(J\P(`MN\6HDAU!:_6U\.VROHIIVW!AG70@'-X]92I8.B#6[]'4%9/J
MUTOLFRI;-[5A7V-L%\4[@+6N:FS`>(>JM$:T#:!9-=^T'"8X6"CI)#$ZF'B4
M-UAEAXI'5_Q;Z)VV>#1\A\8VJ&B,'X03^&C2&BO/"?9L-+B5$RG?T.9%S@<Q
MR`7B3+Z'/%0]DR)_.3F*/A]@H98A8.-XKM^()]9;H0.4=@(O9GS."+W-<I5]
M08ML%\N+-'6O%OKJ4(*B*JC=H89-Z]&Z`NVW#W/LE:<D]6%9>416'E/EE9HD
MZC>G3=H"(CZ&K:V.X2)K4.E;0W)'3%K5,G.%`].?M$W;="Y=?$=P::!8E*V-
MT.)?VK[@F"QM\9>4D@9!O(4VY:#LEUDW/<+8?>@802EY.*H.T-KA!V/U=Q5(
MQP!EX)U!5,IE]79-7A/5T%6EL.,SFE["M7AQL&2_G"]0N^3,=W!!(F[U2/-+
MV/+7L=&<JGT&?`W%M[,HE86#D2OK3S!U-T6R>FA+A`WA2+>NXV+P""ZZV1_&
M(.!^##&PCHC6%<5]*C:1?;TNK"]C['?!-'-H]&DE@NL5\[[R679EE=F@X^>Z
M.R198J$[=;9)1Q1UZ&QC3+\;YK47^*[];1O]?T:1L\UW,<W>Y>_]G$^.;88N
M38O_G8PF_,9)=<N0R10+8V93Y<51R`X.O8?"F1B-F>?%!)\VZ4Z8$6H4?9Z:
M=C@:6P.\%U06##AA.@FFB*O^;@]=Y([H1QU8/B3)!R6Y#91)56K#C4T0`_MI
M*[.!,%FL8;U+40_&8P"M/T2+T_25#\M$!ZSCD@V(*Y76AUBO@EEPP#%.RVPG
MH&ATQ$_`PV4$3B)CYU(&8ON=]_B,&2LC.DSD];K8LT4Z$]$/X6KKT#=#\>5,
M_ZH:O3M2!W;KXZ#88Y)Y]'],COXI3+?&AM90^(D\!:^=<H*3A_N1HF1&`6I_
M`(J"$V%'"`4[+Z*9!JE82NA>W#@%E_8`E4ZHX6-,/JSA&E*D3#S>'PXAKE1U
M>QBCTGMH]XG.AOBIL'Y84=?)ZF<,TM:N#+K^OK:>ZQ2+OA53YD6\8A1SVNH4
MUSG"9-3OU]D.'=>/@!*[+:H_8)![WQ7N"'*2%TN.X^1MDW:[`LWS,I\]'4S7
MO5$TZ\Z&V%E5PB32D0R(B5%<*>9XM'B?MJRT:2$_Z?BXPLS,.T2GQ`B.;'*$
M2Z&U(=P("+=HD-CFA@;<X`CD0@D%J5BGWX&JB-1)H:X3S,^&.H1\"==EM-%V
M1G"E=TK#MV@.[IZ!GBO<`HZQ+YKDX*(HNIO.7G&\-"]O"6N`SKR1]@SI(?_G
M>8GM-8F=XDK/DE&T"V@KDR,?N^3O!_7EB/),3.F,L%,JFB1'0^IY&I?6D-X6
M#L'H;&Z*G=-0)>NCWA[4E:VT:]9G"[0'[*7+(P(@J4RZ*N_H@V+ZP3UYP@_H
M%2E2VRHHTO1[`0PPLT08`NF`"RA@0IV-QKY%'I4=LK9=DC=*TA9"_CY:V/4T
M8ROUV%U@KJ8*^((D86&B5R6Z5(5X`L>1[Y^WQ9X\&,R]5V.;`HFV"3Z6:)<_
M,KII.0ZN!<;\_V3F75QT0FI2B"U3:(5.2'J!]C#\(NGDF:SS$XI<"XE0?:3]
M`+PL/=JR22,%(.'V3>$G:`:U3Y_\LHY-/0@CE2Q01UU$D<H.2+CJ4,RR,V1+
MGO9=S7('74<(:9C:T3ZY_IQ@T4KHX6C3/:!$F;A5,3ZWB+%^('XF:]#2)[&\
M75HO5B73%DD#0.$TB=Q@$R&>+18*=DGL/9LJTCHE@S?&'PFA:K$ARDX`*Y;9
M*Q'M%<9.:?(Y#"3A5DC0F>-UVMFXTB.S#2'UD8;&N[,E6M>/'E'4#W#K3#19
M<-O0(*;_`2BR`G]4)MC_$'E1R?;U(EGY?%T,-/EG=*5-!4DJ[Z"]U(!B+S)T
M^;XH/`#Q"$S)M9JT&[U>TJ.1&`;?\Y3])>PQVEA;>!7LJIW2N5>1;"Y92Z"A
MTZ8W+KX48Y\&'2P6W1V/["9E[--PL4A^Q1)Z%L5Z1S!@1RC)"I5,VGL'M.*M
M(0T8R(YP?)T<_<,T_(J#3G;1ILT`'7];79N>*&047$_1,4?F#*V$<KBL+V]H
M`E+#[#@4DWMC\J9LBC1G\2W[!JB^]>B6WQD/GY)P+[5O4WV.2-1#.A5J*0I.
M-^!+VQ5Y#>ZC:*&6FW/$GK&&Z(.H9$990@VF*.2V:`.H-T^%ZMO54."/"@8Q
MV%<!YCLNP2R2H`6I)[$O3(JNT7$7$>C;88T-U(5?("9PJ@&7XQT(L\ZHNCNJ
MKU'DNT*ASP+\<*F"V/3+,RE/S`_EBW^%]L%QM"J.Y*]THSGNBKV^!X?XU*F?
MCT>_'@E](Q8!+#VH1N]5(LL4;;TB[U59.\A]5=VH::O!>IU],Z@B]S;/>CI/
M6^`:Y-@IH7/.(B]IB793,VEC9,>NZ-&"77JT0865MW,6S41@,6!9++QUF1[^
MNJ3>!U6-W+'HEF5PD91;CC<[F:'\Q3Q/XG;KA5&/]F5B[.-3)SVL:H\Q^=%0
MXV-,^H,\V2871RXXN(:X0!NIEFN)KL!#0?U,TS$7W./`*V0POO#5^MCZL+)6
M0XOIWOES*2,1&3YOGO6@PN[3E/ME:1EM#;H5V*8B'<1M'K6-JK96U5>K^AI-
M74N^CI5UT56E`BJN[US$1!13).U6*A`*:55"%-E#.3[SII4(I-!=+'0[4^^2
M(Y\F?U1.)%$(&T3L*@'CF<YBV`C85"*!*N6D^)<`KA)[,!19%]*V`@X5=J`Q
MA#'-R3%0,F'(OJBP3^.V=18F/X#%G04>:P`_S[O$@L;6,8D35;J0,/6O4C)]
MB*&R04`:'<6G@%H*N@QNK"<R8EV:-A8=7<JV='@BBW<.7Z$MF@U_HW)RI1?)
MC>9OB4Q)'[XOJUS+B*I<0=6.7QK!!<G`?PJXK3J_/.QO]SWVAQA4\H(='M()
ME$1@E0QE<$5MPL+%3@7:8\KS^%7/#:H[ME8:-RA@,#1"(3`3XY44Q;B2,WX*
M0B\Q2ONWB&WB<AB.!S%4))KDB3GBB8,7\[1SSCN_0')8N!L)VLY%,^L$+COQ
M^J9O=]JCYB`B?PA=E'E:_CQ<Y`5_OF?\J%.58AGL3XO)O+CUHH,[2CFT#WFH
M[K\R]HG;;GE&8?>J;%F=_DA,O6=JTQT4]$0OA"M<*R*0;9N!],`]V#W7&(<+
MC:L6.6.PY)LON+ZFF$Y;PJD",PAC'/@ML/U!XL!E,010RN#&GZ4B+F2'$4SZ
M>\3CKL!>$6@`M(03X(V@[;OD'QQ;7;\&R0Q`!,O"2)!#\L^W$(C:Z2QEEP5]
MSN7$YH)V)C&,6O$5W'@(3$*#_/]Y4CO3);)#39ZZ3).?U#Z'X.+0-FO^>?71
M]8^Y(LH06P0_$A0RQG]Y,,J]]VGW6EP88IIFR7",8%T\31:4ME2+_O\U<#'<
MX)'A*>B<@]Y`-REL769)PO])[MX1L7V703([:V-&$4HR+\/=!'J7+%]1"/Y'
M``:/<IE+-,M=L^BO@2^8Q/9=W+7,),=:;AC%@YFM6,<C0[3J7T@%/^)FV$;.
M+&9P*QAT!ED?C"+?8>)6DG,K7R-%`$5F(9,4.TYC[APZ9`:)>I7,*UP<D1KV
M/2UE_F>!(I@*XO7"QTB/<5W16B#*QB[R+7`[[56PC9VQC5+6*F7+3G6?`<%M
MA>!91N!\M&UC%,.RJ52)&B@:#OY+D=25+,[G@I\RQJNS)JK$:M#SRK<EVBG.
M2',O[_IJ/4C!$9/2_;F_DC^84=GA$HV=1=Z'HI_Q(M;'%4WQ@F:Z@*YAQ^"%
M40Y:JQVX+*S@N11#\?B@92?,G,@K]_^A1C;U"]1=O1RZYZMU`H=<<!Y8ONB]
M3PR^CT3V@R\YPQS)I$<15T;@9`-;C)QL1C9+.[[9*$7]B4F8$>/E#XU;WL.H
M&C]C4.15:O77B9%1W/$&>HO_4R-'BG>BF/@9=T9A_)`Q68Z_[Y%#O-[%"62,
MII'(5P8QU<E.\/1["'K\!PFTOZ%)_FZ+3!#<RC"/N]38M!.NZ9:C(A@?%CN3
MYO.X$M7-(1JAP@E\+.1P?INDP07<MW3E"G`C;B5Q7R?3QFX@2O.IU(\1\Z5A
M!$":WJ-04?<K1]]4IC$7)SC'77^:F[0U#CH%<LA*2M1(GHY9RO8@7=^'@4G>
M4N"DN*]<"?>><JGB$!?QWT39M!6F1;MA"H6Q_.ZEH$NX><]E-)G3(CL)^`]8
MH!>Y-P@3`N>+953H:=+B`P"<FZ=:Q'0`8,<V'W[W'8X3/T/7:?,R*]BM"MW3
MMI5*8#]+.?37.Y:53GK%'.X?81MBUKNEDI'/X>Y`'XPB6C\B(NP^RZIXY"@Z
M!>/BYJSDN]P=Q9$R[,IN$P@)"\'@Y.S4!2)RD=Z(-L;(Y2C8:?EZME'-@6F3
MK0J*:.F+^#:;P)D/`,;M-8':1<)ABFH6/UITO9!&1(&]Y%,^9[[_!B]=YM8H
M_3\/UQPFML\'O=+;W*5==[-B;99+#\UQ)X.O@\<<7D'%5OQ7&`,_PG68+TX*
M7P$A`;==YOG7N?6N;]$.4FL6C-T@BO!BQF]0T*=$#S(I5N?0?#%&L3H9=_02
M[1=CHZ:/_Y<E@=VS<_3T@#A`R?Q/03GRX9J#]M_C]B!.3*M(_\5'5+%!4A%!
M8N>\_`@]RW`SQ.+(E'43AFC6&4W0BQAN<D00W!I*T>-<U`#PA[D`;.)??6"X
MSLCF*TM6KX\BAR*J`>^U.`\V5$<5!&:]^=?'^M\X>^ZO#[3^\%CO/W1TOG[P
MU!MMYU\_<.Z'[:=>ZQAX[="15SN[O]]U^(<]73_H[/S!H:X?M'?_4WO?C[M/
M_V!_WP\/'G^]?>"'6$_@_51?[3CQZJ'^5SOAA[VBOG;H*#;5?@KN?/5`^R^.
M]_^_.W:]U0N_ZOV7WN.O=W2_<;CWGSM[?WBH^\<]Q^$B?`4WP&UP\YN]S_U#
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M[U#O7^T^^-;`2V\<>>[[AT[]]>YC/SGV/_[GIIZ?G_S.&SUG_F9W^UO'3__@
M4,_K/?W?.WCLK6,O_MW>OM<.G7RCY]1KW<?^_L"!?^@\_+V^@>\>.O*WG?W_
MV'OJ;SJ._65[W\]>^4O^[B"W*YO17(LDDR03J<(VZ=2N<,8C%//F#SL''KWI
M-]9.6KQUTM+MDQ;OJ%NP+WI+6_BVML@MK5"C2UNCBUNC"_?%%L(QJ'!E<5MD
M:;G2;4M;Q4_\7XD?5M>EXJNVZ,*VZ'P\1J`1:HJ:]8]T$2O=!L_=6;=T>_W2
M7?7S]\5;VJ(M!Z%&\&;X:E\,+L[=%V]NBS6W1^9VAA9VA!;OC2W=6;]X5]U"
M^,F>NI9=]7-W-LS=WCAW:]/<S9-:-DUJ@>.VQI;M#?/IAH5[XG#SXIWU\[<U
MSMW6U`RW;6M8O+WNMEVQC^Z-WK:WKF5O73.UTP*-0&O0J_;(?-';O7&H\Z%"
MWUICV#WQ:O!2T(U=\5OVQ)=")^&K5CCB]3)E%N)%.$8^TA;^"+WO_."W2_>5
M:VPQU85!7>Q7_X9;H+9&;J-ZRS4T7UJF>2LU!8^#]]W>N&13PR(@Z>Z&6[?'
MENQHN'5S;.E?+W^&<@&JULDZ%/*W?&C1UKZ!<DL&FK]B`61HQOAYV\"SDV_=
M'UK<IR\]IBT^)K6<9`M/W3!U@"T\JD"=?UR:?Y*UG&7SS[&6<WC2<H;-/445
M3LZRYO.L^44\MIQBBP?8TI-L,?S\#)L/-YR4YAZ7FX^JS7U:<Y\Z%VJ_/']`
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MIP\$T"IWX#P="7C89P+2AT_`<H7Y>$R=WR?/&Y!:3L.48?,&Y$4];(%`D>?_
MPPC+#\L*W<FKN(NN01&%*M/%]_8?!1;7I<P_(R\XC^\^!]KO)ZS>"$>!GU,!
M<L[Y8S3..(JA/(,##2A:>)XM?!XAU`(H>HG8%-3GL0*BYA)(YK_"%KZ"1X`3
M0N6EH);Q\ZUQ4-1RU:,'KH;QF$XBD.0;B)YP'%#F'6=SD%;R@@$V=T!>`"AZ
MX]YU8"_3_[DS:&\DU_%3(WP4^4Z%<BYQ!44&3^<O[NO;7;_HB#3O!=;RITC>
MV>?H]<\0N3[THQ`?YZMJ69J4A_*X7%W]Z3]`$O",S\&:JZH8[A820(+YS*VN
MSU<J,J7SA!R0;C"YL&6Y9:`*/]4H.D/MGZNJHK=G;B1ZPO&T//LTNPFZ^IS4
M<L)'4<L;]SX%***PJD%."DR2=\;8:,$?'T4NH0A-0I[.7MK7M[=^T5$)V?Z?
ML>8_93>=#TA](]1SR$-N?HG=#,?GV<T?@*)^!>M1I:5/Q0HG4,7%`;D9ZDD)
M?M)\RM>FD,6=1.VEA?@8?G6F@C'Q]!9QFV`FU#)*!#B'QU7S0(&BH`6!)>@J
M=ACJN1N)G@@>-OLLFWD>>SCW!&L>4.9W27,1184<\2*+_J>K6R(KS*[XIP,4
MV>.BJ'=O_8*C4C.A",9KYCDFJ'U#5'AK@-#+;-9+_HC<?(;=''Q;48V0453&
M&NK<7@UKCXX5/AY5$4XT^CY7$4H"WJ^!XGWS\6N0)MH4#?:J\T4%(!$[$G*V
M)>`S/HJP2MC#LX2B%]FLY_'\PR=CN9XA%#U'*'H.Z,::04WR480+28JTA@7_
MPW<I"`)44%0.*[A5*')P$>;[^WMW-"[H5IK/R7-?@);9S#.5,?KPCV<#7G2>
MA@9&&<8Z&''?0*-!;!&#CGJ4)(PR1(X`$AP!"<1#6@A%*/(`0@")7JT%O]6:
M^Y5*FX%9AS\).!NBCJ3D_``_+655_XR/.K0$H9WC"O;S#/7Y/,+^!J+G&>23
ML\^PFZ![IY6Y1^3F7GU^A]+R3_<+%!G!0HW*?],>@Z)*V#]`$?P=3;YWZ/@S
MC?/[)M_6+<TZ$9IS#'B1U`(2\SFVX`8Y@F8"LP9>>0"&.]1R)-P"QWZ]Y92Z
M$/3#E[2E)X`@;.YQ8%GQC\#Q+_1;3[-)+[!YYY4%?:P9[)'G&C[2P6:>4,`(
M77A&@KKXM+SXA+*X7UM\3%]X3%\`K9U46L[(]$2JT#+\MA]P$KD5D/,<6WB6
MS?E3MNAE!C;(`GC<<VS^:38;%*>7I$7GI`4`H6,Z]JT7:@3[";V%/OO$_+!I
M6#Y"?_K9K#XVZW1D02N;TAU9<+AN\7YM_M_?O9H2A,LNHTHZ!+\618[O03(I
M'L\SN;>[3SS2,&=;?<O>\.S>:;<>CL\_+#7WL#DW3NUFS9U2\T&U>;_>O"N,
M=:^.'WND.5ULQGD)S#&PH18.L)M>"MURDLT$[>Y;;!9@"087(+2/S>RN6W(X
MMJ1=GM_)YA]F\[L9GL#'-F5^JSH/:ILZYY`\YS`][@@=X?Q8?&FG,K>3-<.5
M<VS!M]G2OV!+7V"SGD,E?,&?J;>\@/;=HI?4)7WLIDYV4YO:O"?4O#/2O"."
M)]#;=@5[WOUA$W`L,><,--S:&6OI;;IEM][<VK1T6VS!MLC"?WAX`V:H<(K;
M.F,BLX%"1"9;&46>8%:NBT'GTL_.O+2RY3?73%N\KFGNYIE+GHS.VCEIR9ZF
M6VZ<NK<1C]NF+-DT;<F&Z5BW3EVTMVG1F9M^IYW-.,U:7D"?SZ+CA*CG6/.W
MV9R_8//_5%_2QJ:>F/T[6^OF;VI:O'WF1[9.N6W'I-MV-6'=.>FV;9-OVSSU
MMDU4X00^PG5X%CUN"1!A][1;MS8NW!E?T%FW]"";_CQ;]!?LEE=0A(&&-O];
MZ)("'6#!<_(BZ,;`M(]!EZ!CT+VG9R[9.'W)YJG0R(=/O:OJ+J!DP\(U^JSU
M\98GHLU/3E[\2'3.VOHEWWUL,_V+J@!%SM7I'V-09/LHPO`F!B5M_O-+W]O?
M]>/6WK?W]?R\H^_-?8?^96_WC5-_LJ?[W1U8W][=_2_[NGZTKPN.[^SJ'-[2
M\<875O1$%O6S>6?)8=C/II\CYR'I4?..,&`(<S+;NR[LZ_GQGL,_/G#D1_MZ
MW]K3^_;NWI_MPN-;>[M_M*_[S?W=;^[K%5_!]9_OZH;ZL]U=/]G3]=;>SG=:
M>R[LZ/SQ\F?VA^=UH?4Z]V5D1"WDJ08&-><,FP?*4E=HP<_O6@-=@HY!]][<
MCYV$GK^S$RN<?.ADK*;GY?83%UJ/7>HX\4Y[_X7><^\<.CEZ^'G^]@AW,(+N
M+Q2LSDGSO8ZT0L0)5D*Z?NYLR:5T(+#MAK,\1?L"9XN8[VC2NK(;I)8HRS5I
M87P\1SG'T,G1/+^<2VSN[)GZT1X)/7O`A4Z@'@N#.^\Y-N<4"#)M]HZ;;^,7
M1C'B7*"=D47F;)X29O,&,O"BX5\7.=%9BV<-K'!_,8__DS*?P3U,__H?=S=_
M9+=TTS$V!V39B_K2TVS."3;[177)675QC]+2->VC_/GO0I>P8YDB;6AK8+<3
MU/G2ATW#ZFH`,8L\11T;S.#Y:)&_G\5_LH2)#A3==ZNT(K<<C1T'125_(QA2
MQ$N$I63&324]6W@,G!NDX@X/IH,KL2U:$(X+_4OX?_Y&<L.M_;LGW7I`1K_9
M>7T)&$WH_4".T7(FO&1_?,&3,Q;Q!.72F&(+#DK-PHQ^R\^.];#Z_RS/IL4]
M(FO(Q7]RATE63@[_1<T/7GMJQJ)]L?FG0XM?4!8#1(^SV?UL]DNQWS@56M*J
MS-W1M)3_XT^A2_@OK7#W&?I_EB9MLV'@*WSH9"Q7E]+Z*.''11>C13N1`:A2
MQ0)F6+IF.<SACD&10;9;$**E135!HI;-@RT+:(F8V-D#2>K<,)7^:Q.M@_(R
MF`*(.:<(I$SAYZU]Z^H7[M7G'=46@+UV6II_`EG$S>15:SD47_1$TWS,Y,YE
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M*-`_SLE3%E[.-(6VG.1\A+KMC9>F-N8_BWE^**V<\EP!7MD_X-U(U?=+!/_9
M5""?XRX5;Q_LV]2XX)`V]XR*7.@XFW-2`7M_'OD#%PS(BS;'%Z&6@I++\:IQ
MXE.@O+E!E8<_8.">P"IFP^;Y:Z]OJX<&T8]T%N7FO-/R0HR,L-FGM05@SF^:
MLIC__>NX:)+^\[7/X5V!QJKDTANC>E6IZ-5SQRS#OEP\_O^/0IO,(-.@?5+P
MO>@U<04RH&A+0TNWTOR<,N\DH>@T)<S`^)Y&Q^"B[=%%N!K2J_KW$YXOZST>
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MH:A6)EYJ**J5B9<*BAP7#F+8\3QO_;RM?U/#H@YM_BEUT0FV8`!&F=TZP!;W
M28MZM24]^BT;ZI;RM,4M2XRD`)&`2P5%`;HJWY;Q!"@R2]PQW-?>W-2PM%>[
MI4]?VH_X6?P<N_4,6WB<S3VE+3ZHS-DT92G_7V_P`L"5&H0>VMA)IX:B&Z/`
M6!L()!H(,3H&YWG.$^Y@YPL;)G]L"P/,_(<^=MN?A3[Q//O8`/O(7NF6?5/_
MCTV3?NNQZ1^%VWC!Y5E#X,4.JE/&C("EYS^K?`-><!S@)WPDQU]]>]W<_[0N
M=ML&;4EW_'=.L]_L93=])_*)4^I'CT8^MHG->V;J1_G?_82G;%X`X+D(<@?[
M:M=0=&,4KWI8O2H4I3C_NY^>OVOMV4^O>/GWEK_X\;N^^U^6_\_?NN>O_O-#
MSWWBGK-_N/SX9Y:?O'L-OY#G.0\'UQ.`Q&KZC&@<%)G!/8[X%CXG3?Y.^H6'
M-C[WY<=/_-X#+_ZW!U[[@R?^ZK?O_)O_NNS<;WWIW"?O/O_Y%=]Y;`L?M7G&
MYD5`$;!-&_D8MQVLKO?A4:]6*L6[I@KM!2358))G3%[P$%=9@);+DYP/<7Z%
M\\L63])UP(3M&89A!PBQJQF1XVM*0JA5WU,JE9"1"-"..GR$FAV$8XF/&#P+
M+`Y@XP)R[-$4,A_7#4!)U:,KGLMK,/K02S5X`FXD.$;"+`SFTR48[J`.Y=,X
M]4>*?-C@28L7.<^4!&@$GS&O9415*.+\FMO@8L'D.0)JUN-#)3Y<`&S8W#5)
MSL*'/-5!,P/G);KNE%$D1%L-13=""4;!"7@%`*;`??8#%:`C3D:`Y7"?31':
M4)!9CETPC9)KC]&(>)4XJQ)J7I5V9'@.MN38Q7S!5\DL_-K&QUD`FQ%>O&1E
MAGD).I#!BP@G`22O#*0:+[HQBA<P##O@$D+H),U"GMLYS\HYIEFE&`-F3->!
M.II-VV,UZ@J$^'B"\IK'55?`(;0,N/0()&34(SO*<1-`EG`*!6)-!J'(+@.I
MIEK?`,6K`L\XG$3P!Y/8$\BOO,M3!0?9E`<7LIYE5K&4:UL>#T254C1*B$9$
M!2>$8+,HYD!73X&8<WC60F$'1IGME07B5?!SQFNY5OXWES**KH90F3?E;800
M*+II"X6<B=^,NJ4"\:M,J6!YKO^3L?K5=8=[[)V&@Z(P;9>$#$44"7T;[40#
M'PU]R)70)U#5LE-#T0U6QF$7U_*1LNT6Z$[VOT*+-@*U?!SS_YK[R\U6@.*.
M@>4'L+5:N5&*5W4,3LM3OJPL50QY7H6':SA.M99>"(!D7]NN/09+WECUS*P2
MM5?K7354W6CE^FJP'>A$99.M=)4OR!Y';GG71Y'_VW%_&&#)J/I5F8_]4NNO
M5C[D<CWY=8T'22@IU[6RJKR+UY-HOP2!SAC7T_@JM%=#T8U8QG"@LFEV;76J
MU)5QZ[]2N^;C(:&Z"L/0NOZC:X+L!BOEX1ZC^MI50WGM@/XJP_<K#[4W]KG5
M'7#&,)\:E&Z<XHUKB;N!T*F>^]<79;]$^QV/37U`(^/\_"H6Y(WYOE8^]%+-
MB\:W]*\QULHGXYI18U!TK;R[IK7KV6).=1>J[,?KF`*U\B&7ZPZ'-\X]O[1^
MT&]^Q=9JI59JI59JY7]S^?\`#,#^9PT*96YD<W1R96%M#0H-"F5N9&]B:@T*
M#0HW,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H
M(#(T,S<-"CX^#0IS=')E86T-"GB<S5O=;]O($7\7H/]A<>A#6BBZ_>1RT:?+
M)6ES*"YI[.*N0%YH:F6QH4@=/^RX?WUGEN123AP:=;A$8-BBQ>7,_&;G>Z47
MOZ]7?ZQ7=!L912C^N*MXJV3W)SVN5\S=881'A$7N'4Z$W!K#8Q)3N$-%1"J[
M7OU&"D=+2X6$5!SC"ZFNUZO#>K7_"Y+"G[,WZ%9*`0RV4B@!+\)P?O^^D0KO
M&Z'Q?AQ'XF&"G#SG,I::Q(P2K@R+G4Q[!["[*?Q-&H\"O[A<KWY\G5RE`$^0
M2WC`*<(1':!+*0$FE^02T.NM5N0R7:^>?>"2#K]_)I?_6:]>`;%_SL-2ZY&E
MX5M!X8W+__9<9^<6TZ4!*KBS'$`%IKLT0&F6!*CXX@!CM21`"">>&V/W$,[-
M*Z)+VF9$SVSS.=TR&G&'#:^EB,GE+7!^G>5V1]ZU5=TF14.:DKQO<XOR2"X_
M4$6OX`_#"X$73Q)28X1_6$@=G]G7,S(W>8;4:4_]R4J>8A"=,7B:^(\D"!//
M:2\34"1DN8%9F&P`*7=>-)/,1M4ME%ICO2`\0Q>&I[A8#IZ"JG!A>,HL"`\B
M\<+PH/Y>#IZ)%X87B3&TT"WE>DAT'''>]MS?V^NL;JJDR<J"_%INB1!B;DFT
MC,\5+2EEG:*?S\Y)\3/,O9*9,$KRV;.T&8-ID"1MHK`YVM.?/46C\++?[FBK
MHGZWW[U_>_'NU<^7_[JXQ[![_OW?\/E;9/X+7''8/",9_$4BTO^7KU<7LR@`
M?;^7$7KJ;RMOI_0L%N*CE^'#V4)\U$)\%K(#L9`=B(7L0"YD!W(A.Y!G=A"(
M@1D9!$D7/'"Z^+:&-)JP60[2]_VB45O#NC(,.O)(B*Y2>7F7[+*4O"D:6Q6N
M5DGR#?R;;@-H4G,65).>_NR)5U!#-!W*'\YX--1\,L)K5*7:J)AM)%0N%X>D
MLC4I]T_%^-5&C(UBA._ZP'H\,[UEFG7E!DYT`&D'^N?R>(3Z]J(ITX\!+";Z
MYA'!M,5$WUQG?M5BE"11I.\7S!^8T$_]#:%=J<-J=Z`_NW8C"ET8[97+*#>#
M.XI(]K/&RX,EHTO6@TN2LJU(VEEMC58+[^UM97?DZHXTAZPFIZJL3S9MVIID
M19JW.TMP(IGA1)+P#1/1!KNAD>(]:EE=MT"L*4E":IOG67$].WK<.KS9]9^Q
M\L%(2.Q_$;T3YE#F.UN1;&>+)MMG(%96/(`1)#U5V4W26'+*D]0>83F".N6V
M@6=<^WICCU=`*MX03FGTUTXC@TITK#>4TL=5$D`1RD2#(C2.F7M%"-6WXL,>
MG"FDGD$C+VW::80-&DF*7:^53BV1TALMOFHG(52AS>`1@@JO"CR.=*K`?4BN
M<DO:4XFH+;&?;)5FM47I;I.J2HJF/MLN7/*P_KK'_T\=;<GKLB+[MH)GJR`*
MP#.'3@$J\B%!RKAWBJS8E]6QF\A4]CJI=H@,I*D?P%)OX-HF-:K`SI\>H&H8
MQ/75-W_:@&B*C;BG%6K&4.$<![5RT1Z/274'VU6G579RVNGCY(NVS@I;UW.+
MI:#\',1BPL-_<H[[^O%E=,\H("</1D'Q&N&_!RL%RWUI;VQ>GMS.SYZM(O'`
M9LOYV1C/)D#*U>>FQ)5F@R[!UWI3`LLY)=>62#0@%U9#>+E4O1!"Z^Z0\=D8
MO4/T+8JKH'62IQ^B3E+PS-"V^*0@==___68)I"=2E(V/]$EQ-U4NM076%)_G
M3,Q^MUF>.TH5N%1V8QTE9P@87LO4VEU-]E5Y=.\`_22WP_T`=B(-\^F0F;-T
MV$/O,;JR[^$\MR5_+V\A+E0;<FL[>`.T>]D3<D?JD?@\>GNPA=-+YF[<.44/
MS_C\:C\U&'[J(,61U/Z4(N;*;[X:JL11&DB,)$WJPS;$!`6/1T/ZCZ<?PG^D
M&)HX:F+]9?I\^[F#-%6R0]_I:J2?CA:L(^E;9/+J4WI("@B1@QN!Y=T=K\J<
M_/#RS3^V/Y"W!?DE*5I,R$R[N@G^XK(\J=&S3F6%Y97S'6]WZ*0AS(=3#SUB
M8Y,1]<W_/=A)/4KW"/9;6/LG!?F8G$`'S@]#A&U):5BS&^B',#L1"Y]J1]=5
ME*NQO7TH9FU(Z<PJJ[!\W5U;"V_MRL*]@FD6-7:[:)\5*5TA7K=I"C5>6<U?
MYE'I<<QP/#G)*?:<0$U4=8X*%?_LG%B\%";HVT8KH'+\0)7@6@X=30.[63<;
M<DSNNDE&%U.ZW-8EV^QH7;;!UP!10D21S[-"CGE6]7FV.51E>WT@I_8JSU*T
MNZ'7<N:8I-AQH-T6SB;W^ZG8L2%)`\_;FR1SI@^=RT?;=)'0V;2[[<CG=Z2P
MUV63)1B2NA5;<HF9.(06I&^^W4!_Z#UYOU.X/\?DHW61NR:[#"J)!D2$C3FU
M%8"KL;%&WRT[#^Z4!M6T:T6OJO*CK69O#V/J!0]KS"*6YRJBAI]ETGX^L;.@
MFDX)+CO>5EF#5=C<H5M1XV4)<F(DN`F:>#S]^<\YH)(2;&CROL^I-3<\J'8]
M_=FU"VF=:^635,1\G."4]375F^(&XCF&MJSXLOG*BILRAP4D(8<,PL/.7D,R
MQQ*PRNJ/6_+OLH787[;Y#IXKZ@QKS!12P;[-\Z[/P75D#T$7\CVYLM=942"S
MH7.?_W-#[!YF:L8VQ-"^EOFF8<'TQV6X&KI?JME9`F5]S#EK8;$%2B`PUVE;
MU_T0K)L-HLZ"#!:XB,.:\D`_2*#@G'W?@8*&/6[V]$,$"A;[S])#[^X'-RQF
M?=_YJ\U<^8Y.?6'3%I)E9KM!C&^T\'0VZXRY0.O&R4Z#E5<]/I".:Z`((<D)
M7.(&>[@*?6'\=W"&LT?+)W:=TR[+^E-3H[>1$<:?.6,HZ7PVJ7%DX4\QDA0D
M2M([5_[M[!^MN]Y_/J/:DI\`/_2H4!E#4=4=`_13&`B64(Q"SYUA:$VK[)@5
M2>X*ZJ(.TIRRP&>O+-C9*[H^\X>OWZ?K,Q:V]??T9W<`_`RQ&1M9/O;^G.NS
MWG^';ORED:,!^_E1=UJKOS!?9F3'+1)0[5&B05S\3N2/;T`V*$1>EFZEFP`1
M;0"'PS`*Z[ZV"$CQ9'WJ/E-\>@%7BDXN$!):^4D1Y",R*CP3GUH0215-+M`X
M!YM:$.,7G*86&/R"Z*2BJ'A$2@8N-\V$<1Y/`V&"ZVDD3'+S"!<E'M$&6-4C
MF\HB@Q]DFEJA\81B<D6,8\C)%4:Q:9URBA\>G%X1/[*U',%,K^`1GS91+O";
MC],K8C/M!]P-7+ZV`KSYU>_KU7KU/_[3-XP-"F5N9'-T<F5A;0T*#0IE;F1O
M8FH-"@T*,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#(@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S;W5R
M8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V-"`P
M(%(-"B]&86)C-R`V-2`P(%(-"B]&86)C."`V-B`P(%(-"B]&86)C.2`V-R`P
M(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA
M9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*
M#0HR(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@
M,3,T-`T*/CX-"G-T<F5A;0T*>)RM6-MN&S<0?1>P_\!'MX!5<GA_K&]%BB1V
M;15)@;XH\MI6+6N=E00G_?K.<"_6QBNNS!H")%+DGKF<&<XLCSYGHZ_9B(^-
MUXS3)XS<6*OJ:_:0C418$0P,$R;\`TPK-?8>''.<,XTK99Z-/K%EP+)*$Y!V
MCGY8>9N-[K+1S<\$19^M/_A8*8D"QDIJB3_2`W37O=*T[J6E=>>,[`<$=@C2
M"<&<X`RT%R[H=!,,K!9YN\C=L\)'DVSTR]GTR\R2>1-\(#@B@#:F"V""2\TF
M:/S!WZ#X3VSR3S8ZQ4?_>!L!9DL`2T)'!+D#72K!O/<!W:LQ.'3YY-]L=,C'
MW"A@DR>4.OGUZ/TI.S]CQ^<?)Z<?)U=O;B,P;_W_,3$.KFL+7Q(4Z+..68_8
M`?<9@*+H:]CBM684_<!?;Y?>)1JA+;<!&Z&%?AUQEHC3+F`C5Y8VSE#,Q?0V
M[XBI'KW\C1Y](F_^CG*5&)-4@]_XO#6VG2ZRT55KMG3!;&'[S=ZE&SU*L5.I
M1IE'JF%(24EC"JFKS</#M/S.3O+5K)P_KN?%DA4W['Q3LJ/-:K[,5ZM!*P20
MUHI71H!0[;0U(C@8K4@PPN+ATECA82RYM2$S#N2/+)*YPB4'",!`@(B@_VNA
MK1[`)MF85:D$<]T23,.&8!H3P9?SU3T[F\[61;DODUS6X6C;69=(+I*)K+7M
M$&EZ/.*<2"72N4@5(/T).Y'(*#;)-JHBLN\4B1/IC&V)5%M$JIK(D_EJMBA6
MFS)GE_GMM+R>+V_965$^X7`_8IW1%;'"RG:Z?<XD:V]5JSXRJSBOBM?!X;!B
M5G4ULV^LF=MRK!#<MXXU-";'OB^*>_+EU7JZSA_RY7J//+%N6VNLUB^U#I&&
M:J=DBB*MW<M,@=Z84RHY590;2!6EDE,EADVRH:KEPK\^5<#7C(+$!K=F5#D:
M$Z-_KG(J8A=E,<OSZSV//0=U%?:NG75"<$#?7;[`EJ?1=[>;87?O,10GT!<G
MHL_A/+EY<GS(`*Z3XR2&C;*I(TP\4JV7S9%JS'/F"U-G_E6^6%297\SN[XK%
M=;YOC;1>U`<6\';:27U2.Y'21NUA2JT523$9'AVHDH2=`%T]&J^25IMD2K5O
M*;7/55+8NDI>+*:A@<5JN2[G7S;4T.Y)J;8UI4*WTRZEJ'8JI;7:74IUGV^D
M3:847T7BE$J;3&D,FV1CAYM**30=K%!<MI1Z&H?ZC-W.@GV8KM?[IR?4+:S3
M[:Q+)4`RE=#3PD)?#VO1@E0JN1V@$K%3J8QAHVSC3.K+B,%#CZ"1/\&A>MT\
M./WVF)?[-%7$G'&N8D[S=M9ACK1+9,ZXOB3L8\X8DUHJC>5QY@@[L51&L4FV
M\LG,Z>=222_;S;G:7#U]NLOQQ>.O8L..\8`]FR^OV8<"_WFWO"G*A^G^QZS1
M=>6$4#FKZ7:?-63$+@<!QEMCQ<O+J^!Y1$[LQAO@;NC8/@XD3TUZ(]5`Z$B>
MFO11;)(M=.KY;41S^R5`V39T+(TI=-XM9T7Y6)33YG+I&(^#Z7S)3HK9)KQO
ML2_?\9WV!B-L.1N^-*O"2-3=.EC33KL'A4CNJ1N+AMG61H1.[[6WAE3HM%&U
MWZH^Y@!^O!'5&G9>B.+RH7*[+TQI76BAHAM`@8AND(J;N`I*^N@&K?"DBVTP
MTL65M(K'W>"DU]$-7@XHB<7*QF4(`3INAP"0<4.$!#,@1<&`,X26`YP*[9R,
M[S!*VO@.JR#N4N&4'?"I5V9`#^\&F`5N=%P/0'/C$0J@Q=`.9^)I`.#%;H]A
MLIY^SD;9Z#]B06T/#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C,@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R
M(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@
M/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@
M,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3
M970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=
M#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-"`P(&]B:@T*/#P-
M"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0T,3`-"CX^#0IS=')E
M86T-"GB<O5Q9<]M(DGY7A/Y#/<UX-V@N4(5S^\F6W3.>C6E[6W+T3$2_@$"1
MQ#2(0N,0S?[UDUD7BA)%[4HLAT.62("HS*P\OCR*[_]Q??7[]56P3/*8!/A/
M_I4MXTC]5^ZNKT)Y)20T(6$BWZ&$!<L\IQG)`K@21`'I^?75+Z25STJC&!\4
M9QG^(OWF^FI[?;7^3WP4_G/>")91Q&"!9<1B!K]83NGQ]3R*\7K.4KR>90D[
M_4!*WE)&,R`^#`B-\S"3-*TE@^IB:B\&V4SP^[OKJ__ZL5B5*;)W!Q^0@I`/
M-:R'%+AD,;D#YM_\2J/@/\C=OZZO/L)'__<R"R3.`N1%3X<GL">>3M.(Y'DN
MGYY'2YHQ^/N/ZZNWP3+(`OC4'E:]_?KWO[_[^9_DP\?;FY\_?;G[]/DG\OE'
M\OGKS^3]U]M//WV\O7T98>?EFJ>Y5[':Y[^8^*>DF@0D3ZA\>+`,(Y#Q72EE
M&@4H:Y3IW;8>R##M=D5_(-MZLVW@9X2W>,/+D5>D;M>BWQ5C+5I2M!6I!!](
M*T92BG8L:GBS:<BXY4<WCMMB)/#@>M>)?BS:D8R"',2T)/\4$QFV8FHJ4A8]
M7T]-<P"FBNKBS./.1;%FGF9XGV(^CA.M4",RW_5BZ(#7:9#\(2N5**<=;T$,
M>TZVQ3V'E=>\[T$<P`3R`GQ?FEX&Q!J"$TDK*!QE%U\&G-4LEY!&J9$+2_%O
ME,NGMA0][)S:3+$F-[R7>_W!"F9U(#^C3'A;\HNK+1K%(TE$%U^&SAKBP?9H
M[,B9A2!VHW\)_HUR!N%VQ8:_QJ\\N7SJ;G.0T<3:/OHB7)V`O1Z;]TI,HQ<[
MA#BL]2T+9D*B6-NA-CTQ]61=MT5;UD5#AK$8N52V)7DWD&D`Z]N"PM7M0M[-
MOY6\&TDQ2)-%;\2_C617'(B`-_I]/:#9_C[5/5_(6T;>[X:+LQ=GS/+GT6SC
M+'?$&-!(J=.;&['KBO:PN+C^1*?8NKP-1OF#9=XF2[`<I:`^!`F@SZZ8I\LT
M8XE$&F_V_/)"3)/O(L2,?F\AYJ&CC2Q/51`!0[ZX#-,@_1XR3,.'^NY;ABEU
M'2,LH&4(7O#B2T'Z\SUD&,WJ?OF`FD9''C"+8RVOWDO("D/?+AWR/[,*\)/J
ME3X<BJHN+QX^DA,<>4!4=A4/@"IVQ!4&J<7S+$XUCMCQ`L!!*1K,7>I[WAP6
M1,F3?`)XT+<2YQ3-`EZ62XDB,'L!@%L#I`4(,8BFK@I,>X9I-=157?0U'Y:7
M3OIBX./U@CJ3LF9YZ#5EM<]_&?'9V90UPSQUIW)_1NTVTS#5Z<EGP(GOIZ%N
M^3#X$%X<^16>>;Z/?#_#,*),)&$VM8LHE@%0=K]P`FDW*<BF$2M`V:M:C+S<
MMJ(1FP.8@$239%4,,O4G?YNZ&@QG07YL1`^FL2#[>MP2T7&5'`YX$X+KKVV-
M9G.+H'U`BWJWXWU=P@?^*MH-^1_\#^W-@ZO.:&"SBS"<LPNF\YP=9*X-KGVS
MA>1B0;X(^0I_[H#RGSBF"_@6)!I:/+S=0%XF)=#S@1=]N57%#PY.1728E2QT
MVM$TD#:A,.XY:>J2MZ"7&Q0`9C,=2*-%N<CT!M?Q(@`LD"D4$<WV$L=1I@30
M]:(#/S9BB<=N-O@U+&1HCKSL#:6Y0UN(@,=N3A":S6FG=5&.$T@==!$)*T$M
M@>1J*L>Y)./>A^\-1<.EXVZK:1A[3!AY^\=AQP='UO"4$?+%06:Z'@2?9HD)
MWWD>VW@4Y;&I+W&'P`4RV'/(<#EL!%+9;0O(O4L^C9)I<RL?%O!WV4P5J-)_
M>_!P:9)X]7#V^3YB6QI2O\2;Y_L@/J%^8XM]O@_BXYAY)=X^WT=@C)FQ50K@
MT3JB=(Z+LM"K_:%VV=.`H;*==BOP)N!M7$^ZGB!(8)FJ+]#%@"]53HN?<$1@
M^#L(!>@%P+97TRA]FFCQA^RW-827/??AH>(P-^Z7S15(EB>18EOR#"RU9=T5
M6(I?BU)6VFH@?PY?PV$8^4ZZ4>U3C8<&#+`@SMO\6P<1<Y!O6\9*TR.X"<E'
M>P.YE4]=$MF#4"]P71]B"$P7A.6!C9"IS+E1#`KO8*W;#=HO(B0_0PB+74J"
MS(G5F4YA;K;]81!#!VAKVI%F*G]KQ1Y`Q<6+[#1WQ4)9GEEB`J,=4L<GT%@D
MHL52ZTVXP%^8+FW%,#I:`$JP*=IZ@/U\]^0UJ5:7;YW`#D>9;6GDX6S><:3M
MVU*@E'(+3*PX;\F&MUQ&7]#]H@$3A7T'4]9J+"\?V3:8_H:C<CRP`X4=JWHH
MQ;UZB%+W75WV8F9?@64?_">ZI,F6.6ZM+&GNZNKB[:-P7HHNHP!Q'"[U]O)]
M*KN0[`%G,[R*-+`/\SSXLW*S-:0?M=S$V8'7H\I6A':W1=<!0+<]K9UH>#DU
M1:]QYV'A[G,+H*P']U[RIH&;!JY`)/H'[#/4C0M)$?'[V-/8ECMD:+3]&ZW3
MX*E'`6D6Z-[[`P%I9`OTMBL.VH:\(,,'AT^MZP\0L@UHQZG@*$0C-1^4&/XO
M>PYN$6+"?(OCX&5[%&_S(04662>5V.91'.4Z@]`-("#SK^AU[BQ]2Q\8*`K]
M`CC[?!\8B.6F.!`$,QJ@26HQT!Y\E_;6?X`)36V%^PKB;8L=R/CF"_E%]$VU
MKRNNBF@R'!3D`V^*/6;.1XUC"/&\@ZB.Z(FR!:%!0)?D<TL^EZ.0;^;RS6CA
M"?ZP++`)6C8WNI-`>Q"L=S32G<L<DX-O[TWNWO(]6(_2>X4&]UN!'@9"H5L@
M!#M`N;PK?Y_JH9:,WX`04#*F:N)*15=0E--"([4W^>`_L=DW#7++?Q89]N?-
MPC8P[X$]&^N?KIQ:R]>V-TS]?7V/7O#!W(`C561XQ4M4(Y3ND2Q]<!X9N!^&
MT9R:)Y%.S>?M6Y(?@12Q1_)G>A=&!YR-)N6V:&59"."/-`C8OU-2(K\&<?#U
M]AW\"G6M&=^Y?$\XL7SZ;#WGKC@]-RH2%MC%_`*,!.**60E+S6FN&=/VZ&,B
MX_%N7;X'DZ:G!8C*>/F@DAT+,0N=.1/C9M:]V!D[\6'J-+>ZF=L2(Y,H6$TS
MG7!@9MY$FC'Z,6/;3YBT-F/)RHDPZ`%IL,#OV*%]O@^D(86OVQ#)/'9(39K[
MJ<5V6\M5>B@CHNM[]S*5ZH3,RE4XALLM&016?57S`=SU40R68)C<],5Z)%^*
M\K=B`[<\CE=.:=]3*H:?-JFH,W85AZ8<;X@C*]W$PG(O``%3T]8]21E9MP"J
M!O6J&-U8A$.((R8E$J/]X'Y(BDJLUW4)N8'J6]0]B%KT@[E%CPUA=Z/>8`B6
MBNU#&+$=_8H<!)('N2V1UY"&"(6<%+42A/:\:XH2*)/*X2?8T#BV!/H--O`1
M5Q1L;H6PC&H_I>/.GX<G]NX'^=*/)*(L^TZ2B/(CI6!.+992=B0)%R\^:?D(
MW[PT=^2(G6XK1G-;D44F[RQ+L#U)33?UZ*N&A0MXT=GH>]"^Y*PE&/FN`+<'
M?U>\55T?F0/T_![V&_)K)XMX8*JK@Z>]3U)FF?4,N0";S&(-LFQN"-(P/MK[
MA9GOE'ZO]5)9H#2R.YS$\PXGFI2-$!#BT:_VNEP"&1N@A'H%NE@,`\<J*!;0
M9241K%3T%:^6D`KB7Z`8\_S)Q:V(AI9\S_9*8U=0"9WME9F!#&.OJ/(5YSL%
MHU9<E=UF.Y':W:L4VU5M'WL;V#D(IW88L4`'870MV-U!,E3J2P`_E+]!6EIQ
M%2<]Q9PHL,1YCCE1Y(@A2)W^#S43Z`\\K>Q*04JN!(#.ZE]P?3P\V+"+9Y@1
MLY1&-C6BEU\F=03"PKEEGX2A#L(#J8=A,A,;TSB`P5<RXE@D5HK=3GAI8H2Y
MG61A\V$=)@>B)'&HH00`KB[*&;@LAP4&G$`!\AX1JCZEV=*P5]?+2=D(,Z^"
M;W=]?8]E7@F]<,K%\\;C'+%AVN/&XXG!6;:0^%B'D.#9/KWQ`R\G4'8<C!'>
MDH,PM;,ZC,ZH(J.&##3#2I;:!V>/%<H!3"SZ$XAC[(MV*%0N54.*`U[V'G()
M=>Q*;C=L?M&62C^D.OA#$W#%,.D9382I*\Z`.AU,FAW[-X1?LHS-1P(VH1H>
M.H3[V.5X+I=ESF`0,]W((ZLRZ>ELV,Z&PG:NU^HHGGA<.%>Y4ELW"QEG\7$U
MW`F[BYBR++IZ+)KZ#UG$N'P_!!+]D%U@E.A,(2&T`PQ!P&S^2&.6S[.@_!M8
M[JC<'R9.@YSA:T2I*O<C@=03JSE]48H"''I#O@A`<IQ\`'?'%^1VJN%%A&V(
MA_..A+$H3>=RT<@;WFUQ<$,/A8"Y86DW3D)97TNCRY\3`)1LI.#7H.098CHK
M[CQA;>LV&6-L*<<FBZJ2'7)=GMES2,A&]#1DO]\O/6&G-+`4>L9.$')G65`$
MP=:W9-I5_Z474[<$HU,"D2?0\&CD`XF@+N)YV:[H=3@].G0ZZY:J-X*#,J+U
M,PLS#THXZ9=Q3&KLT."$!Z=CY>Q&W19RMEZVP2>PI=X<`P7_U!R.*Z&H40EX
MJ12"+Y64SB3)P_&H<6GVY/7?Y2TI>/,4>Q`G>`V#<R=LP!Y5I8$"BM*E.`9H
M3^.I7['U^4C&6:16#+/32YX1+WXTLA-7`9NK/*%I5ZN3B'*"8`%AO.G(GT`U
M.O0YX+MW(-`UYQ6\:$H!R<@"ST'VY5:IR1HR4MU)N^=]L>%',Z-[/!XIYZVF
M'G9D;`YXC+N!@-<CM(?-BV+2U(`.JI/SOJ]DG%G7D<]]>A8;QBN(N&HR;I[N
M!7@R$P?QS!WGM=,-LF[2P6>^U3A$!US%`9$YI6'[X10":"H:U$>UFCDJ\,-+
M&'XJ]&&GP7#\N(*.DYX0<T`!DU,&^HS2)GGT$J65*P(K)Y<\OW<(D&V"KV!4
M"%NGZR#N/&//&QE5W6$1,[$-D5?/R2`8P.RZEF5^4%4)6N^+OA;H2#9]74[-
M./7NI#>&4;[<++&'W*K.Z=&-6*JNIL>@_)6<IW;&*-&S\UB9,I6-Q]15/0*L
MJA[`@AO4SHV:_\0;/GSXRP6IP]*H(>],<O2:%<+0$0"-Y^\"B*D!6(/:"O`M
MV'\`#+57KFB8-D5/R@*@T*K8()3&&W'CE:."[1K!XK5!'\SV.9+<HS.3'O`)
M9_2:;4UL\3:?3XI%H3G[7F[K3G*FAC#`;V"V6V!A3S)FW4I9M*J?LN+J"+I.
MH-WAQC7B]:K6O7]D1DV-06I=$HZ^#?UX@=\F`=X8G9.9O5*Z=6'6(UNL"^-Y
MYB5CL9D:,\&AXHA_=>^GXV,O&C[M(.),F(P,6`48[+Q8)YH#>F-WK-<Y:'?D
M?"_(4!(PR]&9&8=7K9`[,G._*8$QJM7EO7-PXXO>M@N2D(;Y"28?C0:\9@4`
ML#.3)JR\.1D27[P&H\X:49`KNWL#VO."59X,O/&\RLG`&R<Y!E$P[?]_X`V2
MEP1>N2*P<G+)9XQU+E/G>OXD7*8LU<YW.^V4_^D!(>(I(3MV7&)9$NM$@QXH
MDX/[1'Y)SUBO1"6A$98],`ZO#@_/&DD0>>+L'U:_Y%3SHX'S5S":YIGE]'S>
M]CIIQK;&%R3Z>T;8$A;7Q:"RJ5O+O'U1]=/&/=CGS@DKUX=U5-[CEY+H2@K(
MU4R,R4]+='J/0R)/8M$+,VK+7F$RIZ9)8KZP`/S5;5EC4C98^/NX_/-_H.$I
M*\0RNB'BI!4"E,"D+HQ///?,]X!%X.YCLXGZ@#][F%*RIQ-&N/H6]_O<]3`#
MM'ON!IIEP=D;6`X,G+LARO*S2>_;.(O/$YED:7+VAC3#K3MS0Y8]0V2.W]=P
M5E!!2L^S$89I\(RP:<J>686ES\@BC-+GMC1F<?K,'7C@_NP=29:?EVB8YO%Y
MD8)JL6?HR.DS&TN#D)ZG@X;@WIZY(\^?N8,R]HP50`KPM,3`$C_^X_KJ^NK?
MY(\D5@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HU(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*
M+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B
M8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U(#`@4@T*+T9A
M8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$
M1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4
M>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C8@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`T,C0V#0H^/@T*<W1R96%M#0IXG+U<
M2Y/;-A*^3]7\!QQ<6]DM64N`+_#H5ZIRR#H;>\L^Y`)1D,0U18Y):F:47[_=
M>&LD:YPLD7*5AQ(I`MUH?/WU@WS]^?;FZ^U-LBRJG"3X3QWQ99[I_^K][0U5
M9RAA!:&%^H:1+%M6%>.$)W`F@3.#O+WY1#IUKS++\48YY_B'#-O;F]WMS>8?
M>"O\%WR1++,LA0&669JG\">M&#L]7V4YGJ_2$L]S7J27;\C(2\88C,QI0EA>
M4:[FM%$"ZI.I.YEP/^'7'V]O_OFC6-6<T)1\A!\H1:B;6M$+E#+EY.,>IT3+
MI"`?Z]N;ES!OAL</MS<__"IKV4WDK;R7;7^WA^/Q[^3C?V]OWL$`__[^:92H
MY<O3H"7W\_B!S'Y[!G>GYNZ_L2R9?8`B&.!/3__J(B74+E)29G:14IXPO4CO
M._*^GOJ5',"<%X0E"?S_(`FLEASDFC3=U!-!1ED?AF9JY$CN#D.]$Z,D8CM(
MB<M*?DOR9-K)V07(\MQ+H"T,EH&ELX]3T%!3295Y365XC)IZ]?K7M^2#U\,O
M5@^OK!YF7[_BHOC9[..4@?@56V;J^'<<+0&LF7\X'FJ;%;RTVB[5,6K[H9EV
MY-5*=MM>S#X#V-<5S]3X,&B2`<2:";`$)J<F\+KI92>'[9'\^K>W"_)35R^5
MG<\^ES1QDXEHXC0MW##S(PU-*W?WJEA6%'R7,B#<-+,/!CAVKK'9=P7E?F%@
M4Z1%DOM-L9A?A94?#L`:;N4@J,1CM$G`X<-J;-:-&(ZDW[C]X6WU33_<]8.8
MFKY;DE?MV)/^$L"_/8IU4\^^L8&X!!KS,/)R_I'R4%E%F3OZ0?$8E?5CVP_-
M6CSU9%W?S3V;LF1_D=P(7$5IQ<YYY<1.\!C%EH]U>QB;>PEW'J4`'T5$MR9K
MS\("QZU1%AW;G1PFT71-MR6@)G3F==^M#_6$=B:^?:\8D%BDI1,S(B066>J&
MJ?(ESU*FEPT`?WZ?EUP0*8(G+[Q(\1TY3T-SS)CSXSDMC1^_&_KM(/9H5*OY
M"2+NASQQ!-='(6ENHY"ZW]^U<@(`Z.\!`P5:>M.OE5G?P>P>F[V89'L$FX==
M08Y@YN."'+HU7/RP:\#DXX!E!A.T<X\+&AG\+-!2EI8>+"W=LF#YT+0MD'WY
M!1<,]`-Z:2;@_$-_-S1R0K\SR7K7]6V_11)LL")$A!AKG*9F]FE)G5\L&#5^
M$=:R[L?9^7=6N9'CKA"P)2]B@@D':\:T,MY,;C:RGA#69??[<2_)OGF<#@#+
M"I$'V0HT<5BG6HXCHCA^O1?=82-JN$[A>KAPFWX`G>WW<J@;T:JE;FK%&\!1
MDABTK>#429DY"&3S#Y,'RF1EZ7QDJ8Y1F2-9`6.:=@+4$<5>,>#7NPUS0A84
MD]S8*SK-6K;MH>W'IB9F)@JC8071Z^(ZF,6,%EVSK'0SC>AF&5JW4TB2Y$XA
M+,]-L`4>-UX8G6;L@IRS^]XTXVZ8LWAA.7MN*LW]<%$R7[PJHB:^W/UCY+TX
M;G5M<'G*/9SF)NWU'^7?<5=!<+`?D0W@A^=S/`M]3=/=RQ$1]P5,<0].TP#G
M`;@#0JMF#@TP;#&29AP/<"E;0!"^*&$*XTX@<L.@$<"'%\R*S@M/B-+"$*+^
MH)$?)CQ.??V%B(F\R)8%1V:DI^8@IT:``M>AOP4*4,N3@#*W`25(.4B(/!7/
MZK0NP;>`2^G(!S7*NT?09+>5<2*&BCJY8T8,5>F&P<11H2WKAU<_O_L\>U")
M/ST3:7;4*C.O.42M$DB/0ZW_#[F^.62>!T::E4:)GZ*$!SS+K2M.J<_J*K=\
M&AY,NP:);G,/3(J,HE66_B\(&O9HZEQ;^I)HY*AUN$SJ9J@/^W$2';AJM0W6
M<JR'9@4W7`$E?E#)]+TXDIT`[@9T68$!$>MU@TY>M&%JW:!0##4P[JPV88Y?
M`@4P_/(-Z$%T1YPA`MPRAD-)XE92W/UC.)2RHCZ`"M(NF:%T8+TJ=CJ`L\`U
M5.1-KH%H#_W^@FV!GC<09.IKY0`^8X\VA":``(V$J%^US591\M'$HWCQ"54Z
MCVDCV$Y9ND1;6C*_A;@QG2MA]*7]$(;6#_)2Q(D*^",1)^JL`]4-9-\/4;9/
MF;LL!_.$'K1A4&2>F*P^@$/>-[\C&/518K`<SEA9(L9@.2T#E3$:Q$#4JNPT
MJ0#QV%Y`K(/Y[6D`O8U+\M%8>XSUS'S2*/<F7=BLE=]@==]-$EP$3@D,#[B2
MM5FS:\FJGW:*U#0J@'.94K#*+6;EGT37-KMZ%OZ132/;-:#"`.>5<>`^D(^3
M[$[3N3'TP5(7L/I*?F88XUG^&#ZW8MC*V6>2%VXJD1/I".E>:#18EQ.S*9>Q
M1J!^)H>BXW4\I31"[OOVL->N'-!.I:7,6D,8`8CX>&Q%AX=*BSTN-=G)?>.O
MB;*^B8N_2Q\1T,ROKS+@<PL>[V3=;,!(`Q/6@J,1BWK7@%U8$,:OMKUH3\,I
MW,*_^"RP,200GTC87(!WH&8`_?M&K%H9YJ0BZ*'@E5OR,@V6G+ELM4JY6`&#
M;`PNZ-,5=DFYA5_LIZX@N-45M#O1=:,J5G`O4%<,)93,@5_BJXR%16;%_\A/
MG84O16$Q_H,E[-"C^1)3_P!7C+OF3J73`11QZFT+2CG``J+(P)./^'N[[,B9
M^ZZ36JFJ_J3<?4B!'.\Q7"&&#O+<Y0>X#PL2;K;$&=.*08BQBAF3$+O[QR#$
M!>67*!'/JZL9EA.E+DBS0>,8#S5NN\T!@<!:2DCI_@"_BF$LOH<*<XE.U,R@
MQHF+P+4\\Q(*"'%V>(!7R$<$.>T&2']GF`&>`90%AZ^"SRC%ZHR73J#(=:>*
MAJK+*N]CT^2L6KT28X.("'XG5-_"\:V5:DIKIE;3XPCKG/N.@BSA08RGYSK(
M6N),[0IM)$[/31;B%,#'<0-6CV>TC?9'T>K0OG,\+W`JJZ,QC<VF:1MT!`L;
M&1F18=!^VZF8`((I\,N=7,^?3"ZSS$D?)9F<%UE4J'/WCP%U>>:BOZ2J@NC/
M&,:/FK(O@BC]>Q+)8-@J*:3:,91-V^1!F%2VB8(S+[EQ2:@86R'U]6(>-->D
M!O(V/<Q)F`P66OH)/W0,LNFN!SOX2Q`0F`\<=/U$6F1?>`GJ8.FU$*L&5@`'
MMK+&3!RS)%`IA)P!Y;!6A)[Q`RH"/=E[QX%FS[X6R06)Y\\K%X4;)GXG2@ED
MWNL7Q#$Y994>B[$]J&M(4+&#:4C(6>[I8PT[=I31<KI)[F81LVV4TD!8BFOG
M.FSP^,1PR<]2C,#/5#SXBTI)SEY,YOR"V+-;+ZLR-\S\+H4!$[)W?[HW9B^-
MI4FX@@DO?`(@+PMOKB:%K.+O3B4T+G2.*L`V$!4D>H'CMA``X[<?)JF35Q%V
M75;Y+$;0ZI527\/8-Q-,0'=VW8-K,KNOZ<`-P\</$W`LFZ[XU`]?=!^,:$$F
M,2AA4,Y2M_BN=<['I:HQ!@9O91-_SLM9YR3VX!4G,O80(>-^P)SW,8HB7'6;
MED$:0QVC(G3'&M!'G/X@@9(.FF"(,0X8P7SLG&*"$3`1+WI2!O4\9G-9KS0/
MP522PZ79MQ3\[%S<^1M*@-?:869L*/GF<*P(M5MQO\,R;H#B)Q6NKP8IZIVK
M4UT@+0MD?K;&B89GJ:H.B(ZS^_]@4\0-:DL::HFFWA]RXPXW`(N+*&WF1?H7
M"8G:#+M(?'HG+?C3P%V'PPIIFNUN&BU>]H<6:WXN:VA*6BZ;:-)\<KW`#I08
MU:X,_)N5(V*U*^-)H"Z:51Z164EMM4NV.N>Y0$7(1B7^T7$\*D)\WA7@6H1P
MF\588-<8`<[4-YRRRC=&^!:A7L_U:.H#X&7M<A(![G/<D?&P5YO>2-9TNB<"
M(UR5F2-KH`C@7<$I@Z#R*^:'32G,N$UPE=IR3B,_,#151U=%7WV/&-I@/IOI
M/:K/9NIIV[+&!1^S4-2HV=B%0PN'<!Z^AU\<U4=UCS4:NRJ4`(A.H"FXIS>#
MIWU8)WH_:<B"B!K_FI:L:'TC&76/Z27,MSV4B2F46C,U+5\_O_MLCUN!!8Q!
M*,^P%D>;"[@6+<R?V`(14M.Y$2OUY.X?(_64^MZ+)*A3V]`+_3%L.%`M/JT&
M6@ZI^-/>I;.NOC5VHQC;4;E+4>O\35#T5A3V:D8K@M6EOMTB3ZC//K&GU7EA
M.FA.J@J:O-OLFF_P$K;"AL[H>*=%]V)C3V??WNO0QG:`:?@]P4+4HFJ>[^Z!
MU#2(`C%4X#L4N'\:V3V,'#:-*<!5.;,',:"S'1$W=%%A5,@!D",,5(!MV*N?
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MT"(+&I2L/9QN6YR$(M!GP3>J``';U8T"=2A'J:,/*^_S^U^-T#;RX-A###PH
MB]RI(')07U2ALG/;UZ\P(,;"NC?G,)KYZEI9&._N5\(!D(FC="\%TAY\/+O1
M=*U9XQK5/J*Z>)59*G='X\)A)571/=A;P9[">V"*-(82F'O?2AFT%2L,4$I0
MP:"R0IU+L,X'#)X,8A)6%!`2=K/8RME[=("`LV2&Z.$*P:?!*Q_\>U`@IC!:
MP";8,\ZEE'+AZ038RX.F+8/<-J-^[X$O2@?L_95^L)]6::JZM($KJ7QUM#IK
M53I1(V:(RR0--9K[Q`:@AZD2G&IA_DHDOR#H_.55&()>>N5$G/)J10.U)CS/
M37DU"C!0_TJ!(@W>*Y;;YPVZ(_@N]22%7\I6/(Q+#$K1S4T6"+^S#<-W8&P:
MH`3";!_]'A4]EG]=QI.=%*GGC)H']M5C9K[I!,B:X:?N>3I5]1I'VR4Q_ZM]
MN)M,S-H.1+;4OPZ!X7-IRJ`_O'LS?_-W<4&D^5\@5+)0I,A[%&MPU+_E(4]\
MT@#?_61RNO>Z.(LV#"[%4.3IS,=<\"W*33S(ME7NXFE"0'5RPL9<:**)Q%IL
MICC-%]2_*J&J?#8@MT6J\V?V/IUM<:V`BYL<%**IAWEHJT=F-!U&E5H@=V((
M<>#=&\R/O05FHD9D:5`GKP7V<S6QVKBI?Z:^2'Q7&F.&.:PD\'SI>]1/9VV"
M/T:?#?ZT^@;4U]=#8PK)7Z2\^WXEQGC%@@V5@4O[U\XD]JTO%Y?-J^(`?+E5
M\P>&#X',8+>!3HEV;O)N8ZCP=R4A+AI[X**J:Z##\I;Z>"(@<ML"X*RL0#@E
MF)=`O:(3SE/*KYVG^!JZ;YW_JBXIJ+H`PN1SU1777CN3DL)Z<N/&LZ?3S]FU
MR;U$_W_M/%"%Y.H%P'33JQ>D/+^JOY<9OZ[`ESD'T+MV0<%9=?6"LGQFDAR;
M4*Y=4!7\NA0TP>3=U2MH45T?A++R&570M,R>N2)+\8F]JU?PDEZ_(L=BV=4K
MBHI>UR@M>?7,/#A[9EUIA:]"NVI]2<*>L<\$WY=T]0K*JNN;@%%,U7WK"MAG
M[S[?WMS>_`\@C^:C#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C<@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R
M(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@
M/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@
M,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3
M970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=
M#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*."`P(&]B:@T*/#P-
M"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,Q-S0-"CX^#0IS=')E
M86T-"GB<S5M)D^.V%;YW5?\''*923DJC$``7\&B/[4HJ3NQ,.F4??$%3D`0/
M%PV7ULB_/N^!!$#U0LTBN%)3U=T200#O>_LRW_QR>_/^]B9:IWE"(OQG_A+K
M)!Y_%-7M#35/*&$IH:GYAL$??)WG3!`1122/,M*JVYN?26WVRN($-TJ$P%^D
MW=W>[&]OMG_!K?#?[(MH'<<<#EC'/.'PB^>,G3_/XP2?YSS#YT*D_/D-&7G-
M**,Y$30B+,FI,'?:&@+'AY%[&`E_X6_N;F_^^KV\+S)".;F#%PP09E-+.@6*
M(R[(7857HAE+R%UQ>_,:[LWP[^/MS5>'X;[417DB0[U1+7D[E(K0./XU2J)W
M\(.29DOZO2+_4<70ZEZKCGQ=]&ORLR*5/)%NZ`ZJWI@E0Z?LZE;M=->WLM=-
M3;I>]JI2=8]/CWM=[&&-[LBA;>#EHA\Z`I\D.<BV)]NFA3]9]&=R]]OMS7=`
MY;^O@D66Y1Z,G*WC**+D[G=`X/6UCS*P,VIACRFUL/,<_T;8-X`=X+/1]8X<
M5*N;S4AY!ZC6)_S='QO2ZPKPUC7![RB[]D49*(V[:5A,6)Z?@2)XZF0QH?$(
M2M74_7Z"8TW^7I-"M;T$\M4#2$^W`B2*<C"8P9<H9^;!QTM<$$Y'\404HZ#L
MEJ@LRR8%>T[*-PWPM6YZ<J^*I@(ZMEM8HA^483EH(\A"H60'J_H&%LT6;$`-
M`8`G-$]2M!D4OO(8N:,B>PEORUVKU"8$$+G(+`Z,>N8*>&1P@$L=4.@;\O4W
M;[\EA>SV*Y3S4K\?]`;X!7>7E=PIN"VR<`"FC>R58%_@&R7A&R,B@(^L:P"C
M[61[0A[[U;`GJ$O5#/"B>C_($D^DOT9@W&$=FK4/QJPA?B%0R")G;D7N4.!B
M,K?U4-V#F<4K[V4+[-VK<D/N3R,HLC?\/Z>(5$/9ZT.IE5F())P<"8>A+?8@
M)V!,=0$_I?:[H4$QVTQ'P?K:G+="T_N@-PKM-IP9`@?PBQ,.23YS.U;5\>Y]
MTP-[)EX!R;(L)_^!],@3*K!1&E04$.]*]R@EP$_UH4`III'E*VXG=R#;.Q"D
M)5#6GTULND`L'XG]ZE<6?[;C>G'_U.]_=4ZE$`;AR893D=-:[L*#_YJH`.$U
M(C6+`GZR('^-)J4RJF?6P)?6S(S.?+),P*:F5N2D9`L/RK(YHAW[5_.@C$J(
M%7A]N`*PMP++9:Q7`,$4X(BL8,[B(6H)!M$JAPX-[;VJU587&F2T.=9@:_;Z
M`$08HW54(*M(9TW\"V#EAUJC18+K*]"X'OY8S<3:*J(Q:/`9U-/A"<YMBVX>
M?G?=(.]+8\9UC\(,G]'+-4'P$,RRGV<.#W#7,T6]S/HU^7YHD:*J:=5E.<#8
M!N6@NR`(K=JV*`?;MJF"$)\F5AAH[GPW3_%O$Z7I%KSNZ(YU[3Y!&-*"<S9Q
M"%BHYP1EA:\\%8B5$6_`"`UO36AB#5@SM)-TK`,8*!$G00V4VS^$@1+,93`\
MFX72>3HRZ0XD%`1,[1IDR$9U1:L/)B2:M.ZR^!J-Q*5O__3M[%MP/1A!Z"VZ
M7A!#9#9\#V+0G]"A@'@"5^M"A=)-2IUNYHYR)O(IB4"A>3.T+=[UK3HT$%@"
MU=\W;47$U:^3"G>?P.E3YBD'<J,D%Y9TFD=3-/D/,H:,/Q9]@T:#I:/5,-9Y
MJTMX=-3]?DQ=OWN#N#@#0\>E5U>TA&?NXI^O"0MJG.4TJ!J[_4.H<9;9/"DR
M/MC:6C:I\8]S#F66FY"W*&,[40%!R^3,9?HX3SJ5Q>@X1&@?IYFC8`R3@`F,
M7_T8R"`]4#3.TZ?V;M&279UQ/'^&[OCJQX`#L<><61>3Z%S]M(3-4&:1CP,3
MGN0CRL9ZV"Q:UP_@O)NV"V3HL\3FSC3R01A/,VJ+=!.?L12$6<V#27-*68Q2
MSU:9R%91%-D(<XHHBJ:J3#FD*=YA<BFGC`@>OXK78-$/:@H[C`<\RK:5F'-A
MKFZ/'`[X,4FR57RV?P@88IL\1XDOI7`JF/=W3TC""%RUA7;I'A*7KB%E\L1A
M_+EKF\[4'#%U-!2\HGP5Q7Q%T\C4,V'K0ZE,BCF6)Q_##.=^JPKG1$(@P%S:
MS"+G]K@KHAB_1=XT1U4;CKV!*YNDX8<?WA!9X-UE-U;&?%KB[B]W^!/!,*6#
M)_3AD[%:!F87TY`QVX8DY"7)"`%!E+J8?%8YS:+,U9$$7Z7TDJR_2M8L_G@!
MI^DJ8^S2GN=R=?UB0I:F#H`@(40JTJ`AA-L_1`B1IBYWYTGL/:.890*.Q5Y^
M4=B]!;<5U]%HF$0;6/Q/>2)\#`PA]E`?#MKD:.!5IT05DULEMQ"*K$`LQO+$
M:&_DYK>AZUT:$4`ET%]-=C'+,U^DR2>5`(KJIM(%G-_K:Y\/X-KSP\;]>30C
ME++8.X`L=OEX.9C,;JMD/[18-3DKQER?>@:>^8\AGZ5T3C_WK01(_AZ1#UZL
MQW9`,Y5&1@/5'4K,4%$(.UWI4K:N_&\EMH3OT4E@];U4X`]GOA,<XP8Q#2+!
MW!9:&*7"-TGXY-?PSFBD"UF61B4ANQZZJ2=IH[!"M\50=;V$C+M;DP5M?^SR
M<.MNN,=7>PU'G(C>8")?C.V!_OF=0N!`A4^"O"9SJ\EGIFIEZMR'?BS28V:C
M7=U_NJYQV>?N<&_+DD^"HD<.L96F!&D*48\#)N2'.="=>)KZ1Y!</ZBK-V?S
MV$$3O#>;1JX+R7T>*B8=,^5IL/+5&3YR]`77+ZI0=YW`=*?)G/!Y8&4;E9YR
MS_T9^Z>6D9&XH?9UL453,L?P9=L3@,F)<.E=G+$Q<?7W"M(%2M(X:&CE]@\1
M6B6QST"I#ZU2ZWH@/3IJ<+,XXS&VGCOL2M8[4JO^+*N2!_CT05>06H"=?479
MBD>1R4VQ+0U^2->#(AOP3&5SL#UZ4\FDY&]-UY,[5>SKIFQVI[%O<`"W5I@>
MMQF%""$LW#5M<U]QB5.:>*M<R?:=PLQ!MCN3(X*'PEO?0Y)5@S1C+.(JCKM&
MFIY/U[>JWF'?%9'"Y8#-9B@`,7U0);QH=$T6A2H5]O&GQC[F':@;L$LIAQH2
M,MBL5D?[>A`?G5"?>\9>!$0V1=<8\`[EP=SX(`\8",L:^%Q"-(9YIVMJ26R.
MK,P7$$C#+R0+*^NZWK82,`$*!G0R/G3K9#GUQ4:<\0VU!?;W`70U!9-FB0V2
M9,5YP'YMG-G\F''F@\3<AE(8%LUJI/-NXGDB),?!F:)L3"=K:I8\K0H<(?&9
M9E6FB1-3CAU<9_A\-`P;7SBN9&9P0LAIG/@.+J>^@QM/VCHCOI1'D)^?9AW4
M1_=]KHG]:%0&7L)^`H0`+XP8G?49BN9!S>9S4*X#%<OBV.8*3/BV&-CQF=&:
M0L*74F&0`,M]VP#S]8^SVH=A=GFRA%U,LOW.IK(6;NHH9HFOG'JWE::N6&28
M]V4SB6<<Q@]@"D':-O(T;V#/2X.F@8V8%A(]IN[',2Y3>0B!0N33"N%;!K%M
M%/KIL>=(H?PB+2,7,6E0[P?=CBQ_I]3A\Y$-``//_="ESZX`'#N*A\ST6`P0
MBY1CL52VI1['LO`CMA:Q*&1OKWQN9>9"%%#9E!LSI`>!+=A%\_$+1VE#`.*;
M'+%O(,>YE8M/F]X--9J+8ZC\N>9/D"E4/FNO_=].YB:"_4&0)&`O9I"DB=>;
MS/9=+L[EAA!=UQ)CD2\%QFF<V6CTRT:!`XWEAD#"=<58DKG:6>*Z8E\V"3R-
MY9KA6NN_OW0X-P0(OC$F/`BQE8:KC`._.)MKMG/@?/J0;@@\(I\%4.8MNVT4
MOC`">T[)1P\(7V5:-P`*3+A40*3Y4R/QB0/"2)*+88/4B-C4P0I5(W+[A\@\
MF>M.L"CUT42&A=N/&L3[N!F\IQFH?3*6%\#,U9TLQH(0%I14!4O[0!+&_82H
MUS.>4F]\6P6B\TFC@G_DW%[,<D=$V$@BYMR=A'-[L7!VFK%'8WO/3'I=GMMC
M868NF&\\\`B+X;_;08NSP]#HIEE$LAP.,H?XW<S_Z8/G$.TO/6<T6GP.*:QX
M\?G[<8D8;T"39^A,%Y@3<7C7^M!QQ.BKY#&!-*-+]WLMZ.+]7U,!EG=I`<-A
MWJ4%/,O9XH(8&;VT(!%`ZM*"-+MPR2P5RT>(-%FF(D_C92IH=$&47E.:7D""
M,AQ865S!6;[,4,IQ='MQ12SX,IXT$6(94)J*"X)%,W:!K2#XZ85["/Q/"XLK
M\IPMKV`1>M#E%9R]C!BHT7>_W-[<WOP/F#(8+@T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HY(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3`@,"!2(%T-"B]-
M961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V
M-"`P(%(-"B]&86)C-R`V-2`P(%(-"B]&86)C."`V-B`P(%(-"B]&86)C.2`V
M-R`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO
M26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B
M:@T*#0HQ,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N
M9W1H(#,Q,3$-"CX^#0IS=')E86T-"GB<M5M+D]NX$;Y/U?P''%(I)Z51`!`D
MR.QIO?$F6SELXIDJ[\$7BH0DV!0I\S':\:]/-UZ4QA)G(P_+5?:,0#7ZA:^_
M;M!O?[N]^7)[0Y=)%A.*?\Q/Z3(6]J]B=WO#S`HC/"$L,9]PDL;++.,I22DE
M61J35MW>?""U$25%C'+B-,5_2+NYO=G>WJS_BI+PS]$'="E$!/*7(HHC^"?*
M.#]=ST2,ZUDD<3U-D^B\0$[N.(T8:,8HX7'&4J/3VMAG%VE8I.FH\-N'VYN_
M_9RO"HG6/<`7C!^,4&^YH#%A-(K)`QC_YB,7]"_DX=/MS3OX[G__^`[@O^C"
M#E$"?U-0&G?(XF4JI"0/7V]O[NB2,=CX`!N__^7^W^3G'W]Z^/7]_54*3)@(
MGLNR]#L-G)*?C/+)5<*SR]Y+,`F9$0XY1"%C'@KCNCC)K.M^J4E>EKK734WZ
MAO1;11KXJR6Z7C?M+C<+15/WN:Y52?*ZA)6B:?=-F_?PP>H)-%JK5M6%@A40
MH#NR;YMNKXI^Z!;DJ1E(MVV&JB1%#H\.5?6$`CM=PBZXWVL;C1%+A#.:"\Q.
M:[3((I<PZZ:JFH.N-V2=%WW3=F2EP%Q%]D-;;/,.5_+ZB31KHV'1[';@AJYO
MBL_P&9I;DJ&V!IS8NYPC_828-_V\_%DBP:6+!,NR+$1"9"[_WNON<T?^J5Y[
MZS@[VIK3-`E;Q_@S;EVK-J\PZ7\=6O)V@*"KKE/='!&D<MX(>OG717`"?K%N
M9-2";[),DE0$\!5,6C]^4/Z`KQ1YU.J`.-'!^2$J;ZNG5U<)JFK0B2\%I<SH
M].;N]7?*CJV/4BCTWOJ("VM]U^<;@Q![`(Q7/_Y<LJ#"E=&=3LU4TEE3,\B_
M6OF)VI8"-W+@PL;:%B7X,\;FP6+W2M>VC@&<-W#6W]5?GW8J'/G75HQ#Q?6:
M":,4.)?SU]\F/G9`)&1P0"K<T>Q`9*5SK,W#'BL\.$3]#IG:.7>8ZI;O\Y6N
M@`.HSKOH)T;>_;YOP3OXX/U3UZN=*?Y&PM7'>L(<F<A@SBL<ZXF=,.NCQ/LM
MEB%Q!)7LZ%`O2*D>5=7L=PKH3T4@B0:@",Y#;W5S7VBD/5W().,AMPA4!SYK
MT:?_:9MR*'H,QI=!@XA^F_?DH!`O@6VT0$'@P:^O`)M3_H45;_:\_I50&$8'
M@X#4.UB:G[]%S5?'!M/N9#[$(AJK/TV<!ECT@89B8/Q!F`PI<D#5%CJO]->`
M)F.<G\8H`\LEW;#Z!(304^K6L)QB``:YRUL-##CO>U67R#.OIL`OV`_?=A%@
M/$"#2+B#AF8/]`?M,&<>R>XL:<>`<GM59C[6479L="1"KT-I<B;K%MC(5$.(
MP=%A1X_4ZD!Z56SKIFHV>(HQ$?8NQ@OSC1SHXFZ%P82E9U]W3V*>S!!<F<8^
MN>78WD32M3>HS_L__^,$V1>NDZF[OG6*@9H`/W6M*I,#I88EO1K,FL?Z75Z#
MS[Q5F[8Y]-L%XA0\#?G<J=)V?8J,/15FNV^LKC_;ETB%A,+O[9^%$LGD>^<9
MTY0HR)^#K4N1>KX*+."(K?O<`+:^S1\A>0ETKA"A)YOL/:D:['X6)O*[_(G4
M34_R8JLAKTG3PD?:#`$PL]>ZMWGU^H073>#SCEN"_#DHJ61^W$+I>#2YI/*9
M^^&(%<6P&RHS1BFABA3:G+%\#Q[^7>_@<X"6/PFVE&2GJ\J<RI[<JSUPL95J
M2407A`.V+<E;5>1#IY!2@%!5*3N;P;*%,``G43]:>H?!G0&/DDR,K?;(IYS-
MAG&6."QJ^JW1JLLKIPR4P\^JM_.6T@*N+H!L=<-^W[0]`<A>KR$K#\YO(`M)
M%=1H,XAJ58X05"'X=J>9;`36:@-%[A%);K<E:P"H6<A&(L.4@V?QR,-3UR1^
MV"HS5#,!LD?JY!@M`MYVP`,]Q3RR9=\"T[!L`G*@USM@IP=("DB</?`(K&6D
MRENH;ON\[1?$<7W,@V/<UJ;2+_P&<W@BH:$E.^I(I'3SGF>]%UCA7'.14VN(
MY*I2:/Q&U2:US4`2:;-+)'"-'5J:7T>9!XQ[?4+=U`EGF\,!(K1D,DK'VNQ'
MCR--1&)IPV32UP<%,[R&F"_)0T-*L'9,_A)2_Q';A&K7=#UAE'ZD(O9?M+Y8
MM\W.CG%/"-Z9OG=)`(S*9A8G\-!?<9D<G0?G!%-;ZAX@;X_A1*QK-9[Z"R9,
M,O2N:6HSB850`QY*3`=$U79I)GO/K`ZU#9HOGU=S>("&]H/3$1$D=1Z`&*O>
MY#(238N")I%5_:EY,L;J'6`$AMM"!3ZTT1!-!)'@.TQV76PAQW$`YQV)G+1\
M5&V')03DX%$QR+&::>:!!<";/./,(X'^<?0L!PG>LPFEF9]Y6+0C^P9:K![3
M:H;XQAD/[:4X&B#PD8&?$B5R/^;VY?D!M(X#?-0:IK5R91T?=V(P6SM5X!QB
M/9AQ1`&T.U\U[ISDFU89MMX=EP<[_)G#"S(.3682C74_=6XP79+3?.H(@U5P
MU-?8,;OIT[\0X!Y\_V7LSLNR-0]O\="HLO,B]]N\W>6%@LX%J0/Z?J4;Y!)0
M%LL!NQKU'8W(E/UQZME>.LZ1(N%2\5X#<<.N>O$\AI=+4J@/4/="*ABHQL)@
M1PJ="6JG-[4&V@A@0/)=,V#087$]N.X/_:#JK9G^V0E&.\ND(18L#-,B'I*`
M"3=,.^ZBE^1'R'+8HANJWA0V;Q6B$VKI,!\(H2^$-I,]V3LV&\&M=OF00P50
MK1E2+DR;J[X,"A]9A'&;D8.9,Q/FQUR$:2P/H!!ER`C0$8&^G$3.W;Z&ZH>9
M?HXC+LF[1U4CA3N8LGV!2![4N0K7P2E`2&G:T9%S>(`&'AQE1_/HS'4")[HB
M^\G)EP$(JX(S@KKE=3V`(U9YIV>Y2A7IO!=Q0?X<K;UP5RF97-(8*Y]K[6.?
M7Q^4HP'K7)N+33N\,<?*=P"6+1S,8T@,M&7>GA?,XO1XWBNF('^.?AZ(^PAN
MX_TU#AO#&-D[C^RKW+XLH79[9*#=*?1@#+"%!_S+][HTW=G"-L4(8X!>IJ2-
MS3%`8=?@?&Y)?NFQ()1Z#;`!T'D4W3"3FZ>U%RP9Y^CI"&J1FZ-C]C@JT@U%
M@6ZPI*/#\_VL["E47QM8MN5IC34?>AI+4RM#7?X^0PY&63)K#@;Y<PPDHSB;
M5WDO?Q;E.9]7>2]_#N5Y.N\HF,\YQ^9BWCEJD#\'[O)H))7I.$;A+!IQ]PA8
MS$M9X7K&8$NGVD>-78:#)?OFF9FS-2/8G%0_"^"Z]@@-SZO'IGI$-KJIFA50
M$]NI^YO<;@[$Y6RDD='85&2QN\4*H&G4K4&Y!>R!TU(_1CVZM`&7%.:UII,6
MXAPAQKJEZT$Y]^#HP3@'^A)H(;1KK*QH,ZPQ0[BFZA9S.(%EX>4MQL;K2RE<
M9SD:W)F7$\+]7*'*H77U$RN.F3W;WUK#@,&D0]-^7C<M]$7P4U4>=*F,>_*J
M:\[Z`ZP>\$++W/\/1XDVA^5IF*!R]NW\\'D)=9I"()!`O_8QQ[=ODQGI&\H7
ME^0;[B@ED1G(-G)'`>8E9XXO(+.I]8BRR76&[VA/K5.97ES_8K>0(`&>E&<L
M!Z=<?DT"OVH1E$.+Y*:DT3)A[M+@(T\D^2:BJ;`[LO3\EA/)9;XZ#L^RHXN:
MC/ECU4$G#1W"T6WWR=4V?+9I<SANMI$`D&B+9@?<S^0D-K5XIUQ5JMZX0^B^
M;>:<)P`=H.F'*VR\>#L<\V#DMX4)PP7$]=IPN4''_QLNW/'*<(DP94S&4@#=
MAW]/R=YWA$NTQ?$-FJU_QM7VS1.\(''7:CZ,9UW_@KX7_S,`N,<K?-[UE%WM
M>BJN<CWN>*7K:7C%(F-'+RZS[-G[,ZXPCF72P[$K3#_@\A6Z77)S%-&@W%DW
M\T1<ZV;TXQ5N-CM>YV:>A`EJ-DZ0(Y%$'I"*=M#C!3'6</S%)_`W`XL_H,[%
MEVWC-.ASUK,,"AT6`Q:?$3PQO!$T@N_Z?+*W06^2Y[4NBZ8JT5T&=7)JG65\
MLM3=\72ZUMU%&9U60:30YDX]$*<O*)E(.;V%E-,%_2Z5T;05F4RFM\":/BV"
ML92]\`2/(-&FG\`1R>034<:GW<E$EKX0]!C_J\OD$TGT0E299/$+>J0TG:1A
MD'R4O?1$E/`7GA#LLL?@C+S[[?;F]N9_A,9)G@T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HQ,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$R(#`@4B!=#0HO
M365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E
M<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@
M-C0@,"!2#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@
M-C<@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*
M+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O
M8FH-"@T*,3(@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE
M;F=T:"`S,S`S#0H^/@T*<W1R96%M#0IXG+5;2V_C1A*^&_!_Z,-B,;N0%7;S
MO7M*-A-@3]G-&$@.N;3(EM0Q7\.'/)I?OU7](F5+\H[BAH&Q1B2;55^]OJIN
M__#;_=WG^[M@G>0Q"?!'?<K6<:3_*>K[.ZJN4,(20A/U#2-ANLYSEI$L@"M!
M&))>W-_]2AJU5AK%N%"<9?B+]+O[N_W]W?;ON!3^++X(UE$4P@O641B'\"O,
M&3N]GD<Q7L_#%*]G61*>7Y"1!YJ'+"49#0B+<YHIF;9*07V1NHM!-@O\P^/]
MW7<_\4V1HGJ/\(`"0BUJ54^4EC%Y!.4__,ZBX&_D\8_[NX_PZ'^_Z07AA1=0
M!B\`D?$%P9JF\/QC<7_W@,`P2AZ?X;V\_&,:1C+N!1%?.M$,8H"75'P4)1E;
M\LM??UR1FO=/8I3-;D4&7L$-O"G)3C2BYY7ZS,M:-G(8>S[*@R"\@%]RE'"G
M;&"UH6MA75RNV/-FI[]6*ZW)O[?D&9[H!6G:D7A!(*`&`1;$S"&0I$PC,$Q%
M(89A.U4HEMAN92%%,U9'T+N9MJ#,U(/NI)UZTO5M.17C0-H>K_(=7H`%]@Z\
M%4()VA3M5)5D`ZHU`,]!]`"`K#M8C;2-6@MPF2I<:DO:3B!T@-)*7?(`0YY%
MU@_R('(H1/@94=C*AC>%!(,6;5-*%$:9%AT#O@'K3^`1!\DWLI+C44D-DFZF
M03:`WOI6D2\%!XJ<1'\^-BZNG\SKWX9W?AWO*'5>M\`[MGC_(H>G@7SJ1"'!
MX3`V?@8X/S9?C[4@/QA4?8#*4K^@VO5O`S6Y#BH\B8OG"10**"F/7Q6J-&:Q
M1A4QU-F*#'M,*KN^?1[WI!00G>6`H5>T`\9V(YYM-$/8C_H31J#R>K,&A\S0
MC1`7PH=_9WG@U11N_7?/)U"Y,JB<)I]DR5Q7HCS4EGB$O+&=('4*8A*L31DO
M?)P\RZHR!@)S"8[6,2G2)ANL'#H'M=,`EU5BDK6`CZ4XB*KMU%?6CD)9UT,2
MS>+$%=,DGXLI<!*EM"L/XYZ#]Y1ECPJ*0UL=L%`8K^K%YTGVHH8BH[T-'96/
M4#T+53Y16ZC);0U%8TU^U=41:O)152&-S+\H^?BEP^4Q47\Z#J.HU5IXL<42
MY$7_,'?Z1W,I#1$6HW_72S'R'FPFBGW35NT.:0"H!`72RO?2`VP<5O!?;<@:
MO@(D\&:(8+@%H(-:JP)XW+=02RW4ED%LN:SP-?Y]`+BD+:1T]H&8&1_0CMBT
M!\V%K)PK%%*3`BMJNQFY;#1!`)<`R@7"0,0TULA`OF"I@QC&V5?T$A5"<)+H
M<#UXI&CK#JC:V/;XQKT$9N(#@R!V?D`7?A"F&H-:[O8CDI]2(IT"FH.$":P*
MII2;2DG;BQUHOR;?-T=0TD3ZBFSAQMEU"N`CK75HR`V#HDCPM`W[F;R9M'!J
M?Q>0'D!(,\NL&8WF#)A$QA&TI7JAA#&>C+6H1T-;I9XE&++D-=\)[WPJ33*O
M]<:M[Z/>I+%E\11;)@UVJ"@<@OW3U".<*Z3P2%D[#DT-1-R>'W1C`VD)RGBY
M4DYB.HY*/F$),8^8:J53E;E_!8Y6\>-@[S%NA^%XXFV*+D-]\^%F872^@4M/
M:\Z:_`1.);[PNJN$;B.@EVG[<=#E$[\&QWNI!0C-R1[B%:[T[;3;=Q.D%%U/
MT!=WMMRT_8Y#CU=K2$?^))!+-8,LH7?9`(Q5"ZT=6,`'!C1U9"./%V0ZM*$&
MUJ[;7E</):`J(`VJ#FFHQ@Y-79\3$I3H1GL(%&#@%H7LL.E5&:A`O2<%'&;7
M#K0;(!4)LN'%D\FSMB5:@FD!]P%!$#@(XD7_%H5SV1F$>`)K8N(KVJKBF]8T
MY!WO1^C6%9FH^5&UVMB:FE3\)$0']T":>I;C7KE(SSM9FE2U-6T[!D'K"+;J
M@1>9^"3=ME[H1Y(YSLFH"X4P"^=0P&(@#/]2Q+(60D\W3E@7Z(3?:4VZ"E4'
MD7FQEZ#-&?9//@$;LT_A2`#J*^';K2C&!;&;'[!<UP<(2>(:RVS!/_#S"0>5
M35%-I?B'ATJ21(G72N+6OQG`:\('N5_A[?H^A(]3YE5XM[X7X=]CV'E->+N^
M#^&CW"][<NM[$3ZA?H6WZ_O(>%#D;,9C+'$9+XNS>=3@9M>0QJ$YPD]\&-I"
MJD&V*FM3LYCTVI;SA-#-8VM<197Z[>7<?E+P--GWH3QSU"?'V<K+.<L`3%4/
M18"HU"<]!%"9"T/=LZ-G'RU'%/B=-KKU?4P;0S,_R]-UFB+?,-/&-$WF::,>
M7`GE%XH0JS'.8NM`]-8[7AG(!^)AZG>HZ-;WT>3A=IUV]@"WY"S!BP,V`_YR
M>%1,?:^W:WI1J=B]:`:<+7#@A.#V<AQ.MW?L',G01!S>J7B!V#G=!BHX,&4<
M2GH(]C!T\\5D0?)93&>2CXWKU%CJ;F9(<E1;:I/=O"*?)^QI<*#R?);R`SG$
M<8H>.JBMN)7>TSKB708$M0-80Z='#J*'%FC:#",NB_D$^H,1?OL`@>8NW:/B
M!H34@K"<B&%[-\FJU(3?FL9'7+'<+VMTZ_N(*Y:YF>7"K<#'EKLF+YU<3>0D
M.H9RN^9H0PT=Q0Q+>-]C9ZB-89I'V9>JX<185-.\O1B6>\*K$W^TDT]SIP^'
M8HF;5M(\F=M&&K_:`"[:NA8]5DSYE=NA#H:(;,II&'MT?:$3T&(`K6=#KI+:
M/O%%IEK9W'-VO4&/+5J(-&\X1.XH@!IB6RH1VND]SLQ*48!-5FY?`HE5@1S*
M20:6`H,*E4GFF=D&GM&0P+U\-.WUTJ?@D_$H-5(XFZ+7Y'L@;H:?J-SE`X?0
M'0B@^6)PF]L)/LZ)3%D?R=2U9J0H>E"]5A00T>DJR(5S.5!&!]]_;X%#R'M6
MXIRM(W6<`9C(AX?W?U.\P(:&^2)51)'UD7X\OK39XQX'AVH7!@`2/=3B:<#J
M\=Q>L+,R;26\'/A@U`U,0]R$MZ/BV(2[VEC<]4)E+9VTVL8,=W!;Y0)Y@$"0
M9L#8M,_PB-822R^R:C5#Q2FHK"6&RX8/$J`YPUC,"1$,HQ4&A?`R+Z2YZQL8
MG:E49@W9J_,'H+2;B&)@(AHK.]D6?3]U>D]<-JL3_]\<35H_3?<Z\<F7U<2<
M`))S15'YLM#U1'=4WO:J:.8&IY0ZCP[3,%]NTY@C.K@;H`_IH(3\P&7E=J8J
M/C4@(H#S76LXD\WFBYG;8BOAS$2^`SQPT%R=][(5^4];;;D7&!(W.TV7.W8&
MA4?>%_NV1CM_6G^_MGN'>SY`9A>-T1"-R4DSU1NH!2]U!^\&4S+,3^A&[32>
M.)%:"[160\E2[7J>!J&>M_M0/7*L.D[F^0'-8C<Q/<C2G-1RK#\.@.]L9$%J
M,6+\@[I;T:.XNLB[Q*\JY3QKZ$71*KKL;G!#]9K_T?:N5@A'HAN!_`,WS34+
MDGXR`LMG&-@"!C,]5QOTZCB!WC0QL)0FV&O,\W(@\VW..1:-`020W6HJU^3'
M(R\!06WY&A*C.5580B8%U^_X49D?M2Y$KSJ97M3M07$+'Q!0S8-![R"<IRF,
M!A8#Z'LZ)]-XJB]NE76`RA=9@Z5!T[_0=4!J655PU<L!.+^SWOSLJ!?GM.@?
M:0[KJC7GA]7A6+@>`&6\<CW,\ZO769X&5Z\'D*RN7`=S91>O?U:W)"PFD.<`
MG]>H`&`7G23%1S5-9E`M3;8(UPDU=?-WEJ3DE6]FD7XCS<Z_\HI;JD==9-)T
M;E`2.V<ZK4/0+^D/KPAI+_&3BC6HR#K4[(&0Y5F4?]X@_B4_BD$Q*__KWA6=
M)<MNM42<TULLH=YXFR7B?'&X9RX5$366T,6]*72-,*D<!\&(O_@B![4=>`WG
MMX2[A',8ADZZ\SC']&:<X^@FG/&--^(<VY:<!>%B$]/2$<1Y!":-QP^VKTY9
MG-".&_W]+>$O^WO@I#]O!\#M5CN88P[?:@=\XXUV<'\=$(9,V^'#H":(X,JO
MCA__B7?AH1W[,DW"01_&WO4-N7O#:\/\F84CML")X1^H&'^-H^6A/W=F\QW?
MS5C@&3;&(C^P,9:>P#;3K=AM7K6=;%1_^2*HWU&,,/&-8)AX0A`(P`)!NCC[
MI=&;1GTZVAZK79R6AE:L[;M6G=_1'?E6B%*=7H)DJH^*FMF=2Y*XS@W27TJ4
M:<ZNP()[@VEZ:Z*,3$__C8E2O?&V1!EE;F;(%CUDFAAB`(W>R>QW.1'HIDTE
MA[WJ#0>!C?:K9N'_$.XB,8"\;:4[7Y`BQ95I_&T;H%$`A,/.D/29NP_IRTXA
MBJ_Q](?\>I\`'4QPM1%X8/@7=]=N"'-*K]X09?%U&6,\QWOMA@2-?.V&-(VO
M:Y&E5_H5A5/V!@XTR,(W[H#ZE[]Q1QY?;:L>*,NCZVCB2Z[#2:,\?4...'S#
MJ#2AZ1MRI#2XVJ(^T"P(W[HCQ)"[>D<47D8,(N#C;_=W]W?_`SD?:8P-"F5N
M9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3,@,"!O8FH-"CP\#0HO0V]N=&5N=',@
M6R`Q-"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N
M="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#8X
M(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U(#`@4@T*+T9A8F,X(#8V
M(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E
M>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]0
M86=E#0H^/@T*96YD;V)J#0H-"C$T(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA
M=&5$96-O9&4-"B],96YG=&@@,S<R,0T*/CX-"G-T<F5A;0T*>)S-6TN3V\81
MOF_5_H>Y14FM:+P?1\F68A]2=JQUV8=<AL"0'`O`T'AP1?WZ=/<\`%)+;B)S
M4BF5M-0"&$R_OOZZI_GVM_N[/^[O@E56IBS`/_2I6*6)_J=J[^]"NA*R*&-A
M1K^)6%&NRC(J6!$$K"Q"UHO[NU]91TOE28KKI$6!/UB_O;_;W=]M_H8KX9_%
M+X)5DL2P_BJ)TQA^Q&44G5XODQ2OEW&.UXLBBY]?,&*OPR(J8=MAP**T#`O:
MTX;DTQ<+=S$HY@V_?;R_^^8]7U<Y"V/V"`^0'FA1*WD&_P1QP1Y;W%(892E[
MK.[O7N.&@X0]/MW?O?I>/8F#Z!_8DQQW;-P))C[M9<]'J3JF-DQ-/:M4-_:\
M&EG+NVD#'Z9>=EO&M[T0K>A&_2S>.0BXMWY@O*N9ZIHC4[`B+/[,"O1.P7@O
MV%_9X^_W=^]`HG_>1.XP`KFCT,J=6*F3("RUU-74][!QV.`TRD9^1G%@IQ(E
MZ`^R$@-L'Z1@?&"=$+6HV9H/<EBQ1]!0RW]7O1R/5C_[7M5311KKQ1^3[$DK
M`ZBE:=A:L`&T.6PD+G(D%0_POD:<J=.+%M#,6@LARFZLG^>IU@.\'<1'2?8"
M;*YWB"+]I!HY["[9K1'\@%N>!G:8F@X>78,XHV*<;;ALX"94#2RY43T\60E<
M5HZKKY8QNRQC66@17_TK2H*;KY_-ZW_=YK.K!BJSG!8'HP1Y$ED#A7E::`/]
M++930\$X@`V.K)&M')GJF6SW'-P5;<77VH:@_T&`QVU%)T99\0;<6W1;"0[<
M@V6-EPY,=N2$FPFMN?)ADB3W:Q*[_LUC!A"SC`,3,G%0N)!)T\)`QZ^"U8"8
MC=J#<C\?6S$K=L*X9FO`/-:I[M9[BR&6[>;*",`L`(3[##MZ??LW%0LUA$7L
MU)`X-5QPLE96O5+]EG=R:(<'=`"`T"=T2_@Y[M0`.+'C(]OQ@V!35XM^JSI`
M1-6B7C&C^`#"$B^2-$&!H65P,`T,#JH-[M3(Q%I5RPW(AF&WP@OX]R=K9=BR
M/("HFUZU)[&F'X,KL_P8J7__QX_P`?/<,*U_%P"F$*B]BVN`1EQ^`TFFY\T#
M&T;`88!8!8M2'@4,%7+;^5!+468N268.?9+0ILFM`FK048KG(&DEQ4#Z@"0(
M=K2_8KQN)<@["LICXA-\Q`\@N\88QO?[!I2$26(A.%QOQ%8.YK\(;YV"-S6-
M>L*W0'8!3>GH$J0*'RK(2^L9,_Y&9:05T/+^HQAQ,XL\?^8":%_$5,Y&V0KT
M`]Y!2D3QR+_9**I=9WQ$(9MJ6]%7DOZ_$4`K4"_(FR3AO`]$+M+2*R*[]7T@
M<H&&T5Z:1@LOS8R7_@"ZK[7R'JQ_J?[(>&7=;`_F@JB"[#G*K?:V2DU-#7</
M4S.B]8#UBFX0$*FU:/AQP,>(O&*F%;74C&Y49[Y@<P'%B`_WC%(K>Q"&#KBR
MQ#@H;&/;\Y:VBTE]=B[YV7%X+26&I/5@BF+BLK^L/JS8>Z5J"K#O^FG+WIAP
MUD4`8=C[[]X`B7>DF>)9#)K+\E8LM>Y#"8&M8:(4ZBF;DB-3P@!B=C7OZP5<
MC,B6:DPUO9JV.PO3+E-1^6+SD9:F/GG:F!5_:Y8`=6@?`UAN!3Q9JT9M+2)^
M)\!]:D\T/B]=+9,7+GLE26"<0'649^WN_S)8P"4'0+N"?4!!C1@&]`<)`@)J
M4:J9P./E2."[/LE0#>AJW!W1]/#X08JG@9::N@T_*,WX\5HM`/?!80Q)E1OT
M"C]%79Z[:B:;J5F"=(7T0#F6;P1P88#3"E(7Q87>$FVVVO%N"XZ+&C#NO/!=
MU.(>"I_J.,?'NZD'-X!*\)?.!@,N]NZ7!Z`PPR*=#4;)II1<`L.#%V6DN:,T
MP4QIDC1UR&"+4C2;SF24EC>SF[L$AO(^[62U(Z*"X=)C?L)?M\`_$$+&7L)R
M!^)O'2P!%`"T1_BQT(+6W'M0D_C$VWT#5(:W"E]+8.I#$8EEJD$<.T5$16R\
M8EF2/X#A0!VRA2#>0%V/.W=(9XMWS.:WWF<$_FHWZI>\1V6\4$D8S8$2EZ51
MR4$>*)&)#=+<"DI'093M@2W)NOHD*\(X9*+F#O0><(SST@<PI*N:J5[F&"^V
MCAR/CZ-LMC5^IGX&^K.'V@M8B'VU7^MER4+&,%Z@7!`;&1&Y3\NL&:V6[.=Y
M=CYJZHYUA>;F_5F'82>)M)XU%I8L?.VK794'MAP)L@79"?$S2J[9ET8R73&:
M!MQY(?Y_SL:S(O/*QMWZ7V>D\JJ1LLP63%&R:`R4L6'C/\OAX\`^[$6%-33Z
MSH]@H;=2?0!O[+"S^A;[)$!%?&@V\5OGN/5]-`.S.'+-P#)*%LW`Q+6>,$*Q
MQ8IZ77)]07'P;<C>?<+,/&`Z^W"$H&^Q?V#[^O:*TB2-[\6$K!CB9A02?-U'
M?S8+([\FL>O[*#W3TI9?49@[1$J*(-86>=-`(8#5`6K_G48AZ][$#^<Z`I%S
M4%!S`KY.2*;X%UF4[L&GI@&[2)<,"J:W'4@/()SF[L!H$=YTG$+%U@0<<4[[
MZD)LDQC8S3D"5(.C`A'$TX5GR],_X;D^Y,_"N=NP5$#I>+4)EA\VE\7'&*5Z
MM%:P83G069<ILD"L2I>;MG(2).8M,?*2@.C05D*-,!"7473[UY1+199Q/E>M
M^)D\R1PZ$?-`SV\DT.\:M2''FZ?=/`W<CKX>*J[@7)J$7G'.K>\%YR);64=!
M.=LJ+8VM+J5PU@*4H4^+`V\F.D#D&/L'6P7K[A!1`M=OD1TV"#K==N-]<[RY
M]^6S1'[I>IHG2]V5A:M)*)F;[M16L+541#RQGCH2(`)U!T6N1<4![;T`69"[
M(C"<3_[ST#0(T#S+/M$U)$:L^@*(X?/-3YY0GV;?GL^X(,TM-!04KJ\8%R;5
M58VD0H'`R?WGCXEW(]0&8KA$HY@<&!3+4"6#@R_:0"OVJQ=#)Z6K]LOY<"M)
ML]P>8NB#%0A3>TX/61S">-A,6/7L>$^QC!:^9'U>[:2@W@]&L*(NH3P(R(+O
MIU[/>)@$=_8F<!E4'Z[M0_3<U<I)N*R5#3^K^%X7L;.Y+HIH2]R9H["#:J;V
MBJ$Y=@_YH#JNB\9A!(6\:09UH@V<KW$J\:&$U);-T:+;`UX1V;+YU-Z6CIV<
M79CHWTS=%@3?2>QXZ\[W?H)BF[0$LN%P#SS5V:;JLTD!_-\-A!B_X=U1:U'Y
M`3LJ14T"BQT()YG!.EZ1T'+8F3;@\\YZHB;+L8W/?*AZ(3K,:[/+X+"0,,,4
M7:69#$B)[5-6RZ'"X].C;1E[/BE*(G=*E@>+YG@2VB-NUHDGQ+)O]/A(KPYZ
M*@1]F=7]M`7G_>`T<.X=1@W?@Y.SQSF5&8X.5MU/_1ZL:\:>3"^5#7+;T6%Z
MY_VL+`GF8JV<<3"S74_$(=D!:(VZ*3^W+%W[4\/`0=`!@>N.$OZ#W#?/06GH
M-NTYVZ7I0CUANIB)BS+370!Q-:AC#*_8(]0N-(F`GK%@+#2X<5K6GC0BS.`?
M]V'AN+"U:9#,41Z5MC4ZM-B;[J9VC1T_'8BWWT;J]N'7:"&4G+/$83Q/:,1E
M87+[F@]GHUUD*6#<D-L,:QO5R)=:(8.VJA'5U&!_^`"U*B&@&0S3#=9]PRL!
M16Y']:LYW'(CFSN<`&R\G/;&N:T;XRB?![#RW!3@-1VU(H9,>R2BD+6001-$
MR;Z^^8Z*U&W)L[TA><_"AT4^!VEJVR]@VO&(IW%0.%4[,VGTV131F&^!U0!`
M3V[*[S]"<3*S.?33/1T<A^@IKWLQ<>I*IGB1K4M;,V'S:`W95H^*"2`10*C%
MWLH$[E[9'M/(/\)]C>JVX-P6J!F=61+]L'D?'^S0>W<<![3D5G;4\H>UD,L*
M,[2,[@WTOI)[W96!UY/[2R_'67'L"I`%GL4.SQKY$8\P:%ZLY4;Z"D)>3UR#
M&^S-:?VE1M3-$TDV[]IC_RC.,O>:VS<\XJQ<JCY/YLYN9.D23C[+;D)VL`PA
M2)*J'V]_*I0FP0T$OK1Z!HN'?W8F]_KA11R8P^U\E468M#Z;PPO;-_WV:UJ_
M7Y9<&OUI/+]2#>0M95J(/@[JHB+PVM-SZ_OHZ469JXV#>2XBSK*O,HCY7L"S
M]=Y%FY@OAM#D!V8NG);"MKDA$5A]>4#5*'%3K>FBF6E3J"WV-I*RA=VOZL\F
MXQ\N%[C/E(YGU>*7"GS>H;W('Y6N'S0SB'`^O]`C@'/G!@V[=K*I6F#Y1@-^
M.#R$TU^BFZ"4&WO!V]/AUQ-[VV1*3&2M3]$GS*WS%X2J:1@5N-U@>D.H)"\Z
M".>94>T"KYR=;]YOSG+W/K\,$<CA+%@49O%\(FE'),R8SLM=RA5[PQK>;X%.
M04:;S]86_*?&&.$=M<)Z\03\?QGJ=IC_&9#V\54F=Q(;YHM1]20(G5MO*>+H
MX$&/;%*AL\S>N@-P<G0.]&I8]#QT%^0-@I5V<'UV`>'`2:_P[--.$*!=A,.*
M>PGKT!W,1D&P://:Z<>*[VF@ATYH79S1Q**]!/MNT73Z"VF\HD$A/(34'3%J
MW%!]WRG]U2_5,.QA@8O<OON1XA<S\_]%(9W&P4)[0$D6)_E)9OG>,T#VO`?Y
ML.U\5IK,9S5)$"=V=V>Y>H'>8*A-(Q%U]4P[%O\"X'=\P@IJTF>KI]@++J&'
M,LDA='\>2F>;HW7=HU>C-N;4XQF6,K/PPE<W/TS<?&\R3UO$96XS-[:G'*A=
MBK]3(H@3*'CHG9>P*]K1_&KZ*BY<#X`27;F>XMG_E>O@N?&UZW%09M>N1SC@
M=N5Z&(#O7KK^A[E%OP%\Y[\B[N!A\*RE"]KQ7A7G"@02=65[KXOL^O6P**[J
M_W547!$0;XB+*+IZ0Y*GUU^1YO%5&[W.\O"Z%#E^/_RJ&O(7]%#F+R@2>'IV
MU5/@CC(*KM\18N1=O2,JL^O:#.,R>6$?2?2"3<,TC%_8QTMQ!W>4Y0MWY#%@
MQO4[(#POW@'^_>ZW^[O[NW\#QU]%O@T*96YD<W1R96%M#0H-"F5N9&]B:@T*
M#0HQ-2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$V(#`@4B!=#0HO365D:6%"
M;W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E
M<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2
M#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2
M#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E
M0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*
M,38@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S
M,C(Q#0H^/@T*<W1R96%M#0IXG+5;2W/C-A*^N\K_`<?LEJSE^W',))/*GK);
MXZWDL!>(@B1D*%(#D/8HOS[=#8"`9)G>G9B5JO&,`8+HU]=?=S,??KN_^W)_
M%ZV+.F<1_D=_J]9Y9OYHCO=W,:W$+"E87-!O$A9'Q;JNDXI54<3J(F-*W-_]
MRCHZJ\QR/"BO*OS!U/[^[G!_M_L['H7_!;^(UEF6P@O669JG\".MD^1RO<YR
M7*_3$M>KJDAO'YBPA[A,XY15<<22O(XKNM..!#2+T;085?["'Q[O[_[Q$]\T
M)8KW"`^0(NA0)WJ,$J<Y>P3AO_MODD5_8X^_W]]]A$?__3XO*((7L&\]/7WE
M]`+^B$`A>'JT3J*L9H_-_=T#J+V`WS[#.S_)KA'L6;!MS[I^8,VHE.B&]LQ.
MO=9":S8<!-O)CG>-Y"V\7_>C:H1FG8`_-5=G-O1L*YY$VY\8[[:LZ8]'H7"W
M_$/`,0.<AX]NU;AG)]5OQV;`8_G`COR,)X[M\.ZRD^FBV,H>%^"K3O8$7(J$
MWZG^R$`<]D/,/GX]P4VT[#OVZ:P'<5RQ7I'P7F00%(0[M6(0(.F9\1.(\P2B
MP0]4!FQY/LCF0')M\,DOHU1BRW;F*"TF^5>H\^.H!P;:$8K)#@Y?0`=UE5D5
M1$6=.!6D:1P;%31]V_)-K_@@GT`HI7BW%T>XDYXWZX4QU^R?`Y.:B:\GT0P@
M+QG7"'QQY+-L6U0,ZF,GO^).H8Z:SJ<U.`$4MH@BBM+Y`CSM]%`X5^`[M`*W
MMSH))?LMZW=LD$<!XNU0&C`XW`VC!$)$/,,^$$/N@N@);`D;V)5R]TH8/:S(
MZ31OA5<)N,G8P)&H"EQ=0@5YY'PAGZ(AC3*C@2DRT7E1&+C4A<VWZW='/[A3
M&BV*KM/YWZ;08EZAN`B'U\6Z@&SV^`=I-,ZBW*CT5\$.'"S?RJ,<C+MT""'=
MH/J6]4_B!<!@W""R>,^!9]`@$(D`I!B3Z!Q@J[WB1[V$1:HZ7=0BT_E+I+NJ
M+*9L5_EL5T;)\A:Q4/@];`;@P%_NQF%4XN)1$UX+!'>5UP[?TMA'=YU:@,.(
M!E@#Y#VBB%*Q?M/*/4!3WP$`>_!>LT<"[I>WWBC!(;EA+@/4!DJ`XM-1$[0!
MG`T'-FK<U,.:>I9PU([+UB3/#I5D'UI""5GBE)"7/N''=7TSVS7P0PX2S*S'
M!A/X;FR!^2`$RPZ2`8(__/O(NTZH-?MI5"B20>^7ZA$MZ(^0,\B<$ZIR);7L
M]O#LX-QC"04DN5-`74SRYU7^9K8'@UF/UN-N)QN)UKR@/A@85BQ\9(5Z&7>@
M1/!Q_(?Z+`8\!O,:I<X+PD-)E)O8,"MP%+YX"2U$U10+93[%0E5:-?0-T%S#
MP'RNXYM6A)9#"PVB.71]V^_11WIUQ8$NXGX!)"ZK:E$DGLY?`HG+TG'O)"F]
M*^)19(-_374!QA0_B7&0C0\7:P6`Z,W9X@E!"X4>T.8>[&!-$L8A$C0];G['
M2`1;<M:*;C\<3$R/4.JH@4-H*[$?6WQB$2@N<\>YXZPJ)]$CC$C+M!!L'*W4
MXEH%@X`[!LAA2*>I-L26'!?Q=5X51"RO?/O2?^&M4.40]UZ$<I>IH]Q)D4^U
M1YZ4I=&#"SX%E23B$0+,40(I'OI.T+U4?^;M`+4H/]L"@LHKU,B&:W".\03U
M&C[G`9SQ[1,4JR8=O8`A^*?JQ_W!H!D6,4L(GCBBG61!S5UG-@T%*$IB7M>1
MBX!)M"S1GLY?`DR**IT*>:Q<72$?6X4"8V$__?B]*:AMG%"RN8$M$`]`@@23
M`VMXA]%A4I>@I(]N\9^.N.&G`0@.1.D'L_]ETL?'=^"O`#-8[2WE347A.&V<
M5+Z$I^*#2M?3J94-$3E$@8VDA-4`QVU$AQ5XL$X8.AAMK>@O3BL@S%9ND=*1
M$L=N*]2^!U8(,*TI.B$N@<"L0$M-.VZ1R_!.'L%KT84/([`!UK2R@U>UBZ@A
MFPANE7ENE[FD/BB`->RK$$2@;0;^&8T+;G`67)DN@VW)8)+0`S<)")DO"(\\
M!LS](Q\X<&/,$]BYP181@,O!R6]3C&[$:9`65I^X.N.2Q/+_I,1@6?426D@]
MPRU\),0VJUKA^['=0@IM^7EE2AUT#+C8DR%U4_)SP`.I"/CN%G0`]UZQYH"\
M4+/+3'GJP8W.U+MQ3C,!UW94J`!RJ*EWXG8MH89XXKEEXA$V25Y!V%#FO>@:
M;#L^20A:N"85->`/H"8,>PSEJY!R@MR**$QB#1^U,/JF1*P$$A!T@7='\C(O
M)^&_'6IG\D1>+]ONGLY?(D_DY=3LSBM/.%RS\X,PEKJB!+)[ZEO+/RXLOR-G
MN"@"T)EL=S=@(+0M2#44%^!60J],X]`^LD`D$`I86`Q*WMPFAX`,AY!GO1^X
M]1Z;'MWQ&AC&X=`K4QN#R*O_81N*N(>"\B;`P'*_3%\WSR:R7<>!^#8KZ+9_
M;L\W&O#8V>E",--09B"&T46;OD.L!"_``B5P@#7[]8`I_QGY!9A:GDP7!(<9
MO9Y*^QM4G/I.2R@@*3TW\M5&DEJGQ^RFH)IOA`,YD[HO7-V6]\BA0"-4IJ,_
MW[+UF>H/DJ;K36KTKS#E1"<D/?V,6]3+]MD26H@C7VY.2JA*FP\.7`,)&`*8
MOU)`2(S>5@'Y#6YYR9X@NP`.F"&(KS00=:QK_!`O(7]6.X8,I#CQ"D@L#MP8
M;Z%I4"].ZNYML5T)^BJW]GKP!?QH^UZ+B3[U?.,H+?UH)R]>$9VL%Y;"Q@5N
ML7]T!=%J\0RRBC7[Y6;C[T61;;J<$QEVS!%K=N*5BVAAZO\F44`,B\IJ`47S
M(UN/RT1P`\=_U?J(\3O;=O!-O4?JEE^2*VJ6[7"SD/LN2!W:%FBM7F36F4W=
MWZ2J?/I/JVHJE*@PI,[>K::3K0R#LDB[&E'WK:T/>PQE4A+0[`ZJ#O'^+`^H
M#'#9O\[#9J@2#:ELDRKH4;CVW$=(?\P,18$>60?68$ZY`Y^&)(^]<0+[L'IZ
MK36.$6)=_P8Y<-E9AHY%%Y!V[KJ`LZ25[Q$G?B!<9[8YY9I2-^Z+G$YJ?WUJ
M_G<##CFHV++5G^U,25!.0PEAU#:$3)4&V1&=RS;.N9,]G#-@TEZV5YF6_A,)
MWUS(TJ@,8P:$!(%=40Q)WO=,IE(0AR8T/9Z&`NJZ'8MS-MF-$_\T;&$K=8,0
M<38U(ZSTHP;.-G:?N_Z9&J&`K$=M<O02.O#]VJ2N@]&995"3:1B-_@+Y@N]7
MR+4UP$%S87W[Y.I*+U1%N%]@:,'?9$ODRK=74-ZMXL^@+]/'7+*B3J=F;9R%
MC86B#KZ5H0XM69XZ!JZ=/@'AZF8N(+S79CCD,/@$BD(VO0!RIG'Y%Y%S?NJ?
MVDYG78*_(+^R8_^\L#7'SX*W`[:@%$8O35S146PCQJ3/'<#$ABQN/C/BOG1P
M+?TENL!)M6P7>#I_B>H^*2:.FT2^U*U22W%^,13S9ZS#'EW-=D;DV@B,)T])
M<30$C%`/;PU1+"<,VTG(;,Q<_Q:'6"T1FTGF&6[PY4YI\<DCQNG`U9$W="4S
M3@AHVN1OMTK4%\.A5XX*E#C-XYS.EY`\F9J^U#ARQ6WD&O_>S.:;#.0B:+43
M5X/#8.IA4P(RB1=HZ7$S*FU&1)9\@/C:SHOZL$W@OL_B3Y#?B>(3$@;]D(,)
M]R6DCZ=F;U8'WW34]I,MOCU"B0%)QQ0P`5-?(<`^81UF;R<[C9G'-+`,?>W5
MGG>V^"$7D6K[WD)DD%6<%'4"]#(RGTE]]_#N;\KB4%])Y,E,E%MO0:>@8:*P
MHV*('"4XUJ?`-YH#;W%<3(%$Z0G=X2BV2TTTXCJ?\*SV38LZ]G-B.P$&FVFA
MGDS*_!2P\&FD#7*)K^`*]"F/[>9<^KD&7CIJV]1L@UK^$*0K#V/X3G03X2J@
M;I&:+9XZMG'N:[8L=K-R@.E1X3C7?HFU%5]&TW$#;V7&H,0>@6W<BM6K/@UH
M1G2T,I*:CJ@Z3M-V4"YK$=QT^`4,[`$/(40T'2/5PU:\P1+*F'JYX,D^P=7I
M5)-`WND0UA!V35U&MC7D4W"%P_'.D_(@;UU1+?I,H2Q86<-EZ:+^1O2!/4Z,
M\VANO8CBV?4,OSV>6X_*<FX]C>ID;CW!N)Y9CR/PK=?6OY@M0-]P1YS_?RPP
M`S/'B4O*)B]]5U\K.(YGY7^HH_GUN*IG%?205`!Z<QO2LIQ_15;FLSI^R,MT
MUDD>BK*8?T595O,G5%4\OZ%.JWQ^0YW.>L)##*XTK\HXKJMY74)M6,Q?(T[3
MMRR:Q?D;]\BCZG6OI1T%_B\=\SO2(GUC!R#LJSO`>S_^=G]W?_<GL]+-MPT*
M96YD<W1R96%M#0H-"F5N9&]B:@T*#0HQ-R`P(&]B:@T*/#P-"B]#;VYT96YT
M<R!;(#$X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R
M96YT(#4X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M-C@@,"!2#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@
M-C8@,"!2#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO
M5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@
M+U!A9V4-"CX^#0IE;F1O8FH-"@T*,3@@,"!O8FH-"CP\#0HO1FEL=&5R("]&
M;&%T941E8V]D90T*+TQE;F=T:"`S-#0T#0H^/@T*<W1R96%M#0IXG,5;2Y/;
MN!&^3]7\!YP2)Z51^'X<QUX[V;VL8T_*>\@%(B$),5\&R!G+OS[=>)&:T=`;
M9Y"4JVQ)`$'TZ^NO&_#KWZZOOEQ?!=NL3$F`?]2G8ILF^J^JO;X*U4A(HHR$
MF?HE(FFT+<NH($4`(T%8$,&NKSZ13JV5)RDNE!8%_D/$X?KJ>'VU_S,NA7\6
M/P3;)(GA!=LD3F/X)RZCZ'R\3%(<+^,<QXLBBR\O&)&;,(N3DA1A0**T-'O:
M*P'U8.P&@\6&7]]=7_WE'=U5(%Y,[N`!I0BUJ!4]C$#*N"!W('R9;\,X3LC=
MM^NKFV`;IAG\_G!]]>JVOF=",L+N63=*PCLR'AG9<];4I-_C%T$'-HV\(H/H
MZZF"22T]$:J?:^#3?L^JD4R2](+TDR!5WS1TUPLZ]D)N_T3N_G5]]1;V^_??
M+U6.1EN1*M12O?IGE`0O_H)L\0+RHZL_9Y0,72\(U>K!-@I!G+M*V23)DUC;
MY,TD!%BC.6W(`R-4,-+U(V'=@1Y8C2:JP5I-/_#N<-E`>V.)_J$CM*KZJ1LW
M9#>-\*P<&<4U1M;59.P7QF+D@8]'4HOI\.)2@Y1ED3BAR\P)742A%KKJVX%V
MG$G<%?LZ"";E9>D$^S(QD*,FNQ/.:)6\Z+93,_(6)1DF,?3@U=J#N;`::QEJ
M8H2G47>T4YK0Z_(>="5)QQZ4"N36BQ*RW"@A+(O4*2$M2ZV$3PR#:T.._0-L
M6&R,T4U8@D`4-GK/1U23#=5IG,!#+IA\2W[>HP-="DNKD(L:WIB7^5!`&E@O
M0,PV"D@5-*$"SC"&=4H.)HB<=G*DW<AI`SMOZ$DNP@"-JFQ)!WC\'J=,#+T(
MU7/H08^=FB+886JH-O1R-OQ3@;-MR2,L]"%^'%O[1V5LQ8\1]Y7X@@V]&'60
M'UC'C'E.I&IXQRO8["A`!UH]#48RB-GVXDQ.60DP9W="[P?9,!#J)PL\@^T;
M(F%"A3H'9V$-AHD//2#ZFCB(9S!(\+/6PY>)"]8J.YCH!L,X[T#[S7Z`=G;6
M!,%ZE(R,IX%)HX,9%@%F6B8J="1)&^8C/15EYC4[N?5])*<B+ZUE\K*8+1/F
MVC*_`I*\"<E;#=`82Q]/@,4M.0)X[ACK%+J"PZ&R)ZF@:YB:09EL`'<3UA[P
M+.2W(Z^.Q)A;DG<_W<Z6A`4Q!@1M@&5`\%)1P[K42V`6663%#H&.V<#,4R.V
MI'NV023]ZX?;CQLES-'M#\6%/;=<8KC@U/&DIHS]5UYQ^%+3D6J(AIAFW;=3
MRP!NB.#R,^3VCH'#-ICOV%<N1TQ[=%1>?5'3#[QIO.@`&+#!YL1A4U+&2V1F
MEU,R"JO%,IL_TGMV41-<2DC>8$790Q"BYA3KP#3N)1:CU&\LVO6]Q&)06*=,
MB]DB89D[MH`0#>E*)?B:`6RWO-,I3@,\>FC?@BF0,W658D2]#N%C+T?PZ`.0
M+MD"+D[`^,$-!Y52@&(<D$CA7.6EUB6%)J13!Q0-:#_8SX,GYF7H!$]F@AS@
M9QN-O].Q^N?P"A_>TXHW?+2"TAU^.Z$"]AP9`GJU8:+("S':54;9\?ZEI<ZA
M)K5BEQ'(BC4"%&NO;E[^3<E"P5&2.Y3/U6=4\#+(40L^;)PGC@HE#G"+Q.Q`
MY_!%MH:,,`%H_LTR8^V+%>T@!@!#T?"3H)U"*(I\$&JFLT@`+U#(N4/.C"D%
MX)C6$!=@?OB&]4<#$51K=`?>R1O"H63RDF]48M$&"((YM#/+@^54(2?5&UUL
MS=2#*""I.98Q4'KC.!LA9`$(X$<HS8$J8]D`CBPQ^DW0VWG`_S'S8H%T!@)2
MP[;*XHI4^A`\<05`/M>^:1HEUO-ZT4^'HTKYDE%1'9F.1+UAC6?+G6H=&7NS
M^L?KMI4TDD>!US3BUO^QS9?K*@]B5W/%<\T5XF=4^0?`=TENAZ&!`F'7N-+I
MC0L^_LU%TFL.C@'HR,2)O#?IWX/"LR+VJG"W_H\I?+WKEF6:H)?9-@N0K"..
M&VV^].NR='Y=OLV218\OMV#R?0L"=QA85T-RZQ9]`L23@8H1ILHC'[ST\K+$
M;['DUO=!T+*HG,O8?%'&&H+VFE44:R!`[;I733P%6QA<+>TFH!_C)+!FX-U>
M4*B\ITHU<Q0W`2+7J<P'.`CH7>G.F.W;-%0`P$NHZ-F+"Q;.DOFE(EF8+'58
M1-F<$'+3"M!EQ:)H]$5(LM"6@,&"=,9A81J4YQ8S32/FVA,+KK((-DR[EP)N
M\YAP+I]FSSZF&8P.5HQ5#VI(2UL%AG&9S-P[-G4@;HUA4T[[[5D+^3%@D(9_
M-C4$J[`UA>6OHN6W.]8=>HI"8@E].)$/?_AI0W[NJBWYI#E.U7>2U_H]M*XY
MJA2BX?QM/A20%XZ:97-O*LM-CW8I(-)09"N&C0)7?,I$'YBVFDVMELV!'Y^6
M@O6JN,#^B0`F1H'_#:-]1A^N(.MKFI<G.%E1.*E_'"=70#Y-_9[7N/5]9/,T
M"6UZC8O<9=>B,"!_D2:]84TS-;V$^NDM>$'7-ZIEBRD`ZP]&)0?3>N&J:13Z
M5;9=WT=&38/YE&B147-W7-F8@*MF!3.C8'E4/0S!;)^*_*/CV`CXB(6!_*/!
M3=T&Z0AO3:^]Y\T&D*P28!6(84!9`TF250#VIM%@EL7A44#=Z`-ZDL(=#RV@
M)[;"UY`.*CYN+J>:"QHQO?$S-2"0L$:R!X58%YQ2)30*];;@V&2!E5$Q`,9;
M="ARV_8`R*H\E[8*]Z&*W-6)T:+W50:F!32WFWOLK@*:`B6J/N-V)3]T'#0%
M13"D:7ZO1L&"BR.2_=35F%=05%MFFD.%^4B)(Q?N\$C(L@Z3]-6Y*ZN.H.+^
MP!FHP4]3.DEMX19D83&?%J6&D3RP1G7)+0-YZ2T4Y7(+ZJ36;"&977+6EVZ,
M&<X":MF2=Y-`!\%>@G65)W:[1WX#+&AL8`[?8U;$-@?2'"YTAW&8=@UVFWOX
M&T\^63O`,OR;I\,I=0IE&%`0+=1N9.;@$W)TIXYX6L%KS8:0Y``M62.%JFD)
M]$"JO*\(P9/`W9([?%9?`W@4ON_!7X$6Z;-0']*'CH^G<3@WG4VS@-8M[SB4
M*EH:-*?F=LU)VU4;2QL'-0!$#SQBE)<ARA$HCN>S+>6=JG)VV+&&Q0"D5!\0
MM(DH)2<(4_,"@"9?!R%)$,TPG,^'06%B2Y(#YA%QAC07T$7UCP%"^A8$7CC'
MLL%N^W/J*!_BY-#CDSLJ((*$?%P97`)[#PJ("U<#Y-%\32'.K`*,FZJ$\.M,
M[Y^M!+Y/^C$1R>EP@,AR9PV0C9TBL"(`6MWBA0!DQ8"YS1GW]J&&S%4"Z>P'
MJ?JL8D&<=Y[-8327YK32"[V+$[]<VJWO@TO'86*Y-*@T=60ZLT7VW1.Z8NGS
MSUT]`>S@00\Y<M4@MGQN)-.`R$K:D^!4W5O;LQH/CE4(2G7`T[`#EXOK'_-M
M$'U\B=58!:\Z:#,JJ/&@@:C,K0:**,J<!NPQZW*;BIRX.ROZA`ZO-^$-CD:S
MTB?7\!!':@#2KG97@BXU$KRX9I3G7EW3K>^C\HBRP/7R%O?3,GLI[__BF2]_
M"2TK(R=J&6WC(-<E[7]EL^=?EB[T"EG%Z37/`M/?NSV/.P\PKFXS:`Y;)C.'
M3;/,G;4=R?\L[MYA_?658@]H0R9%(_#9MSHAOD>.>_*BA<BRVB`/74Z/X]"T
MM6XKQ>"C($@WNFK<?MR2GQAF<4OO]28WIC*24V-.6.T5#OW,1P:E]$B%JAUO
M#X)7,-&VM2_/L@LC"WB@W/3(?6@A<.PVC&9NGR<FI7\`8O*@NF[O)JB2,=2[
M&E*YNOOSX=U'W&)7N\NRP,4'9?U>M39ACCHWE1H@N*9UMS-E[N=;&O:F#$=/
M0`5;PGQV]\V#"L+2L=LB7-SPLE>='I2_2SQE1_\^4M&J?6DFJX[-U=?NGHN^
MLZY!M=!`RS!V3!0]:3YL]*\@]DL+EJ9+R:)T<9206`AW35K>V8-_R//#T*@.
M?,O8Z,OMPGS15)\)=1`D3^X[;B&?N+:PCL1+00AA(N<*^3D<602U+B4Z1"%E
MK*D^X?WI7V@W81#"E`RG^!`^G:\QY8MK3!9_7438@($XT[6=.BVCQA<MYF+$
M4)3+@%"+Y0$@DI)`)5M]`XI"<:E=$9OKPB3;'94<4/@UQ4NQ?6<B#J',WHG5
MNMEXT402NDP4S(5E&LP.>@D720O\`H#G,U/1I0I"!"'3/U!F?W^+G2#X9DMF
MJTC3%86*6@&K3D^HJRW!U*M^%%9TK?GQ!YGO=X2/W(6?))E;NT$6VAA8PU+X
M^AAQE<$U6LWIN-_O)<3Q(A7;9BA\QW":`(1JKA#YN)RVS-8^I`_<A1\=_Z\<
M)3A[&]Y93!.\"P9O4F^9EU/_=PC&@S!9&\_*?'4\+:'$6QL/P$U7QI,`>-S*
M>!Q$\=IXA/?X5L9!5<_O[XL144T`'O,?U5\)7K*S.<*8(0P>ZS];U?X-WN%?
M&P\+H-1K$R+THK4)<5ZL&N@FR?-5#=ZD1;#^B@R*S]4)>9&N3RB2:-5+;HH2
MDMZJ(LOL.YH,@W!=E6&$EQ/69\3KT703QEA\K\Y($+M69Z1!^KT9<5E^9T:2
M/J\P<,VWOUU?75_]&X+_F^@-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3D@
M,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`R,"`P(%(@70T*+TUE9&EA0F]X(%L@
M,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-
M"B]&;VYT(#P\#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A
M8F,W(#8U(#`@4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-
M"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B])
M;6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(P(#`@
M;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S$Q.`T*
M/CX-"G-T<F5A;0T*>)R]6TMSW#82OJM*_P&G+>_6:,+WXVA[G4T.>6SBK>2P
M%PR)F4'"(1B`U$3Y]=N-%R%+IFL=(7:5-1H0(/KU]=<-^,W/MS>_W=XD^ZHM
M28)_]:=F7Q;FG^YR>Y/JD91D%4DK_4U&ZGK?MEE#FB0A;9L3R6YO?B*C7JHN
M2ERG;!K\0>3I]N9\>W/\!ZZ$?X,ODGU1Y+#^OLC+''[D;98]'F^+$L?;O,;Q
MIJGRYQ?,R%U:YK!6DR8D*]NTT7LZ:OG,8.8'DV;=\)OWMS=??$D/78W2O8<)
M6@]Z42=YFI$TR4OR'F1_]=^L2/Y.WO]R>_,.IO[[95Y0!2\@G[5Z2])\:_N@
M$%P==)PU\*+N]N8NV9<U?K["2W_@ZE=%7D_3P+N7?G^3A._/,E2#>7]1XV=\
M/ST,C,R"?+=(\F[\X^'"R)M%\9$IM2-ON/BQXVSLF/+?$CKV."#9$7Z7#^1[
M*?JEF]6+VR8##V^BVMZO_WFFKS9-WS:I7KRM][![>-$?6O5IE>1&]:^'F<F1
MSOP>+,"Z\R@&<>*@Z@M](#V_\)&K,YG/C(R,]>0H))FTKOEX(DJ`I9@VF-+/
M7&'2E9%>[&,8HDKC&L*M_WF&J#]NB`IPLBAL"*1-T_H0*%IKAV_H^$#$D0@(
M`:-1J^<9G%VZ7\`"?"1')B]L!+NI/?D130#S4/MV`E'LA.,*37$6DPXMQ218
M&(TZBIE`U,!*,V''(\?8FO&11;$7EQS-EM56\J1$)1C)\P0_H^2X<R\1R@"!
MKIC>/+M,@WC8DR_!Z]CO%'YC.W+@XJ5WF;6IWV:;[8LD276DO+I[^3>5@4*R
MLDX]&B?X&17"YC.%,-08)T`[,H;(1=+^12(7,+**G+9%[;V_2:P/'!<V*.>_
M7(SPADDRI9V8DDZ,BO=,ZC1QH?)7-A,Q34+.R\CG!PU*,1P79MI-YZG?=-Y6
M=M,.^#IQF217"(C/I:0]^4I<V3V3.X(B4=F=R8'ATR`7/@%!?>7S&0(;0X$N
M:N*8ZR"H+_07$$TA\-KXEY`0_[/_<0\1@PH9R$G`RB,&3PP5-`A/UFYE@%KX
M62=N<-%.R)&<),@HP5A*B8Y3;4,$&[4`J:"(+V$&<9I['M1VY'KFH"1N<LIC
M-,2%+48@0G2+E#!K>$#T>O&D@P37J>#SL\)&2FOJ/&I*\^O'X!9-6>G%P2.2
M+/6T,LL\K6368@H-_,/?_DD.2W]BLR$7]'ADG7$,10?C\)C]',=C*@:):/(J
MKL;=^C%(1).VGD2D03361M](G[M%S4`))*J\&Y:>>=#1X3D'#UA]/R'<DY@A
MI#B`2R^7DX8W)"=/)CY+S&.`4))YJ:LZH$X!"*U[9@"^IP>[:R2R"#AVN\]@
M\Y<#_%RH]U)TQ]!3#;52'Z@1W@C?<EA8GN`M?]CYG5B&/H8*=*5F"Z@@?;8V
MT,X4N!TEBI]&#H0.\9:9Z!)&HIY=<,].%9,7_P>7D7"XARPUB$DG$R?_T>H'
MUE@TD>R`G)R8UA6]IWS021F4`^N"(^RB2%\U/@NM2:@J;/6(]$`,O#=9Q]IP
M.E-YH1U;9M"'X5+6,X#Z@B=+CIM5$QM[3,60P(7D,_H+/LI'-?-YP05ALM$%
M!;^9X#W@\J"X[QXAE;7\(0J!KLO4B5]A,K+RYYFU/E![+A8%.;"G%WJ"='H`
M=(6(#?VA9YUD%/P8]#/P(V"N"UV0]POP"TBC[*J-:<@8!@'[7>MG7L"^N*B)
M!/8[!^V`TAX'GL>'.#Z0%ZL25NQ+6TN::4?!R7D7F@YV$M`C\%0AZ2S0\D27
ML?P>_?HHEM'X3I2$4Z=%U(3CUX^1XJNV=BD^30JO]M03P+=B/$)(8*T)%%:#
M2R<&KVH7&!B,>O!@0R:&IJNZCJIIOWZ,U%Y5KMC(DFKU[\HEN=>`;!<L>3"8
M)RIGEX4!RL"+-:[=B^%>8Y$N*PRL"7!S@UV^^(`O3Y)>`,1^,AV!:9$*P'TM
MJ;C!]R-G0X\D'&E#K-16%;[$J,ML1;<F]^BN/<PXV'P6BCG1'WG:GGP#^5WH
M.JOGBIXD8[8+LN69-N<1G$@D/YUA`F0Y?)Q#-3(,#-/?H#7)Y/RP)Z\!66/H
M(:N<'K*V6JO-K'Y.#Q\31R+E9GJ8'OB`U3%*<Y@IVG-!)`_F8;X,%(5X/K*3
M;@9"-@%_HT@A%DP.@T'(,Y_,!GP2B*&*Q-/<.O,=HR++"J>*0'!7+3Z17Q<5
M,7"F;-JH../7CX$S9>W)M,X<+MQ*&VYOP<G15YX+,:MC.B@!5*?#SB/2;`;Y
M5DC/GHV7&8:T%7%VJD$I34>A])#,%"U+E$JB+!V-3C1WMC%6NA@[2G$AN@F!
MVX+X%X^#13D00NH?B+XC1V#"0:3-_((1)-EI&5!VX&,32'D/JML16/["1Z0>
M9J$/H6K!Q@@0=E0C+!*GN57FGE/7;5!498U5A14(K`4,CZC%=XH]U\=A4URL
M98-I"%V`!G;`"6UAA,ZTEARO3:/;<,E@[A.NX-K9,:3//*4NDG0%V\2RR5`D
MJ*0@+<9!DB3NB89?/P:2%(UCY$F[>E!>Y;8L`W)QY0,4Y%SWL$.O",XVP)N6
M0:.`#CYK=T]:'%>!E`[0,)MPF,]2+*<SU#$=&W7?%2//O<64_9K<Z+HX@OL4
M5;WFZO5(H\TMB`[\PK&MB_63U&46@B.4X,L1,NHB7?%D>MDA!.H2_6G]JD\]
M_/'<P_/E[)Y\#:$F>U`#KK+H`(TA?>G[XF5PFIL6C4O/H:5-G'OYG!UWV+V]
MZH#7;6$#-1AT.S2QPU%K:;',&G2TXJ3$#H2&C)W654>G@.S8`P)4D0+^%D4#
MN>.L6;["1]$FK3_2"F36KM@+??"F/=(,^UWK3@1N][H>T!T8<8?BGJ%*X^-7
MC@S8Z0=[+[\M7(&_!>ZDA==-U1C2IYZI)OD:]Z5M1X1R@4L>42P\P5Q&)Y%:
M.NS?'Y=A>/A,7/#%C$5GXTX(-\"389KI5?&Q@WF#T,WD%^_?UVWC=1'E="!O
M_VRO>KNZS^O6-_#SM7UOS/C]<@!\)?><716V$=E\]ITT?<8S$*Z@;#3-?(UX
M^@39$L='=PEPSE_!S/,R+C/WZ\?(IWF1^0Y`OC+SJL[6[KZ-'./I/</N'&86
MW0]8)F1:CPL_AQT!_*H.2UU$7(^MDKQ-R5="S>2]3S%[\B_?.J-10%3W+RT#
M+<J@$K%5'EV@V+<]6<T,=SJM6=]S:(C-BTDHA%#C@PB)U@]/D"(A?09W"LSM
ME3,_V`<G"?F8=]YKG]/#N\#Q8Z@A:9[M?SBS.UX#)$)"`0*UR#)_9*\[[0B\
M@YI##@\?:D(9)!UU7:%5N4)OH$7=U'V*PK@+IE>(TM[%&QC^K#W00IHY3J$K
MSQY<4F%1M!X>0@'E,C[$QC134-3+8SW$9U;_6;*^C<99:?AT6^VKO*G\52U]
M;0MU\+6]Y6.`N1=@4:0*1FSG[!1S*AM/'%B59'U06X<EE3T/<@5Y-\#C+P[(
M6%8[H:+DQRR/VUKWZ\>`^RQ=K\2L]7?ICO3>GUD8GP[X+4ZMIRX^5)]+"7A7
MPGC+&AONLMACC/R8VT2)]<2WNK.J#4XS+?";@VL$'3Q_QJX0WB`Q+,)<)EF9
M]=N!\HMM47]*%$-"%3TZ]!O5<IE,@P)5JO`,M<?:0KK61@3IT\;WN\O@-"_S
MEXKNN13FQ`J)%1^/PZ(K2&?)&8^W>G<&^2FA74%QPG+AJ3/8&N*>ZB-$7TQB
MQ1E#]LI7#F43R&[+YNV:5]\;>E+R?FO[U4XVR:BY)`06#'5S$3T_<M",.;%7
M%_4XT[GV,>8[U,H)%L+[B#&T4/CV=ENMN:YL;!<R.+.T#43;0W-\1H:']F;+
M853LR!I!J*8.Y1CH@0WXS4"OF@>M2]ND;S30T<7$07!>'"L2\I7P5JLWE%7N
MFG#/7UIXM!6\IU>6#11CL`V]A?5=^C\)P'@"+]H8K]MV<[QJP6VWQA,H"S;&
MRZ0NML8+/%G=&,\32!<;XUG2;NXO3>J/Z^<WHR*SP;3\_UA+@?\!Q*4Q0^%?
MI>F']FG*K=W=-=O:NTOK;?/<976]J9^[O"XW#7!7U,WV*TJ\J;KU0-7DVP_4
M!938FP^T9;VMI[;85F0+?[8UF;3-]B92B,EM3:3`6[:W`00^V?3'.Z"T^:>>
MR)O-F(`GH$3ZZ!/@>.]^OKVYO?D?X8)M1PT*96YD<W1R96%M#0H-"F5N9&]B
M:@T*#0HR,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#(R(#`@4B!=#0HO365D
M:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@
M,"!2#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@
M,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM
M86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-
M"@T*,C(@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T
M:"`S-#`X#0H^/@T*<W1R96%M#0IXG+5;2X_;R!&^#S#_H4_!)M`H?#^.]L:+
M["'89#V!]["7%MF2>LV'EDW.>/SK4U7]HC0:&C%$&+8U(MGL^NKU557/^]_N
M[_Z\OPNV69FR`/_0IV*;)OJ?JKV_"^E*R**,A1E]$[$PRK9E&16L"`)6)@D;
MQ/W=)];16GF2XD)I4>!_;#C<WQWO[_9_PZ7PS^R+8)LD,;Q@F\1I#/_%912=
M7R^3%*^7<8[7BR*+KR\8L8<PB6/841BP*"W#@O:T)P'UQ<A=#`J_X?>/]W=_
M_XGOJIR%,7N$!P@(6M2*GL$_`:S]V.*6PCS.V6-%NTOQF>?[NQ\>CX*I:?>'
MJ$;6[]E!=&*4%6^:%];VM=Q+4;-^./!.JE:Q(U>P@TK()_BZ$P<^PB=VFG:-
MK.3XPF3'/DQ#?Q*,=_#<>!0#J_JI&P<IU(8]'V5UI$7XT$\*UM"/LK^RQS_N
M[SZ`2/^YB>`AJ#J(0BMX$J9&\"3(0BUX+79\%%N&`/#Z20SJNB"P_:9FC>`U
M&WMV&`0\-<!N#E,#TO<=23H.O!;PI0)!*_Q6,;@BVU,_C.H25][`"BC[T-=3
M-:HM^WG/E&QEPX=UD`@2@T04&QSB,,\T#N>RP^*<!&!]54V#0B!`B^R_G1QA
MRQ]'D!X4:<1!B04?0*<(`OPP-2/O1B>9`6_G36P&8=VW@!<M<H8E7P.#LL@M
M!&$1$@@/8`U9X:RA@FT!#$;>6K2XEWT_L'X:+@72DFZ_=Y_9&_N,RLQM](?O
M1N&MU1&%S"S^>Y0$-U\_\^M_W^;+916F@?7GHHR<"F/\C"K\A:+-^TG)3BC%
M?I7JLP+OYB/[)-A/O!)K`!H'ZP)JU_\^0+-E0/$B+%[FVSS/2_;XE1`-\[S0
MB`)N[:1&,/INE-U$P:O?[P'E3CQ[GZ``**ICUS?]`>+\S?T"]EJ4\:I`N_5O
M'GP@!Q<8:[7EEH&WW#2>Y6#9U1-F#]XPT7U]@=!(N.YD[Z!]<3?AQ0%2TY$/
M$*W%(+]";-Z]L(&?Y%P7D&_PINX@-EI+F.L@SMF,Y..W5.O$W2(M?1(NG>A$
M2E!TVC&8E7CJFR?9'1@0CJ;>LE\@Z.ZG<1HP=505.O2S;!J(RR>!S**CL,QW
MLL%L#5FEY;(;X2^(4?7M";*3IB:]DI19GN5X1'%/)@N=@P1)D'?PEBW[E2!<
M`XDDLADHBF.'1&Z-X'Q#M7@237]J!6134"PQ*05"OIC<@WGJ+#%=.B$D7<`!
M$>UWJF\$4)TUW#**UG5+N_XJ;AFDCAE'GA/$J4DH[[H7C^^(B>196,7`S\!@
M#T=2PH\A^V</<?+1>RH9JS9$XA1'>3B"F<]-L^7#9X'L[U^\P[A*WJFI]E>N
M.>0*9I@7KAQ(@\P)'4:I%MKL$.R&/&9R#-!LER@1N.310W/D((UE=17XSP@&
M#&8*T%1(%G_]RS_(//4*N+0:^7ZO;7;/*_1A:>(=/*Z=FNH%_&8-#')?&:0^
M'@=EJ3&PLH@O)XBM`@(#N=L.XPMNWQ#6?@`N?P(8GG@#FP7".($T$+/PGC/'
M=))OV;NJZH<:/C8O&S(>:Q*]\6\@RWS7"(Q1UM;6@"!U)4$:.3-(PRR]C$9&
M,4Z>MH>8#%19@CGK>N[9<.*N%IHMO_VP3D(]\&RP=RU]T_!=/W"2WX:JU10?
MYRX1IX53?)*:;-3UW<Q#J2[C,P59A2AP`+2,?B8J>#!*H\9;;SN&$L7NNXS`
M2H.0F-H/#[=_4SI#*,H2EZ_3),HU0@+H7T7ABZK8CAH`"HWU+!OU]!G3-KHQ
M7MH97@X_`72<PL`:&HX"W^V8Q?3$V+7.GB;TR`Z2/C(N(+BUI@F^8$7]3@J,
M'$A6*X"2_`S<HM:W;=ZL#]&#GP7_+#I63^3$4.E/NJ*&&(*A<#?5!Z$Q6@.`
M('8`>`4F46)B6],K:DC4$HGD;D*_PT!+&4C[<PNY:M11G7>N-Z(U;YG7%>S6
MX!=9L2[M=^NOP2^RS-+^(,^M)F+K28\7.151_4#,W]6PM]Y3--M40AL"7*/H
M]J])9K*':9EZ,\P3+;V:Y80!JA/PC1:-L.(4,<#DSLF2SB*R0L?LE`G/O[R&
MC%73`)EH!+]=P;DH)&JIXCAQ*BV38DZ>A-+<:4\L#ZE2PX>#.$OU&TBAF#KQ
MOAIY.K;-M#FXFH6HEQ('+`+HLTFWPA%+1.7YV(/_8OEV`$9ZVK!CWZR2/+/8
M%C!!Z1A#G`5&=F)"7V0+S`G`SX/?`XBY1B)UQ'+5$,D3%IW=>*WBU;>?&EZ!
M=C\@0)H6*W%&D["!K*:=PEZCI*Z$96PN+&U602!T!4,4>/J0)J9@,)FM[_#]
MBC?B@OW=?D]%-M]4[/<4Y)%+>)J'8P734073TZ[(Q90\='(/%2?HXYSM0J;:
MLI^F`0O/S14=8**[><P$`N+%22,K3[@-(MLP`.=0Z.=ZMK""DM/2%4B!=_&L
MS+R+-P)=D@-^<Z:[T641I]`&L4K0';4<(&T*L`)@MM6$+7[L=4S$"#Q[M+,1
M4P%HDNVYUHBS!/U:M".07:XC?.$JHRSTU6&4O6I2:-)G*Q1`I14#\8%YQ=RY
M"N<Z9%ZJ-^IHJ)<:!?%-]:WPL6`-P;/$>9%O+L>%;2Z?AQ]0">R9ACBR`QA\
M%4-AFZ(Z3HQ05_@DE/0F*9BVS<J)/@7J:R5:,=&G<3H'+BMFO4U;2X,=8/(;
M'=<!N+2)"!?V]^M0X32QM4R0A5ZG8>AUZHQV&B"PK-"Z!L:51C<8NBS0S#34
M)<\#RJDCY@^?1-/<^E40G.VKUJU#B]*]",=UJ2_CBL"0Y\]=_]SI_M!.C#[S
MBWIST3+W[J<G%[Z_=1:(T`21G"C>BO-V!12"3Q+S)P1V=-T5##4I7<U&[F1[
M<C;GO)?]QXHRL_)$%UA2IPMOD@N_/KP917\$I@4AU.1M8&![:F]!#6A#U!5,
M^B?3S[$KKB&Z'XUDY:Q>MY.1F0S(]J\BP2%%8!_1=@Q-[Y5F5E2"XS4L,48H
M'3R+P02\'_KVHN=JDSAQ]@MC6@,`-R")0E\GY47I\PZ9+W'\9W!KXOH5KT4K
M*SMV-S.<#M0Y3EH,O')`#7:47OD!0)/"]+&1C4/(4]."]@$WT5$GTK@#XK4&
M`'XNDN0^@926P.JL/_"3F$8CL>9^L*U1R,[-R6Y>QL:!V]RZ`2^"6M+#$`8^
MXL4TET48#'VD.#:G6Y)X"#@GJ%6`T4,MJ4^9/$E2'K8D%9UR49?3!0P%*[:8
MDV@V7IG-Z].K7-*:I>NL7NLO7@MMG[`,!LN0)Z@`]3K]6Y&"(@-&`X!-G_>H
MS\+!&B@$KIPH9V,_%^'`FW&8[M,4$4L2P3(F.A2CSD:"8`-@\798Z/(535'7
M83&QF1M]/XM9/HP0FYE,F4$<P!O-883$GM?"PPA@L)T`G=D^++8?S;S)-!?T
MS'B[QN&9.`U7[46Z]=?H15*[2IMA6,:^OHGMX1D_;_<3O#\G*%YU]\G4I;.N
MRX:=^`!^AR4M'FI3NC'ELZZ?E(IK$U(JFVP8DU]7J>KBT,U[0N]\<6[G/1`D
M@`I!;("Z]-]STB?WIFK51^'VYDS8F0.:@/3A"S:T%-[W\46-HG7=W*LA:.2?
MX<>F[[`AV`\6Y55FO7'@AB%I/IOUENGYG/-UC^C(:^H'8>=B@V@LZ_8U!L@>
MOIP(RE'-&<1\P*O/;=BIZ2H6$!6.6@.WGJ755R4@-F5:G5[G?,.RC"44.&+P
M$1**H/&PAF"#VI7[MRW!#1,YZZ9VA^:P7P4"UXJ/XM!W",O88'`AK3F2^JX9
MCW3``63>B4;"9MT9"&J`J&F_ERC4B$W[(PZ&CC3>!;X](4D#N5U#U#1"A=#)
MN=\U\F`NV(,4_Q"5(!36@,#U[8,R]*,8;),0!'&X85$0%'I422D&G?A*FKDX
MA$0S"S1?:ND#J6BFVC3H9B,R>X+)!(V+Y@^V_@0QVF<ZG;4*`*YW'V:YGPK&
MD:DPS0[W4W-^TN'$7W3\IT+IJAE7KK2<Z`#`K!>&G4N(,3J%O!+SXIT`#$Y'
MUQ#>M92#//59P!T<%?L]'=.FMMV[G>@./4=9!>0%2%2PJPW[N:NV9Q)4$"@U
M5:,.X-Q4S@#`)`GKJ*,\Z2[#/.EQFUY,D'#):(U3X*ZO'86%-X'"@&#3W\;,
M:/K#0+4U=D`J/`?_ZL"&'<O)3OL#1@+4(#R+1[TAZHL!!&[UT41ZUID*'?69
M-TT=3OK]:\CO6]OV]R"HM1V?G6Q`,=&G>05IV8[A4'32NSW$(/QY,"1&+>3T
M<P+JCUON(==UAPVBHJ"`<Z?<10?85,*2"2Q>,)(V7+:WY^]Y4CCY+^@E_7Y`
M"M0S+V%I6M8_3[^J0K]``+7<P@U%62Q>S\NT7+P>I-'2]2S(\J7K:0#T=N%Z
M$H#?+UR/@V)Q?U&0?P.@O'CS^I_ZED3O`&+1_U4:)<#AH`BR,S'=W@VC5SI<
M!N`A+Q<%?`CS?!'AARC/%B%XB/-E#!^2(EQ>(2V2Y1NR!,Q_\88R^Q8,RX;V
M4`9!MGQ#62[O(0SBZ!M8AV&QO(LP@GIE^8XX2+YU!Y;LRW<DR=MP@5U]^.W^
M[O[N?\E@2"T-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,C,@,"!O8FH-"CP\
M#0HO0V]N=&5N=',@6R`R-"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W
M.3(@70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\
M#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U(#`@
M4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C4V5T
M(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*
M/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(T(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S,S.`T*/CX-"G-T<F5A
M;0T*>)R]6UF3V[@1?I^J^0]X2CDIS80$[\?XV%2JLKN5V"GO0UXH$I*PID@9
M)$<>__IT-RYJ/$-7=H4M'S/B`:"_OKYN0*]_N;WY?'L3W>=5QB+\0[^5]UFJ
M_VN.MS<QW8D9SUF<TQ7.XJ2XKRI>LC**6)4D3(G;FX^LI[&*-,.!LK+$'TSM
M;V\.MS>[O^!0^&=Q(;I/TP0FN$^3+($?2<7YY?TJS?!^E11XORSSY/D!.;N+
MDZ2"=<<1XUD5E[2F'0FH;Y;N9E3Z!;_^<'OSUQ_J;5.@>!_@!0*"!K6BQR!Q
ME&3L`PC_ZK\\C?[,/OQZ>_,.7OW7=2;(%Q.PWSIZ\L+H.?P7`2`X>G0?E1PF
M:FYO[@#O-*G8AS-,^H\=&V;%FOHDI[J#\4?XV(B1U4HPV8_S;B<;*?J)30,[
M"C$]>?SS+)4XPOV130<US/L#>RL:<=P*Q9)XPW@4E1MV%NPLNXX=Z@>!`ZE:
MCH+5;2LG.?0PT&[NVQ'O7!L#4F$4&PQB$-QA4!6IQJ`9^DGV,ZSL(%@K'D0W
MG%`D-FAP)M$<^J$;]A)QZ5O6#,=3)R;]`GPX"M7(NI-?:Q0'7SNIH9V;:=PP
MN8-7'C>([-S!-'NV4\/QFW'O&6AB-T\SP!X`@PK>UA#P*+<(I'FN`2!UC+AN
MK8=V8$/3S&J#`CZR8_T(&I]!8ZWL9A(1-(42B"]R))G&:6@^'8:N%0I$^2CH
MG7Z8V!;4O.W6E(ZC"75$^ZDG,KL0\N>%-8&T=&Z0@D]H!.JF$:?)KG2&52E<
M&&C.+.X,BQL'L`T`!>Z=M80@W=Q?RK?PF(6HQF%(R_#NKI;=LZ\0)!LR,L0W
M!!)9Y)RAK+PSE"8@O.N_/AX%>SV/LA?CR.2X$'$O>J'JZ6+)'3K,:(Q^!U)N
M92>GQXW%R/H\V-.$8@-ZC:A'03BV<CP-`,&P@X^]P$O'00GK><,)IP,(P:BN
M'GL!BR0*&MO=^+]M\?FZ(O$F#%X5]UF2@AU_)4W&>64T^=$$W5Z(%A4@OIRL
M75F_O?:R>)2Z=6'&R;R!)9E9%AB%^B0H:N!RQKJ#T./RSGT`-9=5$E3-;OP0
M&;PL<A^Y')QI#$-I+1\D^";X&OF9@MS;3]VC4;;0ZGX.<8@T#7G6AAYYZO87
MEN,3I+,B2`Q'_%@W!PD!($2D(NO1DN<9=Y+SHM"2$Q&!E0E(QA"36A"NGY&4
MP`>*1WLUG*<#R;S#>`[/OY;#>PQ;R'"<K"#&.$,"&,?=W'6/!BY*[F]B]N[+
M":QSQ*SW_G&$V5QTOI@\!`#HU1J`F+NLG5C:`FM[WR@A>E2L7MH]>S,K119`
M\5<)$.>D)$@DX3?D)C,&73"3R=K!`&Y'^*"\_^DE"O-^(@P-$)KR]).JX:VS
M!$@QTFM,`&\]3KTG$A@"!IZYC%64/G=')J#@\B"/3$INYVE0HQ-&@GI47YL4
MK(4!0M8WW=PB9M-9F[8:NDZ0C0BY[\$6MJ-L)4"&M.SM`JR3&(#W$4>A*`JZ
M'QZ%(85X]51+^"4(")'E\3'Q5@-"AJ$'08#UU0ITW0%W048J23O$KK1^#)/[
M)$B#LL<+4K$:GMOWZ.9"*0GPD=!OC+9%>ZG=A8Q;2.'D:NAI2(A%/VKZ2VL(
M`$%1Q8[#)N6"Q":6QO]>L=\NK>@$^>B`0EHNKXG[K+4-P_28M02$2;0%]Q!%
M6*$>)(:8$"@4J<L':>'Y6VJB(@0SD%.UH"<UD50_(Y%"N@;<G);G[=84.W15
M8DVCRYZ+E`&0@);W$%#J;CI0A0>1!4H$X&9R:&538\P4_1YL!"A_?VV9BSAV
M0E<<_3XFKO/J[OHS90MXHTRC^\K"%42;F:U+DI@[M\YR[DM3+!OK'DM)<$C*
MX4#*(;6#P[6H+1N9P68WE)'!M,<)[51;.UBPV$%LFX)PJR(I@G(K-WX(;E5P
M5PM5^:(LCDU$^5'G/TJ1`"Z0A(-&'])N/:(N*/!-5.5M+J^#"H@W0$$_VL3;
MS%`G'ZT;ZF*J8P(T.!QE@YK4!2/,A963Z:X$L;O(DG2>Q+X>KJS=S<2*(#P,
M$."I(O.=(5/[F\0`@OA880P-2_D>HT1CV<B2*WD@(;[V>\K$NH\"I:"T'93+
M*0)`D)>.6//(!](R,2V!902L=SO-@NR"+T/D44!@;"'4?B!WHZ>(/CV:M@^Z
MXJ(;`!P:LB4U??QUWR4#.X+A%\^;Y!X"A-QR;!Z7L;.#,C*=(;M2MA6Z`W36
MM*JGNL`8O'B!55(CJ.[&0?<!T)0O'E("/03L`WC#@S8LN-35C;@(</KA$,)G
MCE\GR3*5VK;8D_7I?H5G"-2P`D``EWOV7AXE:`F)M]QIF!;@`!&7-50=&`F\
MW2RB^T7D?FH*>Q@(B`I%%=TI#(%&XFAVQ'V7-$]BC08F?='(5GRC^;I]$,`U
M,/#YE9/>]?(/<G\0SP<,(Q%2%'I6"0)IYR9H]2-Z3.)Q<M(!*00$KEE^P3"S
MQ-3:K40:A?Z,)8:.D;I%)5SS"PT`93S['BA5YD^;?+KJ/)T@7@)6'<JLD[6&
M)$"JSJHR:*IVXX=(U5GI>O@I]\V`B.=N'P,07[2XEM4MT=NEQ2X:(L"I'B02
M93+=IL;DLP-K[<D?9U53KX!<'8*\)U/:(GUX)YO4DPY!&K=9[HA_Y?T3C-/D
M*^-E"BA]/T-`^ALXX,;4P4]\21C'W-H^D4UIS[FH3_S6GKW0-C`YN>&:64<(
M!%+7Q,^J12O,-CR=Z#_,"N16&X87G@O'(^86$KI_3N;-TGL7.QC'&G(?_#-D
MCKB-[G^C^_J!W$*N[65%F3D4?KN;K<4('I;.N_%#=,2S6--Y,(HH+IR+\+PT
MK/:?PTB-P4_B$:O7<>A[4%TSS%W+#F`SI->M:0L&V7%(J[`[#F[\$#$X+6S1
M$!?<D\7$\J6/NC6&`0`8OR=P`]6AV(?L&WG"5ASM#X^6YA_KOM[KU@-U3RA+
M2LB6FGGK(-89W9TI"+L.RQ$FFS0#&;'9&2#LI)DM%*(B*OV&1F*J1'D\86,4
M%VFZX<O-XV'[JVB(/SYA^T"$U2Q=5UX)C"SXZ?-<=R"]N$#"F^M$G1?(04>[
M7_SO/[UEYT%]TBEI&X0:T8$!K?O2-RK2-+7--P6B-'7GJD/=4*<2P%>![?`L
M(1)?1#,C1DM3N)!8-^;U<^+"31D4##UF.]^;V@+9#K0G0=S#D.38<V1>.8YL
M=>!W%*CXFZA'LZ;LE[W`(>$K9S(V8TK6TMZ`[>W8>__>S[KIMPD"1&2KA:BJ
M\D6UD&DD_MZ)OF<_B?8,TL/?'VL%*^=1E&^631,BTEAD*MJ4<6*/MMW:ST>A
M!MW4!J9B3V#43=T*[)D0W9LT\1D%32+[$0:G<PJ:LP00/RE=.SY-%G0T->)W
M4`WJ=&*VPZF=`HQ_H&,%B],&>+H`&$LM.W1EK`*UJ2SLY/DX<*:T=2*N0>T^
MPNLTJW'6E577U=O!;)\'XJ1)X5KRJ2=DEH^9[K(EEZY%CB<`D"U?G'\)D&R3
M+`Z:;-WX(9)MDCBZG^4^V1JRCP4S!C[<PO`EC*U)=-OP2<,)*W2DP4A^&[(E
MV;<SMC/\!A9$EOITZB"0&\:K\[;1F]$G[IJ8HUZ!SJ@DL2/Z25HNSJC8/8Z+
M@U.ZZ?82"D\C92_.RX#J=P-]_-W8'9ZGA\&>170;)L!$KC7MV[.Q;4R[<U?/
MY4M"!`1;1)ZZ<6`LR1/NDPYN$V@ZR'$AEZ;%2&ZDWD[5V^G^1)M).^'X<E&E
M#H<@U0XOP[)Q-WZ(`,%SQ\;CW/?KBK+T(4*W6P=EMR5[.2SV`KV+Z#ZF*V\O
M7W//XW%0ZH=`CK+'OB@M*Q\N]&$N-NIN*/S\&N9L!$\M*>>9BXY99'J5IWG;
MT8:*X0Q$0XEUVEW=5E,I)^FUE\BKPJU1TV4P,LZO/4T"$MMIKF]E290N@(Z3
M<K%-8F/QTD*N/G_^QX!8!`6Q6((8E;&CBTEF3V%WT@9KYV.Z*>XVU`9;+RZ3
MD/=3':RA[(!X+?#8EPRR1\"Y/Y*UZ,)RNT=`R?8XS#I=^GC1#%"?X_D`R#`/
M4ISUL;+MY0GS1=].M^RPF>#/G@(-><#=!R#^4#1-XO+0"<2UR\==,`L!0^RJ
M0)[[(XY%;M2Y*&V#!9AXL8Z`OA%C&C/37-\WXKA:@OF'!YBX_&-`+(."6%Z`
M6'*_<Y5P0P:^=<67>MRV_!R4K3XONJ57K],RX$B_'YNU;_!4/.P7>*IG%X\S
MQVF5`8N%D6E4_SI]APF_F5)!R%AYH*KXZOVRBI*U^P7V9M;N1WBXZN7[6564
M:_>AU"]6[T?)ZOJ`OJP"Q"/.UP%<6=]G_4B6TA,PT?^UGY!&^(ZM0W4-]BI.
MOM%QNBK`7;D.P%U<QJL(WO'R.S,D9;X^0EJN*^DNPR\"K3V01SQ:?:"(HE4[
MN2NC?%61=U64KJ^A2LIU'/#4POHB8DAFJ^YT%_.H^MX3:9I^YXDL>ADML)IW
MO]S>W-[\#^7[H&,-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,C4@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`R-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U
M(#`@4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C
M4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@
M70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(V(#`@;V)J#0H\
M/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S,Y.`T*/CX-"G-T
M<F5A;0T*>)RU6TN/XS82OC?0_X''[,+MU?MQW.PF2"[[P'20'/9"RY3-C"PY
MHF2/\^NWJO@0W>T1L-DF!ICNL2BZZF,]OJKB?/O+\]-OST_1MJAS%N$?^JW:
MYIG^JSD]/\7T)&9)P>*"/DE8G6SK.JE8%46L+BLVBN>GGUE/6Y59COOD584_
MV'AX?CH^/[5_QIWPC_=!M,VR%/;?9FF>PH^T3I+[YW66X_,Z+?%Y517IXPT3
M]A(G61&S*HY8DM>QEJDE_?3#W#V,/(&_?7U^^LOW?->4+$[9*[Q`.-"F5O,"
M_HK2BKV>4*2XRC+VVCP_O:#X9<%>K\]/W_Q+C&KH>]&QYLC[@U#LQ&]L+]4X
MGR<VS",;SF+DDQQZM64_R%'V!\;[/9M&+GO\1R^N[.QVN<JN8Z*?N(0=!S4I
M6JSWO(A1;SD*!3\:H1_^B;W^^OST'2CT[P]1.TY`[22V:N=9XM2.\'=4FT\3
M"`E*L78<3K#_1?2S^'!)TG01!6POBR+X_7?X_I>/_ZK2USI)B])JG4>1.>R#
MZ.DLX=1$VP[C!$?Z/>H_R9-@TT`_-^PJ&._4`,=XX`<!Q]BKN9MX#X<):[A2
M4DUL5DSV=)J[6<E>*'V8OK6\'H4288XWRIRB>>&.MP9'(D5]D948+Z`0BKL7
M9P%_]1/J!`;<3,.H-B3W%?2>CF(4``O\NA]8/TSLR/6KI[DYZG>&C@U@Q[A6
MC@QVD!<Y2;1DA;C!>_:Q_W!H":D`4-15:0V]@`!FD4B*3",A3N=NN`D!Q_%/
MD,`'!IUR!V*VK>PDGP2`(*<C&T9F7MJSW8T-B`H[\Q$5T5BI`:P%WR9XS)9H
M5/"J7L[W%ZF&\<;X.&)4.0G\0MH^!`9E9*TA@0!J,:C`)0@#+1/Z.QW&=.03
MB0^2MYUL)I2[&4YG,0DMHS[<8=?)@[9EM/L9(/RQO^BPH?"=\SA`#%.P)<3+
M!L]=0S:1W>N8J'1$1&/J!:[FH^QN05"`5&0M(5V</ZT,"CO1X+FA'8+@(-UT
MV_YA.8H5.5(MQS?_2;+HP_<OEOW_F/#%.HCXS1BLBVV>YQ2K7S"'H%DAB#_V
M?`?>,MW0(@#&230ZI<$OQW[HA@-:6#/,W1Z\8SS1,^\58V9!@*_J(BCP;O\/
MMUX@*E59.YY2I\Z'<YNZ,'BIN4$/TAZE8SGF((Q-;.C?0CWL@(3@TXF"CZ8A
MLJ</^5[\-L,#>X1(!$R,UL$"UHFN@R<S[YR[L!8#7)@X7A6)C6%QYKP7:)K1
M_\Z^4!<0:C\W$V5AS#8_]1)#^*<)U#*IF#0!6X2T)3$!_-B:%(71R$(`P<BW
MXX>*;XS=2LR7-F^$``$SF`$A\D"PI&W7">UWF%H;\=[Q4&T!P.A'5FB)27Q_
M@:0'=(9H">OXE;(RI3),^?+0+U!9C"PPB`-\/G'(:*,\'#410M1#@)`XQE[4
M"W5-8\-M%`>1Q1>T:B0=DZ?-.SO8&+/O;P0&[U$YRMJB)VTI92E07K:R`8!0
M54#Y1&9EG0,RN\Z(#W"`92$PB!?Z[O&[*+?>0!GVW;E9RNF4`)705!L^*TK-
M&W)A\84#P0&6QP&YYC,B-\Z=,9^3F([#7M'"O6@AQJ#^C^.!QF#[T;&VI'HP
M_C^#[4JF*.LX:*9P^X?(%&69.=M(:V<;<6Y2],^"'0=(ORV%,Z5F./F?MI^V
M=YD@*>TC^A?4.]UP%7LZY[$GTH<'K=_8P,=--Y,A-!V7)\,A&T?U_Q:S[[Z<
MH:Q5F$D^W=0D3B'\HLP=VZ^B1?<L24V$!&4NP#`'J,X,$U=G@5G"1`<0]`>H
MRMFKC9HW'2+R2&/$^[<80'%@4#H;7]"H,'X^`WDV_/AZE%`A07;9B4Y",8T^
M<I'[(`&RS"S=CY/$@9!6N2EY=N/`]WYFMVG[T2EMZ,D,5>'8W5"[]PB1\O#Q
MIV84@EH>YH"I#6(#HT[&^!%$VI,8&PG@A=`^66@^NIE-#ZDQ?_]8MJ#*%4YC
MI-K6'MQY4-+4,"W;R6%:-'5)PC=YJACN7P6C&073[80.&,3<-Q`0B5F1`5V&
MCBI##+-?@J`0%1:%TJ.+:6V*G4X<`'X4IN4Z:/\V"V5`^5EH"HG%KZ,4"P5Z
MD.6H233W?(;<,,K?P2$@H>A23XY[6QT#">UNEAF8#$V!(A!G+"K+F9.H6+)D
M4>4:!%^1>YHT"N;5JQ?>2>WBH@=?:02A8L,E.`^N%VV+[G1!PFAY-`8&A9U`
M<'0EP#TFC2Y&$/2-@8*$YLUVNQ`XE)8[QW6Z]#CSO+;=(%`5+7DW8'_C$6E<
M'%BW<02Z]UD#R+%><XXDOD@UV29H.T_S*!Y&1,.2FR,XB.@/)H;BIR$0R!UQ
M3J(E*%2&,B*7A;`W=Q/R-9/XS('HOI#3RD^22!OO-"1L3%V%FN"^H*.:6V"/
M$A;`6>OH2RZ%3=5)YR'C0H:YXQ>%0&'I=><>+[!=H+?G#D9)0NU!SFXX4W;7
M%0/B8`QBR[Z?1]3@1'U!HPPJ[[4306VS"7#ID^SX2%[3F3P*H?#M%X?0?FG^
MQK%?/!G.O!?(\\&7@2WOO:`.IN!+ATTNJ);V)LY["CM31@4@QF/4P!IZV0K2
MADFUUE[PO19G`3K&$B6832<0S2L$#DMO./(["75JH\&#JO#C23Q(DE=94)KM
M]@]!L_-B:2Q[[I1DQIS^@3T$2**F;?(PUX"3*`:$\"`QH2Q9P"-G6_;7IAE&
M)!H=<E&JK.\*TF%T9`6_R-);_PL#6%&>.Y)9Q4MNS;+X?3^&)B8C)L;Y#,32
MSX>/:"BVG26&#6DHBJ^*Q`Q\XAH:+&6P6)_X9]'CCO.(S:V3X`J"LGI+7$+`
MD"YLLUA:ZTE=OZ<8=Z+K0MQ):K.%C0&/&G`6GSL^L<P4UE!20GQ&-$(@$#NF
M6>1>.R9U`#PDCIZ$2+$PSHZFD3#<60`>*#]`9>'-2-S0!AMO7<=WP\BI]:;+
M"S?"V;)_("D!>#HH:C8AU,]JUY?-EF(KB_*W\Z6WH@[OATW`,+!Q*U73#4JL
M069G<C[+L%0=;`J+L';NWK0NM=V$P*!RO=G(F[%1=XXZ<I;Z?BUS?H4JS#N%
MX$@JH<`?)*14$QT?VM%@"(S$6L8YQE4"E@>JO71[/(P?9(6CF'GJ(D&15)5'
MK^XK@0`I-3,=XE`IU>T?8KB4F<XN3I2BPAE27.6QG2X]ZC)"B#!SR+>#)3MY
M#P-U5(6%VNX?@KVDM6L@>TV2/,V7:9+7IK&#)>VERA\J]4*:@5"+\?MMB?2@
M5T"=-J\KL($`!D<U"MX<==V(1]J(7ME9=`!O39<F:9EZ_1$[$K\*.P;0(P!*
M2Y1[1G'@(Q5PJX4RE(TZOM$VU"3<F.8/M3],W8B=@TY^%KHO@LLV#ZME5Z*'
MP&)IFL9UN?0+HWBY%4/A%'^!DI`?="JFLS$Y"(+LD2X!0`J3OYMK`J:G^*ZA
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M'TRP@XT[9EZ'4U_J;=\/-+SR<FW"Z[8.`4)J>74<+9?7TL+.<W09\:8-N1CI
M9V\H::6<E[M]IF8RABS[7^>>FOB+WEAW3+1NQ-%=:T9YVE#\IO^N&W!6'J;/
M0/?V3(YVD3DMX]K>_'#7>EJ-@\U%&X_'86*F^XEPD"YI;4S1C.HL"8?N9UZ1
MZ.`E$,\1]OR$[4`/2TIBW#@>K+;N%<PKHGCI7U9>M6GHBG?*4EGJ"M7PQG*5
M'1XEG.JHL],9[UY;K;#SJVUAZ,D(T)X6.FH2EQ<'*6H\J,+-+E.P*[Z5([!I
MOEA$;;J/3F)D*[`YA]!`HF$@VS#9TH.NHQ!/T9*&$821,6U[`08LJ>,W>^$%
M;>;.I'3A!4X!FV/.F8`FG2>$P-;Q?I\_!!)+(S:/O*OLD>D^V`LK'H?<LK]C
M?-3Y@>H-?E7@YC3RX++#9.+Q%C]>.F`U2G:(,QO;\)&A8N8"V^EQH?WN#[\-
M4U8.@R"W8>B^74`2Y?:_%QZ_.<&60%G#SK3K\CK]+Q%8$-=1LKH@PHN#*POJ
M*BW6GE=U4J\]+^LL6WL.82E>>Y[7:;3V/*N+5?G2.EM%**GS?/5YM"Y?')5?
MW_\WLT0C%.?_6\<'7!0.T%(<W>[Y)L[>&4&T"M!+5:T>P$M<QZL6\)+@4'QM
M`435]049C@'6%N115:XN**)R]9A>RGC=#E^J.%Z7H<KR=1S`$M=EB*-DW5E>
M@)RLFRNLR-<-#E<47P<+;.*[7YZ?GI_^"Q*&CT`-"F5N9'-T<F5A;0T*#0IE
M;F1O8FH-"@T*,C<@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`R."`P(%(@70T*
M+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`U."`P(%(-"B]2
M97-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V
M(#8T(#`@4@T*+T9A8F,W(#8U(#`@4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y
M(#8W(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C(X(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],
M96YG=&@@,S4Y-0T*/CX-"G-T<F5A;0T*>)R]6UF3X[81?I^J^0]X\(.3TBB\
MCT?;99>W4CD]*?O!+Q`)B?!0A!8D9U;^]>EN'.0<RSC.(+6UNQ)!@NBOKZ\;
MT-<_W=Y\O+V)]D6=LPC_T*=JGV?FG^9\>Q/32,R2@L4%74E85>SK.JE8%46L
MKC*FQ>W-CVR@J<HLQWGRJL+_F#[=WG2W-\<_XDSX9W4AVF=9"O/OLS1/X;^T
M3I+GXW66XWB=ECA>547Z]H0)NXOCK$I9%4<LR>NXHC4=23XS6/K!J%H6_/7]
M[<V?ON.'IF1QRN[A`<*!)G62%_!/E%;L_HQ+BJ,B8??-[<T=++B,:W;_='OS
MY7>SGCJA=PS^91/_I`9UE@UK>CZ.\B@;/DDU,'5D:M;LFYAU:IR8TB<^R/',
MGOC(6C$)?9:#:-D\RN%DGVUXS\Y*7SK5JY/Y)J9.M>.>_45I`6.MT`/[`[O_
MY?;F6Y#F'^\B<YR`S$GL9,Z=Q%F,CZ#$GQ72KH_)H<5+`$?'I\_(+?N>'00L
MS<T!T@,6G+7R>!1:#!,[B6&&*T/+QHMHI`#!?Q3P?9*-O/CIG^34$?9!@(@R
M!T199!X*-$J"`I9(0(SBXRR&1M!J^1'T24L2GV#A$TC6J/.E%\X2<(@/@YKX
M^@I@1-.)'7L2'J"#F'"VBQHEW@QS36JQ&'IPP2D`!'556@22I(X]`A4X.2%@
M5;,2XONUHO?L!Y#(C8(4HSSTPBG4:-`^1P;2J+EOWS(,/X!WC_/A%P`6IT5#
M`%O1\M1-L(HG1"@$#&7D8,A3'P7R.(L-#(<K4Q@&C(T>1"_%(RCRP$=8#^H8
MG$`\\GY^IG(M>K@(RP<I03JX.@(LSH[PF5:.S0PPJ&$TEHX7&_@V]Q.&BHM6
M1T'CO!]W!D\^7`&AI@N"`X1KYQ#IX@^0(@B&Y]IX<CJ3`X@NVQV)]03>S7JP
MYI/%XM%ZBQS'6:!Y"Q#/>($%$C^.'<UVT8"8[/?LPQ&OMK)EX$CN\@X?'\%E
M>A$6AK2P,$195#L<DCJR26$MGL;%O?<:ZM2OH4[V612!'?X*+[Y[]Q>5*V'C
M),^7#(B?7P@+/BO/(ZENY<D?9ZE-X`+C`&7+`3YRUF@(!^^]WBPJ_D_(9/#8
M"IJJK+P_%-X,&K!E]%.N-1].X@P`["!F79E65PXNC)%3(TI'I1N#T3BI2Q";
M1<9RI@5&45VMC#8QJX4D=1:ZD>"JO_HP-=KPC7&'-Y-\E!-EXM^[P.+S"ZQJ
ML\`O?TZRZ-WG+Y;YWQU=X(E5E2Q,H?"6D$7622`KM(I"U7'N^RNPMT%.R@2^
MRWP`2Z%8WZMQUB:=4CXAY@"9%"]=A.84]*7))T"SYG'28$OBQ'6+(_"(A#E%
MTPV>-;800'MU0=,+8595D7O!H_AU2A!',.UI7`=LFPC%AO`P,HJ5\"`R9+T!
MDC[:I>-\F[+:%U/.65%L2I$A<,A\G9"42Y2L(XL#+/?*'J7J.1)"H[])]#V(
M-,/*(9&#?J<KA@.C>9-$#1FD6+IFOOR!HLH%'],2+W&"!F[O).0\$WWET/1S
MN\ZV>Z!G3P"2WE%^#(%#ZFN':BD>?$CD5H,D@\L2H'3@,ZAD8';CA((")`T0
M0JL^"2L>;40Z\X&;2$IC9`"D?,!O1!L!<F"+,BB?A"G,U#PU-I*AW,LJ0B`0
M+T5#LBH:TM+53P]$<T!W$['8V2D;9+M2C*"T.:K^4;3.VX_\$4U#OWD/6#HD
MU%X,IZF[(A!2$9V<Y%D$B=5EG06-U7[^W[?X8E-!96EJFKI`^I83/P`-`9E?
M@C6B?,!*PZ(+RFIG4%8O^4&"/UW#P)J786%U\X=(@646+9E@28&IBX`+JAU6
M.X@DT'1I/-+ABRG"!/$=&ONS(8IL$KVD%4O=/T.B4!A-&Z4O2COF8@*<92Y+
MEA`040/X?)DL=5&V*HP*6R8W'):):>R765.,!S&.:L8J#P/5DP0A9BA[Y$2@
MM+.VU1U)/HD1$_\.8]]\A.!%P_A5/PBB!##CR'OP]7M*G%J.#Q`Z-99>G>FF
M0!A!M`*S`5*\*8P*3P;2Q)7)H(ZF$V<,UZ"?DY8-Q/U90_#&4'[IN#[S1LR3
MB>=&>BRI.]E3$7CFD#3A[VMW!/F`/'"HG7=,3CY(&K+54(V)AG!16*!B=G%/
M_D]L=@.)HJI]'DR6TB#+;>OHP^!6#JE`'4BJ<3X>)78`ID4<LWC(>(Q*>TA=
MC;@8*VE,IV5E0JNLPD\P(XPO$K_&S)1K-@EC"1W(*HK2DV-LU3HLHLIF1'+?
M3AZD:0:]68@X:W`6#''Y<`7G)P"H*=+W_(#^K[1GF^@!/H1C/+`.2.Y($Y!1
MV*EW]&V!)P02N6/+2;HT#K+*-0Z,*L2G1EB2.*D)O6,<!3A"@(Q3I'G0C./G
M#Y'(B[CR)6U1>+895VGNG`QX_T`V!"C.`Q`F\A@P!R%/4%/,&H)C<V7'?D8>
M/E&CS2B!MT@Z!80/?CQZGD9,-8@F\KH*J@D_?XC<GU?QTB/RG#>MRO0M16"J
M&C&200:<G'=B+?-)GJ&6`<BKXN<HRRDKU#%]M)E\$)-]'.)E@OUYO`<^Y#M4
M#O;;H5CHKZ;7^.(5[)&/00)<7CC*GR1+>QCFM*T5X"7K;:!%B*-M`0Q0F[[W
MN@`4O["PK;`$U+!`$%6%CVQIGEKV=U;#U(U,#"UHXP=(8>)\@*2<1CM<:+%G
M?P-@'L25RN+%5`S%,5P&@?IVQD(9\N"_!BIWOU?`?OZLD`T%V@3*L](GKWC1
M;91;3O-WH2ZHRG\*V\H`)7_3R8&3!7X86LF-</(M'\"-/*2S4Z?5?.I>W-3*
M<=+R,&-.,]4N-3V>.H6TQNQV8,DLX24Z%+?-4[_WD:QR5NERENDR$`L%*;\:
M)1^615E';*7&$$HMX/;=S0\>=8L,;.A0.2YPQ-3K<,2NME0?F`50BIX/D]VR
MN?`KTNT1I9]!11"XSLA%&CZBQEK:0QRH+21]2J*.'_6!I@ZM??_#GK5(<708
MNIK'OH"IJJ5ID;E]O@^#I68#<4@;R`ZX82U&(Q1GPTP^#8-(/9&]FOX56OEZ
M&P`;X/BX`G\YV:3[&T7_"B(Z]3HQQ`?`(:M=`9/$R4)5J:A#'*PTXM-%C4:8
MIL/._EJ`*Q(XNLJ`C@IK!C8[$=W_7#3`(LA8RQH;VE,$+\/9V^4EO1JQI@P!
M0KEL%525=_FXB&/G\B;W@J:_2.)TEY4Q+=ZOC8H/FZ(I=W\1%[NRRO?LNX`9
M+ZV6M8<-!&E5^#>].!F"WO,;$AXYQF>5"HB%T&N1>+TFD;?N)*EM(?:<A'T1
MQ_$N`A9!^^_G"[?N^T++V%-]_EQ2TF,AR4T&2W;BA%5U#C.[-Q%N"[U-D_JW
MZ#I__UYA42WB_WY"OU&-9%D2M!KQ\X>H1K+D,WM2]LC6NMC;"-L=?Q2N;W;!
MR@%#'':6[+7C/,V0"P:!<?KQ1:6XZNY<M&S,9I:8I+O3MF=">'GD=Z*J>-5Y
M<BELU4EYQCQZA5VW)0E#LNU'M5LGN%=U\PO$$!Q"#1M5IG[&?3C"Q&YCP/N&
MAMI1]DA3"`C2>CG`EBP&$-O0C'JTE3PQ&;.SBM8`D0Y2.XR-!I/GY`-9_&K[
MR>[ACF_!<K%[F=9D=LYFB+QP;$$!&J,(%.C3<JE'XX7%5+GU@(6WK4YDO&Z*
M*/W$-9Y>&R;-T6*PUW9Q31)W40NSIXEG%_!<UQ%JH%=SP;W#:+;=1M/8=YN9
M+1+A(*=TTMR?74NKQ0IJ&[2/O7HRW,KNS'>B/0E3KY`1#R[53<3GB<#3/<\#
M@#WZB0+VOEVYV#D0X4F8`@#;WR"_ZF5+@J]+-RSJQB`%;+KLRU"B=\[@#RN1
MWQ^4>C#F"I4:6*FK34W#W7C#2ZT&V0-+DRAHYO'SA\@\:;3L`ZWWP%)+G._Q
MG-O9ASXPB'9VIX!LS:.Q'7#@&HQ"XY$^^@Y\@NN3PGK*..*1@=]JI>5X!B;)
M;7O`3$%]_!'WO,&ZA#LR.&G54X`.8&))Y<]!Q;E/.6F1V^KQ52_U>?5C&_[F
MV"/`(S&CV(2QRJ/+[I?8&7_#OAKM?8F^?];*1VM]LY'T[IU;W/5TX@=A8DE1
M!/4'/W^(#GV2+95D5F9+Q9':5/RUS41&6WJ^K%OP#T)<<(OGJ-79[?NX/I/7
M--G,T&C!1S=&U720X)0D8<^H^?E#!*<D7LJ_N%A.`*:.&/^5F\U8.F4RO'N<
M2"N_A+`E6PS%A7O3\ZR7UI4KV3"LMG($7D]QEHX*`_T[2HU15G`]=1]G_H!?
M.LAWLN$#?KZH)PBQIDR'*"1Z@=%K'NR/(&`"+OM9FT$3H:%PF";>/,"E,P8S
MI'\A?JU0^[W%)"M6I,^ZVIKFOLP5!W%5]LCY.E5XIS3M.C_!,]9$?!^/V('@
MHO68$H^`L'\E\K1G'[`D:*4]I29"I:*X=-5/DB<>A3QV6X*XY`:RZW6]VWYX
M*PJM]N"QZ8'E&U#825!$4LX&S(%"%$8U#>8KW'8:ED:.9BT_<ZR?7+_'!C>+
M6P@(BGCAO4L!Z'^S@6T:C=3T[1*-Z#B18_/CF[EI$!K\=8XYK<_QIRD6L1`[
MH?2KBH!!UL__''Q\<XKGQ\L:9J99E\?I5V=P0U)5T>8-<95MWQ#A^<"-&^HZ
M*K?&*_RMW,9XB1W;C?$"(=L8S^ML<WU9G6Q"E-9INC6>U-OK2Z)\6P51^?GU
M?[2WF!7$^7]'6"`EP;..RIKS!%_&^4LKJ3?QN:O3[7&(TYL"W@%"VS>D>9YO
MWD#%W=8->51O&ME=$>?QY@TE1M3-&Y#O;=U0I<GV&NHDW[34NSB*J_]T1[YM
MC7C'ACV"PK_]Z?;F]N;?16X%(`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HR
M.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#,P(#`@4B!=#0HO365D:6%";W@@
M6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E<R`\
M/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2#0HO
M1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S`@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,#`V
M#0H^/@T*<W1R96%M#0IXG+U;2Y/;N!&^3]7\!QR=E$9+XL%'?(J3354.J:VL
MIVKWX`M$0A)MBI3Y&*WRZ],-$"#'0W%L9I":LL410*#[ZT;CZP;FP^_W=U_O
M[X)ME`H2X(]^2K:"F_^RT_U=J%M"0B,21OH;2CC=IBE-2!)`2P`/C;J_^XU4
M>JR8"QQ()`E^D.9P?W>\O]O_&8?"G\D7P99S!A-L.1,,/EA*Z?/VE`ML3UF,
M[4D2L?D!*7D(`YZF)`D#0D4:&IGV6D'3F+C&8"+PA\?[NY_^(7<9J,?(([R@
M@="#6M5#"EJRA#R"\@_!-DA92AXS_1R**"2/E_N[=[\I(AM%<G565:ZJCM05
M:=63:F1)OJ@KR?JVJT^J:;=_(H^?[^]^AHG__?WBQ8C^@GBA$>_=)\J#-Y\@
MFDQ`UHY^"]T(?2@(]>@`*$V9!9>E06S`_6=%:!"(#>F."D"^X'_=I1Y!A0;9
M$9EE=5]U*B?[NB'R?&[J/XJ3[%1YA3D^!>"92F9'4N])I3K2RE*U6V(&Y\\&
MKQ;&?FL`P'YIPD?]^41_9O1'=0Z-`DT:E*:RVCQ7Y'$"SK%1:J)"80`DEV/=
M0FLC<P5"9JIXDKM2D9TL996IEJBO/8R5$YA/_9$IE<.SL%-U=0?./+[6;KQ@
M$<46BX"'#@O!AX76J'.C6EAA177XUL81BKHAL?F054Z&;^"-L\JZX@FZ;49=
M!J.V$Z6VY.]]@T.#-Y"JJ-1;JR@B[G1,Z99KW_\/*/;P]C,E$S2#F"<.S2@2
M!LU3775'L'N%EOZHSITZ[<#)6+!!AXGLFI"M%U.+P)J:4S&Z/1V$JZO1AU]?
MX>F6SRP*S];DG#LU_%J3@_DF@`5BM&;"HN^QYJOQTX>)&7/^E\9.8AX.$B^'
M["W3%L6%/%AW9BG?B(#/U`/_A9XO_7MS*R+Z@`)U-L8+Z6B\.!HVN=5!>"DB
MB@F$T3;Y\6@(D/H`(P&N-H"1ALXON+!+OZQ;;;)=W\*JA>=]4Y\(!@1T$Y+5
MIUU1R:X`E@6]ZKXA;7&HBGV12>!>$\-7^4]UHY?_7A9ECYX!CE&7)0"@OY[1
MFLBN:XI=W^E?H/\PKP\<$FIQ2*()#HS;%0T2+VH(TI<YD3E0S19-+O=[5`U?
ML.!IB_=EIQ&MS\!)$3@-#MD#C%56@/FSNLH+;-BN5G2!HB81]<I0W?CKA$^7
MK00KR%B)A8'C)"(*!D[R:]%^:<FOJI08R<!A?@'T_U:?(!Z3CUV=??$!*!5^
M`;7CKP-T.9]*@C&=BAR@E%G"_U%EL&]WA=(N^Z&H.Y4=J[JL#U=<^V=989/4
M:Z-3%7FJ`?H"XY4'I./$;W+EQO>16\6Q2ZW$2`!YF`Q(8WS'W0_WCG-39`;Q
MW0SB5]*B*^MDXJ`JG=D"]MK?U1\050H%VQ<\=HTZ*3,8V9=]UO4FWIC-Y$F6
MP^\XT0G']1!78V$S*LK'C%*$/!TVVQLN=2FZ8]UW&`S;HNTPD8?]-`<E#,?0
M,5/)!KCDP3@@ZBOK!@"430'Q]U@<CI!0M;B!5SC.$^[,=05H.=4!21A'-GE+
MVAX24A\`L'@$(')V3U-+O-K!0F@]IP\HY[XU^NJ]PIBN?>$IV']BSY.\0N;<
MD9T"M4!%V'SR+?DK6+A2!XE\@V20O1X4NA#NO>=^5Q;96VL?@Y&M^B:9AI5+
MZ9M/(]@$Y90;+WOG)5.*J27^E(:N^L03/M`$6'T9D-N!#FEHFUJ3O)O+&;W=
M<(=<\\?6<`Q<XH,/-&"T)B^586+8.DLCMN073"O(KJEE#C[0?%%>4HDX8"Z2
MC14X'F(BI#T:G+&H<G"\Y@ID+^OJQKADKK)&2?3>;V.=U2LS6[56?C.C-^@*
MZ<D)Z?F6_,MH.(UL&TPP+JHL\=/&1@\01(E+(>+8)<R<)0,$Y[J$33-#+H]A
M"H)/?2JRD=D-X0:%E<U&,]ZVU4[3`'0=Y$UMARM>LUW8@1N(Z%?SQ3?JEFW]
MG=CZ@"%RR8,80UL8#2A,K:G+>S(WZF]>N+A9`#I>[3[KC*"&+2!_KBY&*TR9
MX%$'1NM;1965/2J\`:;=Z<A7%J?"4,"-R3D@T:@OT.4O;TY,8GC5`K&>.2S0
MGHBG7FF/&]^+\*'?=,.-[T-X$?NE]FY\+\(SOVS9C>]%^.$@PIOP=GP?PO.(
M>Q7>C>]%>!K[%=Z.[T-XE@9>A7?C>Q%>,+_"V_&]"#\45;T);\?W(3R-_>ZP
M;GPOPG._.ZP;WXOP@=\=UHWO@_Z&0[T(Z&\4TY'_XO-P6JXS0-EV&\-VCW69
M8ZWX*)]LQ:RHVJ[H>B2K[5ALRTH)60_P6TP*,)<XF'J%W./1,]9XZEQG14/!
MK>BN-I<?$C_'_:4M&[UYW@TYMX7`9WK/PPG2?M/[<"S2Q=&8UU%[2CM:"/(9
MA'9B5;(O=%WJIAG;ONB(/$BT..DA>;LH<M%Y#R0PF`_U.RQ'=7@&4$+J6Y*]
M&FH[F"Y!UBL/ZJ2J[LT1AH3>:N[3D$$\`9B)L1P8,SY<L&CQR,?4Z;3B/FP\
M5B0I<R+PF#%[KZ$%N+&J=K%):5X\J4:?C>K#+U-Q@?QZ>K:#":E)3G4A%E?B
MN&Z]W#5B?EFF&]_'N4,8QO;<P5QI&JYQQ<%0%\:#FQ%H6^]"EYB+<::4X(H(
M7D\A4K_\.)VEQP@91_89PS^J!QW?UE?PT"$22`R6.M"$+G<(XS19[!`D:;C4
M(4V#:*D]26*VU!XG*5UJC_"ZXT*[2,-%C#@><B^TLW19/A;PQ?%I$"W*'P;Q
M;?F_&A510]R*9EP'E+L=7N%59J(KW;)DJ,>Q;10.M>E/-(K)BQ61<#,C+,+9
M*1>"*;[*[+$YY>.%.4$#:FO!5=U7F=ZV6G-)Y$)<"5Q72`OH\F0/HAK=83CI
M:<GN"ALE?CL4A\\*N%+=M._7J'%KT8DD='J\#';&J=9:1*1\C47TC.LL(E)[
M1$[#\;Q)A.%@$7/PHVNIXY4#!1P4;ZIHQ"?\!2A'>6V[>;Q?$_(6WBQ*G93S
M>,,.O19O$:_"&V=<B;>PU)0FP7C`:7.`2<D?K[\TJLI;R]2?GP;9(Y-YK%\1
M\#;6H9-P'FN,ARNQ'L["?A1KG'$EUC1TOLWY>)8JXA>^/6$)SP^Z:W-&-G\0
M-X_]*P+?PIX+ZB2>Q9XGP5KL><+68*]G7(<]'Z]&BWB\(,4&OI:K)U769Q/G
M`?^\/F%0R8@Y#82LU=P2@V!SJ(%-5]@3?L&3LNR*:Z-1A[XT=IHUPVNRWPSO
M&NE;7!8;(?E8:P8>K3(#SKC2#-S=RDZ$F-S7F]UP;^V?FC-/;K')[&M?M,5P
MJ`A1"/8"V)W)639=I9KV6)SA^\\U&)+@-8J^47K83)Z+3E]9.YV*3L\Y;[M7
M%+YYM@9LR6H\;SNDFRMM%Z2K;(<SKK1=Z"X/H%,ZLD3GE]!9ZFLO:#T=LX`5
M0<*C.ME<25,<CM#KJ##AL4:&!]WSA@U>$?QF&)M(/FL#W,]7VH#%=(T-](SK
M;(!_P&3_PF.R?L*03>^[XH7?<]$\N]>*04S?5NTQ;#68G';6$+.`OR;ETIYM
MQ9P'G-'5@#.Q"G"<<27@+'+EEG'+CH<92WG!LACZ.T0??6MSIW>#L4[V?H4\
MMZ!%_:Q`L]!2X*4KH:5IL@9:/>,Z:.EX=YL%IH;RSI2&WW">$-ZQ$RW_8<7_
M,@FE$VVXK?%V]5O.P=C_01$63Q2AP7@Y2.CGBS/1BYLM]5S%:S:PO";<S<`2
MCRC/>[]877J@T:K2@YYQI?='XXW]9"2D;LY]CS2%-/55ECJ9U<7;9Y=(-Z38
M`T&];G30T5>2OF4^[V?+T-\A^<WM-`Z<Z/-&H*NK#3K"KC`"75UMH%2XK&!R
MJYE:7S=W5V=N]XVT9E)N&/(V6`75D+R]K.!^A[PWH6?4"7RCT*-K<Z'XL7HV
MA!+BG-$L^'=A]&W]5BP6#A_2>+%P^$"#X)4.(EXLS3XP8#R+'30+6NH@PFBQ
M>OH0A6)9AH@OU[`?]%'04H>$QHLU[(>4!J]T$#Q=[A`%MX$"8_[\^_W=_=U_
M`4-"HR(-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,S$@,"!O8FH-"CP\#0HO
M0V]N=&5N=',@6R`S,B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@
M70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO
M1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U(#`@4@T*
M+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C,R(#`@;V)J#0H\/`T*+T9I
M;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S,U-PT*/CX-"G-T<F5A;0T*
M>)R]6TN3VS82OD_5_`><MKQ;,UH^0)#8G.+$J<TAY=WU5"6'7"`2DA#S(1/D
MS,B_?KL!$-18$B>FQ92K_!B20+_[ZP_PV]]N;S[=W@0KQA,2X"_SMVR54/M;
M7MW>A.9)2")&0F9^$A&:K3B/,I(%\"2((M+*VYM?26W62FF""R59AG^0=GM[
ML[N]V?P#E\)?1S\(5I3&L,&*QDD,?\0<USI^SFF"SWF<XO,L8_'Y!2-RSVD:
MDBP,2)3P,#,B;8Q^YAGSSX)L%/?MP^W-/W\2ZSPE84P>X'UC!K/DH#A#'>.,
M/%0H4!2!71[RVYM[D!K%>7BZO7GSOF_)IUZTG6S+`VGVLA6=JK>PD>[+3I.=
M>)1D4_9YUXM.%D35I-M)LA>Z(Z(NB&@E*=5'"1]W#2D:HIOAG4W?]:U<D8>=
MU.,:JJDUR9N^+$@N>GC0@`2Z:_*/Y._DX8_;FW>@V7^OH7X8H8M#IWZ84.;5
M#[/$JK]O52Y1<J\BT6I;JXW*1=VA15I2R+Q4-2CRH:E`W(U53N1=TVKRM%/Y
M[D2?4SN^V$+5>=D7\E]S-6:7'`Y>]2J_N?;JQIZ!6_SWB`;77I\=K;^`\)S1
M)67WRR\A>I0N*OJP_`*B9SQ84G2__!*B0VE?4O1A^25$QX<+BCXLOX#H*8N6
M%-TOOX3H0;:HZ,/R"XC.TD4+NU]^"='C1>NZ7WX!T9-LT>+HE[\VM`)DF;#8
M(:N`\VQ`5C&+N$56WY-2M%M`BDV+F`]Q$R(C^;R7M9;:`,=6EH"2'A$\;M2S
M+.X<,D+@Y%_<``0#M*5*U2FI[XC\U*M])6N+/P%HZ::N9;DBW^=YT^*WY0$6
MVA`M2OC<H;<%P*4!E!9;<BSE#ELF26HM@-"Q(773D6W;/!$!.M>=RM7>`.FB
M-[@3U%2M&"P$:%&*U@#*NFL!8FH$H-OF4;:U4=F_L&UA,6WT%#7HNQ&J!+2-
M2S;K3@`$K^73RV4:P*WM$G9`EUL[I#`%#7:(J;.#@\IWY$F22AR,1=:2B'5I
MQ`6G@5;[IK:N@^V+/O\21@_1L"(_C8J*?*<DC"?'9BWA!Z5&6UKW&V1^AY"]
ME1!)\FX)`X31D`K9428DF=7_Y4"Q$VUU84;`2!<P6D'"Y#UD#R2%SD6),:Z:
M8K5`_:%\T5[KEU^@_M`T&0;;@!]E'W>#[8\VO\RPVFBMUEA`#A@8+R912!1T
M1@MA4_=8EJ"F#,%F(G8M2Q-DW4YTPZ1\96T22KTZ/%I1,P1]!AWNK[Y1=F0W
M2JW9WG3-M?=)^%^D$#2AHT`(??4Q*8EAX#P&=:""Q%(:?>Y:T6D"7K\TT&2@
M7T+&4A^E4<JL>-@%L1X**/(-LBL%U(GC?FE)%"P!4!TJ4>=R1=Z?%1XB62-!
MX336OM964G8F#S"N\\X%/E9(P[I4HOTHL9F*\J"7,0(-?:K&HQ'2S#4(S#E5
M/TJ-;6)%?JYMLN5"0[D>Z2'+U3P9JF7?-FMH((>1G%F@.$:+0F+Z33P-F[9X
M8#$K3U=IA%/#9V/RD(<.G?UZMA57@!L,=D"C?U]!VX&F13X8Z[][SG>BWB+;
MITW<7=_@<;8HD/?++]"-8I8.>1[&GF>,4SJRK%"!*LAK&\L[0(-K*6MC38`M
MC:5,+]E<`RZ6Y!?P6)3>D2@(DA7:"*E5*`Y*@R,!7^J^Q0)ALP=:UY,JRV/W
M7C^SXR3P0\"(?.@`?*#4Z,UA2K,KBP10P,MDR6Z(I2BZ]B[P9-0\3**15P\B
MYW%ML+<"3%'XC-$=5#K1%@@L#&WL>.`[(B`RMA:@P\-*U:KJ*QLJNZ8LX*?7
M#MDD^@L,Q1+F=[E^UB7\./[",!F;?^CH?9P5.YB.7(];(`%B/P4'B<^`*!FP
M?R[VJA.E^FRZ[AWTK6N'?!@D7HI%L5:(N>75#0,?]''B8KX3SQC2"$+<:$[T
M#A&.'<5,_[9UZV<+;EZ41(6S^I5EIO0O,@ZEQ\:!4/#!"#]UP>A*_:9MJJF2
M:*8.BW*@=@/JR^&C9:IWZ`F,,!S+=QJQ4>!3/[E6]?[A!_*V+TL)I8V\;:"L
M(<=@$*@E&C[UC<6:`$`+U5=WX%Z8JPRYTUB((=Q0AM!C`*D:,"I.RZ`-)&\K
MD?8P:/7Z^D?<$Q>,CC4\&LY&NUVCY9$>&O"QK+0-X0^R+(TJ7]K'NZYJ(/0+
MM=G@-(\XRYX/ZDJ`U<RI*S0(Y+0,%L=$T>YC=Z`*:ZR;?KNS3)>&1K"$$;+(
M@W,VGI`RQD9PW@&NT"(_/KL%V0I9BH,L_`&O.Q&US^U4@D-)V3R!MB;Y[7AM
M>$$(%:B%HM##:?%:%?9`67\<7D8^Q-FE>5$P%K`"&X;(T,R3+A5XZG+7N':%
M=:O;*3P5WR-%<.=1ECDFWX)".&MZGQ^(R$$1C7&".KINX-J1.11NA=)8+N'5
MHE!H87A>2_Q*M(?AB]75#XJ95WD)7CNBR9)(WB^_P.@4179BY\DJC+"BN]$I
M"%,_.CE:U\[3Z,4](/-"/:H"ZIO^\O[#`N9=]IS)+[_`H`0CZ%!NTLCWG"2.
M1^N:7*KE(U8-H?!:A=X=6=?U#EMLL6(X;XPL,+H#4V[JP\%'#3+JTDQ(1_=5
MEKB*DM*SIP7,*0XR&X8?*MVIR*8(&K(?S7)G:XYMI\,[4K0U*`UO;50-8Z""
M.I(CJ6Y:%]K)MN5U#^4(JHME.N&-IH)F.Q1OL=E`2*/Q^B68H#!)/5=W9(24
M.EH"YE;=PV#4*<20VC8&BRW0+*VT4B)U`9)KL!)2MZ5\!.>;ZOSDD_-%2A[3
M2/@Q=*\2;?`HRM[X?FC.`I:#**C)(ETFI'YH9&E\"C@L"6;"P'BXJ?$&4IZ#
M[.:<IQ@8;?G<X4MFT/^2((/6!'92D`>@MJ'6[(TE^]0U4OM!T4AM<\=_8XY*
M:GM>X@F$>@GT"=75)P128:X2F)-B-,;HB-$L2Q33,%CTEH=?_J7H)ADHH.Z4
MP\IFU?%S<T,0PR7CT>0+<99,OP#HCDV^8"C!J1<"'M.I%SB'F6KB.:@03#U/
M>3(I(>/QI)$2#F!@ZGDP+1\-V.3Z<<`GY8_"8-K"07IY_4_6A!GL@!WB3'!!
MW%U,HA0_M=$5K>+,@?=XQ4(WD/\>07<Y29F,VATA^,YN.9&VYE/?Q^(X&XDO
MZN:%5P^TGU2'_RQ+L6[@17LR;.BP(T:ZE;5\DF:D;.6^%#`#?S='D4N)B6V7
M7^2#T2<TGNT3=R_@:WV".\[T"?5M-1YGN"3@?I"5V%=QJ("!H_-=H%`ZQ[L%
M!R(W@(3`.26,9&9:@8E<E7@B4[NIK6T.HL1I];P?7A'^DA\H'Z4_[P?,KIE^
M"/@L/^".,_T0'M'A(S_&6#3Z`:`-&AA-BNT5_F[0&'CD14[8FQ%5)5M$<NJS
MO1"Q;YNB-TED$N;IBU'[%1^]HMC%81$*[*#961]EC,_U499&<WQD=ISGHRSU
ML(.RD?3BS#&V6Z@\+6!G>RA9]+J#]/"DE`?,'EJ_J%X6/CNJXLB;5U0AH9'7
M88*Y_Z8=F-_AU-_?M#`_,G]`N4=]$><.]?WO;S_:^Q=@79C&]'<S]K\8R$DX
MH1@&<AS-#N0XF17(N./,0(Z9+_JAMR3-PG`L-J)H]G[^0RYJWYD30E?_77SC
MJ"CKSS!_ZJ-!T=>:-0Q;\%I3X:4"]^4[\SIYZX;)LUYZ1;6+7@*L-.AVUDLI
M`BH`9O3KO93R;(Z7S(Z@RMDMI[V4CAQSQJR70M@\CO^TDWX(R;\;W9$'F>_J
MIFRVASO\V;MG&-FTQN\^&%[:?`X//N2ME$@%##\'_ZU5T_G/S8M7UM*3R&&<
M^!L>,)T,Y`;>>@,0UW<J-[Q$M1<U,M]KB8):/A3@'HB**K]5S8=<R1I)X*D0
M>TWBBZ@C#;S(YT,LHK-#C-)9(88[SC0^]=QUXF["(<'`TS'$%(!OD\T8+L[(
MZ`39*0,V(-3PNNA)/1B+``#Q%T0^?"&?W;FV?PDOGYX6ARMJF^(\[-2=;G[S
M=V!'!N7#%;E3,NP;?1;Y_Y9G"`_<PQ?9LZ'^REX7&0@SQUSB<W&^SM*Y/8^Y
M_WOSE:%N=IS7\YAGCP%@AR/`3OAQ.76<IPE9"ZUABL%_FA.Y$9BI1VENV];R
M$MZ&0M3*#40Q8,#_N"@_BZU?T^EBLX,/!J7.NR>9S0VP9!8W8':<Z9[$<P,T
MXR.VSOA7ER(YMC??N92YSVU?1=\9)L&UR)-V^!VVN1GJ7?)4&HSZG?54PMG<
MGL'"68R!V7%>_<&X&QJV@R7!*F7#842A=-M;4.)N`U:B[O&0H&_MR<I>Y.8Z
M=6MOJ8Z7\M>M.^`_.L^\\+$[X2_\^;\;<?^`&4J>A2C?HG'@N7=S[P$K+OZ_
MC&YW<KCZ)S:ZS"<G?J<+^6S(P##YNH-)"FNRH678\^DW8?HEHSS-I-[S=)+)
MO0\3;!83+T0!@(JI%^(@FR1C[VD83]+-]PD>"TR^0-DDY7W/XG!:!FBETW;*
MPO25%Y)HDE.&%]++A@)?O?OM]N;VYO^O.">_#0IE;F1S=')E86T-"@T*96YD
M;V)J#0H-"C,S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,S0@,"!2(%T-"B]-
M961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V
M-"`P(%(-"B]&86)C-R`V-2`P(%(-"B]&86)C."`V-B`P(%(-"B]&86)C.2`V
M-R`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO
M26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B
M:@T*#0HS-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N
M9W1H(#,S.3<-"CX^#0IS=')E86T-"GB<M5M+C^.X$;XWT/^!AQPV@<>1*.J5
MG&:SNT`.BR"8!G8/>Z$EVF9&%KV4U)[>7Y^JHD3)W;9ZQV.A,6V/19.LKUY?
M%=G?__KX\/OC0[!.\I@%^$/OLG4LW*_B\/@0TI.0\82%"7W"F0C6><XSE@7P
M)(@"9M7CPR^LIKE2$>-$<9;A"[.[QX?]X\/V;S@5_DP^"-9"1+#`6D1Q!"]1
MSOGY\US$^#R/4GR>94ET>4+./F1"Y"P+`\;C/,QH2UN2CYY%_EF0C=O]_NGQ
MX>\_R4T!PD7L"<83##3E('C(4<:,/8'H'X)U&/*0/17N?93F[.GT^/#=?SK+
M9-WJO[*G_ST^_`C3_O<>:\?YN';.UR((8.T_8+T/=UX(<#T7,LE'(4%%)&0K
M/ROSK"PKU5;5C6)':YYUHTW=L(-\@8];>'@TK0(D9,5D\7NGK;(-0%/"TZ-5
M3<,,0-6TIO@,7]>%6M\B28JV>`4RV*T7Y3MVY]G)&,)^\M^X".X]?S*9_];-
M7U4R>BM:T`%="]ZF@XZC).).Q_]2MI6ZGJK6;$EG!3S16UW(5N%'NBZ,/1HK
M6QBT8IN72IZ<HG]0\%9:Q>!EQ63#3JJJ\+7HYY8[J]0!C`0?L;U\5NRDVSVM
MHKZHHFOULVI6]Q8?=)=G8I`^&=U8<-Z[<6&ZJF0;Q;I&P>L+;0DD[0X;V"X8
M>2UWM'/6&OC?9\5TRYINT[223+YZ80<#DI=Z"TAU5<NV!@(#:_?:ENPH;?N"
MW^P=@Q6F;JVI$,ZN6;.GO3IWJ@4`2-(>@""*D@$`GN%[!`!DK;I2P885;+VJ
MS$G7NW_<WXERD2[I0W[Z!?P_AV\NN?5A^@6VGD$677#K?OHEMHX6NN#6A^D7
MV'J:YTMNW4^_Q-83ONC6A^F7V#J/%]WZ,/T"03H-LB%+Y6GFLU021"Y(O\D3
M1+YT`]G+0G[R>;9].2I*WZV5=2.+E@;K^ME4SQ#6(5E#)FH[8&IF2MN*O:QA
M%IB@ST\7,A.N**O&L$H?(`7>'X,D'W@*3R+/4^(0WR,&GD7N354"Q;SW#H)Q
M"X)6!SOB_.ZK)'Z5^QM2D$]1C-(1Q2#H^8[<Z$KWG.2(ZE7GMM+N98M<X*7G
M]^J`0S=D'/"QMO"^:>%_0/SA34_T1TM\97CLM->%XWD+6$SJN5TPRAK%:6\Q
M4VMA![W;M\R`#/:DP;2M*A203J!J4*0<='<@XN9$;/9`9L&/L/)!7@3_P#4Z
M:QTEM)]5NTPI@T+%8LDHYJ>_21_S13.YK2LG`PR6O3Z"K(]BO_34OP\R%4:D
MJ8[6"R2%)%R4=OKI%ZC<DB`8S#L<K3L+T[$!8;#H`.16X()@T*WI*V\PSKK0
M1PCM9S[0FIU"!_!E"(6`+_H`%1X4,E&RCG\+1#S4?Z9KL<PI44^%.1Q,W9?Q
MDG+,#^!!4"4MX=EQ%@U%BXBRT9)$+WO(5XP'0;)FB,+6=#7(1Y(7>ZVV8TTY
M(+1B/X/;LA\/LMI*NUF!2UO3[?98J=D.`AK(XT(5N+MNG-?C`Z5H6B@&%4RD
MI7U9T4.<#DWJX]I/N@0.2>(C')^4[GTP?\(=KI@Y0:P]5R4/;E'D".M/G45#
M<;+^!#&]P!#/^@5/>P,1=,1$0[#$\A\'+P""R.=`:(X&:O>^X=04JBXE]AE`
MKE<JOP!3F'P+3`B$KJ!L!@#JTGG>`N)'?/"%;!('A.C[-U95DMHG)+)=3R0&
M/9%>:M->"A4K8H$70P6A]0HL)(]EJ3&UP^CW(L4"0(2QCX=)Y(%(XWR2[J^;
M]$=0$*S9=%5+9@TV<RZQWCKB`^S%1TK`4%<5\A^Y`4T#%8+08EN8J=&[FIIC
M0`E*A?TMUR/;5IVJ"^7(PS*\1^2^6A"9S[,BY,(!,6E:H4G*[5;J/C'0KD"?
M+:8#J[`I]2H+][105BOF6D/X'!U;58IH'8IYGFV&;^"3*2Q#NW")H"`RW]5,
MA?<*$<5#YWK"0]?LWZ/IHNXAP$,&A%#1NF8FF?&I!DSV^M@3WPI^DWNH9P+R
M;9'DFGB$@".7`+0JB#V?D<3!218`(1&>[$]`R..^M^=X[(JA"!`,X)<7`X7T
MK/XUIX<-RZIZQ<U^-I;.`EQ..!O\9Q#%&+0``B+U".07JIWJ)%]P:QCCRDG3
M>;)]^U8>JA)>10=0,_PJP*;1(RI'`UZ8ZQ\7$E-0UU"`P)EP/G->#)E%+"#R
M'#$)QL9!B.\)@$GCG>C-"4"@+5-.\-40**\!@.P"!8U8MGOJIU^@H(GRR!<T
M8\8)L]37,YA=-9#/3:M*5#[:5B7M#OWIS'WNCVNT;&LW^M;6[DQE$\4#K0W"
M/!S/)(+8`?N1O/"3.K8NB4>!)UP034\(]14*3@35:Z2FT\?M*Q[S%[X6$+&A
M_H0XU5<.;&-U"6&Q,K(&JE!5RP7M*/)T-LY'CQTB5M.HUK'I@['M#A)Y27FH
M4N7.V5@#M4U/MB>[[G$Q\]!`*MQ2#(!@![(/I&8'5)X2==,A3=28\0K9[-FV
M,J=E(E?$!UK+XW`,W2'OFP5C;#(;ZFUN.^38-1"[IH$R#+=]A+Q"N>=,X93H
MRDZMQF#G,EVIMI+8'Z9L^AY^B_6\QXVD!@5":"FEPR);R'M%A07/`B`$L>]Y
MYF.W+@KZ!`X&JL$:*E"((QJD>^S?C?F*.G83F^BE5"5)-RGE*.+7X`!4W[Y&
M33U#_(<,3H>@V!0S!]TTQE+F5FX5O<0!)<\\FXVY&!U"Y!,FMP7S1%N%O2$@
M3F4KMNE:5+)+PJ6B'`\JLU"7UA)9^%LYA\*_T1`"I.V1`ZF-M73VV4`]9PYL
M(^O/E+1-WS$Y')0ML%N^``3I2&;')![E/9^O5.THV,?ZA0UP8+UAP1U.S#U&
M_4(@`&Y'[9T&QNG::1.M8LKP7W&WF7"Q\M3-^T4C#TMX`H]]+S=*Q=CM2GL,
MH&31+9Y3RPT4F^`++PRJF@J-'MDF1&H\:Z=#>@7$&S_8:%>06@5Q@JHALZGT
M3CHZ)IMWD@AQ^@7R-E#U)?.VGWX!/L1#W^`%ANGC59AP?L:(U)>C:5PV&@^9
MK&X^-WT!CFHA+T/[=65HSU(ISH!+*Z@GNUM+QQDI1))-Q0AXXHT-9NMSCXL>
MM&D%%6SKVAI4]#4]8_C4%\,B$(,7+8!WWP'&C1)GPE.I3V"B$D+9_>^##<LM
M>^\L/1,K$*.S\VRX6_>E@M+J8T%M61C-[W\R`!%WV,8B5\:R18L>/_T2%\:2
MR.?CC(\WIH+PW,>=@Z)K^((:^X+>3X!P0:V,)V@&NPG`(\\O4SG78MB1H<X4
M35*J(V8S&&'53C>8ITIV["!N%U1\=[6+'=K2N>3]\U`H?,<]3L:62I"D/@]A
M;=>:U16QJ<-V(8#0O;@^U%%6OA!!OL6U9\2*>>[E^G;?GELHBB8`!I-C_$CD
M\57?_L6UHX!]HGX!OJZ&#`+PJ"7ZZ2'W]5<X-LVB-.US&+7^R'SU`:HN-->A
M!7J6J5S?'9^8KS(#I),*BPJJ3PI9([W:C'<X',&A`RB@J.A>VR50"+FGG&,)
M+L10@@/?!>%]*P_O:?8.3RU4\`%WGZ1DB$>I7==OTNNBIMKA2,WT_DX!GM+`
M@&?=XH$1-=:)5O8$SAR5[<E9HQUYQRH5"'R]A*?G\1CF1D?GHN<`1[P@0)%(
M/@/1'*H/UT4CFBF;H>22)1B&+%[\Q5D$3V,!0L9-UV:<13MC*?#N^'B4<B8;
MZB8!/;`T!\E(JG'[=`4>!L1Y*&8'""3.<P.B3&2S`W@NPMD!(;:9YP8$.=3R
M,P/R7/"YYQE>A9IYGN;)+$H)7GV=>Q[,[R\.\MGY11C.[C\*^>S^>1C,:SF8
MD?]W!R''>VG`9BY8/SC&5?-/\:LN#'(HLOIKP=$Z"?MRZS<.V+UQNDRX%</L
M\I(S#H=?'7O563@6^M&PYLFE`=TT'=X\4U#D8JITQWK4N:>>#$0'56MC7:\+
M^S*CU_DCVW_>L/6K?U\`:AKV_I9PH:$";[U1"UG.;]$"K7B;%K+<TSO*A,-Q
M^G`A?KB?+UE1R:;16PTZ^-Y(6]*YZG#P=PG@]W9U#6".?X*47VLW(\`QOQG@
M.+X)8%SQ1H!]<WO2S1JZNX[R81ZQ&I@DG24VF&3@H[.K.I3U6@8I\8`#RXMX
MO[/):WA'>>YW>1GO,+X9[_Y/6;X6;USQ1KS#L9\^"2O!L":&AK?V"T;N&D#J
M2U%U#5X5&CN^R$R>98'<30U]5T?)ZHX.)*9'X!<U\XXX5T/-1)Z+FDDQ)=RF
MF;0_,?]*S="*MVDFS7R+/YC44O%02Q7=H7-W5]BS(3[9__W-)4^@$A+\`-5Q
MPS:O^\*XS\N(B_!FQ(6X"7%<\4;$A2>U^7A72(CASN#)US#`/Y^I0P[8XAT%
MO/Q:&Z@WY-L['I>T@DZ!WYGVE8_6'$T#;/=-U_1/2'5-0<"%O5@7%10[D@<>
M]W6-P`!O6/9HN4LTWX79:RH^3Y(_Q'R6(W\`"A?/#N!XKCPW(,*[GW,#1!C,
M[T&\4TR`$/G\'A+.9XN)#VD8OS-`0,J9'1#'UX$"5?SXZ^/#X\/_`679Q8P-
M"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,S4@,"!O8FH-"CP\#0HO0V]N=&5N
M=',@6R`S-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A
M<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P
M(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W(#8U(#`@4@T*+T9A8F,X
M(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*
M+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E
M("]086=E#0H^/@T*96YD;V)J#0H-"C,V(#`@;V)J#0H\/`T*+T9I;'1E<B`O
M1FQA=&5$96-O9&4-"B],96YG=&@@,3DT-0T*/CX-"G-T<F5A;0T*>)RU6<MR
MXS86W:M*_X!ESY2D(4#PM>RN2:IZE9J)4\FB-Q`%64CSH09)VYJOGW-!D)3L
M-C/)B.4J6Q8@\)YSSWU!GWY;K[ZM5\$NSB(6T(][E>XBV?_*R_6*NQ7.1,QX
M[-X1+`KX+LM$RM(@8%&<,:O7JU]9Y<Y*9$0'16E*?YA]7*].Z]7Q[W04_5R]
M$>RD#/&`G0RC$'_"3(C;]4Q&M)Z%":VG:1Q^_T#!MHGD&4MYP$24\=29='3X
MW%HPK@7I9.ZGA_7J'S^J?9XP'K('['<TN",'X%PP'H0I>RC)()[$"7O(UZLM
MK!;T^GF]^J!?SKIJ=,-4=6`'\Z1M8^J*U4=6JDH]ZE)7[=_8P^_KU0]XXK_N
M8980?+)+.I,^?!%"W/TQT0W\.!W1A\*C;UAK2LT4X./PIBM:0G[6]EC;TE2/
MK#UIUER:5I>.H+.M<]TT3#^IHE,MF-JP5C<M;:5U"[X.QBW@];?.6'U@!G3:
M@[;LS@"=>\&EQ\>S<``8II"1`]C6+*_+<W%ASZ8].3B37UFN;6N.)N\-)@"F
M.F@(XD"K5C\:("<(YVY?F)RI/*^[RJ$]&@M*6@)_`Y?.;7;L\Y$]@U>K656W
M3.T+S6`*D0U3EN`AD`,/:2A&1TM$M./A-0G7UK)&MPP.QQ)<];/.'1X9R`UA
M*,WCJ65[R*#;_XXUPM&HRFUJX%A\YHD4\-C3L+\0;UVAVMI>F.K:4VU-:S0X
M^5A=<$A^`HUNZ_UIR-)D8"&24[`',AE8Z(H#4P>*<G*$.AX)4=U9MN\:4Y&T
M205'4P&A484/"AC_<$L:>R6L*]8H@HCBGY7=*QQY9YAQF(PX,P%P`2+@/P"W
MO?>#))\>E.Q$@FI!#P*C"#4?7S^]%/K"/N8N;X@@$*"C*"`7D*.7\'`2>`\'
MR&V#AT4:^FSN'(HLCK!C6MG"(.VT)U61OIV?CZ;)X=<+%AGBG$+YGSK7Y1X;
M0[XA#,GNKQH>SQ@>]88CT\O@WIX*6!:&@_*I+H_*#WW\?T9Z.QQ,G[$I(8,*
MG]?A.%,AS56@):^KUM9%XP)?42A#X)`UZ?GM)B=T8Y$>E>U#_'-_\E0>:`^]
M\^;#FR7$00[HQ>&$ZXM!E(F>!(!RZH0-C3DX90`6@GBH`-Y8H#:(?_UGD/^"
MLE`0;2<%];G4H%M4CELZ-D-5Z*JA)MR?AC3+/`V"1U,63'P2/,`N*N[:8=,O
M+:6S[R*O&WWEKZO=E",KU78`XI/=T`2X?V\_][HO4+YT5)I:"667J(=I*@8*
MI!S#(1+HC'LEG%#6*3&T$^1<552K4>G4`8E>M:1][SHXDF`02GU8(CVDL?B_
MT\.[Q\?3\7_)]'B>:^HQ2D=PD*3Q0#9/N"?[Q\XII5&%=I'3G!`!S2`YA$H)
M531MG7]U.:?2U$H\O:K/_?K9FESO%J!?1(O2/QQ_;ZDC\Z?!T.$'43!*/>2A
M3WH?'=-CC>/"U;C8Q3.\\DR_1+9)9+I)HWC..777HMEU-1/-W!FSP(LI^S`)
MXUWT)8`0^G2`^/?G4*Z[?W@G&1\3?39"CH6'O->51E>/_HVJUW.%Z$5;ZC+Q
MB\X[UQ_41^Q`&[C!T&<ALMHV?L(QZ/S.2/8.]*DN4"BH>47K;PEZ<=F\I>;D
M)ZAB4&Y3XN'#V'`L:M4ND362A"\IV_'X!62;1-/`DHZ-G(P&'_[J*^G9ZB=3
M=TUQN9['J)N#O)!10#L&$])E2_UZU3F5SV89:H#RHG.]G]_58>*SQ87>>5;6
M*C?#+:#;<)A/@F3J7L.0>]"?@+"JR(J?H$@"@LCTX?ID;-LY19.RW%S^?JA2
M(;MB#B7NT5"_<<7;N;--I_I)YM\=WN!2?D$*^8I??)QA$"[]^+8$&V+LY=/Q
M;B*4F>_E::C`'*$P1WS/?N>RMY:['G1J==&E-71KT9P1XUT#EFCV\R.P.P=(
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M)L)HTL/$1")]Q7`C#&;*@Z8;6NK)8`E4L$"/'/-%>^3Q^`7ZI"A9U/3Q^%O3
MZ5XVD0EZG0PGNU.GC[LO0;`ASJ2<W0"+YC?(-$EG-X09^KBY#2)#YIW;P+,H
MG-T09(F8WQ`$LT:F63;+4Y)ER>QZ,&]AS,7L^1&7LP`DCV;MQ[PU>[[@\_B1
MY]Y?_^9-['<@3O[4B"[IF[[Q:Y*^N?C`L]=2C1`",P9N,=S-+?,@G'7`5@3I
MK`>W83`OTVTH^2S'6RGB>1LBGLW&TA8R^8,-,IZG":7K?:+`]`^_K5?KU7\!
ME21JF@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HS-R`P(&]B:@T*/#P-"B]#
M;VYT96YT<R!;(#,X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&
M86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@,"!2#0HO
M1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3970@6R`O
M4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*
M+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S@@,"!O8FH-"CP\#0HO1FEL
M=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`R,S,V#0H^/@T*<W1R96%M#0IX
MG+U;7W/CMA%_UXR^`Q[=SEDE``($'YW$E\GTFDML=RX/?8$H2$*.(F6"M*)^
M^NZ"%$FI%C.]DAJ/SY0``KN__8M=W'>_S6>O\UFPD+$@`?[X)[408?U/LIO/
MJ!^AA$E"I?^&$4'E(HZ9(BH(B(")A9G/OI#,KQ6%`A<22N$?4FSFL^U\MOXK
M+H4_O2^"11ARV&`1<L'A#X\9.Q^/0X'C,8]P7"G)WU^0D7NI1$`4#0@3,56>
MI+7GSX^%[5B@.G*_>YG/_O91+Y,(F7N!^1X&O^2)<<H(#7`46+_[%PN#OY"7
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MB?-I'(L%>:Z2;5^'0&W2:F4^D(,MMWE53@$#!,4&!H;&4\/`8]IH=6IWMO04
M?R!Y51#S!VJI_\+!9AM00Q`3()$:]X$8763PT:'.YX!!0=956:'&VDQGB04M
MUAE8Q-Z`*>![\(`P:#0%'$GM:V57MCQ^0`-:58`.?IWDNWUJ/&X`U@0H4-IJ
M(V0')V6@J@DX26HS;X-E`3P`HR!M3YS-ROH)\0#^X>,1O\Q)9@YD8_)-H?=;
MFR!4]11D9V,R`"`%'$J`U^V(7J)T&ZP:=+PF%3VL"N.JM'2@)OG.3(.#`O??
M^#C>PT&)QBA*;XQ]+Z<SL@0OMH)/=FUK[X;*7SE/XC2>BL-K)U(G]52<ACU,
MJ&P-1`0L/'-4I#3%SF9YFF^.Q*$=:S>V@$*I6FJDIP3"*.-C[Q+U>>8RK)F^
M.T4H]V'D#04/WF$K''T7>;'+O5PP40N13("C@`#3TQT6J9HWL'34F=%15/$M
M4(S%;5&407B.8IUYW2U-:LV;&5T9)1S?IH=1BNC&,$K9AQ&LNN;-.(A`X,U'
MQS&BMU#'B-U8'2/>5T<6A;3F#4*^R5;CHQA=ZLDD*"K>[C+ZR0FS"C3:26,6
M5>TF<;00-&[R@9T^CBV2D+_#S]@2@9A[OLG4L:K#3\6+,,1\#_$[V#0=7:<O
M>9L"0"5N"R!8SVD_<`MQ$Z0<'-K2U=@`4A[>`$&*K]X20MI3>@A14=RX5CAO
MV\3NIPA2C%[R.`62C,K;(LF8Z",9-M6JN_KL[L;>35[:VB0@1K3=9?08Q:*^
M^0:JJ0?=P?%[[)V4ND$X9.?NB)Z.'OM49Z,;$6>7ZCV%_#EGT\F?\S.#B;MS
M?BAY8ZB@"UC7R`S6[]Y,5^%ZTX75I])472"!,6=W-M4%.>0%I(7XS?)(5M8E
ME7.GN06FC%/D6S+HJCAMQ8+)IJ17%]2RE6V*5J[$NO3FB$06UGUUOD9598DI
ML(*-A<O%!*T`?'O"5D"[_`2M`,5X6RX,.ET)\+EI!;BIJO241^W^D]:^*)QM
M.D89Y:QG%.=5^O.J,);+E]IAYR,C256`FI=$.U?M]O4$K&;[O@?,RRNT`;"&
MG<[TQE<5QY87'@X:/L+6/[&Q=V&LAQ8/X)APZFGX9]]2(%^S_)":U<;71K&<
MOJR<S8RK36X"3Q#(D_P"KCKY-9Z@5VG&_0];FVQ[@B"G(HL7:6&TRS.]3,VI
M*=.7*<YPU?)W4`/LCESQ(W7Y6R=EI=-3/1M\$23)X!O7:S-ZO`4,(A6?,.@:
M3:&*&UO%Z@<6]=,C61?Y[ER5ER;1327;`K/F'9;:8F^YS6%F:AWV^$"K31TP
M$NT1&ILQ(3O.IDLDA%0]_`(5M.&$\Z`)C$\@:O(19)H78Z>6$DXZ_\WDZ,4X
M>/6TR_C1`HR_0Y`JV795!(U[`=FDSAP@G>@ZPA-80M1VL#MG(`+:./->"QHI
M`CI6>5*UG<BN@>W[6Y==:^\\P+YW.<0#GQEA:N$/P-@A@H3#6;`)_SHQ;SJM
MZJX6>L%WFX03\"_:EB]7K1RX4N&9.SQO2R[(0YJB:W/FM4*G>"AL69JL;F1B
M%V^B'I<(6H*G[7&)L(<,'%:[.*%.]TY.<;[?%"_+PBZK$@,">OS*=RL!..?#
M05(+-ZNCG-GJ=.UC!+A7\/L.O.T$\N6JC7:T:^E+;'$C%Z\0=>HF99U]V`(;
MMK8PY?'4M@1WC]Y:%\?S/ORENB_(D]&@SG7@TZLWB_D.P(!Z#E$-M`/B257X
M$P*F_6GN0,7!3/`JP1%^OQHR?E1`$!CM2BAM$A(*O$>%(!0F]4;<!&O/',JH
MI^&%`4N'D;6%7,5G:QZ;Y\?OIS@'1`&=\AS0+C_!.4"JMJ,BPNX<0&63\#VL
MZD,6.`F;>8=2GQ,S?Y<'XF5]UP<50D/V@U=!+G/":Q<GVN2I;L"O,8\^B1+D
MYB]AC"*Y`563LCXRXQ6U2+3\4]\5\?RG4WG'J-M]4N<8R78?S!^Y;(4<<7G5
M-UX+>ZG=;,NN3'#UL/VER:WQ"AA*>H^K+$&JX*C0U>Y7>*]H(F1!>6\"+2J0
M"#IH:5>IX/0JM/X>UGO^>'S')/FD!8IV^0E(AY>F)+U=_IQTO'BL`AZ3",:9
M7[5[W5]_A@F1`(T8FB#!M`8G""QH#TT(!6;T`Q.X@'QG:`+#>XA#$X`(.C@A
M$-$@D;$0@S@I(>70>"2'*912#:X/^<`@`V'$!NGG,AY<G\EA_E',PP!&ZNKX
M:\T"K_4$4KW_[:8U_A\`?BJ,-*5^%ERJLF#A$('WH1P>IX)>YP`G,!$,BO">
MJ6$ENP<A_!F-;%#1[\6?6,(]F/J@+<$$<5U1`<G'W^:S^>P_H9H.#0T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HS.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#0P(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#4X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@
M,"!2#0HO1F%B8S8@-C0@,"!2#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@
M,"!2#0HO1F%B8SD@-C<@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X
M=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A
M9V4-"CX^#0IE;F1O8FH-"@T*-#`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T
M941E8V]D90T*+TQE;F=T:"`R-#@X#0H^/@T*<W1R96%M#0IXG,5:69/;QA%^
M9Q7_PSREG!07F0O'/%K>5>R*(CG:==D/>@'!61(1"%`X1&U^?;H'@P$H+2%;
MP22E*G&)HV?ZZ^ZOC^&+W]:K#^L5#2(5$HK_S%])$,K^O^RX7C%SAQ$>$1:9
M*YPD/%"*)R2AE*@D(;5>KWXEI1$5RQ#EA'`9/DB]7Z\.Z]7C7U`2_IM<H(&4
M`N0'4H0"/H3B_/*^DB'>5R+&^TD2B><%<G(3<161A%'"0\7Z+3T:]<R]Q-VC
MD^V^>%BO_OHRW68QZO8`SQL4C,A!;\8)HW@7-/_N'9?TS^3A7^O5';SZST7D
M1Q/YY%N$@P!Q1;@(P4!*&>%*!'$8<O+P[_7JA@94QN3A#&O^<G]'WKPD/[]]
M\\/=W>W]TNIQHF+E$STG_IO`BZ^#%P%V$3>R:<!I`LMD!CH9,]EC]W#0I#FD
MM6Y(]4BRZGBL2M*T5?:>;'5>[N'JHZ[UCL`CI*D*73R1QZHF+;R79EG5E:UY
M$[\WNBCP%?/ZH2IVNF[(J:N;+BU;TE;X4%[#(F5;IUG;I06HL\\;^-;FL.S"
MVJ/A()1[[1F+DT%[$>/?J'V=[P]M$Y!?-3GG14'*JH4U,IU_!.W*)W*JJTSK
M74,>Z^IH=`2@TD([C1URU_0/R(_567_4]8:<[2+#`OB*_J3K+&\TK)1G3JP'
M((#K+!!22N<&3$0]$.>TKE,TY?F@2U!]1W*SE2=C]V&7.VM$N-!J,&E336ZA
M5V1I<PB^=?MS`4@3KP$XB/>P]23QNG4G?G'BY3%)8M83KPPH<I3EW3"V7G-_
M]^K53Z__1NX?WOSP]Q_?O+J]>^N!?9.0>45P$.^!?1,A!_;E,7=AEZCX#[+O
M]NDZPV*$MH<*2"1OFFX,TF<?SDMS#^CF8]KZ8)J$Q0/3A%#S.*9)K,JG(LWT
M42/7@+ZG0K>P8]#Z=?51'[>Z)HFAGUL@2?.5;0BG-#(71RW3+9#PG)[="60Z
M=K6\ZEC.`I7[R#E84EH`:#3FG"BV`$#Z*W5F$MXY;P\7YG#@7&+S.1@F8:'9
M^_2I:U2_O>Y+H&=5`RR(V$G7Q[R]`&YY#.)$#!@([OQ>8%EK,+@P%6S*N/E4
M`TPF-M7VJ3<_]O:&SX#<?<KTJ75U2'4N0<XA/WV9EB]@Z%UH=(.-N:)'81Z`
MB*(!B`1SK8T&J40/Q/=;7>ZKE+S(*PU*[)_(VS_=;LA/91;TWG$^@/90.1Q2
M+$E`GZ)(MQ463/#]E-;MH'K:D)UNLCK?]H[='O(&ZY?F!,[604"4Z`!+4YP(
MG8J]=D#27"R]BF1N%<P_C#E>`>]B-A=UQV-:/T&L(`@G$U_@`&\Z+V:5RII5
MR"CL%7_1-7FIFV9IY9E;S:J-$,<+KQ++B4Y,`.`#P(FT`+\%$@)BNH5BMJA.
MAL$W2R.KQFV,[B077@48U*VR>-+G5$R1C,*QYQ+4EDUE5>K9GLD$^R'=]3U(
MU>3HS1MD2=,DU*2"5VMR3)'Z31=5F`[*$(&A#0AX_+39WD,`B+&M%&.6CX:6
M_)0VF&-JK<F33K$-^L7P#^X&-GV<]$Q95X-^VG2*V2&%;)WNX;V^1`#F@T]3
M`N4E\+_+F->*F[GLZ@$&YOK+)`Y'>L>_+XN=S4CBJ)TITMYK?;)-Y:0+;EK8
MJZD!`*+S(<\.7W`Y?$L-^1,-B3,SN0`:\;SHF[.T+G+`VB*\0]41#BO*!PZ1
M2L8IP]A>1HF=,MB$;/3?:N@P&[`8,0UC"1?ZKZ=N6^19\613U=L.DC]TJ^]H
M2-_#?VQ0Z'YTF>^SUM1"Q_2)-!W`8S-\-]9\U['U`$/"!G=0X0B##"T,7[,F
MUB`I4,C2G`0E^;`UQ0-)*3.]W'<W2R\$R7B"@61L4OK9-+(#4X$Y=AB\4(OF
M53\Y@/+EB&P'G^VYK_-,/.,UQA?>9TCE_P:0$%X8`:%JI$J!_33B`>4IT%2/
M1$!^>D2>V.G'M"M:4[=WM>\A612Y)E6.7AO2H4:M("SW?7YYCL5.Z4QO6N0?
MNAP9:`<\=$SWO5%Q3/1_*EC!&(.^'@M6:':'5?J"=:P"DF2F8/5@7!D[9E:N
M&Y6ALIV8+9$]%:^PRK`!C\4K8VRBY^^N7H.EV4^,V_COJ]=K$RLN8K>*CWEE
MQ&.?TS8GWL.T+6)N\F(0LKYN)F_#M*TUDZ,M.,$9R*F!$O/Z7`V*B;[0SDM(
M4<>>?X&,TWHW#%R@?==0E&,1?C&%&"<02."7@[TG#V$>*C=PX6,A*A(;Y3J%
MNF.NXTC-7L<Y$Q\&35?*]G&$<E4DUF1XGN*&<)C*O1UPF)FTG;KQR=1-\,\.
M./HZ^1^P.=%/T^*`O.QJM/.QJO7&YIT9C=/G]'U>7?N2\0TSQ,W;S3"V](!!
MZ/K.1(U-6<@L!L.I30?.X+9YKCJHO;,42V9SYQGE<,][;4+!-%4YX)A",UKD
MD-D;K..-;<T#4,DT4"G@X*JY'A\8%39&/.`@N<-A'!5)P83+>1<1V4.PQ:)F
MC^&-U8K1\QH>"V]9Q+';LW2)8^FB5T#A,4&&11.:4-9#FN<-A@4Z=.<GL*B)
MAWO;83.!S=GN2G-V]PG:^7+OQ=.YZ[M%.$:["BW?05^(&V)*R`UR6PH)?Z=W
M)O9&#:'5!!TAGLO.L-X\;_?-6^\K.#,&)U&!4N^H#(?G6SP\K;H6VLS2I(A1
MG`<,Z'BD.VDVZ=!87&S^L2H@XYDM740_V@^4*3JSW<_M;)[=:>3!O+0=])43
MAN%,9O[<97D4I'+MYGC8(KE2TX[;="Q(SF;VX(ZLT6\#\KIJ,=B=S6##L/,B
M/^9MW_20&8TVT_.&WPD"'MQX`")V7=PX?QGB>H?SM-T7KO^U@T4H@&I]JFHD
M1(@BXPYVI&CJ*!]'_<:7_=6?3KR'^E,*UX-P&4U&'V)RVGNM5,(;!`RS(4UU
M-$/>R9@X=]ER:)3-B1D("H!Q%W>GD"5.&7]=<LCE!#)J^,Q"1JDE\I^+U!SC
MW.(`)-]V&)!+]VT1]&U?:KOTJ4,$*PRK+-ZW19)Z%`ZRF;^F$,0+Y5=\[%=\
MZ%>\\"O>KVFY7]-ROZ;E?DW+_9J6^S4M\VM:YM>TS*-I\1?7'DV+/[A^GNQQ
MX01G0;$"R4;J^+KYP3D^0*-X]H&8\OD'(CPPF7L@I'B2/_.`9%3-/B!H',T^
MP*D*9Q]@3,QOTOR.9.8!!6O,W4_8_!9C+F?E1SR:U2#DR:P"DH>S\@6?!X#S
MKU@1AV>S`,;)U?L?>@A[([/PC_WV5%+XGPZC"OO[&LX^=W4U:YX;%<WZX`U3
M\OK^\0'.D]DXN!%,SF\!NO%9B&_"KT3232CDK)/=A))>MQ+@=/?;>K5>_0=G
M5!,@#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C0Q(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@-#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-
M"B]087)E;G0@-3@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A
M8F,Q,"`V."`P(%(-"B]&86)C-B`V-"`P(%(-"B]&86)C-R`V-2`P(%(-"B]&
M86)C."`V-B`P(%(-"B]&86)C.2`V-R`P(%(-"CX^#0HO4')O8U-E="!;("]0
M1$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO
M5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HT,B`P(&]B:@T*/#P-"B]&:6QT
M97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#8W,C$-"CX^#0IS=')E86T-"GB<
MU5W;DMLXDGUWA/\!3Q.]$VHUK@3YZ&NT>[O;7MNQ.Q/1+[**Y=*.2JJ15/;4
M?/T@$P`O*C(II<NU.S$1;DT!>7`R">0!2!!\_I>G3_[^](F<%Y43$OZ'O\JY
ML_&?Y?73)PI+E-"%4`7^18<?\ZK2I2AE*)&AXJY^^N1_Q`:QO'4`Y,H2_B-V
MGY\^N7KZY/+/``7_Z_Q!SJTUH8&Y-<Z$_YA*ZWYY91V45\9#>5D69AA0BQ^=
MD8&1DD*[2I5(Z1+]@S)=-66R;.D^__CTR4^O%Y^67B@C/H;Z&`:$S(X7X*,I
MQ<=K("2-$Q^73Y_\&-A*J\7'KT^?_/!L+[:7XF6]K*\_U3NA]$QH*8N9.%S5
MNUI\A7]T-?.VG)6N$/NKQ:Y&D^WM3BRWU]?;C=@?MLN_A3\<]H?%YF*U^3P7
M_R$^_N_3)Z\"Q_\ZQY%BQ!$5+IQ4T9$?_M!6/C1^T<'GDA^["H&\#5<"L*'.
M$EW0_H%;T>XQ6@F=Z1%:"0/G$5HI[&.TXOUCM%+)QV@E))-':28,Q\=H1E>/
MTHQ]E/&OW(,F@/%,V6:`[Y(IK4QR%<7JAS\_M`-5T\:W*,EH&C8=%[2QC>3:
M$GZ#Y+ZO;X*&UIM#T-&OFWJWOUK=@**NZ_T^R.YB(]0?TKKY`SNNC6P]_PX"
M;?6W1Y70YP;^.U`W1G]/Z@W\=Z"NK?V>U!OX[S&C"_/)[SFAR_#?@;H;ZR_@
M5N7*(/M!D37BM@`X[X<*,N1JJD(I%5VAJ,J*KB!+359PLO)D!2O#_(BJ$-8L
MAJR@E:))JC#G)BM(%:X-4:%2-,=2&[(!KQWI0J$+T@.G+8EO-1T!H^C+J(N0
M]*AR611T`#T1OV8%:L)\NRJ4N(Y!#;_6Z9>#7[$8?Z;%Z]^;8F,J4-1SQT\5
MXCHR@%I6P;?$*A-LR!C\B15,GU<N#P,H+'?/XH6FH4\/$VOK.^T;8HECGTVL
M<$PLE:M0W=@!9L7XI,)*&9C%3!RF$M(KFZ<5RI=%G%:\;>82[W:K[>XXZ7U;
M^V#KF_8+73;MES[=23ALX9Z!>'MY6>]6F\\C5]6%%60*7HYC/V*QPE'P<KE2
M9_>V:.HGKVJAFJN:.?;9Q`K'Q%*YKV#1>E90G0U#1X8,",PJ.R\*N%/SSQA5
M%Q(71O7W6[PO$Z:'QQ?T6YIV9=.?PBS5RC37_A#O[CQH2VW/J8IYB&J%/OZ`
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MCA[J4N*5*/;)Q`K'O%(Y(WK6^4[T8':/P7M7[Y;UYK#X/-;_,/M'HIESGUVL
MH`<4&_H?4[%/B"`F[40L<>RSB16.B:5R?_[$-9J.$3M2KT@L<^RSB17T@'J%
M/S+5ZX2`>6D;7HEBGTRL<,PKE?OSTUUA&0/6IT1\W1+N4_-M?NYH12H_/WK1
M\H3H58U4^%8K.F1BA6->J9P1/:\E:\"BEB:B52,8'7:QPC'15,X5V]$()L74
M:EPQZ5O"5>B`*08P9VX?8:;IS[-/]>;S=B&>K[9UF`A]OA/O__1R)MYLEO,_
MI),J_*/NK89`X[1BRV.B-.@M*ES`/E\[HB4%[4V$EF<'TE2NP:YT"%^0$)QZ
MZ)DRQ<P[?=P8*AG+CVA)^($RQH-&2Q+:<T/D.IVM%R(_OQ<<%"GH0.K\9M`T
M]VGE57I8(ZT;7'F%5L[/:M&2B).SJ9<R'"BJ,[L2*A3+CVA)^('RQ(/6;@+:
M&&Z(BJH<#M&]1E!^6/RC)<'?I[S+@.Z,A&%H+;FA\>5((KK?2*6:,<:1),H!
M<%`2B[@)29)%NR2VG26QC9+TZCHLR+<;\6ZQ.\#:''1(C^J0Y"_3)*&ZJ":2
MLX:)EA0TZ!!`GY]DK9(-=N_R5\5,ROOIW!JF$]&2<`*EA`?MY!2TY\;':=GI
M7F,/P5%#)']Y19%'Z9"<J72TI*!MZI(,T2GM<+\IY%"_0=U@.1$M"2=0-WC0
M:$E!&\.-3^'5<'S,X+A"\6`Y$2T))WS*K4S9(:&UY,;'=_K/^+A"W>"-JVA*
MKX+*TG`EIRS;YR_!/$M.Z#`]Q7F]N%ZM[\3K[>WF8G%8A;^`]I@Q[0%"3.W)
MA$:U![!YVD-#!^U!:)[V9.S>&"G=F/;PG(B6A!.@($QH)Z>@/3<^H#T9F]8>
M[#<\[2')@X(`-D][:&B;NB1/>P;[S;CV\)R(EH03H"!,:+2DH(WAQ@>T9S`^
M>G!<@8+PG(B6A!,^)5F>]M#06G+CXSO]A]8>YKB*I@1Y<,Y6J#V#CP`GM,?G
M'8W2^>;1O[$F[6A\7B]VXL,A_+O9BP_U\G:W.JSJO7BQW=UL=U&&7C]_*WZ9
M0ZTO]49DN7I@GL[D1VL>^F1^4*IT6I>]>?],O/_IK7CS!E31CJHB/)IW0H]<
M9E(5"S6AB@&;J8IN;&]*5D6`9J@B#*H<N>[HM86:N1%99'F!EI07*&X\:+"D
MH3TW0*[;M;H!4O/[=^QT;(9Y7S`W<\)]06B%*9-4G%`F(4X,!WPY'"<CQW62
MY05:4EZ@VO&@P9*$-H8;H*)P(QUI>*2AW+&\\)TQ/2Z4/.C.:!@72EZ`4"B;
M(4`*91IC'*&DR(-SRK$%R!2/*)3?P%-5S6*RU,TS-86BB>\H;`]7`M02=-*-
MZB0L'9DZJ:=6C[`%FJ>3:FQS:=9)@&;J9,+N/Q[R@^D-U8[E1;0DO$"UXT&C
M)0GMN0%RG9[57P;,BT&=A.[#U,G4S"DZ&5IAZB05)]1)B!-3)X?B5!#K2987
MT9+P`M6.!XV6%+0QW`"A3@X%2*G!`*':L;SPG3$]KI,\Z,YH&-=)7H!0)YLA
M0.ID&F,<G:3(P]L35<&^F2EEHS^==^0TO,2(^O/QJA;O5IO-8KFNQ>O;S<5,
M_#I_A_LYBC$U`C[<>YF2>'?-X$L6!5>-2&AO(C1O/T?&/GH(;[V9.7?OS4]0
M%9X?J$>4'Z`J3&C0(QK:<T/D.CVM?[MW;H;T"#L04X^D/%6/H!6F'E%Q`CW"
M.#'U:"A.5NF9'M8CGA>H1Y07H"I,:.TFH(WA!JAPQ=A8DV'E9NZ/-=`5GA^H
M2)0?/J5>IB*1T%IR0^3]2(B*>36D2\RQAKITVEB#,`423(7RI<J-R,Y*#E=U
M(%"OM[N#^&T!2[/P[Z'>!8%Z!_+D1^4)]FSSY"F3&9>G@,V3)QH:Y`F@>8NE
MC-V_%U3ZF:R&Q8GE!5I27J`X\:#!DH;VW`"Y3B<[NJDX+$[0?7CBU.G+D^(4
M6N&)$QDG%">($T^<SNE(*$XL+]"2\@+%B0<-EB2T,=P`P5;#P0`-+I-X_'UG
M-(^+$@^Z,P[&18D7&MAJ>&)H*M6,,,92B70`''0E6X@*G6\I^J+9]V$T_#X2
MHKS;,$M1.2I%@0Y7B@KBJ`P4E(#-E"(2&J0(H'F[/C+V\=-I)>\E6]03EA-H
M23F!>L*#=G(*VG/C`[L^VEY&[?K`?L/;]4&21_T(V$SE(:%MZI*\71]G]!N4
M#Y83:$DY@?+!@P9+$MH8;GQ0>(;B,RP\+/YH2?'W*;LRA8>$UI(;&A2>TT)3
M*>ZP0E/*`7#05&SAL?DYG(3U;Q8>/%8';]'-Q?OMUQI.FUC6XME^OUVN%H=Z
MW[YY58WJCZG8^F.I31"@(H:[OX*&!OTQ<?O`N;D;S"ALU`T6;;0DH4$W>-!@
M24-[;D2<GJ"-BF%83WC1E,0&R3#<O1,TM$W][WS:A9H("8H$BS9:DM`@$CQH
ML"2AC>%&Q,N)#HC:P**-EB1T2IU,52&AM61'I)RXD*@(O&&#IA0V'I<E66*B
M0[1U/FU&2M-Y8<K8(3'YN5ZL#U?BPW)5;Y;U/CT``EG!_0A*C@I+8,@5%DT<
MI(?R`!>.)RPD-`@+0#/OL27L_JT1,[HA@>=%M"2\0+7@0:,E">VY`<)[;$,!
M4O-[W0=U`[H/\QY;T\&G[['!<U^>^%!Q0O&!.#'OL9W1D5!16%Y$2\(+5!0>
M-%I2T,9P`X1+G:$`#8L2B[_OC.9Q4>)!=\;!N"CQ0H-+G=-"4ZEFA''4B7(`
M')2\$R9`G:1KMR.HLMV.4.I3Y.G==G>XW*Y7VZY&C1X[`3RY&B4GCIT`;*9&
MD="@49)UIH)5+?;Q-H41A6+Y$"TGCIQ@0J/EQ)$3S/#@O3>9SX(@[[U)UHOP
MT90Z!P)T17*/F*"A;>J1#$6JY!G=!E6%Y4.TG#A>@@F-EA/'2S##@WHT%)YA
M/6+QCY83QTLPH=%RXG@)9FA0CTX+3:6XHRJ:TL=+%"7O>(F@1T69MY%K5Z@L
M1TX6:7?VQY?BM]O#[6*-*Z/]`S:N0N!SZR%Z%L\GA>C]^*"-=%V4UK<;`"OO
M&A>'5H%16P>/TCB!T-CEU*5I"-T_+AR4%Y"9HMT`CXDV8/-$FX;V)D+SGIAU
M>D%G/3"JVCPGHB7A!&@O$]K)*6C/C8_KC!):M;'?\%2;)`_:"]@\U::A;>J2
MO"=F9_0;$%^>$]&2<`+$EPF-EA2T,=SX@&P/QF=0MGG\HR7!WZ=$R9-M&EI+
M;FA`MD\,3:6XPRJ:$@Z`@P7OB`[0M'S0M9^'4>;;<YJCI/WW8KU:BA?;ZYO%
MYDZ\><"VE5)MXY.JS6[$-8W`,\&BW14)'P5"%\<E>_`$DA/8C$JV:^,](MD%
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MA`;1!FCF.KOM!%-G]J'RLIR(EH03J+P\:">GH#TW/KC.;OHON<Z&?L,4;HH\
MRF_`9@HW"6U3EV0*]^G]!N67Y42T))Q`^>5!HR4%;0PW/BC<0_$9%FX6_VA)
M\/<I43*%FX36DAL:%.[30E,I[K"*IH0#X*"2K--+0+A-^VY>T7X0`(XECX>7
M+.X.5_5VTZRUPW\_K3;UA7CY_*>7+](+>^.2SF1F@H1G:M.2SF[$=?R7KGDC
MQ#G?%_2';#1D*M5^?DYIU9X_FC]"U<P?<.8P>F0,4&`>&5/HB5=/`)LI\&IB
MAQ9"\YY^9^Q^HIZ5P_N`>3Y$RXG]64QHM)S8GY7#PUF34]BHSXJU922:4M@@
MT(J[%8N&MJDS\AY\G]YC4)]9/D3+B8U83&BTG-B(Q0P/*OM0>(:5G<4_6DYL
MQ&)"H^7$1BQF:%#93PM-I;BC*IK2&[%<Q=Z(Y:IV(Y9KG@JKR@UMP_J]_BI^
MWNY6_]QNNEN$47]&#XD!<LP%9B8WJC^`S=,?&CKH#T)S[@JW,3WZV,+H#F&>
M%]%R8O\5$QHM)_9?,0/DL+\.!,@,?_('NP]OAW!NYH0=PM`*3Y;(.($L89QX
M.X3/Z4@@+SPOHN7$CBPF-%I.[,AB!@B$:3!`@\+$X^\[HWE4F)C0G7$P*DS,
MT(`PG1B:2C4CC"%,I`/@H//<)2>>^Y*$2=OV!1:=WX9\L3K<P5>:093^NMW]
M3;RL+^O=+JPY81%:;_;Q<,]WZ\7F(9F%E)>I32XY^8VT_E=FKFRXGNG1MG0V
MK3I__^L+^,+H3U:J_QQ:>G(;#TM/EX[4AL?J%7P%,3]65WGI>;U8K\6+Q8UX
MMEQN;S?Q[K55!L_BP?G`Z*D\P(NY'G6C'['/\P''/97'D:>(PWS`\4[E";.^
M)IR])W[ET$%?*.HL)]"2<@)%G0?MY!2TY\8';CAG;/J&,_8;WJJ4)(\B[KB'
M\-#0-G5)W@WG,_H-:CC+";2DG$`-YT&#)0EM##<^J/Y#\1E6?Q9_M*3X^Y1F
MF>I/0FO)#0VJ_VFAJ11W6*$IY0`X:'AG\(#Z6]VHOZW:CR]):287IIW'J:/G
M\0`U[J+43MP4Q;<T>")$0H,(&?9Y/!F[_U9F-2M'1(CE!%I23J"4\*"=G(+V
MW/B@"-E3SN/!?L,4(8H\2HGAGL=#0]O4)9DB='J_02EA.8&6E!,H)3QHL"2A
MC>'&!T5H*#[#(L3BCY84?Y\R+5.$2&@MN:%!$3HM-)7B#BLT'76@_3X[INV0
M[J^C+(5?Z_2K@E^QN.I_G3T5,X_R@><L2;]4^[E:V!T4UZY!NC9BL;G(#TQG
MXM=?7Z!DW3_"I^,':$3T([O4IQ\K''F2R[EZI\?.J.@0`VU*Q!+'/IM8X9A8
M*F>*Y0F\4(\2KT2Q3R96..:5RKFW?Q.Q?L:4<F:,'N,)XA9Y9LI]<K'"$<]<
MSM3I4^('FIIX)8I],K'",:]4SA3Y$WBAGF9>ON75D(D5[O'RW.N*,P1MJ!E"
MAQU(<F27B?8IQ0I'['(Y=WHQ&K:V/DX%$K'$L6'C\2=6\$?$4CES;J+'%@EM
M?93_Q,LVZ:-#)E8XYI7*N3?7]=!1P.0PQ:E"Y(G3BL@S_L2K&2L<7=A<SIR[
MG#`<<(Z0>)DF?73(Q`K'O%(Y=^(SE.9&&2;=O6[)]FGY5HY;AKF<.6LZ)7*Z
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MS-G-Z,<]^K.;[%3RK^])K##L5"QSK;$[\B16.'8JE7.F1D75>-43`C=SI9K9
MTHY-CL)D);F9/>[3BQ6.F.9RYCVCJ2_;``O>O.N4`0ZSC.RR:7):_&GS!.?>
M.,KES!,Z3QG@/DGR=<NQSR96."*6RWG3+3+99D*\&=-)UZ)JYB,P#<HNZT94
M8H5CEU,Y\VS04ZY%*=MK436SD`Z;6.&86"IGWA4C+P9$U*>7P,_$1E/J?6J8
M`7GV:^`T-DR!//<U<!H:YC^>]98SSG\H;)R(L&A'RXGWOIG0:#GQWC<S(C@+
MH;!Q-N#9[WW3V"#GGOO>-PUM4__CG35-8J,,LFA'RXDWO9G0:#GQIC<S(JAD
M%#9*"HMVM)QXP9L)/97_4$^8$2DG+B3F==ZPB:;T>]W&EO$DM#,7YF%0R/:^
M@0V#!*>+^#`#=X.%YH;3.3;I\52ML[>HY3;AC30='[#(>5&Z_#7M^F97[^O-
M82_T3)EBYIT6^ZM%^"/L&=S>[L1R>WV]W8C]`5XV7^WWM_6%.&S%X:H6^WJ]
M7FT^Q[*K[?JBWHG5!HMN=JLOBT/X[WJQK*]#`X!SLZX/P3J@_;[]4E]_"M7+
MF=!2%K/[[UQ_D]NF/<2M*G5R.V"E%^B_7JV65^)Z<2<VVX/X5(N+U?YFNP=N
ME^+3'>7<U_"S%EO\?;/8'<3MYK!:'SODY^*WW5S\LOBR"G_[L%A_7EQL9^)=
MB.OJ`J*!S[2N5O7E0SM>-)^?+MO3ZXPLTHL*K_Y1+V\/JR^U>'MYN5H&<L'C
M$7=GXFJQ%U^V!_@[$%YMOM3[`U[-F^U7L/T2_D'KU&6^PKN,XP&<"_A\[N+B
M(E3&#O;`SKOFBU2Z\^U>;Y/SSS[5F\_;A7B^VM:;>O?Y3KS_T\OX;L9,+,1O
MH7>''K\*7;7YZ/TL='FA;,C"K]:?=JN+S[5XM[C;U#/QX785^K=6>A8N9`WO
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MU;S-T;G4JIDCGY4J)VB,/KKP-O,83)3P;8A*PI.+^[`%M>-3@H>]C8'Z:`,9
M3@\!7"-V"P(/>T+ICQ5,38ERI:N*K*##920K&!!_JH*5:J*"@2^S4A6L&O<R
MA.'57YX^>?KD7YA'6]8-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-#,@,"!O
M8FH-"CP\#0HO0V]N=&5N=',@6R`T-"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P
M(#8Q,B`W.3(@70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W
M(#8U(#`@4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0
M<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G
M94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C0T(#`@;V)J
M#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,C4S,PT*/CX-
M"G-T<F5A;0T*>)S56UESG$@2?E>$_D,]>C<P4S=4[),EVQ/>M6.UMB)V'N:E
M1)?4["!H`ZUC?OUF%D>W+:"E/L;MD-QJ0U&57UY?5@)GOYV>?#T]H:$VBE#\
M\=_B4,GF([D]/6'^#"-<$Z;]$4YB'1K#8Q)32DPL2>E.3_Y+<C]5)!7.H^(8
M_Y#RYO1D?GIR_7><"7_6#M!02@'SAU(H`7^$X?S;\T8J/&]$A.?C6(OA"3EY
M+3E*S2CARK#8BW3MX?ESLC]'XY6X9Y>G)[^\MU=)A-@N8;S7@I^RP\TX,8J2
M2P#^ZG<NZ=_(Y?].3][!E?_9R_1Z-3W9]]Q@*;#2`47OIS^`Z#HVAQ2]G_X`
MHJO#.HPZH,-("-\#BMY/?P#1A6&'%+V?_A"BB^B@HG?3'T!T'HM#BMY/?PC1
M^4$S3#_]`41GT4'#M)_^6]%19U0+12(#,_M95Y=[1L8!C)JI`<Q0/3T@IE),
M#HB8T),#-(.Z86J`8E`C3`V0#&)F:H!@T;20G*E)13'&-)\<0/FTD%""3:X0
M"SJ)(1)\$H+F9G)^Q:=5`$XX>5Y`L3AYGG$ZZ6I,;%!@-*Z_KXT*-<0I1(H:
M#A$Q$2)4-+6/X:&0$H+I3PQ'JJB"#X9Q.12;X+BX9@3_7KJH6%N4AHQ1X*,$
MO\9:P]=[6/Y#GF3+F:NP1`@H5.?5W);PW^*:%,N2),7M;9&3JBZ2/TA:54LW
M(W5!ZKDCE<NR-+]ISLV+;.9*DN;^U*),[VP-?S.;N%N7USC/(G,U7`VSO75P
M]`J&LP""GVIB\]F3C+<K;,XZV%)&+6RA==3`!ET\!ZV]RAQ9+N"8>W!EDE8.
MAR+$>UN6-J^KYRFE6B;SIUH)R:<R)/\,]XZ=R@Z[T<IC?PU;)F4:[%]J=^=R
M\N[6E561!Z0J`.25R]UUFJ2V?.P@#F`)R-Q6Y*ZH\3A:+<WO7%5[$R^*>P!;
MW,&'O[K5['T.VKEZ')MQW^!-''78*=!8BQT)H@%_"6+8V0Q$\U8_<[8DH!!;
MYA7YXI)EF=8IB'U>E(NBM'4*IG]_]F\TTK=J(Y^+>DX^?'X3$(NXKLDL+5V"
M'NX/IA50!FQ.W^55YA[)&[ATZ0+RL:C(F_S&9:X*]HT\:FI\(T.C<)?UIX=.
M8]T@/[=9>EV4>6J)H93+<(OEQ^L+T:__M'A!8H'B`K(FA.6+TZ818CAKZ@U9
M$]=$,"]>5*P6W90UA12!.JZLN1-LM'";-2/31P_DS0:WCH/HQV?-,YCED7P:
M3!V[H(^-:=%3PQJCLY`R<%\/_E]I74.T5XW(F#1O&X.TX"[2/+<)''Z_!,M\
MLKF]\0)#U(<?P_,P\*-N(-&6-B,+6]9Y<W%_X9O9'2BKK/"*B_'Q>'C?T&/>
M&3Y"O(WA>83T@=C_(BY`/D0U0S*MDLRFM]6*F#)_?5G-T\7>T6O5H1=JQ1E1
M&^V@<N^*#8P`O#IQB[IS7O=0(V08-(>DOP`.R3V+IGGM8'B-@TJ7`M&FUZ"G
MQY!\QT&7W_M.9WY++MT#Z#A+;U-,`JT+H`8&R6,G%<BF3$3&@!J]<P"*AU$'
M`$UB,7&!D""R+VSY!SDKEIF[LR5(_&4)(D**IP&YR&Q>M*)'BAJQ7:".<8W0
MHI=VD&LBJCS7,/-BKHD9&^:::`/7X)H>S4L7%:M%D6MTW'(-PVZYU_QGMP"=
M.\R:@O-`Q>R8V&87X)'IZU05=^E6@7D;KI&!`I/\8*YY7Y3UWG%'?8T:1;PS
M.&ZM/?!/%NO+<[M(:YM!+OAX#D*7D%L[[AFAA"%D%K-)!R^Q"YND]6/0ZZIJ
M>&PJB>\;NZ:]L_=U%35M=;X=8[RU>>HR\JLK;VW^G:X:GD8NQDM7A.WM^E33
M!S*X[*M)VAJ<@<&9'#4XF@*AM9B<!?-UG#A,B<\EJ10BHBC'N&K?P'E73T(&
M:6`+PUO8FWAQS43P66/%\?$"6?&MRRQ$MQLF1F0JV*5=V3*QX"(%.7>YO[BE
M*,CF\!V4^A[2`P1!4@R2Z4ZPJ1G:BD%I99[NQ20$PB!#;I1@?#>V$F&0(573
MP]J&(77$AQDRWL"0JMU:;J//;E%0(>==UI"1X$\8DM/`P`)'1)`[X59]7:I%
MU`60Z!A2!BR6QTJ0.^%>]2PY%QU+,,6?09#[%(53L2Z+85U=3/WW-HG]<#[>
M2=6K/NG/Q<<[@5XU2'\^/MX%N.J[HU3)KN1FK*.E%S#R14NY?RDG[P1]N#WZ
M0D[>*,$4)ZNI#JG4;,O[2FJL06HV4#(NN66S6:WZHY1U6Q@MXW;/>AF2SY"M
MR$69)HZ\J:H"HJ/&,/B0)R%!X?8H#V>T%Z@I,U_]#KRQUQ6^@:S::I:&RG2I
M<@SR/O4.Y<!3G'*OEF7K[B0I]KY;=V)#\;#]0F9-H9S3J&\Y^>]-S[$CCC42
MM$V+E-RG];QE1$BIS;V7M7$59NQ?(*]ZOAEESETBH&^5<X7$T4@O8MV&`$@%
M-.Y&V?-ZF<^\E`VD`K)^DJ5>]"RM,(/"`"R]X$!N;UU7EM:^H+-70,V>',EB
M62Z*JJD`<4#I%I"FD5U+]W4)BFGTL5_TLF^50X76!8,TD>P[IBC*V@VU=P_)
MW.8W$!F)ISUFA`S(6-!`A?`(M$IF#J3WE>E5H\GOJ1:GLEG6EUR-HEL%>B7]
M8]_(5YURWC=ON)9M/3@'.'?(;*/0W`/N5JKL<:W)7<\M>"_\5KXZO+9)'8SB
M;<J*7K7A^%)`NW;?\/M6.8U-WR<6PK1[DGLH!`%:X^K5\JI*9]T]Y6_%_+4L
MEHN&#P)R/T\!DQ=WL;S*T@2FJ$LH%6;D.LVQ)``%8#Z`*RN"M2;Z-^['L$S9
M`N$836L5]Q"':1JR$SB\D"^D:7RV9?7T!^;9GJ89G>3IV*\9:?GB1?%2'C_M
M+5,3J:<[YT@=U_,?N^%>]=3UBELD[UH&ZEE@#[UWW@+SF.-&P,\=Z$''Q0?F
MMW-<$<D1QV4;'!?7W-*`W:)^7]K?DQ.\8YAUS_VA?@LUTI`==X&N^ML#1O65
MA53=@QS'Y[2;P(XZ+5BV0SOHM!S*C"V=EM,1I^4;G!;7W-9RG#[M4XHH,@/9
M]MB2[2ZP:;\STEJODFW7(U.!/,I<NPGRJ-M*U6,>=EL8L)W;<JU'W%9L<ENI
MMK5?M^@SW)8'\9&Y[0ZPI9ET6QDH?91NNP'RE-MVF`?=%IO:6[HMXR-N*S>X
M+:ZYK?W8P%VA0;<51_9H\TZPH2B8=%M]I)7M)LA3;MMA'G9;L>V6S#]V,NBV
MTT_DQW[-;>VGXN=6MB+@/]!MM1RL;'>!+ME/5MEN`CM5V79HAYV6-B^ZL*$&
MA1[7(E92C'9\W;C/J^]ZW?B6RN1K,J\]A4R<9]1,OD?TFE,^^4;6:V[4]``A
MZ+2,$)'C[_(`RG>_G9Z<GOP?&CUL=PT*96YD<W1R96%M#0H-"F5N9&]B:@T*
M#0HT-2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#0V(#`@4B!=#0HO365D:6%"
M;W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#4X(#`@4@T*+U)E<V]U<F-E
M<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@-C@@,"!2#0HO1F%B8S8@-C0@,"!2
M#0HO1F%B8S<@-C4@,"!2#0HO1F%B8S@@-C8@,"!2#0HO1F%B8SD@-C<@,"!2
M#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E
M0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*
M-#8@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`Q
M,3$T#0H^/@T*<W1R96%M#0IXG,U8VV[;1A!]%\!_V,>VD-B]7QX=)RT*!"[2
M"D@"](6B:$N-1-JD9-7Y^LXL1<J)J)4C48`A@")VAS-S9L[,7MY\B@8/T8#&
MVBE"\>??;*QD_4B7T8#Y&4:X)DS[$4Z,8+%SW!)+*1'"D3*+!A])[G49J5"1
MLA;_2'D7#6;1X/875(6_9P,TEE*`@5@*)>!/.,Z_G7=2X;P3!N>MU:);(2<C
MP0TEEE'"E6/6NW3K\?DYW<Y1NW/WS3@:_/I;,DD-@AN#O`^#5]D`9YPP*A09
M`_2?_N&2_DS&_T:#=_#IAU[TZV?Z2=_*.7&67=+W5OTE7.?FHJXWZB_@N@7"
M7M#U5OVWKH-ASC1SQ#C0[+7N/O<5@P+4B:``I2HHP!R%R(4$+.,T*&`8,#XD
MH!GE00'%.`L*2*;"3@HF@H$"`U('!0!EV$G*=="$XRX(P@H:Q&"X">K7/!P#
MQ<.)E-#&@_.,RM"\8"P804[UD0":P_8?ZA`Z@VN3D-TU)$)='98)+"+'8R$T
MM+&O6*]44:;AR;!RNZI76&_4:/G#5N'3UBJ-(3CPFN(K=096@`W8_RN[+[,J
MRU<5KJY#"BML-4M@B!2WI%B7)"V6RR(GU:I(OY!Y5:VS*5D59#7+2)4M%O/\
MKIZ;%8MI5I)Y[J?NR_ECLH+_19)F2U"/>NX7V0J^!FUO,QB=@#@;8OUKDN33
MO:YX+G#*&N!*.@]\!$L_,[)&SO2+X":314;6]S"6_9>5Z;S*4!0Q;I*R3#!P
M+XI*M4YG^V&)3T%]J%$;J+X6]OXJ@^R5XD3V.O"GF[SF&'G!YHDY;(Q""CFT
MWYJ[PD`3^IZ[7`S5*Z/N&;"E:6!KK5OF8O/VN.70O$[>'H%\D+>PA6\P=]+6
M6G<J;6'+TTU;>X2V://4_&V-'J<MTZ^-MF?`MDX$:2N&XE72]ACD$&T;S-VT
MI?X<JP_LMP.TM4H?H*T[1ENPB6!^U"A^NC4*^;-P&M_F#]9+ML];V"H(P5^>
M3,S4&0F]+4H8+Q]Q/*E(58#>GL'#YKP&3P7*^9K5RFUK=E=5R1T^3RNZF%P7
MFRSWM7<-@DG^-"3OWU]#!$A"-@!V\=0C+`W;G@87,$GZK0$R:=2G$3B\[8+'
M\)IFRQS%]98YQ2:'@%3K236?SI/R"1E01Z+G)'+>;OE<DT-L1>C$[V6QOA^2
M/_(T'D*LY]`?(.P/ZV*;+,SGS=7?;Z\^D'6.I/-D?%I.BD6O;CK>^EDW23BS
M<]&KA5TDG(D-UC)F_?K/CS=QCW:DI!U(9*\6=&MAO\.>HUC1YV2AMEVEX0A:
MTV4,V4^F4VAOU8ZN787KU_BKQRQ?MYVM9U;3^K;.J5AS/,U]K1LS-:9V]6J9
ME?,TJ8;D)MN0ST7Y!=X^8Y/F])2$'UKP.#C2.-.YX!E9'Y^9ZE"L`^F`?8%1
MS7%-U5SZCDFH/GR!,F(L>#LP8E0&;X%&#(_%(0$NPA=-(&`.WT``BG>?HD$T
M^!^?W3`H#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C0W(#`@;V)J#0H\/`T*
M+T-O;G1E;G1S(%L@-#@@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR
M(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*
M+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V-"`P(%(-"B]&86)C-R`V-2`P(%(-
M"B]&86)C."`V-B`P(%(-"B]&86)C.2`V-R`P(%(-"CX^#0HO4')O8U-E="!;
M("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^
M#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HT."`P(&]B:@T*/#P-"B]&
M:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(V-S4-"CX^#0IS=')E86T-
M"GB<O5O?C]LV$GXWX/^!C[G#KLO?$MNG!&V!`(>VU^ZA?<B++,MK76S)E>1L
M]O[ZFR$E2L[*<J*8P0)9KT7-##_.#+\9,F_^6B[^7B[H2AM%*/[83_%*2?=/
M>E@NF'W""->$:?L-)YQ%*V-X3&)*2:P$J;+EXD]26%F15"A(Q3'^(M7C<K%;
M+K;_1%'X,_B"KJ04H&`E!0BA*V$X/W]NI,+G1D3X/(ZU&!?(R3TW("IFE'!E
M6&Q-VMKYV6?</Z-Q;^Z;A^7BNY^3=0J3$^0!QEL8K,ANXD((PB@SY`'F;N1*
M4,W)P_^6BWNZHEJ1AZ?EXM5O_WK]"_GU9_+CVS\>?G_[YC\/;W_]Y1_DX;_+
MQ4^@XM^?;4>$((_;P3@QQEGQZAV7]-;B=2^>S)1]"4)-B8FYE4U77,J(/*06
M/T6-=`#^F9&DRD#L8UXW6947CZ399:3>P;<U*0NRSG;)?DO*K?L^V^]Q3-V4
MZ?M=N=]D5;TBKVMRJK,-R0L8E-?D6)7U,4N;4WUGWP+!AYO/C2D_.6WG!:O#
MQ:VUP*L]A,Q0WD$H)7Y&",<PN;$9$<3\R\G*6VL1TFNYN2]&(AHZHQ(>R<A^
M1B3S(MV?-N!WZ#0WUH]AC%G#JA><*Q\+$6^3R7&?;1ZS#)QV4Q;V=U,E1;W-
MJ@QCH2(EV%61^I2F65V7-U]E'L7>1L-7DE)F$]ZK^ULKBGLP,)LJEQ@`_ULK
M,OP;S<CHP?*R6/A4)Q4WG7=!'LKJID]B+LE569KE'R!])5L88'UODS292WEG
MV8QLJ_)`$E(D!QC>B0G@J#+NXH1*UL\$/]N,TV<:DM1@T&.^;>Z(\U_XG51-
M`4EHEQ_)!M)ZE:]/30ZYW+MP4=YZI04PA,[LH"LM=#3`AW'1P8-4Q:&3['%#
MV\,:;GP$KVZ\;<M(>C-FY\HIRL'CH)2#?Z7I4Y2#L79U*!!'OSRR#<.'"S2"
M')+G.Q=A37X`TE#:WW=V,$F*9W3?!#XZ*I)7GJ1L25H>#N#?5AR2%ASM_L@^
MIKNDP*@X)-7[K$$AX!.;,($;(ZURCAGAQS9PA8G=W+=)FN_SYAEM?-KEZ6Y(
MMI"'H6G@M6`D<*ECE7_`1&1].$DQA(%L`7XUO`-.;B$#@D:2AFSSC^Z](GLL
MF]SZ/KP/&Y5]XR+B2-Q"`!%%'1"*]AG,9@4$PBYGD:'!A[+*.GJY+??[\@GM
M/&3-KMS4@%)6?)*PO[]]M,4J"AEM7GR`1!%S&M3T3GP`TR.M0YKNQ8<PG0>M
M"+WX`*9KPT.:[L6',%VIH*9WXD.8SH+NYUY\`--5S$*:[L6',%W*H*9WXD.8
M3H-N25Y\``(H#>TV?ZUZ%L24O,X`@>'5I:-\+2TZ%5CF_'X"4L\`;_<GDH4_
MLO14Y4T.8UZG4/[D6Y)\2/)]LMX#W:L26^DTP/[\.V?%W*TK@DA+/_,0#B&C
MH!N]%Q_"(91PA:%>&45=%_?5FZI\GU4W5F94KRQD%6J,UX-M0=U[N=2MEV\R
MH.C@U%GQF#P"&U\_7^R@.L>O*BQ4@`-W5?K:(G3K+I,TXMM@)$TT!(GB%M76
M@HK%YR!!L8==BSS-CUCQ0/%C"YP5">(ER%&^"03:Z`$$%(]HO)\8=0X!^D#;
MB@I0D$FANX40ROB%B%5;E6,%G=<UEIA8E&WR.BU/1=.VO"XZ[CNJ:%FYW`LE
MW3K$:@D,MM;\L`Y+Q0`GSKAW6!GCU_UJ$:C&:]MZ>\R*QH8L0G0\5>DNJ>$Y
MU+-N^[KK`?1/`32&+AY@E=OC,CSM4;P_[>F.RY*#6U0(MW4V:!5,]`@V)2G*
MAF0?<=?$>=09&3I+4FP&W@*"LX]I!NGN:9<T!#;<]`3B#DGU[$Z',M(\'UW3
M)L#TJ3]?8*9?/-VU7X:-%##G0[G_@'-_#9X+O&";-_;$"XV$E<,NHE_&%TTF
MR.9)&'>7D?83">ON,1T@QK@T?9]&LT_='1TC0?Z4%YBD]^20/^X:=*--EF$[
MW/G4[1<5<M08FQ2L-=&2NR<D@F!A[XD0DD,WO40;5^3'[I4[>*'`DQU\X>Z%
MD]?Y`;AEY:,$(Z*H,<)=\KL+,7?M&]UJ<!!`NX.`I''-?:2\MF&Z<YW!@>,^
MY4"E86'6955DSFU'XOQ*DS!YK#*K(`<8#T6^?;;IWF:_.](Z25F%"8@("$L'
M1-"`0,!5U[MF<7^$A*=)@VAH,+4-Z$IM4]O+W&*AM'W:[O3<+0GXRSY/UM@)
MSMN^;WXXEGB";M,/2@?DR^*RU]ZZ=F'23SU$[2)$T!:"%Q_`=&Z"FN[%GYN.
MBIE1,3@_2+92^]?M%1P<(`6?'$"%F1S`C-!Z<D`L@2!.#8CP(&QJ@):230Y0
M$BK$J0%`E:>-%#*:!`JV-MA#I@;8[#HU@&HZJ<)H,3F)6,O).438P)MXKM4T
M!DI-+Z0T4(Q-/9=23#T74DTB"+$Q#:!DD_H9G5C"OQV$`OOBX'$C,0;A-W%W
M!EYUM)A#P=,>2(J59FVA_H[KB+S('+%T&F%=1E5.["/XJNQ:8!S)OC_!5^W&
M75:;O$!2['9,V$C/-Q`D')_L*(,#P_%M]BLLQMM^G<G36^Q7*5%GN$0]WU21
M.=MAZW(/>RNP.%\SU3_,L.12WE6F7Z&7>P:&8XQ'/.#U,WRM9=1?Z&M6(TQE
M5.457Z.BY_".M+"5Y*J]#K'>8[UB#Y8_UXWF&L.U\-9<=:/Y2J+AE&/F4(8R
M5RE^YD66^@)%S@['!LFK[2H/#]R[^AT8M*6YP,%R>U$&PP]&V(L'\&WE;L\X
M$N?PA'=ONXI1[!LT/.X;-%'<1D9?>,%,VGL$]G+`[BQUC(7)-:LNA0F'J.S,
M&@\3J>:FY*B]._.E88(:YZ7D2/K>2&0\P(J;#N`VU=13M?U7F,`I]S9<#X[9
M2O1@H@QO>7>>A->TSVKZ83'?.CR6CFV?^N;SET*$GS^6:H/YVVLHOH@[K^*P
M:8=;3)+:\G\T<*Y8<7%_4?U4QP,'V>3,P&EO5WUIX*#&F8'#?(](]7#2J+O)
MX^]8G5\VA*T&H:TV29%FD(L;M^E4IT%!G!R/L-';[D4G9'0=KAA_<1V8\M:/
MKH..V-QUT)&<LPY6X[QUT%'7"(-MWE][E*:[]]A>%]L_#^^`#4GD&+37[+FX
M-^C>H'%H8;>9"ZV(9D&+&F="*[H^FXA\BU'S5F.]`P;@.CFC$%[1>['ZAY*P
M4SP*H<*:;2:$E,Z!T&J<"2'UMSX9:^^37]Q#YNIA\$ZGZ.H>,EL)YX/9L#CN
MZS<1LY>'=JXYZA/<:!.U8Y\)P=L'^3:'T"Q.AW5[5'0"1MZ1T@8'-?GQM.\O
M<6(_T`T8<\!K$[W8]8."K)OHN`-B9V:>`RHM9CD@:ISG@$I+GQ[[8];NE#7!
M?OX::NZ.RMLKPHA[=],4UP$6]0?D0C,LNP2R$,:;-@XR%[-!YGH6R*AQ)LB\
MO]>KQ>"\2`SN]=K+"PY6=-Q#WEA'/E7U*2EL)3;8]_?)TXMN]F?8>!%N8'F=
MD:-P<^'ZE4`-7@J>^.^(D&O@W6[VSL%><?6B:\LG^V3W$9WLT]TS+:X,,/%D
MI^V>4W&YU09&_O37<K%<_!^"X_EW#0IE;F1S=')E86T-"@T*96YD;V)J#0H-
M"C0Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@-3`@,"!2(%T-"B]-961I84)O
M>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S;W5R8V5S
M(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V-"`P(%(-
M"B]&86)C-R`V-2`P(%(-"B]&86)C."`V-B`P(%(-"B]&86)C.2`V-R`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU
M,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(U
M-C,-"CX^#0IS=')E86T-"GB<S5I;C]LV%GXWX/_`IT5VX7@E7G1Y3-!)46P"
M9),!D@7Z0DNTAZTL.90TT^FOWW-(B=(DM@9-S>YB@+%LW@X/O_.="_7Z\WKU
M9;V*MDDN2(1_]BG;"N[^%<?U*K8M,:$)B1/["R4QR[=Y3C.211')64R,6J\^
MD=K.E7*!$XDLPP]B#NO5W7JU_P=.A7^S'Z(MYS`:/IA@\,%R2I^VYUQ@>\Y2
M;,^RA)V?D)*7-$I!H#@B5.1Q9D7:V_W9ML2W1=DD[NO;]>J?;^2N2&%/Y!;Z
M6S78*<>-)[#%+":W1Y0G9CPGM\5Z]1*EQ>>']>K%[9TBK:HJ71](VS7%KW=-
M52K3DJ-\)'O3'$FGCXITC?L\5:H\*-(8<C"R[HB$P45O=/=(=-TIH]H.'DC;
M'&TG656DV9,.%[F3T(K?BN9X;&JW&FD>:E62W2/Y.[G]9;VZ@5W]^QI;CRG)
M$SYN/8G3<>N<TMAM':0Z$EF7&Z*MB(^D5'O95W8'*/))F7UCCK(NU+`+;=Q^
M0>1F5^F#['13MQO7VZH&MSAU.DG3:>64V>SWRN!Z5M_G=1)`"3SUYY^ET_F#
ML5@EN%/X]J#[&E``0NJ6G$S3GE31]2V1>SAC\J#(G;Q79*]ARPB!_@2;/RK`
M`P[_:HR;Z4-?*<(I_SD2T0[^Q?C`\`'UU8`V0#<PC2[D#GK"^'O=ZC`J8=&H
MDC1-/"[88!$#7C\Z7./IO2HZ/*,X9VRV5[08A#@\E_B,@RK=VJYG+0ITH^NB
MZDLUQPN`!RRI!6PH-:FB[8M"M6T#PW00'6"CU0%-(T\+@D:#$KPQR_;\9L[B
M8_N=@B:7!<UR)^B+GRF/KCU],DU_;1T#]68(+H>SG&4>9P(<P3+URJIM+&6,
MR%@B4("'@TRA3=$?VP[I"B@)?G^XT\4=*63K`#?A#)KG;'5]>&4B]R:6Q).)
M)0/KG`.YA]R#!GK<.9E'_>Q4K?:ZT+*R'@-&`#.34V].3>N4\@U5`=&B#B^3
M[=?4%T`-G(YJ$)FW,A[GZ>"!_M_(]EON"Z`4*D:E9)Q[I7"1.:7\S]GV'/<%
M4`.,<6I@L=>"P)#%N^6_FFO3+`O)M7[Z`%R;IF.82R,VQ7J"I<]Q+="$K!_)
MSC2_*G-EP6C*O60YW?(H@N??09R75U\HFZD@SL44UB31X&Y*)2O<,5K1`2P*
M3.1.`LB-`L3?-]4]T`N&[H.6%B@3:17XN51@F24:VBX$>:;"A>]N*X!)RJZ]
M2.87`:5%&74K67-[`/X#;5UYQ4R<V1:_\B)Y[!>YNJGE?*8R.MF9@]B#!I)R
MN=-1R=IR]MEH&CH535T#D:'7P6'(P?`/(-INR4^U^ZKN`:<;:Y\(0-VBDVI!
MXD+I>Y<VVGY!C!=S@W&O08T7L<Y23U_1W':32[8[\A8XA+T&+^BT#M8*'9])
MN2%J*NX@*+3ZLTGP.8/V5H"G.-=^D(`QI6-.1I-8>'>8#NZPU&W1]+COT1=^
M#:GM]PJUY`^C**@_'*</X`^3C'EGD$V`$OE0^_BD+/$;]:77QIWY"4"`]9H]
M9@4(+_7;2=4874,<I4L?<.*H`T1>QA8_EK&V)9^&\%4>(.(J7516JF.M]Q9[
M`:"4)#[MBKF'$DM&DCH?!ARDKB'D*Y3IX(E43=MBFE144A_ALY1',#RGETK+
MG:XL\C9#C(GSS7Z^C-(KHRCAS._WNV&T8`$)3T):@)\^A`70W#.*#P@%BYZK
M>SJTEI`0`5S[(4BRU4';4C<=439!P&@)X(PD;,&-60H`PAX]9N$("L?8!E*.
M@VMWO@['!`!^/&:;43I5^N@0`<^C&I0JB,^,6>3%".LS&9_M-^;)++M^ZC*!
MK*3Q*>/,/6(M]RQI;>"0#=%X]'#,<%ADICM47=$T.*.TKM'ID<C"?@M2K!.Y
MF,A\EMSD0W3P=2@E,2K`PDCI]WLA%(```+%XQA`@"-MC[0&]!&!>[[6+%RYT
M'W*)(+@6:>9C]-RGRDSD0W!PE'`N6!F:&1H8:PM1C*J?&NN@GB#89S-1@V*?
M`7-..HG29-()CY^@WQ;)YK"_!'B]]Z'`!D_=EN"PXG2^X!3@C!.?OXNI'!WG
M`UO/RAZ(R^X2>?>VU/FT)(8ZL*A]-C+>.)X?ZX]MO_L%IABCGMF4`?;/?1X:
MBVP*6L:B6*DJR'C,XWA,SIF<3:X"%(8$Y2'#`#]]@#!`1/[^*V.SRQZ63'&`
MK#M][2.-N%\ZK".$`;,]QC,R2+-\),A:G_K*Q>NFKQSR/ZC#^-N[\P'KS6^0
M)P*ASB[`N,T5L7;\B'9A\W5L:GKSU+-@H'Q],^&YO[K#6Y31XP\5+O3!]T[T
MYC))!+`/G@9-%/WT`2)\+L**+OZ,Z,F"$Q2"@!4[`XNW$!<Y`P.'B+9G\?#V
MYL=7;\F[5[>W-Q\^!E!='/1JTD\?@!59[G/DC$ZLR/E$BO>RTB6^U_&-R_S&
MUNV;#9@MG;W&&MWI2;8VI3K!./3)T`3QY(^0.=4[90[DUD@@GL.&O-^^VFX"
MD`=+<Q\S<<\>;+SW?Z?E46_(FZHQNI0;W*F[0(4$0'9=8VJ(#8`;#;C>ZG%V
M(PE?FH>Z'=\:D8<#YAR=`FZFFT@D"ZH+4;5BP]UK(%CZZ4.(SL**SOZ,Z$MD
M!,AB=$A[&7C[.'/>_N;S^YL/MP&XAT4TJ*;&Z0-P#\U\-DOSZ8VT-)]59B"C
M;1O@'["B$O*06M;VZK_MX`<?^O[P*$M=D)\PP:MM(".K#7PMMAB@*&F&A/QR
MOVMOCL9^=]Q?[]"KKR)F.HQ8[JF,VK=9;(V3O*KK'C3V09T:TQ&\_W_3F"-0
MTK5O21+JI0D:Z*9),BW$MX(C7G"A?WU\;=]LN+[#H(DO/-#8O\7"LGBH)(_9
M]2-@C2AP?B7Y017J".X,DO0-H5$D7-705B)D#_[455%N#!:;_T;^T_2`T;=O
MW^,EEZV,GW`>2+5=C=VZU5._JP"_LK!7(`CJO3;'C7L]H4-?VMV%*3Q1X:^4
MTTA,R9.@_@U*;6!6BS%;+6OJ\:V+TOV@ZXW-!>#7QD`_:]&N`15A%(8.=:&V
MY"/>Y#UO^.Z^^NQD`13`?%J>15/EC45#4=6+C_HWD*/;=T5MB&,O)IUJ-N0`
MR7L]7M+)OKMKS!!:V6YXGGB<>.-B.AM)S$[;7O4A=N!+@.2%QD&3>S]]@'@A
MSH.*[J=_*CKJC&9`""EDH]3..@VW[W9C!^2JI0XQY<L=(AKG2QT@&\<[RH4.
M&1;_ESJD%._S%SHD#*QCJ8/`E\J7.D".MJBHF#&6+7:@[!DA8YXL+Q'Q;'$7
M.?J2A?:,IXL+I'Q9"0E?/DF109:\U$XA75MH!SY:5"&C8E&#E*:+ZR/2EA6<
M7E[_RP`4MP-PG7\HLH9X`L:,>9MS02]H\K4]QGP1Z"_390"\C&.ZJ$'HD%U6
M(<AP\WF]6J_^"PG[+VP-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-3$@,"!O
M8FH-"CP\#0HO0V]N=&5N=',@6R`U,B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P
M(#8Q,B`W.3(@70T*+U!A<F5N="`U."`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$P(#8X(#`@4@T*+T9A8F,V(#8T(#`@4@T*+T9A8F,W
M(#8U(#`@4@T*+T9A8F,X(#8V(#`@4@T*+T9A8F,Y(#8W(#`@4@T*/CX-"B]0
M<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G
M94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C4R(#`@;V)J
M#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S(P-PT*/CX-
M"G-T<F5A;0T*>)R]6TESVT86OJM*_Z&/GBF:@UZP34ZR+,TH*4N)Q%22JEQ`
ML&EB`@(T%LO,KY_W>@,DD5!,`RE5210`]MN_MW3CW:_G9Y_.S[QY$/O$PQ_U
M*9K[0O]*M^=G5-VAA`6$!NH*(U1X\SAF$8D\C\3<(Y4\/_N%%&JM4/BXD!]%
M^(=4'\_/-N=GZW_B4OC3N^#-A>!`8"ZXS^$/CQE[>C\6/MZ/>8CWHRC@AQ=D
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MI021ZIU,&[B,`I5M0])-4GT$;35*NEV[S+,4N%I+4%,*4I;EEI1K*_J,/&ZR
M=$.RFN1EFN!"\$VP";DF#TTE93,CM_.K^8S\DM2;K/C8E,5L"C6@O%H-@!=6
M"R+22G@_!QLQSQ?QG/Q6MDKX<MDD64'2<I?)&B5*\IR4%1AK3W;@(5;(KW6,
M=04*.JJZ&6EW\!#>GT`)OF<CH:\%1%"EAEVR1\ZM9+M*UFF5+<%F:RGK%ZKI
M2V5X+G>R,A?6`_X!+I:".L'<UD^45XP=_)!CK,B`IT(!`>#IF[>C$XK[A+A"
M:R0$:6MD4B$-_QZ90D;[A%@H#"$PUMBD!/^;9!(]Y85SR+5<$<(@\$)?!X''
MN:<!>X(`Y-P&()0@72IB7-/&0-A":&%X`7Z01[FLLT:![>/CX[R6Z?QC^1EB
M!BZDI7GL:P&HDA^3:H6Q!Y^RNJD2?#;/_I"(^VIME0\G$!^+`(,_HLM%01!H
M\64.J:8JBPS!8?\LA2+XI$EA,]))V*M0"E*1T6N':$E>ER`U?*G_^/@:B``I
MC`;\OOVU_,D2$RP8`4Q0MI5E\]_*^._WR2I+1V:)4>IXFC3T&/5[PC/.`R=]
M;"/O/U79[N9IN=7AAPZN;`FII*<-DE22%&732\)@47``Y1:M,3T\?P-?KPK9
MD&2U@DQ68PV2%6G>KB2:>0KK1LQ:-W;N+2)F2JT7C"*OP$F2-MEG21KYI8$"
MM)<KRR+?ST_E<Z">CP(V93GOEI^@FH^@Z;,(*EP$\4@P5\QODL_2E+*)@S@5
MSPX?$`BN(<S)P\@<<AH[%B>-)PXIHZ<+]='XFT^-+CAI2J,`P,$^FJJ_-13R
MTD47A-U6J:A,_X!KZ(*J%7CFM">[XU#8L,CB`J4=+H34I(7%L[C),#5VT9\T
M1ZP\)Q<U5NWEHQ4%,D:;:YE=?_(\*E<E/(#X8A*LKOOU%R9.#M0UJA'KLH-@
M1@][DP%-GE)F.^;?E>)7?MEDRPP@%!Q!Y\O#>K*YU13V"78]^Z[!.4C"]3'C
M*R*,A:L3<`9B^Q3\;,LDTW]:;,_1R2'@ER4$/TCON!N_7&50KE@.-7.`HXR-
M327T>GI@-';]6J@^HQYZA<S(*,Y9)^/),#Z0@<)03)F!W/(39*#0MY,$)B+G
MG#[U8FT4C*5Z4[;Y"I:&*A:3N&V/^_AAX$77(L]!R,X9NBMUN]OE)EQMDD.4
M2MIF4U;9G^C\Q;XL(.CS>I*@%'9XP%@7E$(AE:IN2F3W<[:2!(%*I9M5IA()
MH$5/<EW=K60.14^U/U3!60B>D;982:V*-*O2=@OP`X41%/Q;F10:^['(1WUH
MT%Y*J?!KDQ0?)]$"XTX+0=3EJB"RXS0%R\EZG6056"W#.@Y-OP+</"#KG-PT
MNOMP>>>):$]<YH"CP']I6578$"5K3//J`21VBNP#T^F04B?\DQG'Z-B#(PY+
M:1+L\?BDV.--QWH03<JZ6_XDUH>V-B"=J"Y?.T_H,]\.7B#!F_;OYO;R[O['
MNWNUB4'NKLGEU?WBXN:6O+^[_/G#U>WB@;S[C=Q?75_=7]U>7DV@71%,JEV[
M_`1)*6"VM?8B3EW%%/NNA#935JR&:S7G*4='QS!P?`2N+N)C4X$>NY.6^D'<
MC5&"V((P8.*NK!!RH>YW#?7HS1X[(+`8G4KDJ(SN.IS1ON_@5JO;&V$FI:6R
M4EV!:13U1#_?C\R)X)V8DW;.T$_U1&9>1+M:QC<BZ^G!JH2*0TV@7B9>NZ^%
MR=H,31^EZJ'&KSD"ZL9*S/>[F8=A=I75:5Y"S9=M<1J:/*VV,-"Q'K-Q4.'@
M%R_`]:30(U(KJ)F:U!*::XB=%R/8Q8MZQ,79ZDF@3:`$/[;##N93VI7=-N2Q
M#BIJJ#YQ;G%D-(@2/"N?.@GJIQ*HFLTY@&DOEQ+@<XJ)G!_Z4Z8>M_P4K/-)
MSP:XY:=@W9P,F(IUN_P$K(M@T@;:+3\%ZRR<E'6[_`2LX^F@"5EWRT]0(7+?
M[KUY?K?UQ*FM$"_RO(=W.A'LVJIN,9]`KG@`P`3,KX'([Y[O)?"+SLP_J?E'
MX-R"^GAIA9?<G%6F;94U>([BZHMIS2]2A=`TYF*F=D*`,&[,X)=U:GV4&HY5
MIJHG2"F<VRJ`A_A<JO9H1D]>O*,T75D,*-F)XT5=4<,Y?D8+]U4_MC+I(1G'
MKH0I[83$$43@Z2[RC7:_T1VDKU(:!=T.BPA-U6%'+D?'.VHS<E=E965'\/"%
M;5;TSLADM=YNP;JLWN!FPQ*G8W(+P0#?46>PCI59D^QB<L9<I15WE1:SQ?$A
M$36CR=$]63>.5WJ"#WNUC:M@9HIZBGN3[G"ZY2<`:A:Y0I?V?"Z,S.;'1=$[
MZ#`X19XA'*OM'%?@#[K2BZ\?=L=MN<K6&?P[ONNID:I&9*]+4KX[(`+RU.U.
M5K7$5`&-"*:H'?0^]2&G,Q$GO^`Q`MVC)7]9=4?'[U:I<'\"!?C4&3_J'2&@
M)O9TOU:WRUI^:H$9:-&>]JK=<4LU5'YB[P/C8V-+M>%0R5V>I!)EA17ZNZC%
MDZ,UL.R4+L#=GI<?]/N\^)`+:`_5@W_CI3,P>"IW#=8,?5:??'&&SH$-8Y,U
M;3.`7%.`D]H^F0Z<W/)/65>Z#07NKL+*:M7NZ^J0.S[`<((]\`##*=_0`Y3Z
MWN`#'A-\Z`$:8Z89>B!BS!]\(&1"##X0L&B02>JS8%!15+`@'GR`\U>89'@"
M<.@!*NBP%)[@@U+$>+!LX'[$A[40\F%3!B&4ED/W&;1B`_=]4,'0?4&C015R
MY@W29]&P$9GG#=O0"X\[XB<M@@\F0H\[$*40P`.G:^&KND^%0C8RAU[X/+!'
M''YG04A>8`_4`(HBI(.#)`>@57W59E=/=.=L6&S/V=RU%6`]O@1![M7!2G=,
MBKZ`J6_@A(G(L3(\Z?T6(CYS1'"7255L1F!W?N*'AW>JB,`J82^3BN@6]+U,
MY78)>99#5P%.XG]W`F/'`!IRN6/L9?F(+J6V/T]S*>:=Y%)(\4278K9>\6BW
M[\0"3CN7^LF]3Z.]JG[%K4[DA@4=.Z^[U<E$(D=$;5Z&;OL)<Z<6^J>>6W4O
M$T'ID96KVOC8AZ2"(LLX6#`CW[>%A+9"_ZM:J@>H88P;FLL'W?`508YNL@.T
M6T$.NJ'`W'":&PJSC?R5;J@HGN:&HGO)B8>N9V*1/5F,;KB2ZZS(U$G;']5I
M\0?7":Q4>7P!?7H.2</8H)(Y=.GXAHIN(XQA%#RJ4Y*;,E]!.3FB)+B9:449
M.%GV+11"[BB\-/LW+1STK1`P;84W6RE1B=^=0NN8[^+BQX5`W\4*\T3?-9OT
M7^N[2/%$WQ7NS33>'?)CD4U2Z+N7YB7$YP`:C<@*IF7+RZOX>3(1GSDBB)]X
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MG*'[S#\^FP`*5[^>GYV?_1]_YO*[#0IE;F1S=')E86T-"@T*96YD;V)J#0H-
M"C4S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@-30@,"!2(%T-"B]-961I84)O
M>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-3@@,"!2#0HO4F5S;W5R8V5S
M(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`V."`P(%(-"B]&86)C-B`V-"`P(%(-
M"B]&86)C-R`V-2`P(%(-"B]&86)C."`V-B`P(%(-"B]&86)C.2`V-R`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU
M-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#<Y
M-0T*/CX-"G-T<F5A;0T*>)RU5TMOVS`,OAOP?^`Q&]I,U%N[K6@+=*<]`FP#
M>G$=I_'@6*GC-,A^_2@[2=NAT8#"@0-+,BGRXR>14BY^ILE#FK"Q=@I8>+J>
M'2O9O_)%FF`G0>`:4'=?.!BNQLYQ"Y8Q$%)!4Z3)#Z@[6X;&U"AK0P/-?9K,
MTV3V/I@*S[,/;"RE(`=C*92@1CC.7\J=5$'NA`ER:[5XW2"'<XX&+#+@RJ'M
M$,VZ\(*('43,/H&]F*3)A^OL+C>``B:DWI'0&=R'K>G%T,%D$>!PQJB;I\DY
M8=9ATB9-1K_\&A;9E@P_K(M5"QGD?KD%/X-V7JP*F/I\O2CJ=G4&FWF9SV%3
M5A7<%;!L_&,Y+:;0>MB2D:R%VM/D57L&=UO8-&5;UO?@&VB+JEC.?1V&ZQ7]
M0H>LP\Q7E=^$T3N8_$Z3*XKIZP!Q(Z>X&=_%S8S6^[A5UP]QY[YNL[R%LI[Y
M9I&UI:\_OA&&/@[#V1[%Z)9+-K!U_61]8/X$[52GU9X_&ZCL^1,B]`-_E]ML
M6N9P4[=%4W?T9=49#?/QP%@HE9VT>RR"<GR'A=O0#UA0L@"DR7*?K=JL@B^^
M)%QPV92/Q;!P)$UUE/8!CC-C(06MSY\.#VIA>CS?UR5YETP.3(51X%#N?2O.
MY9/O/1>?UTMRWIS!=>6;<IJ!$-*8H==$@'7F4%>4/=05%?H!QZ>VI:K19=5-
M_4B5A0K!MZ+J=LIJ8#B.X%C6\\+'@E,1W_'"&-OQ<LL44QJI03!2#+PK:`,^
M0R`9PP[!Z'QH/_)%I,R8WH\5XHTA'2LO4MN#J[?6ETAAM)*=L#`>K)\`.#LI
M<'8RX,:>$KAY?:N07RZU(>^.+'=6GZ9WMZ"@@%)'%02RN`*G,RJJ@$AWL)@"
M0[KR1130H5)1!8M&1A4,QRA(U.BB1*%"YZ(*DO\'I!`\[H(+&8\"A8Y'P<A'
M3(%.SZ@!R^-K:0QB5([*Q.2:SLJ87"%&.90HHOZ%B:\B=R+JGZ[I\9W(S''Y
M0T^![!&@>B6/=>QR0\S+_;VOOVB-N/TWHXV(YI(VQ_DG`U?TQRU-_@*)F\G'
M#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C4U(#`@;V)J#0H\/`T*+T-O;G1E
M;G1S(%L@-38@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]0
M87)E;G0@-3@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q
M,"`V."`P(%(-"B]&86)C-B`V-"`P(%(-"B]&86)C-R`V-2`P(%(-"B]&86)C
M."`V-B`P(%(-"B]&86)C.2`V-R`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-
M"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP
M92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU-B`P(&]B:@T*/#P-"B]&:6QT97(@
M+T9L871E1&5C;V1E#0HO3&5N9W1H(#$R-#0-"CX^#0IS=')E86T-"GB<M5C;
M;MLX$'TWX'^8Q^XBJY(4+^)CFF:!+!9IM_&B+;`OBDS':F4IE>0-W*_O#"7;
M21,S=6S!021[AH<S9RZ\O/DT'GT;CUBDK0)&'_^61$IV_[+%>,2]A(/0P+7_
M10"/362M2"!A#&P<0^W&HX]0>BPC%0&I)*$'U#?CT7P\FOU.4/2Y]P.+I(QQ
M@DC&*L9';(5X*+=2D=S&AN1)HN.G`=$F,H<S$,KRQ!LT\]Z1M1L)2[:FOIF,
M1Z__3*\S0XY-4-M3X.'63G,!UEJ8H->OX#>8?!F/SG'8/[^.'`>0M?#(%LG4
M"8?)]_'H#Q;Q1,+D#B?\*RV7:;T"GIR`8,R\:/Z09ZR;_]5_0K)C@R?)8.!Z
M"_ZRF(3,ED.:+0<S6PQIMGBYV=@T[`YDH;GO'P2-:<]BK.U)1D4OJ,Q]";S]
M?/KVX@PN+B?G'RY/)Q?O+D__/L&O9]&Q&33&#L?@!OSH@3=J2+/5(&9+IL#P
MP>P6H.V`I.C#UH.0V4.FH#X@!?7N92QF%G2_CF$-2\J8S->SL/1.1:Q.5,)/
M)"YK5_.T=@U4,SBK%HNJA*NVRKX>G<<A>[@>K(?K(7NX/J"'/U/*>LAMA!IR
M&Z&>WD;@M$(Q;L!81/:HV^%^VXD*4EH>5(AIYQI2$%*HH`)7N)$-*3"%6^^`
M`K<*U]>00J*P#X<4C%)!([E6<9`HKI24006IGS$RUCH\A=!)V`MN6-@+IDUP
M"JO#-"0Z',N$*1V2&X5%%)!KQ8,D*B0Q))?2!.>7/!S%6"3!^06=WX)!%F$Y
M,\%4YTSLYN=;YP(N-P*MP,?>38;%.YK,5ETIXZ>@\Z]6_K7H7W$?6_0*W>M\
M8]=:+BS.8O8SC,:J8&\]"-QNP1^O"<\AAW8$F.DR4=W)5D=*;P^V,?5;VA&\
MAP_P#J[@/9S#&4S@7[@ZKG,T5@W'W`;\$7/K-!%2[9V)-'9W*O99+IG/<KY_
MEDOLPV%&"-N*O;&[L0%P3PJ!(RG[@G=C=X%O]1-&JU5,]<F[MV*]@M%;)U8/
MJ[,74U_AV+_W)91Z8BA6+\?66^Q'&?8L<*`VR6A<2_M+)\6QZ5)MQI'`TW=7
MFA\=S-/_'915"^FRG5=U_MU-(2U7,'5IX>H3:/#1W+JZP0U\54/5SET-_?>V
M@IL<AZ^J)=S5>=NZ$O)R5M6+M,U)WRNW\Q15YWD#MW6%4%F[;`@*1R_2K^[H
M/JO-+0-GN)#WMPQKEVMWBZ<25[;>Q`;2IC,$C:\;3T2#(B0A?V1T!)_1T<6R
M:;U>[8H5H)?+\AYU]]R/8/*3TWDW`=)1S6;.,]"XHC@Z`W&\N6=)I.D9T'Q]
M1,.H-`YGSI88L]SY8%3+&IJJR+.\[6,WH[#66TNOERLDY,$XI(A2Y0M^;Z9Y
MYL?=8<@=Q;R%NVI93+W'UXY29D$9,J79"G>3%A%<NKS/D.-G`=5;E_D&=SN4
M^"Q2EI8JHF#J"DS<>D5N_IR:)1I(;GF1ZPH`$V2*M8*N+<LI6IS.VM[N*2;+
M4RC-/,7(9K4C.48\7]PBNQVWGAT:?+]8CDP`[V\NB`!-"=$OR\;TMVU9A360
MEQ@0<BLOUUF0SF9ICJ6P:0P9UN\-JC5YF;FMSS2JFCVZFCND%<9V:_<+>F&X
M@?/0A<N!#9P_?=^"?^>?QJ/QZ`=NX%>6#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"C4W(#`@;V)J#0H\/`T*+U1Y<&4@+T]U=&QI;F5S#0H^/@T*96YD;V)J
M#0H-"C4X(#`@;V)J#0H\/`T*+T-O=6YT(#(Y#0HO2VED<R!;(#8S(#`@4@T*
M,2`P(%(-"C,@,"!2#0HU(#`@4@T*-R`P(%(-"CD@,"!2#0HQ,2`P(%(-"C$S
M(#`@4@T*,34@,"!2#0HQ-R`P(%(-"C$Y(#`@4@T*,C$@,"!2#0HR,R`P(%(-
M"C(U(#`@4@T*,C<@,"!2#0HR.2`P(%(-"C,Q(#`@4@T*,S,@,"!2#0HS-2`P
M(%(-"C,W(#`@4@T*,SD@,"!2#0HT,2`P(%(-"C0S(#`@4@T*-#4@,"!2#0HT
M-R`P(%(-"C0Y(#`@4@T*-3$@,"!2#0HU,R`P(%(-"C4U(#`@4B!=#0HO5'EP
M92`O4&%G97,-"CX^#0IE;F1O8FH-"@T*-3D@,"!O8FH-"B]$979I8V521T(-
M"F5N9&]B:@T*#0IX<F5F#0HP(#8P#0HP,#`P,#`P,#`P(#8U-3,U(&8-"C`P
M,#`P,C4Y,C8@,#`P,#`@;@T*,#`P,#`R-C$Y,B`P,#`P,"!N#0HP,#`P,#(W
M-C(R(#`P,#`P(&X-"C`P,#`P,C<X.#@@,#`P,#`@;@T*,#`P,#`S,C,X-"`P
M,#`P,"!N#0HP,#`P,#,R-C4P(#`P,#`P(&X-"C`P,#`P,S8Y.#(@,#`P,#`@
M;@T*,#`P,#`S-S(T."`P,#`P,"!N#0HP,#`P,#0P-3`X(#`P,#`P(&X-"C`P
M,#`P-#`W-S4@,#`P,#`@;@T*,#`P,#`T,SDW,R`P,#`P,"!N#0HP,#`P,#0T
M,C0Q(#`P,#`P(&X-"C`P,#`P-#<V,S$@,#`P,#`@;@T*,#`P,#`T-S@Y.2`P
M,#`P,"!N#0HP,#`P,#4Q-S`W(#`P,#`P(&X-"C`P,#`P-3$Y-S4@,#`P,#`@
M;@T*,#`P,#`U-3(X,R`P,#`P,"!N#0HP,#`P,#4U-34Q(#`P,#`P(&X-"C`P
M,#`P-3DP.#(@,#`P,#`@;@T*,#`P,#`U.3,U,"`P,#`P,"!N#0HP,#`P,#8R
M-34U(#`P,#`P(&X-"C`P,#`P-C(X,C,@,#`P,#`@;@T*,#`P,#`V-C,Q."`P
M,#`P,"!N#0HP,#`P,#8V-3@V(#`P,#`P(&X-"C`P,#`P-S`P,3$@,#`P,#`@
M;@T*,#`P,#`W,#(W.2`P,#`P,"!N#0HP,#`P,#<S-S8T(#`P,#`P(&X-"C`P
M,#`P-S0P,S(@,#`P,#`@;@T*,#`P,#`W-S<Q-"`P,#`P,"!N#0HP,#`P,#<W
M.3@R(#`P,#`P(&X-"C`P,#`P.#$P-S4@,#`P,#`@;@T*,#`P,#`X,3,T,R`P
M,#`P,"!N#0HP,#`P,#@T-S@W(#`P,#`P(&X-"C`P,#`P.#4P-34@,#`P,#`@
M;@T*,#`P,#`X.#4S.2`P,#`P,"!N#0HP,#`P,#@X.#`W(#`P,#`P(&X-"C`P
M,#`P.3`X,SD@,#`P,#`@;@T*,#`P,#`Y,3$P-R`P,#`P,"!N#0HP,#`P,#DS
M-3,P(#`P,#`P(&X-"C`P,#`P.3,W.3@@,#`P,#`@;@T*,#`P,#`Y-C,W,R`P
M,#`P,"!N#0HP,#`P,#DV-C0Q(#`P,#`P(&X-"C`P,#`Q,#,T-#D@,#`P,#`@
M;@T*,#`P,#$P,S<Q-R`P,#`P,"!N#0HP,#`P,3`V,S,W(#`P,#`P(&X-"C`P
M,#`Q,#8V,#4@,#`P,#`@;@T*,#`P,#$P-S@P-B`P,#`P,"!N#0HP,#`P,3`X
M,#<T(#`P,#`P(&X-"C`P,#`Q,3`X,S8@,#`P,#`@;@T*,#`P,#$Q,3$P-"`P
M,#`P,"!N#0HP,#`P,3$S-S4T(#`P,#`P(&X-"C`P,#`Q,30P,C(@,#`P,#`@
M;@T*,#`P,#$Q-S,Q-B`P,#`P,"!N#0HP,#`P,3$W-3@T(#`P,#`P(&X-"C`P
M,#`Q,3@T-C4@,#`P,#`@;@T*,#`P,#$Q.#<S,R`P,#`P,"!N#0HP,#`P,3(P
M,#8T(#`P,#`P(&X-"C`P,#`Q,C`Q,#D@,#`P,#`@;@T*,#`P,#$R,#,Y.2`P
M,#`P,"!N#0IT<F%I;&5R#0H\/`T*+U-I>F4@-C`-"CX^#0IS=&%R='AR968-
- -"C$X-`T*)25%3T8-"C\_
`
end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dyadiclogo1.jpg
<DESCRIPTION>DYADIC LOGO12
<TEXT>
begin 644 dyadiclogo1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"C`,(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**S-1\1:'
MI%PMOJ>LZ=93,N]8[FZ2-BN2,@,0<9!Y]C5^">&ZMX[BWE26&50\<D;!E=2,
M@@C@@CO5.,DKM`24445(!7D7Q3^*>N>!_$]MIFF6NG2PRV:W#-<QNS;B[K@;
M7`QA1V]:]=KYJ_:%_P"1^L?^P7'_`.C9:]'*Z4*N(49JZLR)NRT#_AH7Q9_T
M#M%_[\R__'*T]&_:)U%+C;KFB6LT+,HWV+-&T:Y^8[7+!SC&!E>G7GCTKP?X
M/\,77@G0+BX\.:1+-+IUN\DDEC$S.QC4DDE<DD]ZY;XH_"71)]`O=<T.W@TR
M]LHGN)8X@5AFC1<D;!PC`+D%0`3G/7<.Z-;+YU/92IVZ7)M)*]SU;2]4LM:T
MRWU'3KE+FSN%WQRIT(_F"#D$'D$$'D5X]\0OBMXO\$^+9]*6RTB6U95GM99(
M9-SQ-G&<2]00R]L[<X`(K-_9WU^X&H:IX=9=ULT7VZ,Y`V."J-VR=P9._&SI
MR:[OXP>"7\7^%1/9C.I:9OG@4*S&5-OSQJ!_$VU2.#RH'&2:YH4:6%QGLJRO
M%]_/9_HQW<HW1V'A_7;+Q-H-IK&G,YM;I2R>8NUE()5E(]001QD<<$CFCQ!K
MMEX9T&[UC46<6MJH9_+7<S$D*J@>I)`YP.>2!S7AG[/_`(K^R:M=>%[AOW5[
MFXM>.DJK\XX'\2+G)(`\OCEJ/V@/%?VO5K7PO;M^ZLL7%UQUE9?D'(_A1LY!
M(/F<\K1_9K^N^P^SO\OZT]1\_NW-KX>_%;Q?XV\6P:4UEI$5JJM/=2QPR;DB
M7&<9EZDE5[XW9P0#7ME>>?!_P2_A#PJ9[P8U+4]D\ZE64Q)M^2-@?XEW,3P.
M6(YP#7>7U[;Z;I]S?7<GEVUM$TTKX)VHH))P.3P#TKFQTJ4J[C05DM-.HXWM
MJ>1?$OXP:IX1\6G1]&@TZX2&!&N/M,,A9)6RVT$,H(V%#QGJ>>P[?X<>+G\:
M^#H=4N/(6]662&YC@1E1'!R`-Q.?D*'J>OX#YCM[?5OB'XLU&Y99YKV>*XO9
M!#$\NW9&S*@&20I(2->3C<HYX![S]G_Q(]EXFNO#\T^+:_B,L,;;C^_09.W'
M"Y3<22.=BC/`!];%Y?3AA;07OQ2;_7^O(B,WS'T;7A_Q`^,GB'PIXWU'1;&S
MTN2VMO+V-/%(7.Z-7.2'`ZL>U>X5\F?&;_DK&M_]L/\`T1'7#E%&G6KN-175
MOU151M+0WO\`AH7Q9_T#M%_[\R__`!RM[PW^T*\EW#;^)-*@CBDEP]Y9LP$2
M$<$QG<6P>I#=#P"1@^L_\(1X3_Z%?1?_``7Q?_$UY%\8/A9I6E:--XGT)$LD
M@8?:[0$['WN`&C'\)!8#;PN.F,8;II5<OQ$E2=/EOL_,EJ2UN>[P3PW5O'<6
M\J2PRJ'CDC8,KJ1D$$<$$=Z\3^('QD\0^%/&^HZ+8V>ER6UMY>QIXI"YW1JY
MR0X'5CVJ_P#L^:_<7_AG4-%F7,>F2JT+Y'W)2Q*X`[,K'))^_CC`KRWXS?\`
M)6-;_P"V'_HB.IP."A'&3HU5=)?Y6_!CE+W;H^LZ\X^(_P`6;+P2XTZRA2_U
MAE):(OA+<$?*9,<DDX.P8)'.5RN>\U748=(TB]U.X5VALX)+B18P"Q5%+$#)
M`S@>M?*_P[\/?\+$^(K_`-L2>;$?,O[[#>6TWS#(&T<9=USC'&<$'%<N7X:G
M44JU;X8_B.;:T1)/\:O'LMQ)(FLI"CL66*.TA*H"?NC<I.!TY)/J37?^`_CM
M]MN[?2_%<<$#/\BZE&=B;L`#S%Z+D[B7!`&1\H&2/98=*TZWTPZ9!86L5@59
M#:I"JQ%6SN&P#&#DY&.<FO`/B9\([U?%ML_A'27EM=15W:"+B.WE7EN2`L:$
M$%06Z[@,#`KMI5\%BFZ4J:AV>G_`_4EJ4=;G8SP:K<:[C3)=434$EU.6Y6,W
M"QRR+<;K5'8,(DD,(PK2AUV>6&1E*"NX\*S+<2Z[/;AQ92:COM@R,@`,$)DP
MI`VGSO-W#`(??GYLU3T+PNE_X9TD^,M'TN^UN&U6&:6:%;AL`G:"[Y);!RV#
MC<6(X-=3!!#:V\=O;Q)%#$H2..-0JHH&``!P`!VKS,16BUR+II^/]6\BTB2B
MBBN,H*^:OVA?^1^L?^P7'_Z-EKZ5KYJ_:%_Y'ZQ_[!<?_HV6O5R;_>EZ,BI\
M)[OX(_Y$'PY_V"[;_P!%+6]6#X(_Y$'PY_V"[;_T4M:>JZC#I&D7NIW"NT-G
M!)<2+&`6*HI8@9(&<#UKSZJ;JR2[E+8^5_@S_P`E8T3_`+;_`/HB2OK.OECX
M':=->_$ZTN(V0)8P37$@8G)4H8\#CKF1>N.`:^IZ]3/&GB5Z+\V13V/E3XF^
M';CP#\15OM,7R+::47]@ZQC;$X;)0#:%^5QPHSA2F>M'PR\.W'C[XBM?:FOG
MVT,IO[]VC&V5RV0A&TK\SGE3C*A\=*]._:&@A;P3IUPT2&9-15$D*C<JM'(6
M`/4`E5R.^T>E'[/,$*^"=1N%B03/J+(\@4;F58XRH)ZD`LV!VW'UKL^N2_L_
MVOVOAO\`U_5R>7W['KM>:_''Q!_8_P`/Y+**7;<ZG*MNH6;8XC'S.0.K+@!"
M.G[SGT/I5?,_Q\UUM1\<1:2K/Y.EP*I5E4#S9`'9@1R05\L<]U.!W/E971]K
MB8WV6OW?\$N;LCI?V=M"46^K^(9%0NS"QA(9MR@`/)D=,',6#R?E/3OYQK,;
M_#GXMSFT7$>FWZSQ10S,,P-AQ&7//,;!6SGJ>O>_X9^,GB'PIX>M=%L;/2Y+
M:VW[&GBD+G<Y<Y(<#JQ[5SOC+QEJ/CC5XM3U.&UBFB@%NJVRLJ[0S-D[F)SE
MCW]*^@I4*_UJI.HO<EIO]W]>9DVN56/LF">&ZMX[BWE26&50\<D;!E=2,@@C
M@@CO7RA\9O\`DK&M_P#;#_T1'7NGP9UUM<^&]DLK.TVGLUB[,JJ"$P4QCJ!&
MR#)YR#UZGPOXS?\`)6-;_P"V'_HB.O-RFDZ6,G3?1/\`-%S=XIGUG6#XW_Y$
M'Q'_`-@NY_\`135O5RWQ)U&'2_AOX@N)U=D>S>W`0`G=+^[4\D<9<9]L]:\:
M@FZL4NZ-'L>)_L]?\C]??]@N3_T;%6#\9O\`DK&M_P#;#_T1'74_L[:=-+XG
MU?4U9/)M[,6[J2=Q:1PRD<8QB)L\]Q^'+?&;_DK&M_\`;#_T1'7U--IYG/\`
MP_Y&+^`][^,$\UO\*M<>"5XG*Q(61BI*M,BL..Q!(([@D5P'[-__`#,W_;K_
M`.UJ]'^*FG3:I\,=>MX&172`7!+D@;8G61AP#SA#CWQTKRW]G/488M7UW3&5
M_.N((KA&`&T+&S*P/.<YE7''8_CY6'URRJEO?_(M_&CZ"HHKEO%'Q"\/^#]3
ML+'6+EXGO%=]\:;Q"J]"ZCY@&.0"%.2#TP:\FG3G4ERP5V:-V.IHJII>J66M
M:9;ZCIURES9W"[XY4Z$?S!!R"#R""#R*MU+33LP"BBBD`5\U?M"_\C]8_P#8
M+C_]&RU]*UR?B?P9X.\1:E'=^(;6&6[2$1(SW;Q'8"Q`PK@=2W-=N`Q,,-6]
MI/;R)E%R5D>2Z'\?O[&T#3M+_P"$9\[[%:Q6_F_;]N_8H7./+.,XSC)K!\=_
M&34_&6DOI$.G0:?I\NPS+O\`-DD*MN`W$`!<A3@#.5ZX)%>O?\*M^&'_`$#[
M7_P92_\`QRM;0/"?@3PQ=F[TBTT^"Y/29[CS73@CY6=B5R&(.,9[UW+&Y?"7
MM(4WS;Z]_O?Y"]G4>C.=^"W@.X\+Z)/JFJVODZIJ&-L;@;X8!R%/&59CRRY[
M)D`@BO4JJ?VII_\`S_VO_?Y?\:/[4T__`)_[7_O\O^->37KRKU'4GNRU!I6L
M>8_M"_\`(@V/_84C_P#14M'[/7_(@WW_`&%)/_145=QXATWPOXKT^.QUI[6Z
MMHY1,J?:BF'`(!RK`]&/YT>'M-\+^%-/DL=%>UM;:24S,GVHOER`"<LQ/11^
M5=7UNG]3^K];W\A>SES7L;5]>V^FZ?<WUW)Y=M;1--*^"=J*"2<#D\`]*^4_
M`FE7'Q`^*B7%S%`8WNGU.^38&CV!]S+M8\JS,J8YP&R<X-?3NJ-HNL:9<:=?
M7D+VMPNR5$NS&67N-RL#@]",\C(/!K)\.>&?!7A.XGN-$ALK6:90CR&Z,C;0
M<X!=B0,XR!C.!GH*>#QD,/2J)?'+1=D$J<FUH7O^$(\)_P#0KZ+_`."^+_XF
ML+QI\-]&U7P=J=GHVAZ7::DT6ZWE@LXD<NI#!0W&W=MVYSQN_"NP_M33_P#G
M_M?^_P`O^-']J:?_`,_]K_W^7_&N6&)J0DI*6WF/D?8^>?V?M=6P\6WNCRLB
MIJ4`:/*L6:6++!01P!L:0G/]T<]CSOQF_P"2L:W_`-L/_1$=>^67@?P!INMI
MK%C;VMK?1RF5)(+^1`K'J`H?:%Y(VXQ@XQCBC6?`_@#Q#JT^J:I;VMQ>S[?,
ME^WR)NVJ%'"N`.`!TKUXYGAXXMXA)V:L]M]//LB/93Y;'G__``TA_P!2I_Y4
M?_M5</XY^)>L_$9[;2X]/2WLQ.KP6D`,LLDI&T9;&6.2V`H'WL')`->T_P#"
MK?AA_P!`^U_\&4O_`,<K=\/>'_!GA3S#HL&GVLDF=TOG;Y"#C*[V);;\H.W.
M,C.*F.-R^B^>C3?,MK_\.P]G4>C*'PL\%-X+\))!>1(NJW;>=>%2K;3T5-P'
M(4=LD;F?!P:\$^,W_)6-;_[8?^B(Z^J/[4T__G_M?^_R_P"-<GK/@?P!XAU:
M?5-4M[6XO9]OF2_;Y$W;5"CA7`'``Z5SX/,(TL1*O6UNNGJARIR:LD=G/!#=
M6\EO<1)+#*I22.10RNI&""#P01VKY0UW2-;^$?Q`AO+5,1Q2O)I]Q*!(D\1R
MI5C@?-M;:P&",Y&,J:^J/[4T_P#Y_P"U_P"_R_XUFZ[9^&?$VF-IVL-97=J6
M#[&G"E6'0A@05/49!'!(Z$UE@<:L/)J2O&6Z'*FV><0_M$Z&VF&2?1-12_VL
M1`C(T6[G:/,)!P>,G9QD\''/D6K:EJWQ1^(".D6VYOY4@MX-SNEO&.!S@D*!
MEF(&/O-@=*]AG^"7@"6XDD36;V%'8LL4=[$50$_=&Y"<#IR2?4FNT\+^&_!W
M@^W":0+*.8KMDNI)E>:3A<Y<G(!*@[1A<\@"N^&-P.&3GAXOF??H3[.;W-W1
M=(M-`T2STFQ3;;6D0C3(`+8ZLV``6)R2<<DDU?JJFI6+NJ)>V[,QP%$JDD_G
M5JO#<G)W9=K!1112`*^=OC+_`,C\_P#UZQ_UKZ)KA?%GPPL/%FM?VG/J%S!(
M8EC*1JI'&>>?K433:T/1RS$4\/7YZFUCYOHKW/\`X45I7_08O?\`OA:/^%%:
M5_T&+W_OA:SY)'T/]LX3N_N9X917N?\`PHK2O^@Q>_\`?"T?\**TK_H,7O\`
MWPM')(/[9PG=_<SPRBO<_P#A16E?]!B]_P"^%H_X45I7_08O?^^%HY)!_;.$
M[O[F>&45[G_PHK2O^@Q>_P#?"UXIJ%NMIJ5U;(Q989GC!/4@$BI<6MSJPV.H
MXEM4GL5Z*[KX<^!;3QK_`&E]JO)K?[)Y6WRE!W;]^<Y_W:[G_A16E?\`08O?
M^^%IJ+>IE7S/#T*CIS>J\CPRBO<_^%%:5_T&+W_OA:X/XB^![7P7-IZ6MY-<
M"Z60MYJ@;=NWIC_>H<6MQT,SP]>:IP>K\CB**N:39KJ.L6-B[E%N;B.$L!R`
MS`9_6O9_^%%:5_T&+W_OA:2BWL:8G'4<,TJCW/#**]S_`.%%:5_T&+W_`+X6
MC_A16E?]!B]_[X6JY)'+_;.$[O[F>&45[G_PHK2O^@Q>_P#?"T?\**TK_H,7
MO_?"T<D@_MG"=W]S/#**]S_X45I7_08O?^^%H_X45I7_`$&+W_OA:.20?VSA
M.[^YGBVF_P#(5L_^NZ?^A"OL"O+;;X(:3;W<,_\`:UZWENK[=J#.#G'2O4JN
M$6MSQ<VQE+$N'LGM?]`HHHK0\<****`"BBB@`HHHH`****`"OD/6_P#D/:C_
M`-?4O_H1KZ\KY#UO_D/:C_U]2_\`H1K*IT/H,@^.?HCU?X"_\S!_V[?^U:]E
MKQKX"_\`,P?]NW_M6O9:N'PG#F_^^3^7Y(*\6^/'_'SH7^Y/_-*]IKQ;X\?\
M?.A?[D_\TI5-AY1_OD/G^3/,_#'_`"-FC?\`7]!_Z&*^M:^2O#'_`"-FC?\`
M7]!_Z&*^M:FGU.W/_P")#T84445J?/A1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%?(>M_\A[4?^OJ7_P!"-?7E?(>M_P#(>U'_`*^I?_0C653H
M?09!\<_1'J_P%_YF#_MV_P#:M>RUXU\!?^9@_P"W;_VK7LM7#X3AS?\`WR?R
M_)!7BWQX_P"/G0O]R?\`FE>TUXM\>/\`CYT+_<G_`)I2J;#RC_?(?/\`)GF?
MAC_D;-&_Z_H/_0Q7UK7R5X8_Y&S1O^OZ#_T,5]:U-/J=N?\`\2'HPHHHK4^?
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*^0];_P"0]J/_`%]2
M_P#H1KZ\KY#UO_D/:C_U]2_^A&LJG0^@R#XY^B/5_@+_`,S!_P!NW_M6O9:\
M:^`O_,P?]NW_`+5KV6KA\)PYO_OD_E^2"O%OCQ_Q\Z%_N3_S2O::\6^/'_'S
MH7^Y/_-*538>4?[Y#Y_DSS/PQ_R-FC?]?T'_`*&*^M:^2O#'_(V:-_U_0?\`
MH8KZUJ:?4[<__B0]&%%%%:GSX4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!7R'K?_(>U'_KZE_]"-?7E?(>M_\`(>U'_KZE_P#0C653H?09!\<_
M1'J_P%_YF#_MV_\`:M>RUXU\!?\`F8/^W;_VK7LM7#X3AS?_`'R?R_)!7BWQ
MX_X^="_W)_YI7M->+?'C_CYT+_<G_FE*IL/*/]\A\_R9YGX8_P"1LT;_`*_H
M/_0Q7UK7R5X8_P"1LT;_`*_H/_0Q7UK4T^IVY_\`Q(>C"BBBM3Y\****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KEY_ASX2N;B6XFT6%I97+N=[C
M))R>`U=110:4ZM2GK"37H[&3HGAG1_#HG&DV*6OG[?,VLQW;<XZD],G\ZUJ*
M*"9SE-\TG=A63K7AC1O$7D_VM81W1ASY98L"N<9Z$>@K6HH"$Y0?-%V9S%K\
M//"=E=PW5OHT*30N)(VWN=K`Y!P3CK73T446*J5:E1WG)OU=PHHHH,PHHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
5HHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
